Pterosins and Pterosides in Bracken (Pteridium aquilinum (L.) Kuhn) by Mohammad, Rizgar Hassan
  
Pterosins and Pterosides in Bracken 
(Pteridium aquilinum (L.) Kuhn)  
 
 
by  
Rizgar Hassan Mohammad 
 
 
A Thesis Submitted in Partial Fulfilment of the 
Requirements for the Degree of 
Doctor of Philosophy 
 
in the 
School of Chemistry 
College of Physical and Applied Sciences 
Bangor University 
 
 
 
 
© Rizgar Hassan Mohammad 2016 
Bangor University 
 2016 
 
 
 
 
i 
 
Declaration and Consent 
Details of the Work 
I hereby agree to deposit the following item in the digital repository maintained by Bangor 
University and/or in any other repository authorized for use by Bangor University. 
Author Name: …………………………………………………………………….. 
Title: ……………………………………………………………..………………… 
Supervisor/Department: ......................................................................................... 
Funding body (if any): ............................................................................................ 
Qualification/Degree obtained: ………………… ………………………………. 
This item is a product of my own research endeavours and is covered by the agreement below 
in which the item is referred to as “the Work”.  It is identical in content to that deposited in the 
Library, subject to point 4 below. 
Non-exclusive Rights 
Rights granted to the digital repository through this agreement are entirely non-exclusive.  I 
am free to publish the Work in its present version or future versions elsewhere. 
I agree that Bangor University may electronically store, copy or translate the Work to any 
approved medium or format for the purpose of future preservation and accessibility.  Bangor 
University is not under any obligation to reproduce or display the Work in the same formats or 
resolutions in which it was originally deposited. 
Bangor University Digital Repository 
I understand that work deposited in the digital repository will be accessible to a wide variety 
of people and institutions, including automated agents and search engines via the World Wide 
Web. 
I understand that once the Work is deposited, the item and its metadata may be incorporated 
into public access catalogues or services, national databases of electronic theses and 
dissertations such as the British Library’s EThOS or any service provided by the National 
Library of Wales. 
I understand that the Work may be made available via the National Library of Wales Online 
Electronic Theses Service under the declared terms and conditions of use 
(http://www.llgc.org.uk/index.php?id=4676). I agree that as part of this service the National 
Library of Wales may electronically store, copy or convert the Work to any approved medium 
or format for the purpose of future preservation and accessibility.  The National Library of 
Wales is not under any obligation to reproduce or display the Work in the same formats or 
resolutions in which it was originally deposited. 
 
ii 
 
Statement 1: 
This work has not previously been accepted in substance for any degree and is not being 
concurrently submitted in candidature for any degree unless as agreed by the University for 
approved dual awards. 
 
Signed ………………………………………….. (candidate) 
Date …………………………………………….. 
Statement 2: 
This thesis is the result of my own investigations, except where otherwise stated. Where 
correction services have been used, the extent and nature of the correction is clearly marked in 
a footnote(s). 
Other sources are acknowledged by footnotes giving explicit references.  A bibliography is 
appended. 
 
Signed …………………………………………. (candidate) 
Date ……………………………………………. 
Statement 3: 
I hereby give consent for my thesis, if accepted, to be available for photocopying, for inter-
library loan and for electronic repositories, and for the title and summary to be made available 
to outside organisations. 
 
Signed …………………………………………. (candidate) 
Date ……………………………………………. 
NB: Candidates on whose behalf a bar on access has been approved by the Academic 
Registry should use the following version of Statement 3: 
Statement 3 (bar): 
I hereby give consent for my thesis, if accepted, to be available for photocopying, for inter-
library loans and for electronic repositories after expiry of a bar on access. 
 
Signed …………………………………………… (candidate) 
Date ………………………………………………                                                                                         
 
iii 
 
Statement 4: 
Choose one of the following options  
a)   I agree to deposit an electronic copy of my thesis (the Work) in the Bangor 
University (BU) Institutional Digital Repository, the British Library ETHOS 
system, and/or in any other repository authorized for use by Bangor University 
and where necessary have gained the required permissions for the use of third 
party material. 
 
b)   I agree to deposit an electronic copy of my thesis (the Work) in the Bangor 
University (BU) Institutional Digital Repository, the British Library ETHOS 
system, and/or in any other repository authorized for use by Bangor University 
when the approved bar on access has been lifted. 
 
c)    I agree to submit my thesis (the Work) electronically via Bangor University’s e-
submission system, however I opt-out of the electronic deposit to the Bangor 
University (BU) Institutional Digital Repository, the British Library ETHOS 
system, and/or in any other repository authorized for use by Bangor University, 
due to lack of permissions for use of third party material. 
 
Options B should only be used if a bar on access has been approved by the University. 
In addition to the above I also agree to the following: 
1. That I am the author or have the authority of the author(s) to make this agreement and 
do hereby give Bangor University the right to make available the Work in the way 
described above. 
2. That the electronic copy of the Work deposited in the digital repository and covered by 
this agreement, is identical in content to the paper copy of the Work deposited in the 
Bangor University Library, subject to point 4 below. 
3. That I have exercised reasonable care to ensure that the Work is original and, to the best 
of my knowledge, does not breach any laws – including those relating to defamation, 
libel and copyright. 
4. That I have, in instances where the intellectual property of other authors or copyright 
holders is included in the Work, and where appropriate, gained explicit permission for 
the inclusion of that material in the Work, and in the electronic form of the Work as 
accessed through the open access digital repository, or that I have identified and 
removed that material for which adequate and appropriate permission has not been 
obtained and which will be inaccessible via the digital repository. 
5. That Bangor University does not hold any obligation to take legal action on behalf of 
the Depositor, or other rights holders, in the event of a breach of intellectual property 
rights, or any other right, in the material deposited. 
6. That I will indemnify and keep indemnified Bangor University and the National Library 
of Wales from and against any loss, liability, claim or damage, including without 
limitation any related legal fees and court costs (on a full indemnity bases), related to 
any breach by myself of any term of this agreement. 
Signature: ………………………………..……  Date ……………...…………………………  
iv 
 
Dedication 
To my wife Payam for her endurance, prayers and unwavering support 
and 
my children Ronya (5.5 years) and Raman (2.5 years).  
May this inspire them to continue learning.  
v 
 
Acknowledgments 
I would like to express my special appreciation and deepest gratitude to my supervisor Dr Vera 
Thoss for her endless support and productive criticism during my PhD study, you have been a 
tremendous mentor for me. I would also like to thank you for encouraging my research and for 
allowing me to grow as a research scientist. Your advice on both research as well as on my 
career have been priceless.  
I would also like to extend my sincerest gratitude and acknowledge the following people and 
groups who assisted me in different ways in the completion of these studies:  
 Dr Mohammad Nur-e-Alam for his guidance and observations during working in the 
laboratory, for teaching me the basic principles of natural products chemistry and for 
his help in structural elucidation of the isolated compounds. 
 All Plant Chemistry Group members, including Dr Anna Santoro, for their suggestions, 
helpful ideas and discussions during our weekly group meeting in which somehow 
supported progression of this research. 
 My research committee members, Professor Mark Baird and Dr Hongyun Tai, for their 
support and valuable suggestions throughout the study.  
 The technical staff at School of Chemistry, especially Dr David Davenport Hughes and 
Shon Glyn Jones for their help with technical NMR and chromatographic (HPLC) 
problems. I would also like to thank Kathleen Tailliart, Gwynfor Davies and Toby Vye 
for providing technical assistance.  
 The administrative and clerical ladies staff in the general office at School of Chemistry, 
Mrs Caroline Randall, Mrs Tracey Roberts, Miss Siobhan Jones and Miss Bryony 
Jones. 
 Dr Dotsha Raheem, Victor Ebuele and Jason Fitzsimmons for their support and 
contribution with the seasonal plant sampling. 
 Dr Martina Lahmann for her help in the determination of the absolute configuration of 
sugar moieties in pteroside compounds. 
 Mr Nigel Brown from Treborth Botanical Garden, Bangor, for identification of the 
bracken plant as Pteridium aquilinum (L.) Kuhn and depositing a voucher specimen of 
bracken at the Treborth Botanical Garden. 
 Muhammad Yousaf, King Saudi University, Saudi Arabia, for confirming previously 
undescribed compounds.  
vi 
 
 Ifat Parveen from Institute of Biological, Environmental and Rural Sciences (IBERS), 
Aberystwyth University, Aberystwyth, UK, for measuring the high resolution mass 
(FT-ICR-MS) of the isolated novel compounds. 
 Dr Ahmed Tawfike from Strathclyde Institute of Pharmacy and Biomedical Sciences 
(SIPBS), University of Strathclyde, Glasgow, for measuring the high resolution mass 
(HR-ESI-MS) for the previously reported pterosins and pterosides. 
 Dr Graham J. Tizzard and Simon J. Coles, UK National Crystallography Service, 
School of Chemistry, University of Southampton, Southampton, UK, for determining 
the absolute stereochemistry of six compounds through single x-ray crystallography. 
 Dr Derren Heyes from Manchester Institute of Biotechnology (MIB), Faculty of Life 
Sciences, University of Manchester, Manchester, UK, for his assistance to measure the 
CD spectra for all the isolated compounds. 
 Dr Alex F. Drake from Biomolecular Spectroscopy Centre, Pharmaceutical Optical & 
Chiroptical Spectroscopy Facility, King's College London, London, UK, for his 
outstanding interpretation of the Circular Dichroism results. 
 Dr Stephania Christou from MBI, School of Chemistry, University of Manchester, UK, 
for measuring the specific optical rotations for the previously unreported compounds.  
 Mark Fowler and Mark Berry from Strategic Science Group, Unilever R & D Colworth, 
Bedford, UK, for assisting with anti-diabetic activity (Glucose Transport Assay) for six 
selected pterosins and pterosides. 
 Dr Diane Irvin, Syngenta, UK for assessing pesticidal activity.  
 Dr Carol Clements from SIPBS, University of Strathclyde, Glasgow, for biological 
screening including antibacterial activity (MRSA, Klebsiella pneumonia, and 
Mycobacterium marinum) and antitrypanosomal assay (Trypanosoma brucei brucei). 
 Professor Steve Kelly’s Group from Centre for P450 Biodiversity, College of Medicine, 
University of Swansea, for assisting with antifungal assays using Candida albicans 
strains. 
 Professor Karl Hoffman and Dr Helen Whiteland from IBERS, Aberystwyth University 
for assessing the antihelminthic activity of 20 pterosins and pterosides funded through 
the National Research Network. 
 Dr Ana Winters from IBERS, University of Aberystwyth, for conducting the HPLC-
ESI-MSn analysis of methanol extract of bracken rhizomes. 
vii 
 
 The Kurdish Ministry of Higher Education and Scientific Research - Kurdistan 
Regional Government (MHESR-KRG) for awarding me the scholarship to accomplish 
PhD Degree in Chemistry. Without this, the study would not have been possible. 
 My relatives, acquaintances, colleagues and friends.  
 My parents for their endless love and continuous prayers for me which gave me the 
strength and patience to complete my study.  
 My brothers, Umed Hassan and Rasul Hassan, for their continued assistance in my 
home country.  
 Last, but not least, I would like to express appreciation and special thanks to my beloved 
wife Payam who spent sleepless nights with me and was always my support in the 
moments when there was no one to answer my queries. Words cannot express how 
grateful I am to her for all of the sacrifices that she has made on my behalf throughout 
this study.  
 
  
viii 
 
Table of Contents 
Declaration and Consent ............................................................................................................. i 
Dedication ................................................................................................................................. iv 
Acknowledgments...................................................................................................................... v 
Table of Contents ................................................................................................................... viii 
List of Tables ......................................................................................................................... xiii 
List of Figures ......................................................................................................................... xvi 
List of Figures in Appendices ................................................................................................. xxi 
Abbreviations and Acronyms .............................................................................................. xxxii 
Abstract ............................................................................................................................... xxxiv 
CHAPTER ONE .................................................................................................................. 1 
1. Introduction ................................................................................................................. 1 
1.1. Bracken (Pteridium aquilinum)............................................................................ 1 
1.2. Altitudinal and geographical distribution ............................................................ 3 
1.3. Historical uses ...................................................................................................... 5 
1.4. Human and public health risks ............................................................................. 6 
1.5. The chemistry of bracken................................................................................... 10 
1.5.1. Ptaquiloside ................................................................................................ 11 
1.5.2. Pterosins and pterosides.............................................................................. 18 
1.6. Biological activity assessment ........................................................................... 20 
1.7. Glucose uptake in the body ................................................................................ 24 
1.8. Aims of the study: .............................................................................................. 25 
CHAPTER TWO ............................................................................................................... 26 
2. Materials and Methods .............................................................................................. 26 
2.1. Solutions and Reagents ...................................................................................... 26 
2.1.1. General Laboratory Chemicals ................................................................... 26 
2.1.2. HPLC grade solvents .................................................................................. 26 
2.1.3. Deuterated solvents for NMR analysis ....................................................... 26 
2.2. Equipment and Instrumentation ......................................................................... 27 
ix 
 
2.2.1. General apparatus and instruments ............................................................. 27 
2.2.2. Nuclear Magnetic Resonance ..................................................................... 27 
2.2.3. High Performance Liquid Chromatography ............................................... 28 
2.2.4. High Resolution Mass Spectrometry .......................................................... 28 
2.2.5. HPLC-Electrospray Ionisation-Ion Trap Mass Spectrometry (HPLC-ESI-
MSn) 29 
2.2.6. Reverse Phase Flash Chromatography (RP-FC) ........................................ 29 
2.2.7. Circular Dichroism Spectroscopy ............................................................... 30 
2.2.8. X-ray Crystallography procedure: .............................................................. 30 
2.3. Thin layer chromatography (TLC) ..................................................................... 30 
2.4. Bracken plant material and extraction ............................................................... 31 
2.4.1. Plant collection and drying ......................................................................... 31 
2.4.2. Extraction and isolation .............................................................................. 31 
2.5. Acetylation method ............................................................................................ 39 
CHAPTER THREE ........................................................................................................... 40 
3. Results and Discussion .............................................................................................. 40 
3.1. Introduction: ....................................................................................................... 40 
3.2. Structural Elucidation of Novel Compounds ..................................................... 41 
3.4. Physico-Chemical Parameters of Novel Compounds (RH1-RH13): ................. 74 
3.5. Structural Elucidation of Previously Reported Compounds .............................. 76 
3.6. Structural Relationships between New and Known Pterosins and Pterosides . 126 
3.8. Proof and confirmation of sulfate and chlorine-containing compounds using 
HPLC-ESI-MSn method .............................................................................................. 134 
CHAPTER FOUR ............................................................................................................ 138 
4. Biological Activity Assessment of Pterosins and Pterosides in Bracken ................ 138 
4.1. Experimental Part of Bioassays ....................................................................... 138 
4.1.1. Alamar blue assay to determine drug sensitivity of African trypanosomes 
in vitro 138 
4.1.2. Antimicrobial assay - M. marinum ATCC.BAA535 ................................ 139 
4.1.3. Antifungal assay ....................................................................................... 140 
4.1.4. Agrochemical relevant assays .................................................................. 141 
4.1.4.1. Fungicide assays .................................................................................. 141 
4.1.4.2. Herbicide assays................................................................................... 142 
4.1.4.3. Insecticide assays ................................................................................. 142 
4.1.5. Anti-schistosomal screening ..................................................................... 143 
x 
 
4.1.6. Assessment of Effect of Compounds on Glucose Transport Across Cell 
Membranes .............................................................................................................. 143 
4.1.6.1. Glucose Transport Inhibitor Cell Screening Assay ............................. 143 
4.1.6.2. Glucose Transport Assay ..................................................................... 144 
4.2. Results and Discussion .................................................................................... 145 
4.2.1. Glucose Transport Assay: ......................................................................... 145 
4.2.3. Alamar Blue Assay (Antitrypanosomal activity) ..................................... 147 
4.2.4. Antibacterial activity ................................................................................ 147 
4.2.6. Agrochemical Relevant Assays ................................................................ 148 
4.2.7. Antifungal activity .................................................................................... 148 
4.2.8. Anti-schistosomal screening ..................................................................... 151 
CHAPTER FIVE ............................................................................................................. 153 
5. Seasonal Variation and Quantification of Pterosin b and Pteroside b in bracken 
samples ........................................................................................................................... 153 
5.1. Introduction ...................................................................................................... 153 
5.2. Materials and methods ..................................................................................... 156 
5.2.1. General equipment .................................................................................... 156 
5.2.2. Sample collections .................................................................................... 156 
5.2.2.1. Plant and soil samples .......................................................................... 156 
5.2.2.2. Water Samples ..................................................................................... 158 
5.2.3. Pre-treatment of plant and soil samples: ................................................... 158 
5.2.3.1. Bracken plant samples ......................................................................... 158 
5.2.3.2. Soil samples ......................................................................................... 159 
5.2.3.3. Water samples ...................................................................................... 160 
5.2.4. Preparation of solid phase extraction (SPE) cartridges ............................ 160 
5.2.5. Reagents and standards ............................................................................. 160 
5.2.6. Preparation of standard solutions ............................................................. 160 
5.2.7. Sample Preparation and Extraction Procedure by SPE Method: .............. 161 
5.2.7.1. Plant and Soil Samples......................................................................... 161 
5.2.7.2. Method A: ............................................................................................ 161 
5.2.7.3. Method B: ............................................................................................ 161 
5.2.7.4. Water samples ...................................................................................... 162 
5.2.8. RP-HPLC-UV Instrumentation and Conditions ....................................... 162 
5.2.8.1. RP-HPLC-UV instrument .................................................................... 162 
5.2.8.2. RP-HPLC-UV conditions .................................................................... 162 
xi 
 
5.2.8.3. Linear range and sensitivity of the RP-HPLC-UV method ................. 163 
5.2.9. Precision, accuracy and recovery ............................................................. 163 
5.3. Results .............................................................................................................. 165 
5.3.1. Water extraction procedure ...................................................................... 165 
5.3.1.1. Preliminary method:............................................................................. 165 
5.3.1.2. Optimization of the method ................................................................. 165 
5.3.2. Optimization of RP-HPLC-UV Parameters ............................................. 170 
5.3.3. Recovery of pterosin B and pteroside B with SPE-HPLC-UV method in 
bracken stem samples .............................................................................................. 173 
5.3.4. Biomass and water content measurement of bracken organs ................... 174 
5.3.5. Seasonal variations ad Quantification of pterosin B and pteroside B using 
solid phase extraction and RP-HPLC-UV method .................................................. 175 
5.3.5.1. Seasonal variations and quantification of pterosin B and pteroside B in 
bracken rhizomes, stems and fronds .................................................................... 176 
5.3.5.2. Seasonal variations of pterosin B and pteroside B in soil samples ...... 179 
5.3.5.3. Seasonal variations of pterosin B and pteroside B in water samples ... 180 
5.4. Discussion ........................................................................................................ 181 
CHAPTER SIX ................................................................................................................ 184 
6. Conclusions ............................................................................................................. 184 
6.1. Structural elucidation of the isolated compounds ............................................ 184 
6.2. Biological activities of the isolated compounds .............................................. 191 
List of References .................................................................................................................. 194 
Appendices ............................................................................................................................. 209 
Appendix I: NMR spectra of compounds RH3 - RH38. ....................................... 209 
1) NMR spectra of compound RH3 in CDCl3. .................................................... 209 
2) NMR spectra of compound RH4 in CD3OD. .................................................. 211 
3) NMR spectra of compound RH5 in CDCl3. .................................................... 214 
4) NMR spectra of compound RH6 in CD3OD. .................................................. 217 
5) NMR spectra of compound RH7 in CDCl3. .................................................... 219 
6) NMR spectra of compound RH8 in (CD3)2CO................................................ 222 
7) NMR spectra of compound RH9 in CD3OD. .................................................. 225 
8) NMR spectra of compound RH10 in CD3OD. ................................................ 226 
9) NMR spectra of compound RH11 in CD3OD. ................................................ 230 
10) NMR spectra of compound RH12 in CD3OD. .............................................. 233 
11) NMR spectra of compound RH13 in CD3OD. .............................................. 238 
xii 
 
12) NMR spectra of compound RH14 in CD3OD. .............................................. 243 
13) NMR spectra of compound RH15 in CD3OD. .............................................. 246 
14) NMR spectra of compound RH16 in CDCl3. ................................................ 249 
15) NMR spectra of compound RH17 in CD3OD. .............................................. 252 
16) NMR spectra of compound RH18 in CD3OD. .............................................. 254 
17) NMR spectra of compound RH19 in CD3OD. .............................................. 257 
18) NMR spectra of compound RH20 in CDCl3. ................................................ 260 
19) NMR spectra of compound RH21 in CDCl3. ................................................ 261 
20) NMR spectra of compound RH22 in CDCl3. ................................................ 264 
21) NMR spectra of compound RH23 in CDCl3. ................................................ 267 
22) NMR spectra of compound RH24 in CD3OD. .............................................. 270 
23) NMR spectra of compound RH25 in CDCl3. ................................................ 273 
24) NMR spectra of compound RH26 in CDCl3. ................................................ 274 
25) NMR spectra of compound RH27 in CD3OD. .............................................. 277 
26) NMR spectra of compound RH28 in CD3OD. .............................................. 280 
27) NMR spectra of compound RH29 in CD3OD. .............................................. 282 
28) NMR spectra of compound RH30 in CD3OD. .............................................. 285 
29) NMR spectra of compound RH31 in CD3OD. .............................................. 288 
30) NMR spectra of compound RH32 in CD3OD. .............................................. 291 
31) NMR spectra of compound RH33 in CD3OD. .............................................. 293 
32) NMR spectra of compound RH34 in CD3OD. .............................................. 296 
33) NMR spectra of compound RH35 in CD3OD. .............................................. 299 
34) NMR spectra of compound RH36 in CD3OD. .............................................. 302 
35) NMR spectra of compound RH37 in CD3OD. .............................................. 303 
36) NMR spectra of compound RH38 in CDCl3. ................................................ 306 
Appendix II: Accurate MS spectra of compounds RH3 - RH38. ......................... 310 
Appendix III: IR spectra of compounds RH2 - RH13. ......................................... 322 
Appendix IV: UV spectra of compounds RH2 - RH13. ....................................... 334 
Appendix V: Glucose transport assays. ................................................................. 340 
1) Routine cell culture .......................................................................................... 340 
2) Preparation of differentiated Caco-2 cell monolayers ..................................... 340 
 
 
  
xiii 
 
List of Tables 
Table 1: Apparent rate constants (kobs) for ptaquiloside hydrolysis a) in different aqueous 
buffer solutions at 22 °C and b) in an aqueous solution of pH 4.46 at different temperatures.
.................................................................................................................................................. 13 
Table 2: Half-lives of ptaquiloside.......................................................................................... 16 
Table 3: Cytotoxic activities of the compounds against 4 different tumour cell lines ............ 22 
Table 4: Deuterated solvents used in NMR experiments ........................................................ 27 
Table 5: Main fractions obtained from column chromatography of chloroform extract. ....... 32 
Table 6: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound RH1 in 
CDCl3 (δ in ppm, multiplicity, J in Hz). .............................................................................. 42 
Table 7: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound RH2 in CD3OD 
(δ in ppm, multiplicity, J in Hz). .............................................................................................. 50 
Table 8: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound RH3 in CDCl3 
(δ in ppm, multiplicity, J in Hz). .............................................................................................. 57 
Table 9: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound RH4 in CD3OD 
(δ in ppm, multiplicity, J in Hz). .............................................................................................. 59 
Table 10: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound RH5 in CDCl3 
(δ in ppm, multiplicity, J in Hz). .............................................................................................. 60 
Table 11: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound RH8 in 
(CD3)2CO (δ in ppm, multiplicity, J in Hz). ............................................................................ 62 
Table 12: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound RH7 in CDCl3 
(δ in ppm, multiplicity, J in Hz). .............................................................................................. 64 
Table 13: 1H (125 MHz) and 13C (500 MHz) NMR spectral data of compound RH9 in CD3OD 
(δ in ppm, multiplicity, J in Hz). .............................................................................................. 65 
Table 14: 1H (100 MHz) and 13C (400 MHz) NMR spectral data of compound RH6 in CD3OD 
(δ in ppm, multiplicity, J in Hz). .............................................................................................. 67 
Table 15: 1H (100 MHz) and 13C (400 MHz) NMR spectral data of compound RH10 in CD3OD 
(δ in ppm, multiplicity, J in Hz). .............................................................................................. 68 
Table 16: 1H (400 MHz) and 13C (100 MHz) spectral data of compound RH11 in CD3OD (δ 
in ppm, multiplicity, J in Hz). .................................................................................................. 70 
Table 17: 1H (400 MHz) and 13C (100 MHz) spectral data of compound RH12 in CD3OD (δ 
in ppm, multiplicity, J in Hz). .................................................................................................. 71 
xiv 
 
Table 18: 1H (400 MHz) and 13C (100 MHz) spectral data of compound RH13 in CD3OD (δ 
in ppm, multiplicity, J in Hz). .................................................................................................. 73 
Table 19: Compound RH14 [(2S)-Rhedynosin I]................................................................... 76 
Table 20: Compound RH16 [(2R)-Pterosin B] ....................................................................... 77 
Table 21: Compound RH31 [(2R)-Pteroside B] ..................................................................... 80 
Table 22: Compound RH15 [(2S)-Pterosin A] ....................................................................... 82 
Table 23: Compound RH30 [(2S)-Pteroside A] ..................................................................... 85 
Table 24: Compound RH34 [(2S)-Pteroside A2] ................................................................... 87 
Table 25: Compound RH17 [(2R, 3R)-Pterosin C or trans-Pterosin C] ................................. 89 
Table 26: Compound RH18 [(2S, 3R)-Pterosin C or cis-Pterosin C] ..................................... 91 
Table 27: Compound RH28 [(2R, 3R)-Histiopterosin A = trans-Histiopterosin A] .............. 93 
Table 28: Compound RH21 [(2R)-Pterosin F] ....................................................................... 95 
Table 29: Compound RH22 [(2S, 3S)-Pterosin J or trans--Pterosin J] .................................. 97 
Table 30: Compound RH19 [(3S)-Pterosin D] ....................................................................... 98 
Table 31: Compound RH32 [(3S)-Pteroside D] ................................................................... 101 
Table 32: Compound RH20 [(2R)-Pterosin E] ..................................................................... 103 
Table 33: Compound RH23 [(2S)-Pterosin K] ..................................................................... 104 
Table 34: Compound RH35 [(2S)-Pteroside K] ................................................................... 106 
Table 35: Compound RH24 [(2S)-Pterosin N] ..................................................................... 108 
Table 36: Compound RH25 [(2S)-Pterosin P] ...................................................................... 110 
Table 37: Compound RH26 [Pterosin Z] ............................................................................. 111 
Table 38: Compound RH33 [Pteroside Z] ............................................................................ 114 
Table 39: Compound RH27 [(2S)-2-Hydroxymethylpterosin E] ......................................... 116 
Table 40: Compound RH29 [(2S)-12-Hydroxypterosin A] .................................................. 118 
Table 41: Compound RH36 [(5-(β-hydroxy)ethyl-2, 2, 4, 6-tetramethyl-1, 3-indandione] . 120 
Table 42: Compound RH37 [Ptaquiloside] .......................................................................... 121 
Table 43: Compound RH38 [5-Hydroxyisocalamenene] ..................................................... 124 
Table 44: Yield and concentration of minor and major isolated compounds. ...................... 131 
Table 45: Previous description and source details for previously reported pterosins and 
pterosides. .............................................................................................................................. 132 
Table 46: Final assay concentrations µg/ml. ......................................................................... 139 
Table 47: Conditions of M. marinum ATCC.BAA535 assay. .............................................. 140 
Table 48: Candida albicans strains. ...................................................................................... 141 
xv 
 
Table 49: Results of pterosins and pterosides tested for SGLT1 and GLUT2 inhibition activity 
in Caco-2 cells using 5 mM D-glucose (15 min) and 25 mM D-glucose (30 min), respectively.
................................................................................................................................................ 146 
Table 50: Summary of biological assay results for the selected pterosins and pterosides.... 149 
Table 51: Summary of biological assay results for the selected pterosins and pterosides.... 150 
Table 52: Various analytical methods for determination of pterosin B and ptaquiloside in 
different sample matrices. ...................................................................................................... 155 
Table 53: The pH value of water samples............................................................................. 158 
Table 54: The optimised conditions of RP-HPLV-UV method ............................................ 163 
Table 55: Linearity of pterosin B and pteroside B standards and sensitivity of the RP-HPLC-
UV method. ............................................................................................................................ 172 
Table 56: Recoveries (%) of pterosin B and pteroside B in bracken stem samples and the 
associated relative standard deviations (% RSD). ................................................................. 173 
Table 57: A guideline to find the chemical structures of RH compounds throughout the thesis
................................................................................................................................................ 185 
  
xvi 
 
List of Figures 
Figure 1: Generalized life cycle of bracken fern, Pteridium. ............................................. 2 
Figure 2: The distribution of bracken (P. aquilinum) in the British Isles. Each dot 
represents at least one record in a 10 km2 of the British National Grid: (○) pre-1950, (•) 
1950 onwards (Marrs and Watt, 2006). .................................................................................. 4 
Figure 3: The European distribution of bracken (P. aquilinum) (•) on a 50 km2 basis 
(Marrs and Watt, 2006). .......................................................................................................... 4 
Figure 4: How ptaquiloside is exposed to the environment and human. ......................... 10 
Figure 5: Hydrolysis of ptaquiloside as a function of pH (kobs; h
-1). Solid line is 
extrapolated from nonlinear regression fit of Equation 3. σ represen ts standard error of 
log kN (Ayala-Luis et al., 2006). .............................................................................................. 14 
Figure 6: Proposed mechanism for the acid hydrolysis of ptaquiloside (Ayala-Luis et al., 
2006). ....................................................................................................................................... 17 
Figure 7:  Schematic diagram of ptaquiloside degradation in alkaline medium. ............ 17 
Figure 8: Chemical structure of 1-indanone. ...................................................................... 18 
Figure 9: Electronic transition between phenyl ring and keto group in conjugated pterosin 
type compounds. ..................................................................................................................... 20 
Figure 10: Chemical structures bimutipterosins A and B, and dehydropterosin Q from 
Pteris multifida Poir. .............................................................................................................. 22 
Figure 11: Chemical structures of dehydropterosin B, (2R, 3R)-pterosin L 3-O-β-D-
glucopyranoside and (2S, 3S)-pterosin C 3-O-β-D-glucopyranoside from Pteris multifida 
Poir. ......................................................................................................................................... 23 
Figure 12: Glucose concentration timeline during a meal. ............................................... 24 
Figure 13: Extraction and fractionation scheme from the rhizome of bracken (Pteridium 
aquilinum (L.) Kuhn). .............................................................................................................. 34 
Figure 14: Schematic flow diagrams of isolation of pterosins and pterosides from fractions A) 
F4-F5, B) F16-F17, C) F18 and D) F14-F15. .......................................................................... 35 
Figure 15: Flow chart diagrams of isolation of pterosins and pterosides from fractions A) F19, 
B) F20-F22 and C) F23-F29. ................................................................................................... 36 
Figure 16: Flow diagrams of isolation of pterosins and pterosides from fractions A) F38-F41, 
B) F44, C) F45-F47 and D) F48-F51. ...................................................................................... 37 
Figure 17: Schematic diagrams of isolation of pterosins and pterosides from fractions A) F42-
F43 and B) F52-F67. ................................................................................................................ 38 
xvii 
 
Figure 18: Chemical Structure of (2S)-Rhedynosin A (RH1). ........................................... 41 
Figure 19: The CD spectra of the tricyclic compound RH1 recorded in methanol. ....... 43 
Figure 20: 2D NMR key correlations including COSY and HMBC used in the structural 
identification of the compound RH1. ................................................................................... 44 
Figure 21: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH1. ........................... 44 
Figure 22: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of compound RH1 (2.70-
4.05). ........................................................................................................................................ 45 
Figure 23: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH1. .................. 45 
Figure 24: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH1. ......... 46 
Figure 25: 1H-13C HSQC NMR spectrum of compound RH1 in CDCl3. ........................ 46 
Figure 26: 1H-13C HMBC NMR spectrum of compound RH1 in CDCl3. ....................... 47 
Figure 27: FT-ICR-MS spectrum of compound RH1 in [M+H]+ positive ion mode. .... 47 
Figure 28: UV spectrum of compound RH1 in MeOH. .................................................... 48 
Figure 29: FT-IR spectrum of compound RH1 in CHCl3. ................................................ 49 
Figure 30: Chemical Structure of (2S)-Rhedynoside A (RH2). ....................................... 50 
Figure 31: Some of HMBC and COSY key correlations used in the structural 
identification of the compound RH2. ................................................................................... 52 
Figure 32: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH2. ......................... 52 
Figure 33: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH2 (2.7 – 4.3 ppm).
.................................................................................................................................................. 53 
Figure 34: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH2 after acetylation.
.................................................................................................................................................. 53 
Figure 35: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH2. ................ 54 
Figure 36: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH2. ....... 54 
Figure 37: 1H-13C HSQC NMR spectrum of compound RH2 in CD3OD. ...................... 55 
Figure 38: 1H-13C HMBC NMR spectrum of compound RH2 in CD3OD. ..................... 55 
Figure 39: FT-ICR-MS spectrum of compound RH2 in [M+H]+ positive ion mode. .... 56 
Figure 40: Chemical Structure of Rhedynosin B (RH3). .................................................. 56 
Figure 41: 2D NMR key correlations including COSY and HMBC used in the structural 
identification of the compound RH3. ................................................................................... 58 
Figure 42: Chemical Structure of Rhedynosin C (RH4). .................................................. 58 
Figure 43: HMBC key correlations used in the structural identification of RH4........... 59 
Figure 44: Chemical Structure of Rhedynosin D (RH5). .................................................. 60 
xviii 
 
Figure 45: COSY and HMBC key correlations used in the structural identification of 
RH5. ........................................................................................................................................ 61 
Figure 46: Chemical Structure of Rhedynosin G (RH8). .................................................. 62 
Figure 47: Up and down-field shifting of selected signals in 1H NMR of compounds RH5 
and RH8. ................................................................................................................................. 63 
Figure 48: COSY and HMBC key correlations used in the structural identification of 
RH8. ........................................................................................................................................ 63 
Figure 49: Chemical Structure of Rhedynosin F (RH7). .................................................. 64 
Figure 50: Chemical Structure of Rhedynosin H (RH9). .................................................. 65 
Figure 51: Chemical Structure of (3S)-Rhedynosin E (RH6). .......................................... 66 
Figure 52: Chemical Structure of (2R)-Rhedynoside B (RH10). ..................................... 68 
Figure 53: Thermal ellipsoid plot of compound Rhedynoside B (RH10) with ellipsoids 
shown at 50% probability. N.B. Rhedynoside B crystallises as a hemihydrate with four 
molecules of Rhedynoside B and two molecules of water in the asymmetric unit. Only 
one molecule of the Rhedynoside B structure is shown here for clarity.  ......................... 69 
Figure 54: Chemical Structure of Rhedynoside C (RH11). .............................................. 70 
Figure 55: Chemical Structure of Rhedynoside D (RH12). .............................................. 71 
Figure 56: Chemical Structure of (3R)-Rhedynoside E (RH13). ..................................... 73 
Figure 57:  X-ray crystallographic structure of the compound RH31. ............................ 81 
Figure 58: X-ray crystallographic structure of the compound RH15. ............................. 83 
Figure 59: The CD spectra of RH15 and RH30 in methanol illustrating the superposition 
of a longer wavelength positively signed vibronic progression and a shorter wavelength 
negatively signed vibronic progression................................................................................ 84 
Figure 60: X-ray crystallographic structure of the compound RH17. ............................. 90 
Figure 61: The CD spectra of RH17, RH18, and RH22 recorded in methanol. ............. 90 
Figure 62: X-ray crystallographic structure of the compound RH18. ............................. 92 
Figure 63: The CD spectra of the compound RH28 recorded in methanol. .................... 94 
Figure 64: 1H NMR spectra of compounds RH17 and RH19 showing the main 
differences occurred to the selected signals. ....................................................................... 99 
Figure 65: The CD spectrum of RH19 recorded in methanol. ....................................... 100 
Figure 66: The CD spectrum of RH32 recorded in methanol. ....................................... 102 
Figure 67: The CD spectrum of RH23 in methanol showing positive (longer wavelength) 
and negative (shorter wavelength) signed vibronic progressions. ................................... 105 
xix 
 
Figure 68: CD spectra recorded in methanol of the: a) isolated compound RH35 and b) 
(2S)-pteroside K achieved by Kuroyanagi et al (1979b). ................................................. 107 
Figure 69: X-ray crystallographic structure of the compound RH35. ........................... 108 
Figure 70: Combined 1H NMR spectra showing the main variation between RH16 and 
RH26. .................................................................................................................................... 113 
Figure 71: The CD spectra of the compounds RH27 and RH29 recorded in methanol.
................................................................................................................................................ 117 
Figure 72: The expanded 1H NMR (500 MHz) spectrum of RH38 in CDCl3. .............. 125 
Figure 73: Chemical structures of 5, 7 and 8-hydroxycalamenes. ................................. 125 
Figure 74: Structural similarity between the novel compound RH13 and the reported 
glycosides from the literature. ............................................................................................ 127 
Figure 75: Chemical structural similarity between a new compound RH7 and reported 
sulfated pterosins in the literature. ..................................................................................... 128 
Figure 76: Structural similarity of rhedynosins B and I with reported compounds in the 
literature. ............................................................................................................................... 128 
Figure 77: Structural similarity between the new compound, rhedynosin D, and 
setulosopterosin from the literature. ................................................................................... 129 
Figure 78: Similarity between chemical structures of two novel compounds, RH7 and 
RH8, and a published pterosin in the literature. ............................................................... 129 
Figure 79: Reverse phase HPLC-ESI-MS total ion current (TIC) chromatogram of 
methanolic crude extract of bracken rhizomes in the negative ion mode. ...................... 135 
Figure 80: HPLC-ESI–MS/MS base peak chromatogram of methanolic crude extract of 
bracken rhizomes in the negative ion mode. ..................................................................... 135 
Figure 81: HPLC/ESI–MS/MS total ion current chromatogram of a selected peak 
(relative retention time (RRt) = 9.15 min) of methanolic crude extract of bracken rhizomes 
in the negative ion mode. .................................................................................................... 136 
Figure 82: HPLC/MS identification of the sulfated-pterosin (RH9) in methanolic crude 
extract of bracken rhizomes. HPLC/MS spectrum showing [M-H]- (297.14 amu) in the 
negative ion mode at RRt of 9.90 min for compound (RH9). .......................................... 136 
Figure 83: Further HPLC/MS/MS identification of the chlorinated compounds (RH11, 
RH13 and RH35) (loss of 162 amu) in methanol extract of bracken rhizomes. TIC of 
compounds at RRt of 18.8 min: (A) with 35Cl isotope; (B) with 37Cl isotope. 
HPLC/MS/MS spectrum showing [M-H-Glc]- (265 amu) in the negative mode at RRt of 
18.8 min for (C) 35Cl-compounds and (D) 37Cl-compounds. ........................................... 137 
xx 
 
Figure 84: Tabular and graphical representation of the anti-schistosomal activity score 
of a selection of pterosins and pterosides in comparison to the current anti-schistosomal 
drug and controls. ................................................................................................................. 152 
Figure 85: A, Sampling site location and B, aerial view of the sampling site with bracken 
vegetation and bluebell flowers. ......................................................................................... 157 
Figure 86: Main parts of bracken fern (Pteridium aquilinum (L.) Kukn), A: fronds; B: 
rhizomes and crosiers. ......................................................................................................... 159 
Figure 87: Effect of extraction time on the peak areas of pterosin B and pteroside B.  166 
Figure 88: Effect of extraction volume of water on the peak areas of pterosin B and 
pteroside B. ........................................................................................................................... 167 
Figure 89: Effect of percentage of methanol (1st fraction) on the peak areas of pterosin B 
and pteroside B. .................................................................................................................... 167 
Figure 90: Effect of volume of methanol (15%, 1st fraction) on the peak areas of pterosin 
B and pteroside B. ................................................................................................................ 168 
Figure 91: Effect of percentage of methanol (2nd fraction) on the peak areas of pterosin 
B and pteroside B. ................................................................................................................ 169 
Figure 92: Effect of volume of methanol (50%, 2nd fraction) on the peak areas of pterosin 
B and pteroside B. ................................................................................................................ 169 
Figure 93: Effect of volume of methanol (80%, 3rd fraction) on the peak areas of pterosin 
B and pteroside B. ................................................................................................................ 170 
Figure 94: HPLC-UV chromatograms of pterosin B and pteroside B in bracken (rhizome, 
frond and stem), soil and standard solutions. .................................................................... 171 
Figure 95: Biomass percentage of bracken rhizomes, fronds and stems (calculated based 
on dry weight separately). ................................................................................................... 174 
Figure 96: Water content percentage in bracken rhizomes, fronds and stems. ............. 175 
Figure 97: Seasonal variations of pterosin B (1) and pteroside B (2) in bracken rhizomes. 
The areas between the dashed lines represent A: solely dormant rhizomes; B: shoot 
growing; C: stem extension and mature fronds; D: premature senescence fronds and E: 
dead fronds and stems. ......................................................................................................... 177 
Figure 98: Seasonal variation of pterosin B in bracken stems and fronds. The areas 
between the dashed lines represent A: dead bracken and dormancy period; B: crosiers 
emergence; C: stem extension and mature fronds; D: premature senescence fronds. ... 178 
xxi 
 
Figure 99: Seasonal variation of pteroside B in bracken stems and fronds. The areas 
between the dashed lines represent A: dead bracken and dormancy period; B: crosiers 
emergence; C: stem extension and mature fronds; D: premature senescence fronds.  ... 179 
Figure 100: Seasonal variation of pterosin B in soil samples. The areas between the 
dashed lines represent A: solely dormant rhizomes; B: shoot growing; C: stem extension 
and mature fronds; D: premature senescence fronds and E: dead fronds and stems. .... 180 
Figure 101: Concentrations of pterosin B and pteroside B in water samples. .............. 181 
Figure 102: Chromophore core in compounds RH1, RH2, RH7, RH14, RH15, RH23, 
RH27, RH29, RH30, RH34 and RH35............................................................................. 186 
Figure 103: Pterosin compounds having OH substitution on position C-14 hypothesised 
to have arisen from ptaquiloside degradation. ................................................................... 187 
Figure 104: Pterosin compounds having Cl and HSO4 substitutions on position C-14 or 
COOH group on position C-13 hypothesised to have arisen from ptaquiloside 
degradation. .......................................................................................................................... 189 
Figure 105: Examples for six-membered cyclic pterosins in bracken. .................................. 189 
Figure 106: Pterosin glycoside compounds with glucose-O-linkage to the aglycones at 
positions a) C-14, b) C-11 and c) C-2, C-3 and C-12. ........................................................... 190 
 
List of Figures in Appendices 
Figure A-1: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH3. ....................... 209 
Figure A-2: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH3. .............. 209 
Figure A-3: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH3. .......... 210 
Figure A-4: 1H-13C HSQC NMR spectrum of compound RH3 in CDCl3. .................... 210 
Figure A-5: 1H-13C HMBC NMR spectrum of compound RH3 in CDCl3. ................... 211 
Figure A-6: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH4. ..................... 211 
Figure A-7: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH4. ............ 212 
Figure A-8: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH4. ... 212 
Figure A-9: 1H-13C HSQC NMR spectrum of compound RH4 in CD3OD. .................. 213 
Figure A-10: 1H-13C HMBC NMR spectrum of compound RH4 in CD3OD. ............... 213 
Figure A-11: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH5. ..................... 214 
Figure A-12: 13C NMR (CDCl3, 100 MHz) spectrum of compound RH5. ................... 214 
Figure A-13: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH5. ............ 215 
Figure A-14: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH5. ... 215 
xxii 
 
Figure A-15: 1H-13C HSQC NMR spectrum of compound RH5 in CDCl3. .................. 216 
Figure A-16: 1H-13C HMBC NMR spectrum of compound RH5 in CDCl3. ................. 216 
Figure A-17: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH6. ................... 217 
Figure A-18: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH6. .......... 217 
Figure A-19: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH6. . 218 
Figure A-20: 1H-13C HSQC NMR spectrum of compound RH6 in CD3OD. ................ 218 
Figure A-21: 1H-13C HMBC NMR spectrum of compound RH6 in CD3OD. ............... 219 
Figure A-22: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH7. ..................... 219 
Figure A-23: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH7. ............ 220 
Figure A-24: 13C NMR (CDCl3, 100 MHz) spectrum of compound RH7. ................... 220 
Figure A-25: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH7. ... 221 
Figure A-26: 1H-13C HSQC NMR spectrum of compound RH7 in CDCl3. .................. 221 
Figure A-27: 1H-13C HMBC NMR spectrum of compound RH7 in CDCl3. ................. 222 
Figure A-28: 1H NMR ((CD3)2CO, 400 MHz) spectrum of compound RH8. ............... 222 
Figure A-29: DEPTQ NMR ((CD3)2CO, 100 MHz) spectrum of compound RH8. ...... 223 
Figure A-30: 1H-1H COSY NMR ((CD3)2CO, 400 MHz) spectrum of compound RH8.
................................................................................................................................................ 223 
Figure A-31: 1H-13C HSQC NMR spectrum of compound RH8 in (CD3)2CO. ............ 224 
Figure A-32: 1H-13C HMBC NMR spectrum of compound RH8 in (CD3)2CO. ........... 224 
Figure A-33: 1H NMR (CD3OD, 500 MHz) spectrum of compound RH9. ................... 225 
Figure A-34: DEPTQ NMR (CD3OD, 125 MHz) spectrum of compound RH9. .......... 225 
Figure A-35: 1H-13C HMBC NMR spectrum of compound RH9 in CD3OD. ............... 226 
Figure A-36: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH10.................. 226 
Figure A-37: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH10 (3.0 – 3.75 
ppm). ...................................................................................................................................... 227 
Figure A-38: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH10 after acetylation.
................................................................................................................................................ 227 
Figure A-39: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH10. ........ 228 
Figure A-40: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH10.
................................................................................................................................................ 228 
Figure A-41: 1H-13C HSQC NMR spectrum of compound RH10 in CD3OD. .............. 229 
Figure A-42: 1H-13C HMBC NMR spectrum of compound RH10 in CD3OD. ............. 229 
Figure A-43: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH11.................. 230 
xxiii 
 
Figure A-44: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH11 (2.9 – 4.1 ppm).
................................................................................................................................................ 230 
Figure A-45: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH11 after acetylation.
................................................................................................................................................ 231 
Figure A-46: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH11. ........ 231 
Figure A-47: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH11.
................................................................................................................................................ 232 
Figure A-48: 1H-13C HSQC NMR spectrum of compound RH11 in CD3OD. .............. 232 
Figure A-49: 1H-13C HMBC NMR spectrum of compound RH11 in CD3OD. ............. 233 
Figure A-50: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH12.................. 233 
Figure A-51: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH12 (2.6 – 4.0 ppm).
................................................................................................................................................ 234 
Figure A-52: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH12 after acetylation.
................................................................................................................................................ 234 
Figure A-53: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH12. ........ 235 
Figure A-54: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH12 after 
acetylation. ............................................................................................................................ 235 
Figure A-55: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH12.
................................................................................................................................................ 236 
Figure A-56: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH12 after 
acetylation. ............................................................................................................................ 236 
Figure A-57: 1H-13C HSQC NMR spectrum of compound RH12 in CD3OD. .............. 237 
Figure A-58: 1H-13C HMBC NMR spectrum of compound RH12 in CD3OD. ............. 237 
Figure A-59: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH13.................. 238 
Figure A-60: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH13 (3.2 – 4.6 ppm).
................................................................................................................................................ 238 
Figure A-61: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH13 after acetylation.
................................................................................................................................................ 239 
Figure A-62: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH13. ........ 239 
Figure A-63: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH13 after 
acetylation. ............................................................................................................................ 240 
Figure A-64: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH13.
................................................................................................................................................ 240 
xxiv 
 
Figure A-65: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH13 after 
acetylation. ............................................................................................................................ 241 
Figure A-66: 1H-13C HSQC NMR spectrum of compound RH13 in CD3OD. .............. 241 
Figure A-67: 1H-13C HMBC NMR spectrum of compound RH13 in CD3OD. ............. 242 
Figure A-68: 1H-1H NOESY NMR (CD3OD, 400 MHz) spectrum of compound RH13.
................................................................................................................................................ 242 
Figure A-69: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH14.................. 243 
Figure A-70:  Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH14 (2.8 – 4.6 
ppm). ...................................................................................................................................... 243 
Figure A-71: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH14. ........ 244 
Figure A-72: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH14.
................................................................................................................................................ 244 
Figure A 73: 1H-13C HSQC NMR spectrum of compound RH14 in CD3OD. .............. 245 
Figure A-74: 1H-13C HMBC NMR spectrum of compound RH14 in CD3OD. ............. 245 
Figure A-75: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH15.................. 246 
Figure A-76: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH15 (2.7 – 3.7 ppm).
................................................................................................................................................ 246 
Figure A-77: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH15. ........ 247 
Figure A-78: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH15.
................................................................................................................................................ 247 
Figure A-79: 1H-13C HSQC NMR spectrum of compound RH15 in CD3OD. .............. 248 
Figure A-80: 1H-13C HMBC NMR spectrum of compound RH15 in CD3OD. ............. 248 
Figure A-81: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH16. ................... 249 
Figure A-82: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH16 (2.5 – 3.8 ppm).
................................................................................................................................................ 249 
Figure A-83: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH16. .......... 250 
Figure A-84: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH16.. 250 
Figure A-85: 1H-13C HSQC NMR spectrum of compound RH16 in CDCl3. ................ 251 
Figure A-86: 1H-13C HMBC NMR spectrum of compound RH16 in CDCl3. ............... 251 
Figure A-87: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH17.................. 252 
Figure A-88: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH17 (2.4 – 3.7 ppm).
................................................................................................................................................ 252 
Figure A-89: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH17.
................................................................................................................................................ 253 
xxv 
 
Figure A-90: 1H-13C HSQC NMR spectrum of compound RH17 in CD3OD. .............. 253 
Figure A-91: 1H-13C HMBC NMR spectrum of compound RH17 in CD3OD. ............. 254 
Figure A-92: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH18.................. 254 
Figure A-93: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH18 (2.4 – 3.7 ppm).
................................................................................................................................................ 255 
Figure A-94: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH18. ........ 255 
Figure A-95: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH18.
................................................................................................................................................ 256 
Figure A-96: 1H-13C HSQC NMR spectrum of compound RH18 in CD3OD. .............. 256 
Figure A-97: 1H-13C HMBC NMR spectrum of compound RH18 in CD3OD. ............. 257 
Figure A-98: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH19.................. 257 
Figure A-99: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH19. ........ 258 
Figure A-100: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH19.
................................................................................................................................................ 258 
Figure A-101: 1H-13C HSQC NMR spectrum of compound RH19 in CD3OD. ............ 259 
Figure A-102: 1H-13C HMBC NMR spectrum of compound RH19 in CD3OD. ........... 259 
Figure A-103: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH20. ................ 260 
Figure A-104: 1H-13C HSQC NMR spectrum of compound RH20 in CDCl3. .............. 260 
Figure A-105: 1H-13C HMBC NMR spectrum of compound RH20 in CDCl3. ............. 261 
Figure A-106: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH21. ................ 261 
Figure A-107: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH21 (2.5 – 3.6 ppm).
................................................................................................................................................ 262 
Figure A-108: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH21......... 262 
Figure A-109: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH21.
................................................................................................................................................ 263 
Figure A-110: 1H-13C HSQC NMR spectrum of compound RH21 in CDCl3. .............. 263 
Figure A-111: 1H-13C HMBC NMR spectrum of compound RH21 in CDCl3. ............. 264 
Figure A-112: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH22. ................ 264 
Figure A-113: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH22 (2.4 – 3.6 ppm).
................................................................................................................................................ 265 
Figure A-114: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH22......... 265 
Figure A-115: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH22.
................................................................................................................................................ 266 
Figure A-116: 1H-13C HSQC NMR spectrum of compound RH22 in CDCl3. .............. 266 
xxvi 
 
Figure A-117: 1H-13C HMBC NMR spectrum of compound RH22 in CDCl3. ............. 267 
Figure A-118: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH23. ................ 267 
Figure A-119: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH23 (2.70-3.85 
ppm). ...................................................................................................................................... 268 
Figure A-120: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH23......... 268 
Figure A-121: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH23.
................................................................................................................................................ 269 
Figure A-122: 1H-13C HSQC NMR spectrum of compound RH23 in CDCl3. .............. 269 
Figure A-123: 1H-13C HMBC NMR spectrum of compound RH23 in CDCl3. ............. 270 
Figure A-124: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH24. .............. 270 
Figure A-125: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH24. ..... 271 
Figure A-126: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH24.
................................................................................................................................................ 271 
Figure A-127: 1H-13C HSQC NMR spectrum of compound RH24 in CD3OD. ............ 272 
Figure A-128: 1H-13C HMBC NMR spectrum of compound RH24 in CD3OD. ........... 272 
Figure A-129: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH25. ................ 273 
Figure A-130: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH25 (2.6 – 4.0 ppm).
................................................................................................................................................ 273 
Figure A-131: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH25......... 274 
Figure A-132: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH26. ................ 274 
Figure A-133: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH26......... 275 
Figure A-134: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH26.
................................................................................................................................................ 275 
Figure A-135: 1H-13C HSQC NMR spectrum of compound RH26 in CDCl3. .............. 276 
Figure A-136: 1H-13C HMBC NMR spectrum of compound RH26 in CDCl3. ............. 276 
Figure A-137: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH27. .............. 277 
Figure A-138: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH27 (2.7 – 3.8 
ppm). ...................................................................................................................................... 277 
Figure A-139: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH27. ..... 278 
Figure A-140: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH27.
................................................................................................................................................ 278 
Figure A-141: 1H-13C HSQC NMR spectrum of compound RH27 in CD3OD. ............ 279 
Figure A-142: 1H-13C HMBC NMR spectrum of compound RH27 in CD3OD. ........... 279 
Figure A-143: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH28. .............. 280 
xxvii 
 
Figure A-144: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH28. ..... 280 
Figure A-145: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH28.
................................................................................................................................................ 281 
Figure A-146: 1H-13C HSQC NMR spectrum of compound RH28 in CD3OD. ............ 281 
Figure A-147: 1H-13C HMBC NMR spectrum of compound RH28 in CD3OD. ........... 282 
Figure A-148: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH29. .............. 282 
Figure A-149: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH29 (2.7 – 3.7 
ppm). ...................................................................................................................................... 283 
Figure A-150: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH29. ..... 283 
Figure A-151: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH29.
................................................................................................................................................ 284 
Figure A-152: 1H-13C HSQC NMR spectrum of compound RH29 in CD3OD. ............ 284 
Figure A-153: 1H-13C HMBC NMR spectrum of compound RH29 in CD3OD. ........... 285 
Figure A-154: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH30. .............. 285 
Figure A-155: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH30 (2.6 – 3.9 
ppm). ...................................................................................................................................... 286 
Figure A-156: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH30. ..... 286 
Figure A-157: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH30.
................................................................................................................................................ 287 
Figure A-158: 1H-13C HSQC NMR spectrum of compound RH30 in CD3OD. ............ 287 
Figure A-159: 1H-13C HMBC NMR spectrum of compound RH30 in CD3OD. ........... 288 
Figure A-160: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH31. .............. 288 
Figure A-161: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH31 (3.1 – 3.9 
ppm). ...................................................................................................................................... 289 
Figure A-162: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH31. ..... 289 
Figure A-163: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH31.
................................................................................................................................................ 290 
Figure A-164: 1H-13C HSQC NMR spectrum of compound RH31 in CD3OD. ............ 290 
Figure A-165: 1H-13C HMBC NMR spectrum of compound RH31 in CD3OD. ........... 291 
Figure A-166: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH32. .............. 291 
Figure A-167: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH32 (3.1 – 4.4 
ppm). ...................................................................................................................................... 292 
Figure A-168: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH32. ..... 292 
Figure A-169: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH33. .............. 293 
xxviii 
 
Figure A-170: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH33 (3.1 – 3.9 
ppm). ...................................................................................................................................... 293 
Figure A-171: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH33. ..... 294 
Figure A-172: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH33.
................................................................................................................................................ 294 
Figure A-173: 1H-13C HSQC NMR spectrum of compound RH33 in CD3OD. ............ 295 
Figure A-174: 1H-13C HMBC NMR spectrum of compound RH33 in CD3OD. ........... 295 
Figure A-175: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH34. .............. 296 
Figure A-176: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH34 (2.7 – 4.2 
ppm). ...................................................................................................................................... 296 
Figure A-177: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH34. ..... 297 
Figure A-178: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH34.
................................................................................................................................................ 297 
Figure A-179: 1H-13C HSQC NMR spectrum of compound RH34 in CD3OD. ............ 298 
Figure A-180: 1H-13C HMBC NMR spectrum of compound RH34 in CD3OD. ........... 298 
Figure A-181: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH35. .............. 299 
Figure A-182: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH35 (3.2 – 3.8 
ppm). ...................................................................................................................................... 299 
Figure A-183: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH35. ..... 300 
Figure A-184: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH35.
................................................................................................................................................ 300 
Figure A-185: 1H-13C HSQC NMR spectrum of compound RH35 in CD3OD. ............ 301 
Figure A-186: 1H-13C HMBC NMR spectrum of compound RH35 in CD3OD. ........... 301 
Figure A-187: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH36. .............. 302 
Figure A-188: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH36. ..... 302 
Figure A-189: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH37. .............. 303 
Figure A-190: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH37 (0.4 – 2.8 
ppm). ...................................................................................................................................... 303 
Figure A-191: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH37 (3.2 – 4.6 
ppm). ...................................................................................................................................... 304 
Figure A-192: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH37. ..... 304 
Figure A-193: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH37.
................................................................................................................................................ 305 
Figure A-194: 1H-13C HSQC NMR spectrum of compound RH37 in CD3OD. ............ 305 
xxix 
 
Figure A-195: 1H-13C HMBC NMR spectrum of compound RH37 in CD3OD. ........... 306 
Figure A-196: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH38. ................ 306 
Figure A-197: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH38 (0.8 – 3.1 ppm).
................................................................................................................................................ 307 
Figure A-198: 13C NMR (CDCl3, 100 MHz) spectrum of compound RH38. ............... 307 
Figure A-199: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH38.
................................................................................................................................................ 308 
Figure A-200: 1H-13C HSQC NMR spectrum of compound RH38 in CDCl3. .............. 308 
Figure A-201: 1H-13C HSQC-TOCSY NMR spectrum of compound RH38 in CDCl3.
................................................................................................................................................ 309 
Figure A-202: 1H-13C HMBC NMR spectrum of compound RH38 in CDCl3. ............. 309 
Figure A-203: FT-ICR-MS spectrum of compound RH3 in [M+H]+ positive ion mode ... 310 
Figure A-204: FT-ICR-MS spectrum of compound RH4 in [M-H]- negative ion mode. .. 310 
Figure A-205: FT-ICR-MS spectrum of compound RH5 in [M+H]+ positive ion mode. .. 310 
Figure A-206: FT-ICR-MS spectrum of compound RH6 in [M+H]+ positive ion mode. .. 311 
Figure A-207: FT-ICR-MS spectrum of compound RH7 in [M+H]+ positive ion mode. .. 311 
Figure A-208: FT-ICR-MS spectrum of compound RH8 in [M+H]+ positive ion mode. .. 311 
Figure A-209: FT-ICR-MS spectrum of compound RH9 in [M-H]- negative ion mode. .. 312 
Figure A-210: FT-ICR-MS spectrum of compound RH10 in [M+H]+ positive ion mode.
................................................................................................................................................ 312 
Figure A-211: FT-ICR-MS spectrum of compound RH11 in [M+H]+ positive ion mode.
................................................................................................................................................ 312 
Figure A-212: FT-ICR-MS spectrum of compound RH12 in [M-H]- negative ion mode.
................................................................................................................................................ 313 
Figure A-213: FT-ICR-MS spectrum of compound RH13 in [M-H]- negative ion mode.
................................................................................................................................................ 313 
Figure A-214: HR-ESI-MS spectrum of compound RH14 in [M+H]+ positive ion mode.
................................................................................................................................................ 313 
Figure A-215: HR-ESI-MS spectrum of compound RH15 in [M+H]+ positive ion mode.
................................................................................................................................................ 314 
Figure A-216: HR-ESI-MS spectrum of compound RH16 in [M+H]+ positive ion mode.
................................................................................................................................................ 314 
Figure A-217: HR-ESI-MS spectrum of compound RH17 in [M+H]+ positive ion mode.
................................................................................................................................................ 314 
xxx 
 
Figure A-218: HR-ESI-MS spectrum of compound RH18 in [M+H]+ positive ion mode.
................................................................................................................................................ 315 
Figure A-219: HR-ESI-MS spectrum of compound RH19 in [M+H]+ positive ion mode.
................................................................................................................................................ 315 
Figure A-220: HR-ESI-MS spectrum of compound RH20 in [M-H]- negative ion mode.
................................................................................................................................................ 315 
Figure A-221: HR-ESI-MS spectrum of compound RH21 in [M+H]+ positive ion mode.
................................................................................................................................................ 316 
Figure A-222: HR-ESI-MS spectrum of compound RH22 in [M+H]+ positive ion mode.
................................................................................................................................................ 316 
Figure A-223: HR-ESI-MS spectrum of compound RH23 in [M+H]+ positive ion mode.
................................................................................................................................................ 316 
Figure A-224: HR-ESI-MS spectrum of compound RH24 in [M+H]+ positive ion mode.
................................................................................................................................................ 317 
Figure A-225: HR-ESI-MS spectrum of compound RH25 in [M+H]+ positive ion mode.
................................................................................................................................................ 317 
Figure A-226: HR-ESI-MS spectrum of compound RH26 in [M+H]+ positive ion mode.
................................................................................................................................................ 317 
Figure A-227: HR-ESI-MS spectrum of compound RH27 in [M-H]- negative ion mode.
................................................................................................................................................ 318 
Figure A-228: HR-ESI-MS spectrum of compound RH28 in [M-H]- negative ion mode.
................................................................................................................................................ 318 
Figure A-229: HR-ESI-MS spectrum of compound RH29 in [M+H]+ positive ion mode.
................................................................................................................................................ 318 
Figure A-230: HR-ESI-MS spectrum of compound RH30 in [M+H]+ positive ion mode.
................................................................................................................................................ 319 
Figure A-231: HR-ESI-MS spectrum of compound RH31 in [M+H]+ positive ion mode.
................................................................................................................................................ 319 
Figure A-232: HR-ESI-MS spectrum of compound RH32 in [M+H]+ positive ion mode.
................................................................................................................................................ 319 
Figure A-233: HR-ESI-MS spectrum of compound RH33 in [M+H]+ positive ion mode.
................................................................................................................................................ 320 
Figure A-234: HR-ESI-MS spectrum of compound RH34 in [M+H]+ positive ion mode.
................................................................................................................................................ 320 
xxxi 
 
Figure A-235: HR-ESI-MS spectrum of compound RH35 in [M+H]+ positive ion mode.
................................................................................................................................................ 320 
Figure A-236: HR-ESI-MS spectrum of compound RH36 in [M+H]+ positive ion mode.
................................................................................................................................................ 321 
Figure A-237: HR-ESI-MS spectrum of compound RH37 in [M-H]- negative ion mode.
................................................................................................................................................ 321 
Figure A-238: HR-ESI-MS spectrum of compound RH38 in [M-H]- negative ion mode.
................................................................................................................................................ 321 
Figure A-239: FT-IR spectrum of compound RH2 in CH3OH. ...................................... 322 
Figure A-240: FT-IR spectrum of compound RH3 in CHCl3. ........................................ 323 
Figure A-241: FT-IR spectrum of compound RH4 in CH3OH. ...................................... 324 
Figure A-242: FT-IR spectrum of compound RH5 in CHCl3. ........................................ 325 
Figure A-243: FT-IR spectrum of compound RH6 in CH3OH. ...................................... 326 
Figure A-244: FT-IR spectrum of compound RH7 in CHCl3. ........................................ 327 
Figure A-245: FT-IR spectrum of compound RH8 in CH3OH. ...................................... 328 
Figure A-246: FT-IR spectrum of compound RH9 in CH3OH. ...................................... 329 
Figure A-247: FT-IR spectrum of compound RH10 in CH3OH. ................................... 330 
Figure A-248: FT-IR spectrum of compound RH11 in CH3OH. ................................... 331 
Figure A-249: FT-IR spectrum of compound RH12 in CH3OH. ................................... 332 
Figure A-250: FT-IR spectrum of compound RH13 in CH3OH. ................................... 333 
Figure A-251: UV spectrum of compound RH2 in CH3OH. .......................................... 334 
Figure A-252: UV spectrum of compound RH3 in CH3OH. .......................................... 334 
Figure A-253: UV spectrum of compound RH4 in CH3OH. .......................................... 335 
Figure A-254: UV spectrum of compound RH5 in CH3OH. .......................................... 335 
Figure A-255: UV spectrum of compound RH6 in CH3OH. .......................................... 336 
Figure A-256: UV spectrum of compound RH7 in CH3OH. .......................................... 336 
Figure A-257: UV spectrum of compound RH8 in CH3OH. .......................................... 337 
Figure A-258: UV spectrum of compound RH9 in CH3OH. .......................................... 337 
Figure A-259: UV spectrum of compound RH10 in CH3OH. ........................................ 338 
Figure A-260: UV spectrum of compound RH11 in CH3OH. ........................................ 338 
Figure A-261: UV spectrum of compound RH12 in CH3OH. ........................................ 339 
Figure A-262: UV spectrum of compound RH13 in CH3OH. ........................................ 339 
  
xxxii 
 
Abbreviations and Acronyms 
ACN  Acetonitrile  
amu Atomic mass unit 
CC Column chromatography 
CD Circular dichroism 
COSY  Correlation spectroscopy 
d doublet 
dd doublet of doublet 
Da Dalton 
DAD Diode array detector 
DEPTQ  Distortionless enhancement by polarisation transfer 
DW Dry weight  
ELSD Evaporative light scattering detector  
EtOAc Ethyl acetate 
Et2O Diethyl ether 
FA Formic acid 
FC Flash chromatography  
FT-ICR-MS Fourier transform ion cyclotron resonance mass spectroscopy 
FT-IR Fourier transform infrared 
FW Fresh weight  
GLUT  Glucose transporter 
h hours 
HR-ESI-MS High resolution electrospray ionisation mass spectroscopy 
IR Infrared 
J  Coupling constant 
EC50 Half maximal effective concentration 
HPLC High performance liquid chromatography 
HMBC  Heteronuclear multiple-bond correlation 
HSQC  Heteronuclear single quantum correlation 
HSQC-TOCSY  Heteronuclear single quantum coherence - Total correlation 
spectroscopy 
Hz Hertz 
xxxiii 
 
LOD Limit of detection 
LOQ Limit of quantification 
Me Methyl 
MHz MegaHertz 
min minutes 
mL millilitres 
MIC Minimum inhibitory concentration 
MeOH  Methanol  
MRSA Methicillin-resistant staphylococcus aureus 
MWt Molecular weight 
MS Mass spectroscopy 
NOESY Nuclear overhauser effect spectroscopy 
NMR Nuclear magnetic resonance 
ºC Degrees Celsius 
P. aquilinum  Pteridium aquilinum 
ppm part per million 
q quartet 
r Correlation coefficient 
Rf Retention factor 
RP Reverse phase 
RRt Relative retention time 
rpm Revolutions per minute  
RSD Relative standard deviation 
s singlet  
Subsp. Subspecies 
SEM Standard error of the mean 
SGLT Sodium-dependent glucose transporter 
SPE Solid phase extraction 
t triplet  
TIC Total ion current 
TLC  Thin layer chromatography 
TMS Tetramethylsilane 
UV  Ultraviolet 
 
xxxiv 
 
Abstract 
An intensive study was undertaken in order to isolate and identify bioactive compounds in 
bracken, Pteridium aquilinum (L.) Kuhn (Dennstaedtiaceae). A systematic phytochemical 
investigations of the underground rhizomes of this plant afforded thirty-five pterosins and 
pterosides along with the main carcinogen in bracken, ptaquiloside, 5-hydroxyisocalamene and 
5-(β-hydroxy)ethyl-2, 2, 4, 6-tetramethyl-1, 3-indandione. By detailed analysis of one- and 
two-dimensional nuclear magnetic resonance spectroscopy, circular dichroism and high-
resolution mass spectrometric data, thirteen previously undescribed pterosins and pterosides 
have been identified. Interestingly, for the first time 12-O-β-D-glucopyranoside substituted 
pterosins, rhedynosides C and D, and the sulfate-containing pterosin, rhedynosin H, alongside 
the two known compounds, trans-histiopterosin A and (2S)-pteroside A2, were isolated from 
the rhizomes of subsp. aquilinum of bracken. In addition, the six-membered cyclic ether 
pterosins and pterosides rhedynosin A and rhedynoside A are the first examples of this type of 
pterosin-sesquiterpenoids. Additionally, the three previously reported compounds [(2S)-
rhedynosin I, (2S)-2-hydroxymethylpterosin E and (2S)-12-hydroxypterosin A] were obtained 
for the first time from plant source as opposed to mammalian metabolic products. Single crystal 
X-ray diffraction analysis was applied to the previously undescribed compounds (2R)-
rhedynoside B, (2R)-pteroside B and (2S)-pteroside K, yielding the first crystal structures for 
pterosides, and three known pterosins, (2S)-pterosin A, trans-pterosin C and cis-pterosin C. 
Rhedynosin C is the only example of the cyclic lactone pterosin with a keto group at position 
C-14. Six selected pterosins ((2S)-pterosin A, (2R)-pterosin B and trans-pterosin C) and 
associated glycosides ((2S)-pteroside A, (2R)-pteroside B and pteroside Z) were assessed for 
their anti-diabetic activity using an intestinal glucose uptake assay; all were found to be inactive 
at 300 µM. 
A simple, reproducible and rapid reverse phase high performance liquid chromatography 
(RP-HPLC) method was developed which was linked to the UV detection source. The 
method validated for quantification of pterosin B and pteroside B in different plant 
matrices, soil and water samples. A new solid phase extraction (SPE) method was 
developed and established for sample preparation based on using 500 mg Supelco-SPE 
cartridges. The RP-HPLC was performed with mobile phase containing 0.1% formic acid 
(FA) in water and 0.1% FA in acetonitrile with an appropriate gradient and a flow rate of 
1 mL/min. Detection of the analyte peaks was performed at 254 nm. The method showed 
xxxv 
 
good linearity (correlation coefficient (r) > 0.99), and appropriate limit of detection 
(LOD) and limit of quantification (LOQ). The proposed RP-HPLC-UV method has a 
retention time of 20 min (3 samples/h).  
Overall, this work focuses on the application of SPE–HPLC-UV analysis to quantify pterosin 
B and pteroside B in different matrices including soil, water and bracken samples. The method 
involves pre-concentration and clean-up by SPE cartridges. Final analysis of the selected 
compounds was carried out by the developed HPLC-UV method.  
The extraction efficiency was checked by recovery experiment while the accuracy of the 
method was tested by relative standard deviation (% RSD). Recoveries were ranged from 90.29 
to 96.23 % (pterosin B) and 93.64 to 101.03 % (pteroside B). The RSD (%) for both target 
analytes (pterosin B and pteroside B) was less than 2.5 % for all the analysed bracken stem 
samples. Preliminary results demonstrated that the present method was suitable for 
determination of pterosin B and pteroside B in bracken tissues, soil and water samples.  
The simplicity, accuracy and sensitivity of the developed SPE-HPLC-UV method, 
recommending that the method is also convenient and useful for quick check and 
detection of trace amounts of pterosin B and pteroside B in water, soil and plant samples. 
The quantification of pterosin B and pteroside B was applied to bracken, divided into 
rhizomes, stems and fronds, the top soil of the sample cores and a set of water samples. The 
rhizome contained the largest concentration of pteroside B through the completed bracken 
growth period (750-2950 mg/kg). Its concentration was approximately one order of magnitude 
above pterosin B (10-245 mg/kg). The above ground stems and fronds showed distinct 
increases in concentrations of pterosin B (ca. 500 mg/kg) and pteroside B (ca. 250 mg/kg) at 
the time of crosier emergence, that were about one order of magnitude higher than the other 
samples collected during the growth periods. The soil sampled reflected the increased 
mobilisation of pterosin B during the onset of above ground growth (May to June) while no 
pteroside B was detected. The absolute pterosin B concentrations determined were about three 
orders of magnitudes lower (0.02-0.3 mg/kg). Water samples that drain bracken covered areas 
were found to contain pterosin B between 9-47 ng/L and pteroside B in range of 16-85 ng/L. 
Overall, the seasonal variation of pterosin B and pteroside B showed that the compounds are 
stored in the rhizome, preferably as the glycoside, and are mobilised to protect the early tissue 
as a means of chemical defence. The stability of pterosin B was exemplified by its 
environmental presence in plant, soil and water.
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CHAPTER ONE 
BRACKEN 
1. INTRODUCTION 
1.1. BRACKEN (PTERIDIUM AQUILINUM) 
The term ‘bracken’ is used as a common name for the four Pteridium species (P. aquilinum, P. 
caudatum, P. esculentum and P. semihastatum) belonging to the Dennstaedtiaceae family 
(Marrs and Watt, 2006; Rasmussen et al., 2015). This is in agreement with Thomson’s revision 
which classifies bracken into four species: a) the most dominant northern hemisphere P. 
aquilinum comprising eleven subspecies (latiusculum, lanuginosum, pseudocaudatum, feei, 
japonicum, decompositum, wightianum, aquilinum, pinetorum, capense, centrali-africanum); 
b) P. esculentum, predominates mostly in the Southern hemisphere, consisting of two 
subspecies (arachnoideum and esculentum); c) P. caudatum of Central and South America and 
d) P. semihastatum of South-East Asia and Australia (Marrs and Watt, 2006; Thomson and 
Alonso-Amelot, 2002; Thomson, 2008). However, Tryon’s review concluded that bracken fern 
is a single species Pteridium aquilinum including two main subspecies, subsp. aquilinum and 
subsp. caudatum, with twelve varieties between the two subspecies (Marrs and Watt, 2006; 
Tryon, 1941). In Britain two species of bracken, P. aquilinum subsp. aquilinum and P. 
aquilinum subsp. pinetorum, are recorded. The vast majority of bracken in Britain is made up 
by the former while the latter (the second subspecies) has only been found in a local area near 
Aviemore, Scotland’s Highland region (Marrs and Watt, 2006). P. aquilinum is usually 
represented by P. aquilinum (L.) Kuhn with three different subspecies: aquilinum, atlanticum 
and fulvum (Page and Mill, 1995). Throughout the thesis the word bracken is used for P. 
aquilinum. The general life cycle of bracken fern (Pteridium) is illustrated in Figure 1 (Marrs 
and Watt, 2006). 
In Britain, bracken fronds start to emerge in late spring (mid-May) and they become mature in 
late summer (late August to early September). Bracken fronds are usually getting premature 
senescence in autumn (October to November). Sporulation might be initiated by the end of 
July. Sporulation is a complicated process as in all parts of Britain bracken is not producing 
spores every year (Marrs and Watt, 2006; Rasmussen et al., 2013). The only factors that inhibit 
bracken growth and its distribution are severe conditions, such as extremely high temperature 
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and lack of moisture  or waterlogging (Smith and Seawright, 1995). Bracken is mostly found 
on moderately acidic soils in Britain (Marrs and Watt, 2006; Rasmussen et al., 2015).  
 
Figure 1: Generalized life cycle of bracken fern, Pteridium. 
(a) Lower surface of a fertile leaf (pinnulet1); (b) Mature sporangium2 before and after 
release of spores; (c) Spore; (d) Germinated spore; (e, f) Smaller young prothallus 3 with 
antheridia4; (g, h) Larger, older prothallus bearing archegonia5; (i) Spermatozoids6 
released from the antheridia move towards the mature egg cell ; (j) Developing 
sporeling7; (k) The adult sporophyte8 does not become fertile (l) before 3-4 years of age 
(Marrs and Watt, 2006).  
 
                                                          
1 A secondary division of a pinnate leaf, especially of a fern.  
2 A receptacle in which asexual spores are formed. 
3 The gametophyte of ferns and other primitive plants.  
4 The male sex organ of ferns and other nonflowering plants. 
5 The female sex organ in bracken ferns. 
6 A motile male gamete produced by ferns. 
7 A young plant produced by a germinated spore. 
8 The asexual phase of the frond of a fern, producing spores from which the gametophyte arises 
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Globally, bracken (Pteridium aquilinum (L.) Kuhn) is one of the most widely distributed 
vascular plant species to date. In the United Kingdom, P. aquilinum subsp. aquilinum 
comprises the majority of bracken with a dense coverage estimated at 1.5-1.7 million hectares, 
which is equivalent to approximately 7% of the land surface in the UK, including sparse 
bracken (Pakeman et al., 1996; Robinson, 2009). This corresponds to 1.1 - 5 Gigatonne of plant 
material above ground and 5 - 20 Gigatonne of rhizome biomass [dry weight, calculated from 
data in (Marrs and Watt, 2006)]. 
In addition, bracken coverage is increasing annually by 1-3% in the UK (Rasmussen et al., 
2003b). A higher frond biomass (> 1000 g/m2) of subsp. aquilinum has been recorded in Britain 
in comparison with the Northern European countries, e.g. in Denmark the annual frond biomass 
reaches up to 460 g/m2 (Marrs and Watt, 2006; Rasmussen et al., 2015, 2003b). Bracken fern 
is a ubiquitous plant and has the ability to start growing in forests and pastures all over the 
world (Fletcher et al., 2011). A change in methods of land management caused the apparent 
spread of bracken over the last 200 years in Great Britain. For instance, as a result of less 
demand in the use of bracken fern for a variety of purposes within the rural economy, bracken 
has spread (Marrs and Watt, 2006). Bracken rhizomes are located about 10 to 20 cm deep under 
the earth so they are protected against fire and frost. Bracken is an invasive species that can 
produce leaves even on burnt areas quickly. Because of its high canopy, it shadows out the 
surrounding areas and consequently reduces access to light for the other competitors or adjacent 
vegetation. Additionally, it is capable of suppressing the growth of other plants in the nearby 
vicinity by releasing allelopathic phytotoxins or secondary metabolites (Madeja et al., 2009).  
1.2. ALTITUDINAL AND GEOGRAPHICAL DISTRIBUTION 
Bracken, as described by Page in 1976, is the most widely distributed of the Pteridophytes. 
Bracken is a cosmopolitan genus (Madeja et al., 2009) and considered as one of the five most 
abundant plants on the earth (Shahin et al., 1999). It is described as a carcinogenic species (Gil 
da Costa et al., 2012). It has a global range as it occurs on all continents except at high altitudes, 
in desert regions and in Antarctica (Marrs and Watt, 2006; Page, 1976). Figure 2 mapped by 
H.R. Arnold shows the wide distribution of bracken in the British Isles. Bracken also has a 
widespread distribution in Europe which is illustrated in Figure 3 (Jermy et al., 1978; Marrs 
and Watt, 2006). 
Bracken essentially remains in a temperate environment and occurs from sea level to over 3000 
m, and at increasing altitude at lower latitudes. In the UK, the reported altitudinal limit for 
bracken is about 600 m (Marrs and Watt, 2006; Pearman and Corner, 2004).  
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Figure 2: The distribution of bracken (P. aquilinum) in the British Isles. Each dot 
represents at least one record in a 10 km2 of the British National Grid: (○) pre-1950, (•) 
1950 onwards (Marrs and Watt, 2006). 
 
Figure 3: The European distribution of bracken (P. aquilinum) (•) on a 50 km2 basis 
(Marrs and Watt, 2006). 
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1.3. HISTORICAL USES 
Historically, bracken has been used for many purposes by mankind, including thatch roofing, 
animal bedding and soap production. Bracken ash was mixed with oil to make soaps and 
washing detergents. Potash was obtained by lixiviating bracken ashes after evaporating the 
solvent (water). It is a very rich source of potassium carbonate, hence, it was used in the 
manufacturing of soap, glass and bleaching. Moreover, people used bracken rhizomes for 
culinary purposes as an alternative food during shortages, because bracken rhizomes contain 
about 60% starch and were also used as a source of starch (Madeja et al., 2009; Rymer, 1976). 
Bracken has long been recognised for its potential pharmaceutical uses and its toxicity. 
Furthermore, bracken has been used medicinally as an anthelminthic agent (Marrs and Watt, 
2006).  
In many parts of the world, bracken rhizomes were dried and milled in the past and then mixed 
with flour to bake bread (Pieroni, 2005), particularly during famines, for example, in France 
during periods of war. In Great Britain, poor people used fern roots as a source of food to make 
bread. In Wales, the chopped dried fronds and rhizomes of bracken were mixed with hay and 
then given to animals pulling trams (horses and mules) as fodder in winter (Madeja et al., 2009; 
Rymer, 1976). Bracken was used as a human food in Scotland during the First World War 
(Fenwick, 1988). Up to the 1930s, a kind of porridge (called gofio) was prepared in the Canary 
Isles by mixing ground rhizomes with barley meal (Pieroni, 2005). 
In Asia, mainly Japan and Korea, where bracken is part of the diet, an archaic method is used 
to get rid of the toxic compounds present in bracken crosiers. In this method, young shoots of 
bracken, with addition of ash, are soaked in water for a day, then boiled and afterwards served 
and consumed as a vegetable or as a soup (Madeja et al., 2009; Pieroni, 2005). A kind of beer 
has been produced from bracken fern shoots by native peoples in North America and Siberia. 
Shepherds in the Mediterranean frequently use bracken leaves to filter sheep’s milk and to store 
freshly made ricotta cheese (unsalted Italian cheese) (Pieroni, 2005).    
In Brazil, Canada and Japan, bracken crosiers are known as broto de samambaia, as 
“fiddleheads”, and as warabi, respectively, where populations use crosiers as a delicacy (Gil 
da Costa et al., 2012). People used bracken fern commercially in Canada, China, Siberia, parts 
of the USA and Japan as a food or herbal remedy. During the 1970s, the annual consumption 
of bracken in Tokyo was 300 tonnes, also Hirono (1986) stated that 13000 tonnes / year of 
bracken fern in salted form is imported into Japan (Fenwick, 1988).  
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In the middle of the 15th century, dried and powdered bracken rhizomes were used in folk 
medicine due to their chemical properties. The drug was prepared and administered by 
dissolving the powder in wine or honeyed water. It was known for its anti-parasitic and anti-
ascaris properties because of its ability to kill small intestinal ascaris roundworms in the body 
(Madeja et al., 2009). Another use of bracken was that a mixture was made of residue of burnt 
bracken leaves (cinder) and a small quantity of olive oil which was used as a treatment for 
livestock by applying it to bite wounds caused by wolves (Guarrera et al., 2005).  
Composted bracken can provide an extremely useful peat alternative for horticultural uses 
(Pitman and Webber, 2013) and is still used nowadays in the United Kingdom for this purpose 
(Gil da Costa et al., 2012; Sanderson and Prendergast, 2002). It has been reported that 
composting is effective in destroying toxins in bracken, especially ptaquiloside (Gil da Costa 
et al., 2012). For example, during 1992-1993 about 1500 cubic meters of bracken were 
composted and the quantity doubled in the following year (Gil da Costa et al., 2012; Potter and 
R.M. Pitman, 1994). The maximum bracken biomass reported was 11.12 tonnes wet weight 
per hectare. The global increase of land covered with bracken potentially raises the contact of 
bracken with both human society and domestic animals (Smith et al., 1994). As a consequence, 
it is thought that bracken toxicity passing into ruminants may affect human populations as well 
(Gil da Costa et al., 2012). 
1.4. HUMAN AND PUBLIC HEALTH RISKS 
Bracken fern (Pteridium) is a well-recognized vascular plant that can cause a variety of severe 
health issues in animals (Alonso-Amelot and Avendaño, 2001; Fenwick, 1988). There are only 
a few other higher plants as well-known as bracken to cause cancer naturally in vertebrates 
(Shahin et al., 1999). Studies on the carcinogenic nature of bracken fern have recently been 
undertaken (Galpin et al., 1990; Wilson et al., 1998). The lethal properties of bracken for cattle 
were reported for the first time at the end of 19th century and its carcinogenicity was discovered 
in 1960 (Kigoshi et al., 1989). Poisoning of animals such as caprine, bovine and equine 
livestock by bracken has long been recorded  and is known as “bracken poisoning” (Alonso-
Amelot and Avendano, 2002). A water soluble norsesquiterpene glycoside ptaquiloside, is the 
major carcinogen in bracken (Smith and Seawright, 1995). Phytochemical studies of bracken 
are most often concerned with ptaquiloside, because of its established carcinogenicity 
(Fenwick, 1988; Hirono, 1986). Significant health concerns have been raised for both human 
populations and grazing domestic animals and have been linked with bracken fern (Pteridium 
genus) due to the presence of ptaquiloside (Fletcher et al., 2011). 
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In the absence of alternative nutritious feed, young bracken fern will readily be consumed by 
domestic herbivores and pigs as the juvenile parts are soft and easy to cut effortlessly. 
Depending on the age and species of the animals, bracken availability (quantity and quality) 
and the duration and rate of consumption, a number of disease syndromes might occur in 
animals. Acute bracken poisoning happens frequently in livestock, particularly in cattle, and to 
a smaller extent in sheep as a result of the toxic substances in bracken which usually target the 
faster dividing animal cells (Shahin et al., 1999). It has been researched and demonstrated that 
direct consumption of bracken fern by cattle causes diseases such as bovine enzootic 
haematuria (Rasmussen et al., 2015; Somvanshi et al., 2006).  
Most toxic compounds are accumulated in fronds and crosiers which are preferred by grazing 
animals (McGlone et al., 2005; Rasmussen et al., 2003b). There is a probability that both 
animals and people may be affected and suffer from diseases caused by direct or indirect 
exposure to bracken (Alonso-Amelot and Avendaño, 2001). This fact was confirmed by Agnew 
and Lauren (1991) and Fletcher et al. (2011) who stated that considerable health problems for 
both humans and grazing domestic livestock are associated with bracken fern around the globe. 
Consequently, numerous governmental reports have been published concerning the protection 
of the public health against bracken toxins. For example, the British Committee9 on Toxicity 
of Chemicals in Food, Consumer Products and the Environment (COT), has recently addressed 
the risks of contaminated food products with ptaquiloside, in particular the milk of farm 
animals (Attya et al., 2012; Gil da Costa et al., 2012). Ptaquiloside was identified in both the 
milk and the meat of domestic animals which fed on a substantial portion of bracken (D’Mello, 
1997; Francesco et al., 2011). Alonso-Amelot et al. reported that approximately 8.6 ± 1.16 % 
of the total amount of ptaquiloside ingested by cows is effectively excreted into milk (Alonso-
Amelot et al., 1998; Rasmussen et al., 2003b). It is important and necessary to recognise 
bracken as a carcinogenic plant at all stages of ingestion (Gil da Costa et al., 2012). As bracken 
contains high amounts of ptaquiloside, care should be taken to avoid farm animals accessing 
territories covered by bracken and consequently protecting them from grazing on emerging 
toxic crosiers (Rasmussen et al., 2015). 
Epidemiological studies showed a positive correlation between the occurrence of stomach 
cancer and exposure to bracken in rural areas of North Wales (Galpin et al., 1990; Rasmussen 
                                                          
9 It is an independent scientific committee that provides advice to the Food Standards Agency, the Department of 
Health and other Government Departments and Agencies on matters concerning the toxicity of chemicals. 
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et al., 2003b) and Costa Rica (Smith and Seawright, 1995), especially between people who 
spent their childhood in bracken-infested areas.  
It has been evaluated that the rate of gastric cancer is directly increased in areas where bracken 
is consumed (relative risk or risk ratio of 2.34). In other regions, where bracken is not eaten 
directly by people, a lower figure of gastric cancer rate was recorded (relative risk of 2.09) 
(Alonso-Amelot and Avendaño, 2001; Galpin et al., 1990; Hirono et al., 1972). Because of this 
observation, milk has been suggested as the carrier (Bonadies et al., 2004) as it has been 
reported that ptaquiloside is not destroyed completely after heating or cooking or by 
pasteurisation  (Attya et al., 2012) and remains as a chemical residue in agricultural products. 
It has also been noticed that ptaquiloside withstands eighty degree centigrade for three hours 
(Smith and Seawright, 1995). However, concentrations of ptaquiloside in milk have been 
shown to decrease by pasteurisation (50%) and by boiling (75%). Based on these findings, rural 
populations, who are suspected of being exposed to considerable amounts of ptaquiloside, are 
advised to boil milk before drinking it (Gil da Costa et al., 2012; Oliveira, 2012; Tourchi-
Roudsari, 2014). 
Human populations in the world are exposed to bracken carcinogenicity via multiple sources 
(Gil da Costa et al., 2012): Either eating bracken as a traditional dish (directly), or indirectly 
through water, animal products (meat and milk derived from bracken fed cows), inhalation and 
ingestion of bracken spores, and insect vectors (Wilson et al., 1998).  
As a connection between human health and ptaquiloside, ptaquiloside has long been suspected 
to lead to neoplasia in humans (i.e. formation of new abnormal growth tissues), either directly 
via bracken consumption or indirectly from secondary sources through environmental 
contamination. For instance, ptaquiloside was detected in the surface-water, groundwater and 
soils in areas where bracken is dominant (Fletcher et al., 2011; Yamada et al., 2007).  In high 
bracken coverage countries, in particular Venezuela, a considerable increase (high percentage) 
of human gastric cancer has been identified in bracken-rich areas (Alonso-Amelot and 
Avendaño, 2001), and it is thought that the reason behind this is ptaquiloside which comes 
from spores during sporulation every year. The assumption being that the spores might be 
inhaled and also lead to contamination of soil and surface water (Wynn et al., 2000). Moreover, 
Evans and Galpin (1990) investigated that there is a link between spores and occurrence of 
leukaemia as they stated that ‘‘the sporulation of bracken is regional and influenced by several 
factors, but one good sized frond can yield 1.0 g of the brown powder, enough to produce 
leukaemias in 5 susceptible mice’’.  
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The potential risks of bracken to public health have been recognised since Evans and Mason’s 
experiment in 1965 indicated the carcinogenicity of bracken as it showed the development of 
cancer (adenocarcinoma of the mucosa) in rats which had been fed bracken (Hirono et al., 
1984a, 1983). Also, Pamukcu and coworkers demonstrated that the bracken carcinogen is 
excreted in the milk and urine of cows had been fed bracken and not present in the milk of 
cows which did not have access to bracken in their diet (Pamukcu et al., 1978). 
Ptaquiloside readily alkylates the DNA in animals (Ojika et al., 1987) and this causes the 
carcinogenic behaviour of ptaquiloside (Prakash et al., 1996). According to recent findings, 
ptaquiloside was detected indirectly by using HPLC-UV method in liver (up to 0.75 µg/g), 
kidney (up to 1.16 µg/g) and skeletal and cardiac muscles (<0.2 µg/gm) of livestock, in 
particular calves, 15 days after bracken consumption ended (Fletcher et al., 2011; Gil da Costa 
et al., 2012).  
As stated by the International Agency for Research on Cancer (IARC), bracken is categorized 
as a cancer-causing plant to animals and probably carcinogenic to people. The Dutch 
government believed that ptaquiloside should be deemed as a carcinogenic compound to 
human society (Gil da Costa et al., 2012). 
Due to its carcinogenic influences on mammals, such as humans, ptaquiloside caused 
environmental concerns (D’Mello, 1997). The carcinogenic function of ptaquiloside and its 
responsibility for tumours in the urinary bladder in cows has been shown in laboratory 
experiments (Attya et al., 2012). Hence, a significant concern has been raised for humans due 
to the existence of ptaquiloside in secondary products such as milk and honey (Ferguson and 
Philpott, 2008). Figure 4 shows the possible pathways of the human and environmental 
exposure to ptaquiloside (Oliveira, 2012).  
There is a theoretical risk that bracken spores cause carcinogenicity in humans after inhalation 
and subsequent ingestion by people as spores have already been demonstrated to be 
carcinogenic in mice. The aerial spreading of the bracken spores and their inhalation is 
considered as another potential route for transfer of bracken carcinogen to human populations 
(Shahin et al., 1999). But apart from direct ingestion of spores, there have been no studies on 
the exposure of animals to air-borne spores (Wilson et al., 1998). A spatial relationship between 
bracken and cancer has also been studied in England and Wales (Shahin et al., 1999). 
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Figure 4: How ptaquiloside is exposed to the environment and human. 
1.5. THE CHEMISTRY OF BRACKEN 
Studies on the chemistry of bracken have commonly been concentrated on the concern of 
‘bracken poisoning’ to livestock, bracken control and management as an unfavourable weed or 
its use as food and subsequent poisonous impacts on humans and animals. However, there have 
been studies on its distribution, its chemical composition and its taxonomy and the reasons 
behind is its ecological success (Cooper-Driver, 1976).  
Bracken biosynthesis has a wide variety of heterogeneous secondary metabolites (Cooper-
Driver, 1990). The compounds involve sesquiterpene indanones (pterosins and pterosides) 
(Hayashi et al., 1972; Hikino et al., 1970; Saito et al., 1989), ptaquiloside (Niwa et al., 1983; 
Ojika et al., 1985), quercetin (Hirono, 1986; Hirono et al., 1984b), phytoecdysteroids (Jones 
and Firn, 1978) [such as 20-hydroxyecdysone (Kaplanis et al., 1967; Wright et al., 1971)], and 
cyanogenic glycosides which release cyanide (Cooper-Driver et al., 1977). Some of these 
compounds are toxic and play an important role in protecting bracken against potential 
pathogens. This suggests that the chemistry of bracken should have played a vital role in the 
ecological success of bracken (Cooper-Driver, 1990). 
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1.5.1. PTAQUILOSIDE  
The carcinogenic effects of bracken on domestic animals have been studied since the end of 
the nineteenth century. As a result of wide and intensive investigations of toxins in bracken, 
ptaquiloside was isolated and characterized by the Yamada group in 1983 in Japan as the major 
toxin in bracken. Meanwhile, ptaquiloside was also discovered and separated in 1983 by van 
der Hoeven et al. in the Netherlands and named it aquilide A. Ptaquiloside was obtained as a 
colourless and non-crystalline hygroscopic compound. Structural elucidation and 
stereochemistry of ptaquiloside were successfully achieved by Yamada and coworkers (Niwa 
et al., 1983; van der Hoeven et al., 1983; Yamada et al., 2007). Ptaquiloside is soluble in both 
water and ethyl acetate, and its partition ratio between these two solvents (aqueous and organic) 
is about 6:1 (H2O-EtOAc) by weight (Ojika et al., 1987; Yamada et al., 2007). 
Ptaquiloside has been isolated from different bracken ferns such as P. aquilinum and var. 
latiusculum. Its chemical structure has been fully elucidated in 1987 (Ojika et al., 1987). 
Ptaquiloside has also been found in some other fern genera such as Pteris cretica, Prunus 
nipponica, Cheilanthes myriophylla, Dennstaedtia scabra, Histiopteris incisa, Cibotium 
harometz, Pityrogramma calomelanos, Pinus wallichiana, Prionospio oshimensis and Populus 
tremula (Saito et al., 1989; Somvanshi et al., 2006). Toxicologically, ptaquiloside is the most 
interesting compound in bracken. The major carcinogenic properties of bracken fern is 
associated with ptaquiloside (Niwa et al., 1983; Smith and Seawright, 1995). Several methods 
have been developed for the determination and quantification of ptaquiloside in bracken 
samples (Rasmussen et al., 2003a). Ptaquiloside has also been quantified in biological samples 
(milk) (Francesco et al., 2011), soil and groundwater samples (Jensen et al., 2008). 
Rasmussen et al. (2003b, 2015) stated that the ptaquiloside content in fronds from Denmark is 
related to the frond height and its exposure to light in the ecosystem, while different parameters 
determined the content of ptaquiloside in soil materials, e.g. the carbon content, the amount of 
bracken litter, precipitation and the size of bracken stands (Alonso-Amelot et al., 1992b; 
Rasmussen et al., 2003b). The amount of ptaquiloside in bracken fronds is highly changeable. 
It is known that ptaquiloside reaches the highest concentration in young crosiers when they 
emerge at the beginning of the growing season in spring. Afterwards, once the crosier stage is 
over, the concentration quickly diminishes to 10-20% of the maximum level (Rasmussen et al., 
2015, 2003b). It is reported that the two main factors, rainfall wash-off and bracken die off, are 
most likely have the effect on decreasing of ptaquiloside concentrations in fronds (O’Driscoll 
et al., 2016). 
Chapter One Introduction 
 
12 
 
All analysed parts of bracken, including fronds, roots and rhizomes, have shown to contain 
ptaquiloside. It has been reported that the contents of ptaquiloside in fronds ranged from 0.02 
to 0.16% and higher than those in rhizomes, which ranged from 0.03 to 0.12% (calculated 
based on dry matter) (Saito et al., 1989). In general, the ptaquiloside content in rhizomes peaks 
after fronds reaches maturity. It was shown that rhizome content had a negative correlation 
with frond content at different locations if the ptaquiloside content was less than 400 µg/g in 
rhizomes. This outcome confirms the hypothesis that ptaquiloside transfers to the rhizomes at 
the end of the growth period (Rasmussen et al., 2015). It is found that the concentration of 
ptaquiloside in fronds of common bracken ferns globally was in the range of 60-10000 µg/g 
and up to 1200 µg/g in rhizomes (Rasmussen et al., 2003a; Smith et al., 1994). Rasmussen et 
al. (2013, 2015) found that the ptaquiloside content of bracken fronds in Britain ranged from 
50 to 5790 µg/g and it is six-fold lower than the ptaquiloside content of fronds in other parts of 
the globe. Also they demonstrated that the concentration of ptaquiloside decreased as the fronds 
matured, and the maximum concentration was recorded in May. The underground rhizomes in 
Britain have also been analysed and found that the concentration range of ptaquiloside is 11-
657 µg/g (Rasmussen et al., 2015). Rasmussen and coworkers (2003a) in Denmark have also 
shown that the highest content of ptaquiloside in Danish bracken fronds ranged between 213 
and 2145 µg/g at the beginning of growth stage while rhizomes contained ptaquiloside 
concentrations in range of 11-902 µg/g at the end of the growth season. Ptaquiloside has been 
detected in soil materials in Denmark with the concentration range of 0.22–8.49 µg/g which 
was not in correlation with the content of ptaquiloside of fronds or rhizomes (Rasmussen et al., 
2003a). 
Kinetics of ptaquiloside hydrolysis in acidic and alkaline aqueous solutions (pH 2.88–8.93) at 
constant temperature (22 °C) has been studied by Ayala-Luis et al. (2006) and the following is 
an outline of their study. The hydrolysis of several natural toxins, including ptaquiloside, in 
aqueous solutions involves acid-catalysed, base-catalysed and neutral pathways. So, the rate 
law (rate equation) for the vanishing of ptaquiloside with time can be expressed as below:  
𝑑[𝑃𝑇𝑄]
𝑑𝑡
=  −𝑘𝐴[𝐻
+][𝑃𝑇𝑄] − 𝑘𝑁[𝑃𝑇𝑄] − 𝑘𝐵[𝑂𝐻
−][𝑃𝑇𝑄]                (1) 
Where d = the differentiation function, t = the reaction time, [PTQ] = ptaquiloside 
concentration, [H+] = hydronium ion concentration, [OH-] = hydroxide ion concentration, 𝑘𝐴 = 
rate constant for acid catalysis, 𝑘𝐵 = rate constant for base catalysis and 𝑘𝑁 = rate constant for 
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neutral reaction. At constant pH, Equation 1 can be simplified to a pseudo-first order reaction 
as below: 
𝑑[𝑃𝑇𝑄]
𝑑𝑡
= −𝑘𝑜𝑏𝑠 [𝑃𝑇𝑄]                (2) 
𝑘𝑜𝑏𝑠 =  𝑘𝐴[𝐻
+]  + 𝑘𝑁 + 𝑘𝐵[𝑂𝐻
−]              (3) 
Where 𝑘𝑜𝑏𝑠 = the observed rate constant. A nonlinear relationship between 𝑘𝑜𝑏𝑠 and  [𝐻
+] can 
be obtained from the rearrangement of Equation 3 into Equation 4: 
𝑘𝑜𝑏𝑠 =  𝑘𝐴[𝐻
+]  + 𝑘𝑁 + 𝑘𝐵𝑘𝑤[𝐻
+]⁻¹              (4) 
where 𝑘𝑤 = 10
-14.1 at 22 °C. 
Ayala-Luis and coworkers have also been carried out the experiment at different temperatures 
using a constant aqueous buffered solution of pH 4.46 (Table 1). They found that the rate 
constant of ptaquiloside (𝑘𝑜𝑏𝑠) is mainly dependent on pH of the reaction medium (see Table 
1 and Figure 5). Also, they investigated that ptaquiloside is highly sensitive to the temperature, 
i.e. the temperature has a great impact on ptaquiloside hydrolysis. Based on that, it can be stated 
that the high rate constant of ptaquiloside will be available at high temperature, and therefore 
the possibility of ptaquiloside hydrolysis will be increased. They have been noticed that 
ptaquiloside hydrolysis follows first-order kinetics at all pH and temperature conditions.  
Table 1: Apparent rate constants (kobs) for ptaquiloside 
hydrolysis a) in different aqueous buffer solutions at 22 °C and 
b) in an aqueous solution of pH 4.46 at different temperatures. 
a)                     pH rate constant (kobs) h-1 
2.88 4.34 × 10-2 
4.03 2.61 × 10-3 
4.46 1.53 × 10-3 
5.07 1.01 × 10-3 
5.47 3.71 × 10-4 
6.07 1.26 × 10-3 
6.77 5.57 × 10-3 
8.93 2.46 × 10-1 
b)              Temperature  
5 °C 1.80 × 10-4 
13 °C 4.80 × 10-4 
35 °C 4.15 × 10-3 
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Figure 5: Hydrolysis of ptaquiloside as a function of pH (kobs; h-1). Solid line is 
extrapolated from nonlinear regression fit of Equation 3. σ represents standard error of 
log kN (Ayala-Luis et al., 2006). 
As shown in Table 1, ptaquiloside is the most stable and has a lowest reaction rate in aqueous 
solution of pH 5.47 at 22 °C. Based on Equation 4, the researchers also shown the experimental 
data and the corresponding nonlinear-regression curve by plotting log 𝑘𝑜𝑏𝑠 versus −log[𝐻
+] 
as illustrated in Figure 5. Ultimately, Ayala-Luis’s group concluded that ptaquiloside 
hydrolysis is dominated by the acid-catalysed reaction at pH < 4.43, while at pH > 6.93 the 
overall reaction is dominated by base-catalysed reaction. In addition, in the pH range of 4-7, 
the hydrolysis of ptaquiloside is slow as it is mostly controlled by the neutral reaction. It can 
be summarized that ptaquiloside hydrolysis is readily occurred at certain circumstances such 
as low pH, high pH and higher temperatures with an activation energy (Ea) of 74.4 kJ mol
-1, 
while at slightly acidic solutions and low temperatures, the rate of ptaquiloside hydrolysis is 
the lowest. Rasmussen et al. (2005) has previously been mentioned this behaviour who 
investigated ptaquiloside degradation in Danish soils at 25 °C. 
It is possible to transfer ptaquiloside to human populations via drinking water. It was reported 
that ptaquiloside has a very low octanol-water partitioning coefficient (log 𝐾𝑜𝑤 = −0.63 ±
0.01) and consequently it is highly soluble in water, and this shows the very poor affinity of 
ptaquiloside to be sorbed onto humic matters in soils (Rasmussen et al., 2005). As ptaquiloside 
is not sorbed in soil, leaching of ptaquiloside to deep soil layers and aquifers is most 
predominant especially in slightly acidic sandy soils and cold climates. Because of the high 
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solubility of ptaquiloside in aqueous solutions, it has been proposed that ptaquiloside may leach 
through the topsoil into drinking-water reservoirs, thus representing a concern for the public 
sector (Ayala-Luis et al., 2006). Based on this finding, ptaquiloside transferred from living or 
dead plant material to the soil environment by rain water will therefore be leached and 
contaminate the soil and groundwater (Rasmussen et al., 2005, 2003a, 2003b). Ptaquiloside is 
found to be stable in the soil environment for a few months in low temperatures (5 ºC) at pH 
range 4.0-6.5, while it was found that ptaquiloside degrades rapidly at pH below 4 and pH 
above 6.5. It is stated that ptaquiloside concentration in soils can be decreased significantly due 
to both microbial degradation and abiotic hydrolysis process (Ovesen et al., 2008). 
Furthermore, in the upper layers of soil, microorganisms cause degradation of ptaquiloside 
(Rasmussen et al., 2015). In addition, there are also other factors that have an influence on 
ptaquiloside degradation in soils, for example reactive humic substances, the existence of metal 
cations, or enzymatic processes (Ayala-Luis et al., 2006). Very recently, in order to assess the 
risk of ptaquiloside to drinking water, ptaquiloside has been quantified by using LC-MS 
method in receiving water at 3 drinking water abstraction sites in Ireland (1 surface water 
stream and 2 private spring wells). Ptaquiloside has been observed in all three receiving waters. 
The lowest and maximum ptaquiloside concentrations in water samples were detected, 0.01 
µg/L in private spring well and 0.67 µg/L in surface water (O’Driscoll et al., 2016). Similarly, 
Clauson-Kaas and coworkers (2014) confirmed the presence of ptaquiloside in Danish 
groundwater in concentration up to 0.23 nmol/L (0.092 µg/L). 
At room temperature, ptaquiloside is unstable in both acidic and basic solutions which 
ultimately convert ptaquiloside to 1-indanone compounds such as pterosin O or pterosin B with 
the release of D-glucose (depending on the type of solvent used) (Niwa et al., 1983; Ojika et 
al., 1987). Ptaquiloside gradually undergoes aromatization process in weakly acidic aqueous 
solutions to afford the main product, pterosin B, after releasing of glucose molecule (Figure 6) 
(Kigoshi et al., 1989; Niwa et al., 1983; Yamada et al., 2007). The mechanism of acid 
hydrolysis of ptaquiloside is illustrated in Figure 6 (Ayala-Luis et al., 2006). 
In weakly alkaline aqueous solutions (pH 8-11), ptaquiloside is readily converted into 
ptaquilosin with liberation of D-glucose and subsequently an unstable and very high reactive 
intermediate product, called bracken dienone, is yielded quickly (Figure 7). The active form of 
ptaquiloside, bracken dienone, was found to be stable in basic solution at least for 60 minutes 
at 25 ºC while it is exceptionally unstable under weakly acidic aqueous solutions at room 
temperature and immediately transferred to pterosin B, a stable compound under all conditions 
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(Figure 7). The degradation of ptaquiloside in different buffer solutions has also been reported 
by Saito et al. in 1989, and found that the ptaquiloside half-life was around 7 days at pH 4.0 
while at pH 5.5 and 7.0 (at 37 ºC) about 40% and 10% of the original concentration was 
degraded after one week, respectively (Rasmussen et al., 2003b; Saito et al., 1989). The half-
lives of ptaquiloside in various conditions are shown in Table 2 (Ojika et al., 1987; Yamada et 
al., 2007). Saito et al. (1989) also studied the effect of sunlight on the stability of ptaquiloside 
in fronds, and found that less than 75% of the initial concentration of ptaquiloside was degraded 
after 6 weeks (Saito et al., 1989).  
Table 2: Half-lives of ptaquiloside 
Conditions pH Half-life 
Solid state in dry atmosphere at low temperature (-20-0 ºC) - > 6 months 
Solid state in dry atmosphere at room temperature - > 7 days 
Aqueous solution of H2SO4 (5 mM) at 25 ºC 2.0 174 min 
Aqueous solution of Na2CO3 (10 mM) buffer at 25 ºC 
9.0 40 min 
10.0 6.3 min 
11.0 1.2 min 
The reactions of biomolecules with ptaquiloside and its derivatives were discussed. Bracken 
dienone, through its highly reactive electrophile (cyclopropylidene ring), has been shown to 
react with nucleophiles such as water, alcohols, and aminoacids (methionine, cysteine) to 
produce a number of different adducts, e.g. DNA-adduct (Freitas et al., 2001; Ojika et al., 
1987).  
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Figure 6: Proposed mechanism for the acid hydrolysis of ptaquiloside (Ayala-Luis et al., 
2006). 
 
 
 
Figure 7:  Schematic diagram of ptaquiloside degradation in alkaline medium. 
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1.5.2. PTEROSINS AND PTEROSIDES 
Pterosins are a large group of compounds which are naturally occurring in different plant ferns 
including bracken (Sheridan et al., 1999). Pterosins are sesquiterpenoids and their structures 
are derivatives of 1-indanone skeletons (Figure 8). These compounds were first isolated from 
the bracken fern Pteridium aquilinum var. latiusculum (Pteridaceae) in Japan (Chen et al., 
2015; Hikino et al., 1970). They have also been obtained from different subsp. of Pteridium 
aquilinum (Fukuoka et al., 1978; Kuraishi et al., 1985; Murakami et al., 1980; Sengupta et al., 
1976; Tanaka et al., 1982; Yoshihira et al., 1971). Pterosins have been found to occur widely 
in various fern species (Hayashi et al., 1972; Kobayashi et al., 1975; Kuroyanagi et al., 1974a; 
Murakami et al., 1974; Sengupta et al., 1976), and apart from ferns, pterosins are also occurred 
in certain fungi of the class Basidiomycetes including Cyathus bulleri and Fomes annosus 
(Potter, D.M., Baird, 2000). During 1970-1975, more than 30 pterosins have been separated 
from different varieties of ferns. Some pterosins have been isolated as glucosides, named 
pterosides, while the others have been separated in the free state (Sengupta et al., 1976). 
 
Figure 8: Chemical structure of 1-indanone. 
Pterosins have been isolated from the extract of all parts of the bracken, for instance, they are 
found in bracken fronds (Fukuoka et al., 1978; Yoshihira et al., 1971) and rhizomes (Hikino et 
al., 1976; Kuroyanagi et al., 1979a). More than one type of pterosin will be available after 
hydrolysis of unstable precursor ptaquiloside. For example, as a result of acid-base treatment 
of the cleaned-up extracts of P. aquilinum Var. caudatum, pterosins A, B, K and Z along with 
ptaquiloside have been isolated using preparative high performance liquid chromatography 
(HPLC) and have been identified based on NMR data (Castillo et al., 1997). Pterosin A and B 
have been isolated in bracken fronds by Kovganko et al. in Belarus and they structurally 
elucidated using IR, UV and NMR data (Kovganko et al., 2004). 
In the structural elucidation of the natural products, a challenging aspect is frequently 
related to the determination of the absolute configuration (Nugroho and Morita, 2014). In 
order to confirm the absolute stereochemistry of the isolated compounds described and 
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discussed in chapter three, two powerful techniques were utilized which are single crystal X-
ray crystallography and Circular Dichroism (CD) spectroscopy. X-ray crystallography remains 
the definitive tool to determine the absolute configuration but requires crystals of the target 
compound. The application of X-ray crystallography is extensively utilized for the 
determination of molecular structure of the compound, when the molecules are organised 
in a regular crystalline array. No optics are required for this technique and it does not 
need strict resolution of the detector (Miao et al., 1999). X-ray diffraction analysis is 
necessary but has only been used twice for determining the absolute configuration of pterosin 
compounds. X-ray crystal analysis has first been reported for the natural product, pterosin 
H (Sheridan et al., 1990). Afterwards, the absolute configuration of (2R)-pterosin P has 
been determined by X-ray data (Ouyang et al., 2010). In this thesis, the structure of six 
isolated pterosins and pterosides including a novel compound (RH10) was determined by 
single crystal X-ray diffraction. 
CD spectroscopy may offer an alternative approach to determine the absolute 
configuration of chiral compounds containing appropriate chromophores (Nugroho and 
Morita, 2014). CD spectroscopy is a technique that can be used to assign the configuration in 
solution with less than 1 mg of compound (Warnke and Furche, 2012). The UV and CD spectra 
in the 380 nm to 260 nm region associated with the keto group 
 n → π* transition can be complex. The presence of vibronic10 effects (coincidental change of 
vibrational and electronic energy levels) may add further complexity to the signal, e.g., in form 
of additional shoulders in the UV spectra (see appendix IV). The corresponding CD spectra 
obey different selection rules. The CD associated with the n → π* transition may mimic the 
absorption spectrum and be relatively plain or may be fine structured indicating the importance 
of particular vibronic progressions.  
There are mainly two types of the electronic transitions in pterosin compounds, n  * 
and   * transitions which are related to the carbonyl group (C=O) and phenyl ring, 
respectively. However, the absorption may relate to the Phenyl-carbonyl conjugated part 
(  * or charge transfer) marked as an arrow in Figure 9.   
                                                          
10 The Franck–Condon principle is a rule in spectroscopy and quantum chemistry that explains the intensity of 
vibronic transitions. Vibronic transitions are the simultaneous changes in vibrational and electronic energy levels 
of a molecule due to the absorption or emission of a photon of the appropriate energy. Electronic transitions are 
typically observed in the visible and ultraviolet regions, in the wavelength range approximately 200–700 nm 
(50,000–14,000 cm−1), whereas fundamental vibrations are observed below about 4000 cm−1. 
Reference: https://en.wikipedia.org/wiki/Franck%E2%80%93Condon_principle 
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Pterosins and pterosides have been studied previously by Kuroyanagi and coworkers 
using CD spectroscopy. These compounds have shown CD Cotton effects associated with 
transition of electrons of conjugated ketones in the range of 260-380 nm. The 
stereochemistry of pterosin type compounds have then determined based on the electronic 
transitions present in the molecule (Kuroyanagi et al., 1979b).  
 
Figure 9: Electronic transition between phenyl ring and keto group in conjugated 
pterosin type compounds. 
1.6. BIOLOGICAL ACTIVITY ASSESSMENT 
Bracken has historically been associated with incidents of livestock poisoning (Hopkins, 1990; 
Vetter, 2009) resulting in many mechanistic studies on distinct pterosins and their biological 
targets. Many reports regarding the biological activities of pterosins and pterosides have been 
published during the last decades. For example,  pterosins have shown the resistance against 
insects and pests (Cooper-Driver, 1990). In the middle of seventies, isolation of the active 
constituents, pterosins B and O, have been achieved from the fern Pteris inaequalis, and they 
tested for their antimicrobial activities, in which both pterosins B and O were found to inhibit 
the Gram-positive bacterium Bacillus subtilis at minimum inhibitory concentration (MIC) of 
30 µg ml-1 (Kobayashi et al., 1975).  
The carcinogenicity and cytotoxicity tests have been performed by Yoshihira and coworkers 
on some pterosins and pterosides, and the results showed that none of them were found to be 
carcinogenic, especially the major indanones pterosin B and pteroside B, as they did not induce 
tumour under the employed experimental conditions although some pterosins were cytotoxic 
to HeLa cells (Yoshihira et al., 1978). Pterosins B, F, H, I, O, Z, and V have been identified to 
show cytotoxic effects on a ciliate, Paramecium caudatum, and also caused abnormal 
development of the sea urchin embryos, however, in feeding experiments it was shown that 
these pterosins did not inhibit DNA synthesis of the sea urchin embryos (Kobayashi and 
Koshimizu, 1980). Wallichoside (3-β-D-glucoside of (2S, 3S)-pterosin C) has been isolated 
from Pteris wallichiana which grows in the Himalayan region, and it has been reported that 
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the n-butanol extract of the plant rhizomes exhibited appreciable activity against 
Staphylococcus aureus (Sengupta et al., 1976). The effect of pterosin B on chromosomes has 
been examined by incubation of pterosin B with HeLa cells at concentrations 100 and 32 µg/ml. 
While some effect on mitosis was evident, no morphological breakages have been observed. 
Pterosin B has also been found to inhibit the cellular uptake of DNA, RNA and protein 
precursors (Saito et al., 1976). 
In general, pterosins are cytotoxic to cancer cell lines, but are inactive to antioxidant assays 
(Chen et al., 2008). Pterosins have shown bioactivities such as cytotoxic activities (Ouyang et 
al., 2010), antibacterial (Kobayashi et al., 1975), and antispasmodic (Sheridan et al., 1999). 
Furthermore, recently two pterosin dimers named bimutipterosins A and B, and 
dehydropterosin Q (Figure 10) were separated from Pteris multifida Poir and they exhibited 
moderate cytotoxic activities versus HL 60 cancer cells (human leukemia) with the half 
maximal inhibitory concentration (IC50) values of 12.8, 26.6 and 58.7 μM, respectively (Liu et 
al., 2011). Pterosin B and (2R, 3R)-pterosin L 3-O-β-D-glucopyranoside have also been shown 
to have selective activity against HL 60 human leukemia cancer cells with the IC50 values of 
8.7 and 3.7 µg/mL, respectively (Chen et al., 2008). Pterosin Z and calomelanolactone have 
been isolated from the aerial parts of the silver fern called ‘‘Pityrogramma calomelanos L.’’ in 
which the aqueous extract of this plant has been used as a treatment for venereal diseases in 
Guyana (Bardouille et al., 1978; Ng and McMorris, 1984). Pterosin Z has been shown a potent 
relaxant to smooth muscle with the half maximal effective concentration (EC50) value of 1.3 ± 
0.1 µM (Sheridan et al., 1999). 
In addition, the interaction of bracken extract with vitamin C in human submandibular gland 
cells and oral epithelial cell lines has been assessed. The results demonstrated that the bracken 
extract was cytotoxic to both types of cells even in the presence of vitamin C, i.e. vitamin C 
did not have the ability to reduce DNA damage of the cells caused by bracken, and hence it 
was not capable to revert the toxicity effects (Campos-da-Paz et al., 2008). 
The dependency of the biological effect of bracken extract in different cell assays has been 
evaluated. The cytogenetic effects of different bracken-fern extracts (hot water, cold water, 
hexane and ethanol extracts) have been investigated on chromosomes of bone-marrow and 
peritoneal cells of Swiss mice. The results showed that these extracts able to induce structural 
chromosome aberrations in both peritoneal and bone-marrow cells. Thus, it has been suggested 
that cytogenetic damage is induced by bracken fern through breaking DNA strands and 
consequently have an influence on chromosome segregation (Almeida Santos et al., 2006).  
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Figure 10: Chemical structures bimutipterosins A and B, and dehydropterosin Q from 
Pteris multifida Poir. 
In addition, three other compounds from the aerial parts of Pteris multifida Poir have been 
isolated. They were named dehydropterosin B, (2R, 3R)-pterosin L 3-O-β-D-glucopyranoside 
and (2S, 3S)-pterosin C 3-O-β-D-glucopyranoside (Figure 11). These compounds were 
evaluated for their cytotoxicities against different human cancer cells including PANC-1, NCI-
H446, LOVO and A549. They displayed significant inhibitory against NCI-H446 (small-cell 
lung cancer of human) cells with IC50 values of 5.19, 4.27, and 4.95 μM, respectively. They 
also demonstrated moderate cytotoxic effects on PANC-1 (pancreatic cancer of human) tumour 
cells with IC50 values of 14.63, 12.07, and 5.45 μM, respectively (Table 3). These outcomes 
support that pterosins might be played a vital role in development of cytotoxic actions toward 
cancer cell lines (Ouyang et al., 2010).  
Table 3: Cytotoxic activities of the compounds against 4 different tumour cell lines 
Compounds 
IC50 (µM) 
PANC-1 NCI-H446 LOVO A549 
dehydropterosin B 14.63 5.19 37.64 58.80 
(2R, 3R)-pterosin L 3-O-β-D-glucopyranoside 12.07 4.27 29.11 37.61 
(2S, 3S)-pterosin C 3-O-β-D-glucopyranoside 5.45 4.95 35.58 47.98 
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Figure 11: Chemical structures of dehydropterosin B, (2R, 3R)-pterosin L 3-O-β-D-
glucopyranoside and (2S, 3S)-pterosin C 3-O-β-D-glucopyranoside from Pteris multifida 
Poir. 
Pterosins are recently observed to possess anti-diabetic and anti-obesity activities. Several 
biochemical protocols have so far been patented utilising pterosin compounds to treat people 
living with diabetes and obesity, especially pterosin A. In the patent, a total of eighty four 
different pterosin compounds have been examined for their anti-diabetic and anti-obesity 
properties both in vivo and in vitro. The pterosin compounds used have been extracted and 
isolated from the natural plant sources, e.g. bracken, or prepared by a synthetic method. It has 
been stated that specifically 15 compounds including pterosins A, C, D, G, I, L, N, X and 
pteroside Z showed effectively biological activities against diabetes, type I (insulin-
dependent diabetes) and type II (non-insulin-dependent diabetes). Among these 15 pterosin 
compounds, pterosins A, C, D, N, X, and pteroside Z are naturally occurring in different plant 
sources. The compounds have also been indicated to significantly enhance glucose 
consumption/uptake and the insulin sensitivity. It has also been suggested that pterosin 
compounds may activate GLUT4 (Glucose Transporter-4, the insulin-regulated glucose 
transporter) and in turn minimise the levels of blood glucose in diabetic mice (Hsu et al., 2014). 
Ultimately, Hsu et al. concluded that “Taken together, the preliminary results suggest that these 
compounds may activate AMPK, which in turn regulate insulin regulation of carbohydrate and 
fatty acid metabolism, and can be considered as a potential antidiabetic and antiobesity agent”.  
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1.7.  GLUCOSE UPTAKE IN THE BODY 
The glucose transport cell model (detailed in section 4.2.1. and appendix V), is a novel in vitro 
cell system designed to mimic the localised changes in glucose concentration in the small 
intestine during the consumption of a carbohydrate rich meal (Figure 12) (Kellett and Brot-
Laroche, 2005). Before the meal, the concentration of free glucose in the lumen of the intestine 
is low (< 5mM) and the apically expressed SGLT1 transporter actively transports any available 
glucose into the enterocyte. GLUT2 transporters are also active on the basolateral membrane 
of the enterocyte, transporting glucose from the blood into the cell to maintain cellular 
metabolism if required. During a meal, the local concentration of glucose begins to increase 
(5-10 mM) and is transported from the intestinal lumen by SGLT1 and subsequently into the 
systemic circulation via GLUT2. As a consequence of this initial glucose transport across the 
enterocyte, intracellular stores of GLUT2 are mobilised and targeted to the apical membrane. 
Shortly after the meal, very high local concentrations of glucose occur (25-100 mM) as the 
carbohydrate content of the meal is broken down into monosaccharides by alpha-glucosidase 
enzymes located on the apical enterocyte membrane. At these high levels of glucose, the high 
affinity, low capacity transporter SGLT1 becomes saturated and the majority of glucose 
transport across the enterocyte is due to the low affinity, high capacity GLUT2 transporters 
now present in the apical membrane. These localised changes in luminal glucose concentrations 
are mimicked in vitro through an initial short incubation of differentiated Caco-2 cells with a 
low level of D-glucose (5 mM for 15 mins) immediately followed by a sustained incubation 
with a high level of D-glucose (final concentration of 25 mM for 45 mins). 
 
Figure 12: Glucose concentration timeline during a meal. 
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1.8. AIMS OF THE STUDY: 
This PhD project ‘‘Pterosins and pterosides in bracken (Pteridium aquilinum (L.) Kuhn)’’ was 
aimed at the following: 
1. Isolation of pterosins and pterosides from bracken rhizome. 
2. Structural elucidation of isolated pterosins and pterosides, including the determination 
of their absolute stereochemistry. 
3. Biological activity screening of isolated pterosins and pterosides. 
4. Seasonal sampling of bracken (rhizomes, fronds and stems) and associated soil.  
5. Development of a new method for sample preparation using SPE cartridges. 
6. Development of a new HPLC-UV method for quantification of pterosin B and pteroside 
B in bracken rhizomes, fronds and stems alongside soil and water samples. 
7. Seasonal variations of pterosin B and pteroside B in bracken and soil samples using the 
developed new SPE- HPLC-UV method. 
8. Calculation of dry matter content and water percentage in the rhizomes, fronds and 
stems of bracken. 
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CHAPTER TWO 
2. MATERIALS AND METHODS 
2.1. SOLUTIONS AND REAGENTS 
2.1.1. GENERAL LABORATORY CHEMICALS 
All Chemicals used during isolation and structural elucidation of the compounds were 
purchased from Sigma Aldrich, UK.  
Formic acid Sigma Aldrich, UK 
Acetic anhydride Sigma Aldrich, UK 
Phosphomolybdic acid (PMA) Sigma Aldrich, UK 
Dry pyridine Sigma Aldrich, UK 
2.1.2. HPLC GRADE SOLVENTS 
HPLC grade solvents were used for all purposes in this study including extraction and 
chromatographic isolation of compounds in bracken rhizomes. All the solvents (2.5 L) were 
supplied by Fisher Scientific, UK.  
Acetone  Fisher Scientific, UK 
Acetonitrile (ACN) Fisher Scientific, UK 
Chloroform Fisher Scientific, UK 
Diethyl ether  Fisher Scientific, UK 
Ethyl acetate Fisher Scientific, UK 
n-Hexane Fisher Scientific, UK 
Methanol  Fisher Scientific, UK 
Water  Fisher Scientific, UK 
2.1.3. DEUTERATED SOLVENTS FOR NMR ANALYSIS 
All deuterated solvents, acetone-d6 ((CD3)2CO, 99.9%), chloroform-d1 (CDCl3, 99.8%) and 
methanol-d4 (CD3OD, 99.8%), were purchased from Cambridge Isotope Laboratories, Inc., 
UK, and then they were used for NMR analysis as shown in Table 4. Norell® NMR capillary 
tubes [5 mm × 4.2 mm (O.D. × I.D.); 178 mm (L.)], were purchased from Sigma-Aldrich, UK. 
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Table 4: Deuterated solvents used in NMR experiments 
Deuterated  
solvents 
1H shift (s) (ppm)  
(multiplicity) 
13C shift (s) (ppm)  
(multiplicity) 
Trace water peak  
(ppm) 
Chloroform-d (CDCl3) 7.26 (1) 77.16 (3) 1.56 
Methanol-d4 (CD3OD) 3.31 (5) 49.00 (7) 4.87 
Acetone-d6 (CD3)2CO 2.05 (5) 
29.84 (7) 
206.26 (1) 
2.84 
 
2.2. EQUIPMENT AND INSTRUMENTATION 
2.2.1. GENERAL APPARATUS AND INSTRUMENTS 
Three rotary evaporators (Type: R-210 and Stuart® RE300) were used and they purchased from 
BÜCHI, Switzerland and Bibby Scientific, UK. The two UV lamps, UVS-14 EL Series UV 
Lamp and UVGL-55 Handheld UV Lamp, and C-10 Mini Cabinet (for handheld lamps) were 
purchased from UVP, Cambridge, UK. Infrared (IR) spectra for the samples were recorded on 
a PerkinElmer Spectrum 100 FT-IR Spectrometer using sodium chloride (NaCl) plate, and the 
samples were prepared as a solution. Optical rotation measurements of the novel compounds 
were performed in methanol and chloroform solutions on an ADP 440+ Polarimeter from 
Bellingham Stanley Ltd, USA. Column chromatography (CC) was performed using silica gel 
(LC60A 40-63 MICRON, Germany). Techne Dri-Block DB-3 Sample Concentrator, UK with 
the help of stream of nitrogen (N2) was used for accomplishing concentration and dehydration 
of the samples in screw vials [1.8 mL (31 × 7 mm) and 28 mL (72 × 21 mm)]. UV spectra for 
the novel compounds were recorded on PerkinElmer (Singapore) Lambda 35 UV/Vis 
Spectrophotometer. The Stuart® SBH 200D/3 Block Heater was purchased from Bibby 
Scientific Ltd., Staffordshire, UK. The heat gun (DURATOOL 2000W, ADJ) was the product 
of Premier Farnell plc, UK.  
2.2.2. NUCLEAR MAGNETIC RESONANCE 
One and two dimensional Nuclear Magnetic Resonance (NMR) spectra were recorded on a 
Bruker Avance-III UltraShieldTM Plus 400 MHz (9.4 Tesla magnet) and 500 MHz (11.75 Tesla 
magnet) Spectrometers (Bruker BioSpin Group, Germany) in deuterated solvents. A set of 
experiments were run for the isolated compounds including 1H, 13C, COSY, DEPTQ, HSQC 
and HMBC NMR.  NOESY NMR was also run for some of the compounds. All 1H and 13C 
NMR chemical shifts were reported in ppm relative to trace resonance of internal references, 
acetone-d6 at δH 2.05 and δC 206.26, chloroform-d1 at δH 7.26 and δC 77.16, methanol-d4 at δH 
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3.31 and δC 49.00. Spectral analyses were done using MestReNova Version 6.0 software. 
Proton NMR data were reported as follows: chemical shift, integration, multiplicity (s, singlet; 
d, doublet; dd, doublet of doublet; t, triplet; m, multiple), coupling constant. 
2.2.3. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
The High Performance Liquid Chromatography (HPLC) was carried out using Dionex 
UltiMate 3000 system instrument from Thermo Scientific, Germany. The HPLC machine was 
equipped with binary gradient pump, autosampler, diode array detector (DAD) monitoring 
wavelength ranged 190-400 nm (UV-Vis detector) and reverse phase analytical column, 
Spherisil ODS-2 (RP-C18) (250 × 4.6 mm, id, 5µm). The HPLC was used to achieve method 
development, chromatographic profiling and assessment of purity of isolated pterosins and 
pterosides from each fraction of bracken rhizome chloroform extract. High resolution 
chromatograms were recorded based on using different ratios of two mobile phase systems, 
MeOH-H2O and ACN-H2O.  The solvents were acidified with 0.1% formic acid and run at a 
flow rate of 1.0 mL/min at 40 °C. Ultraviolet detection was set at 254 nm. The Chromeleon 7 
Software was used to control gradient setting, data acquisition, auto-sampler, and ultimately 
all chromatograms were recorded. 
2.2.4. HIGH RESOLUTION MASS SPECTROMETRY 
Ultra-high mass accuracy analysis for the novel compounds was performed on a Nano-Flow 
(Triversa Nanomate; Advion biosciences limited, Norfolk, UK) linear trap quadrupole Fourier 
Transformation Ion Cyclotron Resonance Mass Spectrometry Ultra (FT-ICR-MS), where ultra 
refers to the high sensitivity ICR cell. The samples were reconstituted in 100 µL of HPLC 
grade MeOH / ultra-pure water (7:3). The samples were vortexed and then centrifuged for 4 
min at 13,000 rpm at a temperature of 0 ºC. 20 µL of supernatant was transferred to a clean 
well on a 128-well plate, and then the sample was injected (13 µL) by the nano-flow injection 
system, with a 5 µL aliquot being delivered to the ICR cell. Gas pressure was maintained at 0.5 
psi with an applied voltage of 1.5 kV to maintain a consistent current of 60-120 nA. When 
operating in narrow SIM mode, the resolution was 100,000 and the scan window was 30 
m/z. Each scan window was acquired in 60 sec.  
High resolution mass spectra for the reported compounds were recorded on a Thermo Finnigan 
LTQ HR-ESI-MS spectrometer equipped with Dionex Ultimate 3000-ThermoScientific 
Exactive HPLC system instrument, Germany. 
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2.2.5. HPLC-ELECTROSPRAY IONISATION-ION TRAP MASS SPECTROMETRY (HPLC-
ESI-MSN)11 
In order to confirm the presence of chlorinated isolated compounds, 10 g of air-dried ground 
bracken rhizomes was extracted with 100 ml of non-chlorinated organic solvent, methanol, and 
the extract was  analysed by reverse-phase HPLC with on-line photodiode array detection and 
electrospray ionisation-ion trap mass spectrometry (ESI-MSn). HPLC/ESI-MSn analysis was 
performed on a Thermo Finnigan LC-MS system (Thermo Electron Corporation, USA) 
comprising a Finnigan Surveyor PDA Plus detector, a Finnigan LTQ linear ion trap with ESI 
source and a Waters C18 Nova-Pak column (4 μm, 3.9 mm x 100 mm). The autosampler tray 
temperature was maintained at 5 °C and the column temperature at 30 °C. Sample injection 
volume was typically 10μL, the detection wavelength was set to 210-400 nm and the flow rate 
was 1 ml min−1, with 100 μL min−1 going to the mass spectrometer. The mobile phase consisted 
of water:formic acid (A; 100:0.1, v/v) and MeOH:formic acid (B; 100:0.1, v/v). The column 
was equilibrated with 95% solvent A, and the percentage of B increased linearly to 100% 
over 25  min. Ionisation parameters were optimised by infusion of chlorogenic acid standard 
at a constant rate into the LC flow. Mass spectra were acquired in negative ionisation mode 
with the following interface and MS parameters: nitrogen sheath gas 30 arbitrary units, nitrogen 
auxiliary gas 15 units, spray voltage 4 KV, capillary temperature 320 °C, capillary voltage 
−1 V and tube lens offset −68 V.  MS/MS fragmentation was carried out at normalised collision 
energy of 35% and isolation width 2.0 (m/z). 
2.2.6. REVERSE PHASE FLASH CHROMATOGRAPHY (RP-FC) 
The Reveleris® automated Flash Chromatography system (FC) was used for separation and 
purification of pterosins and pterosides. The RP-FC system has four main independent channels 
with up to four different solvents. It was used in a binary gradient during a single run. The 
samples were pre-adsorbed onto silica gel and subsequently run on the Reveleris® C18 (40 µm, 
12 g) column (GRACE) for 64 min. Two different solvent systems, MeOH-H2O and ACN-
H2O (acidified with 0.1% (v/v) formic acid), were used to elute the targeted compounds at a 
flow rate of 18 mL/min. Evaporative Light Scattering Detector (ELSD) and UV detector were 
used in this system to monitor, visualise and record the chromatographic peaks. In the UV 
detector, two selected wavelengths, 254 nm and 280 nm, were used to detect the UV-active 
compounds. The default fraction volume of 25 mL was applied for separation of the 
                                                          
11 HPLC-ESI-MSn analysis of methanol extract of bracken rhizomes has been conducted by Dr Ana Winters from 
IBERS, University of Aberystwyth. 
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components using Reveleris flash system. Fractions were collected in test tubes which were 
put into two automated trays controlled by the Reveleris® X2 Navigator™ software.  
2.2.7. CIRCULAR DICHROISM SPECTROSCOPY 
Circular Dichroism (CD) spectra for the compounds were recorded at 25 °C using a Chirascan 
CD spectrometer (Applied Photophysics Ltd). Samples (~1 mg/ml) were measured in methanol 
using a 1 mm pathlength quartz cuvette. Data were recorded every 0.5 nm between 280 nm and 
400 nm with a 1 nm spectral bandwidth and an integration time of 2 seconds per data point. 
2.2.8. X-RAY CRYSTALLOGRAPHY PROCEDURE: 
Single crystal X-ray diffraction data were collected either on a Rigaku AFC11 quarter chi 
goniometer equipped with an enhanced sensitivity (HG) Saturn944+ detector mounted at the 
window of 007 HF copper rotating anode generator with Varimax optics (cis-pterosin C, trans-
pterosin C and (2S)-pterosin A), or on a Rigaku AFC12 goniometer equipped with an enhanced 
sensitivity (HG) Saturn724+ detector mounted at the window of an FR-E+ SuperBright 
molybdenum rotating anode generator with VHF Varimax optics (70µm focus) ((2R)-pteroside 
B, (2S)-pteroside K and (2R)-rhedynoside B). Rigaku CrystalClear (Rigaku Corporations, The 
Woodlands, Texas, USA) was used to record images. Data integration was carried out using 
Agilent CrysAlisPro (Agilent- Technologies UK Ltd) (cis-pterosin C, trans-pterosin C, (2S)-
pterosin A and rhedynoside B) or Rigaku CrystalClear ((2R)-pteroside B, (2S)-pteroside K). 
The structures were solved by charge-flipping methods using SUPERFLIP (Palatinus and 
Chapuis, 2007) and refined on Fo
2 by full-matrix least squares refinement using SHELXL-2014 
(Sheldrick, 2008). All non-hydrogen atoms were refined with anisotropic displacement 
parameters. Hydrogen atoms were added at calculated positions and refined using a riding 
model with isotropic displacement parameters based on the equivalent isotropic displacement 
parameter (Ueq) of the parent atom. The structures were deposited on the Cambridge Structural 
Database with the deposition numbers CCDC 1050917, 1050918, 1050920, 1406891, 1418452 
and 1418453. 
2.3. THIN LAYER CHROMATOGRAPHY (TLC) 
Thin layer chromatography (TLC) and preparative TLC were conducted using pre-coated E. 
Merck TLC silica gel glass plates (TLC Silica gel 60 F254, Germany, 1.0 mm thickness, 20 × 
20 cm). The plates were visualised with the UV lamp if the components were UV-active or 
using PMA (20% in ethanol) when the compounds were UV-inactive. 
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2.4. BRACKEN PLANT MATERIAL AND EXTRACTION 
2.4.1. PLANT COLLECTION AND DRYING 
The bracken rhizomes (11.8 kg) were collected from Llanberis in Wales, UK, N 53o 07′ and W 
04o 08′, on 21 February 2013. The bracken plant was identified and confirmed by Nigel Brown 
(Bangor University) as Pteridium aquilinum (L.) Kuhn. A voucher specimen was deposited at 
Treborth Botanical Garden, Bangor. The fresh rhizomes were cleaned of soil by manual 
brushing to avoid matter loss and then cut into small pieces. They were left in the laboratory to 
be air-dried at room temperature for a week. Finally, the total dry weight of ca. 3.5 kg rhizomes 
was obtained. 
2.4.2. EXTRACTION AND ISOLATION  
The air-dried chopped (0.5-1.0 cm length) bracken rhizomes (ca. 3.5 kg) were macerated and 
extracted with chloroform (14.0 L) at room temperature for 3 × 24 h. The sample mixture was 
filtered under gravity using filter paper (Wattman No. 1), and the filtrate (organic solvent) was 
reduced and concentrated to dryness under pressure at 40 ºC using rotary evaporator to give 
7.1 g of the crude extract. The TLC characteristics of this extract showed major spots under the 
UV light. The extract was then examined preliminarily for the presence of aromatic proton 
signals of pterosins and pterosides by 1H-NMR. The spectrum was showed the main 
characteristic peaks of pterosins and pterosides. The extract was pre-adsorbed onto silica gel 
(14.0 g) and subjected to CC (5 cm, d; 50 cm, l) to separate these main spots. The column was 
then eluted with gradient mixture of chloroform-methanol (100:0 → 0:100). A total of seventy 
six fractions (F1-F76) were collected (250 ml each). All the eluted fractions were concentrated 
in vacuum and transferred to screwed glass containers (25 ml). In order to identify and combine 
similar fractions: 
a) 1H NMR spectrum in chloroform-d was taken for each fraction.  
b) All fractions were applied to HPLC.  
c) The fractions were monitored with TLC as described below:  
Dilute solution of each fraction was spotted onto TLC plate. The plate was then inserted into a 
jar contained the solvent system. Various solvent systems with different ratios were studied 
such as hexane:chloroform (1:1), hexane:EtOAc (3:7), methanol:chloroform (1:9). The main 
spots were detected and visualised with PMA reagent and/or UV light.  
Similar fractions were pooled together based on their proton NMR spectra, TLC and HPLC 
profiles to give thirteen major fractions, designated BR1, BR2, BR3, BR4, BR5, BR6, BR7, 
BR8, BR9, BR10, BR11, BR12 and BR13, as shown in Table 5.  
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Table 5: Main fractions obtained from column chromatography of chloroform extract. 
Resultant fractions⌂ Weight (mg) Physical appearance 
BR1 25 Pale yellow liquid 
BR2 350 Pale yellow liquid 
BR3 128.9 Pale yellow liquid 
BR4 37 Pale yellow liquid 
BR5 109 Pale yellow liquid 
BR6 375 Pale yellow liquid 
BR7 600 Pale yellow liquid 
BR8 119.7 Pale yellow liquid 
BR9 110 Pale yellow liquid 
BR10 50 Pale yellow liquid 
BR11 261.7 Pale yellow liquid 
BR12 161.8 Pale yellow liquid 
BR13 200 Pale yellow liquid 
⌂ These fractions were further investigated based on their TLC and 1H NMR signals. 
From these fractions, thirteen new compounds (RH1, 6.0 mg; RH2, 11.0 mg; RH3, 5.8 mg; 
RH4, 2.6 mg; RH5, 4.5 mg; RH6, 6.0 mg; RH7, 4.1 mg; RH8, 13.0 mg; RH9, 3.0 mg; RH10, 
11.6 mg; RH11, 3.2 mg; RH12, 9.1 mg; and RH13, 3.8 mg) and twenty five known compounds 
(RH14, 6.0 mg; RH15, 160.0 mg; RH16, 110.0 mg; RH17, 18.0 mg; RH18, 20.0 mg; RH19, 
60.0 mg; RH20, 17.0 mg; RH21, 10.0 mg; RH22, 5.0 mg; RH23, 3.0 mg; RH24, 15.4 mg; 
RH25, 4.0 mg; RH26, 14.0 mg; RH27, 14.7 mg; RH28, 3.0 mg; RH29, 4.0 mg; RH30, 10.2 
mg; RH31, 203.0 mg; RH32, 4.9 mg; RH33, 47.0 mg; RH34, 4.2 mg; RH35, 30.0 mg; RH36, 
4.0 mg; RH37, 21.0 mg and RH38, 4.0 mg were isolated as the following: 
Preparative TLC was applied to purify fraction BR1 (25.0 mg) using n-hexane-acetone (9:1) 
to give RH21 (10.0 mg). Fraction BR2 (350 mg) was further chromatographed on a silica gel 
column eluting with gradient of n-hexane-EtOAc (100:0 → 45:55) to obtain five sub-fractions 
(BR2A-BR2E). Sub-fraction BR2A (170.0 mg) was subjected to RP-FC using a gradient 
elution of ACN-H2O (35-45%, 1 h) to give RH20 (17.0 mg); RH22 (5.0 mg); RH23 (3.0 mg) 
and RH26 (14.0 mg). Sub-fractions BR2B (130.0 mg), BR2D (20.0 mg) and BR2E (10 mg) 
were subjected individually to preparative TLC using n-hexane-EtOAc (4:6), EtOAc (%100) 
and MeOH-Et2O (1:49) to give RH16 (110.0 mg), RH14 (6.0 mg) and RH4 (2.6 mg), 
respectively. Sub-fraction BR2C (22 mg) was purified using preparative TLC (diethyl ether) 
to afford compounds RH1 (6.0 mg) and RH3 (5.8 mg). Fractions BR3 (128.9 mg) and BR4 
(37 mg) were purified separately by preparative TLC using n-hexane-acetone (1:1 and 6:4) to 
afford RH8 (13.0 mg) and RH7 (4.1 mg), respectively. Preparative TLC (diethyl ether) was 
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applied to fraction BR5 (109 mg) to afford RH5 (4.5 mg) and RH24 (15.4 mg). Fraction BR6 
(375 mg) was fractionated by applying it on RP-FC with an isocratic gradient elution (20-20%, 
ACN-H2O, 1 h) to give RH15 (160.0 mg) and RH19 (60.0 mg). Fraction BR7 (600 mg) was 
resolved by a silica gel CC eluted with gradients of n-hexane-EtOAc and EtOAc-MeOH with 
increasing polarity, respectively, to yield four sub-fractions (BR7A-BR7D). Sub-fraction 
BR7A (51.5 mg) was chromatographed on RP-FC using a gradient elution of ACN-H2O (20-
23%, 1 h) to afford RH6 (6.0 mg) and RH27 (14.7 mg). RP-FC was applied on sub-fraction 
BR7B (33.0 mg) using ACN-H2O (20-23%, 1 h) as a gradient elution to obtain RH28 (3.0 mg). 
Sub-fraction BR7C (242.0 mg) was subjected to RP-FC using a gradient elution of ACN-H2O 
(20-23%, 1 h) to obtain four main fractions (BR7C1-BR7C4), and then the second peak 
(BR7C2) (38 mg) was further chromatographed on RP-FC using a gradient elution of ACN-
H2O (06-06-10-11%, 2 h) to afford RH17 (16.5 mg) and RH18 (19.5 mg). Sub-fraction BR7D 
(97.0 mg) was resolved on RP-FC using a gradient elution of ACN-H2O (15-20%, 1 h) to give 
RH25 (4.0 mg). Fraction BR8 (119.7 mg) was subjected to RP-FC using a gradient elution of 
MeOH-H2O (40-50%, 1 h) to give RH10 (11.6 mg) and RH29 (4.0 mg). Fraction BR9 (110 
mg) was separated with RP-FC using a gradient elution of MeOH-H2O (40-50%, 1 h) to obtain 
four sub-fractions (BR9A-BR9D). Sub-fractions BR9A, BR9B and BR9D gave RH11 (3.2 
mg), RH12 (9.1 mg) and RH35 (30.0 mg), respectively. The purification of sub-fraction BR9C 
(15.0 mg) on RP-FC using gradient elution (25-30% ACN-H2O, 1 h) yielded RH13 (3.8 mg). 
Fraction BR11 (261.7 mg) was resolved on RP-FC using MeOH-H2O (40-50%, 1 h) as a mobile 
phase to obtain RH2 (11.0 mg), RH31 (203.0 mg) and RH33 (47.0 mg). Fraction BR13 (200 
mg) was further fractionated by applying it to RP-FC with a gradient elution (10-25% ACN-
H2O, 1 h) to obtain four sub-fractions (BR13A-BR13D). Compounds RH32 (4.9 mg), RH30 
(10.2 mg) and RH34 (4.2 mg) were obtained from sub-fractions BR13A, BR13B and BR13C, 
respectively, while sub-fraction BR13D (30 mg) was re-subjected to RP-FC using a gradient 
elution (40-50% ACN-H2O, 1 h) to afford RH9 (3.0 mg).  
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Figure 13: Extraction and fractionation scheme from the rhizome of bracken (Pteridium aquilinum (L.) Kuhn). 
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Figure 14: Schematic flow diagrams of isolation of pterosins and pterosides from fractions A) F4-
F5, B) F16-F17, C) F18 and D) F14-F15. 
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Figure 15: Flow chart diagrams of isolation of pterosins and pterosides from fractions A) F19, B) 
F20-F22 and C) F23-F29. 
BR5 
(109 mg) 
 
P-TLC 
Et2O 
(100%) 
Rhedynosin D (RH5) 
(4.5 mg) 
 
(2S)-Pterosin N (RH24) 
(15.4 mg) 
 
F19 
BR6 
(375 mg) 
 
RP-FC 
ACN-H2O 
(20-20%) 
(1 h) 
 
(2S)-Pterosin A (RH15) 
(160 mg) 
 
(3S)-Pterosin D (RH19) 
(60 mg) 
 
F20-F22 
F23-F29 
 
BR7 
(600 mg) 
 
CC 
n-Hexane: EtOAc 
EtOAc:MeOH 
BR7B 
(33 mg) 
 
RP-FC 
ACN: H2O 
(20-23%) 
(1 h) 
 
(2R, 3R)-Histiopterosin A (RH28) 
(3 mg) 
 
BR7D 
(97 mg) 
 
RP-FC 
ACN: H2O 
(15-20%) 
(1 h) 
 
(2S)-Pterosin P (RH25) 
(4 mg) 
 
BR7A 
(51.5 mg) 
 
RP-FC 
ACN: H2O 
(20-23%) 
(1 h) 
 
Rhedynosin E (RH6) 
(6 mg) 
 
(2S)-2-Hydroxymethyl 
pterosin E (RH27) 
(14.7 mg) 
 
BR7C 
(242 mg) 
 
RP-FC 
ACN: H2O 
(20-23%) 
(1 h) 
BR7C1 BR7C2 
(38 mg) 
 
BR7C3 BR7C4 
Discarded Discarded Discarded 
trans-Pterosin C (RH17) 
(16.5 mg) 
 
cis-Pterosin C (RH18) 
(19.5 mg) 
 
RP-FC 
ACN: H2O 
(06-06-10-11%) 
(1 h) 
 
A B 
C 
Chapter Two Materials and Methods 
 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Flow diagrams of isolation of pterosins and pterosides from fractions A) F38-F41, B) F44, 
C) F45-F47 and D) F48-F51.
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Figure 17: Schematic diagrams of isolation of pterosins and pterosides from fractions A) F42-F43 
and B) F52-F67.
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2.5. ACETYLATION METHOD 
Accurately 1 mg of each compound, RH2 and RH10- RH13, was dissolved with 100 µL of 
dry pyridine in a HPLC vial and then 50 µL of acetic anhydride was added. The vial was 
immersed and sonicated for 1 hour and left overnight. The reaction mixture was diluted with 
400 µL of CDCl3 containing tetramethylsilane (TMS) as an internal standard. 
1H NMR and 
COSY were recorded in the range of 3.0-6.0 ppm. DEPTQ was recorded from -50 to 250 ppm. 
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CHAPTER THREE 
STRUCTURAL ELUCIDATION OF ISOLATED PTEROSINS AND 
PTEROSIDES 
3. RESULTS AND DISCUSSION 
3.1. INTRODUCTION: 
The underground parts (rhizomes) of bracken fern (Pteridium aquilinum (L.) Kuhn) were air-
dried, chopped and then extracted with chloroform. The extract was subjected repeatedly to 
column, thin-layer and automated reverse phase flash chromatography. The collected fractions 
were further analysed and chromatographed on silica-gel to afford 38 compounds. 
The toxicity of North Wales bracken, ‘Rhedyn’ in the Welsh language, to cattle has been 
studied previously (Potter, D.M., Baird, 2000; Wells, A.J. and McNally, 1989). In the present 
study, a traditional phytochemical investigation of bracken rhizomes using various analytical 
techniques such as one- and two-dimensional NMR spectroscopy combined with mass 
spectrometry led to isolate and  identify thirteen novel natural products (RH1-RH13) 
belonging to the sesquiterpenoid family, together with twenty five previously reported 
compounds: (2S)-rhedynosin I (RH14) (Lee et al., 2012), (2S)-pterosin A (RH15) (Kuroyanagi 
et al., 1979a), (2R)-pterosin B (RH16) (Fukuoka et al., 1983, 1978), (2R, 3R)-pterosin C 
(trans-pterosin C) (RH17) (Ayer and McCaskill, 1981; Kuroyanagi et al., 1979a), (2S, 3R)-
pterosin C (cis-pterosin C) (RH18) (Kuroyanagi et al., 1979a), (3S)-pterosin D (RH19) (Ng 
and McMorris, 1984), (2R)-pterosin E (RH20) (Fukuoka et al., 1978; Nambudiry and Rao, 
1974), (2R)-pterosin F (RH21) (Fukuoka et al., 1983, 1978), (2S, 3S)-pterosin J (RH22) (Ng 
and McMorris, 1984), (2S)-pterosin K (RH23) (Castillo et al., 2003, 1997), (2S)-pterosin N 
(RH24) (Kuroyanagi et al., 1974a; Wu et al., 2014), (2S)-pterosin P (RH25) (Fukuoka et 
al., 1978), pterosin Z (RH26) (Kuraishi et al., 1985; Tanaka et al., 1982), (2S)-2-
hydroxymethylpterosin E (RH27) (Lee et al., 2012), (2R, 3R)-histiopterosin A (trans-
histiopterosin A) (RH28) (Murakami et al., 1980), (2S)-12-hydroxypterosin A (RH29) (Lee et 
al., 2012), (2S)-pteroside A (RH30) (Fukuoka et al., 1983), (2R)-pteroside B (RH31) 
(Fukuoka et al., 1983, 1978), (3S)-pteroside D (RH32) (Kuroyanagi et al., 1979a), pteroside 
Z (RH33) (Hikino et al., 1971), (2S)-pteroside A2 (RH34) (Castillo et al., 2003), (2S)-
pteroside K (RH35) (Kuroyanagi et al., 1979a), 5-(β-hydroxy)ethyl-2, 2, 4, 6-tetramethyl-1, 
3-indandione (RH36) (Ng and McMorris, 1984), ptaquiloside (RH37) (Castillo et al., 1997; 
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Ojika et al., 1987) and 5-hydroxycalamenene (RH38) (Tanaka and Adachi, 1990),  of which 
compounds RH14 and RH27- RH29 are identified for the first time from the genus Pteridium 
which belongs to Dennstaedtiaceae family. Herein described are the isolation and structural 
elucidation of these compounds. 
3.2. STRUCTURAL ELUCIDATION OF NOVEL COMPOUNDS 
Compound RH1 was obtained as a yellow powder (Figure 18). Its molecular formula was 
established as C15H18O3 based on the positive mode quasi-molecular ion peak at m/z 247.1330 
[M + H]+ (Calcd for C15H19O3: 247.1334) showing seven degrees of unsaturation (Figure 27). 
Its UV absorbance maxima at 211, 258 and 306 nm (Figure 28) were consistent with 1-
indanone derivatives. The IR absorption bands at 3014, 1605, 3418 and 1704 cm-1 (Figure 29) 
indicated the presence of aromatic C-H, C=C, hydroxy and carbonyl groups, respectively, 
which concur with the presence of a 1-indanone skeleton (Fukuoka et al., 1978; Kuroyanagi et 
al., 1979a). 1H and 13C NMR data used for the structural identification of compound RH1 is 
listed in Table 6. The spectra yielded by compound RH1 are presented in Figure 21-Figure 26. 
 
Figure 18: Chemical Structure of (2S)-Rhedynosin A (RH1). 
The full assignment of 1H and 13C NMR resonances was deduced from 1H-1H COSY, DEPTQ, 
HSQC and HMBC analyses (Table 6, Figure 23-Figure 26 and appendix I). In addition, the 
signals for all protonated carbons were assigned by analysis of the DEPTQ and HSQC spectra 
to establish the connectivities. The 1H NMR spectrum of RH1 (Figure 21) shows signals of 
one secondary methyl [(3H, s, H-15)], one tertiary methyl [ 1.23 (3H, s, H-10)], two 
methylenes [ 3.06 (1H, d, J = 17.5 Hz, Ha-3), 2.77 (1H, d, J = 17.5 Hz, Hb-3) and 2.76 (2H, 
t, J = 5.9 Hz, H-13)], three oxygenated methylenes [3.78 (1H, d, J = 10.8 Hz, Ha-11), 3.62 
(1H, d, J = 10.8 Hz, Hb-11), 4.80 (2H, s, H-12) and 4.01 (2H, td, J = 1.3, 5.9, 11.8 Hz, H-14)] 
and one methine [ 6.93 (1H, s, H-4)] signal in the aromatic region. The DEPTQ spectrum 
(Figure 23), in combination with HSQC and HMBC experiments, displays 15 carbon 
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resonances, including two quaternary methyls at C 21.1 (C-10) and C 13.1 (C-15), five 
methylenes (including three oxygenated carbons), one methine at C 120.0 (C-4) and seven 
quaternary carbons. As three of the seven degrees of unsaturation are accounted for by a 
tricyclic system of RH1, the remaining four degrees of unsaturation require four double bonds. 
Table 6: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of 
compound RH1 in CDCl3 (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBC± 
1 - 210.5, C - 
2 - 50.9, C  - 
3a 
3b 
3.06 (d, J = 17.5) 
2.77 (d, J = 17.5) 
37.1, CH2 C: 2, 7, 8, 9, 10, 11 
4 6.93 (s) 120.0, CH C: 3, 6, 12 
5 - 142.1, C - 
6 - 131.8, C - 
7 - 138.2, C - 
8 - 131.3, C - 
9 - 151.0, C - 
10 1.23 (s) 21.1, CH3 C: 1, 2, 3, 11 
11a 
11b 
3.78 (d, J =10.8) 
3.62 (d, J =10.8) 
68.3, CH2 C: 1, 3, 10 
12 4.80 (s) 68.8, CH2 C: 4, 5, 6, 14 
13 2.76 (t, J = 5.9) 25.8, CH2 C: 5, 6, 7 
14 4.01 (td, J = 1.3, 5.9, 11.8) 65.6, CH2 C: 6, 12, 13 
15 2.56 (s) 13.1, CH3 C: 6, 7, 8 
± HMBC correlations are from proton(s) stated to the indicated carbon(s) 
The key HMBC correlations are shown in Figure 20. In the HMBC spectrum (Figure 26), the 
signals at  3.06 (1H, d, J = 17.5 Hz, Ha-3) and 2.77 (1H, d, J = 17.5 Hz, Hb-3) show 
correlations with δC 50.9 (C-2), δC 138.2 (C-7), δC 131.3 (C-8), δC 151.0 (C-9), δC 21.1 (C-10) 
and δC 68.3 (C-11). δH 4.80 (2H, s, H-12) displays correlations with δC 120.0 (C-4), δC 142.1 
(C-5), δC 131.8 (C-6) and δC 65.6 (C-14). δH 2.76 (2H, t, J = 5.9 Hz, H-13) exhibits correlations 
with δC 142.1 (C-5), δC 131.8 (C-6) and δC 138.2 (C-7). δH 4.01 (2H, td, J = 1.3, 5.9, 11.8 Hz, 
H-14) reveals correlations with δC 131.8 (C-6), 68.8 (C-12) and δC 25.8 (C-13). 3.78 (1H, d, 
J = 10.8 Hz, Ha-11) and 3.62 (1H, d, J = 10.8 Hz, Hb-11) were correlated with δC 210.5 (C-1), 
δC 50.9 (C-2), δC 37.1 (C-3) and δC 21.1 (C-10). The latter correlations confirmed the position 
of the hydroxymethylene (CH2OH) group at C-2. Other connectivities shown in this spectrum 
are: δH 6.93 (1H, s, H-4) with C-3, C-6 & C-12, δH 1.23 (3H, s, H-10) with C-1, C-2, C-3 & C-
11 and δH 2.56 (3H, s, H-15) with C-6, C-7 & C-8. Additionally, the presence of an ether link 
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was assigned to be between positions C-12 and C-14 as their proton and carbon chemical shifts 
appeared at low field region due to the deshielding influence of the oxygen atom. This was 
further confirmed with the HMBC spectrum that showed the correlations from H-12 ( 4.80) 
to C-14 (C 65.6) and from H-14 ( to C-12 (C 68.8). The J-coupling systems were 
confirmed by the COSY spectrum (Figure 24) that displays coupling between signals: δH 2.76 
& δH 4.01, δH 2.77 & δH 3.06, and δH 3.62 & δH 3.78, respectively (Figure 20).  
The CD spectrum of RH1 (Figure 19) shows a vibronic n → π* transition which concurs with 
C-2 having 2S configuration. The observed transitions for the assignment of the absolute 
stereochemistry were based on the comparison of CD spectrum of RH1 with X-ray 
crystallography data of RH15 (Figure 58) and the CD interpretation provided for RH15 by 
Kuroyanagi et al., 1979. They measured the CD spectra of substituted pterosins and pterosides 
after their absolute configurations were unequivocally determined by degradation and 
correlation reactions. Based on the above analysis, the structure of this compound was 
determined as a new natural product and named rhedynosin A (RH1). Its physical and 
spectroscopic features were consistent with the proposed structure in Figure 18.  
 
Figure 19: The CD spectra of the tricyclic compound RH1 recorded in methanol.  
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Figure 20: 2D NMR key correlations including COSY and HMBC used in the structural 
identification of the compound RH1. 
 
Figure 21: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH1. 
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Figure 22: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of compound RH1 (2.70-4.05). 
 
Figure 23: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH1. 
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Figure 24: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH1. 
 
Figure 25: 1H-13C HSQC NMR spectrum of compound RH1 in CDCl3. 
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Figure 26: 1H-13C HMBC NMR spectrum of compound RH1 in CDCl3. 
 
Figure 27: FT-ICR-MS spectrum of compound RH1 in [M+H]+ positive ion mode. 
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Figure 28: UV spectrum of compound RH1 in MeOH. 
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Figure 29: FT-IR spectrum of compound RH1 in CHCl3.
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Compound RH2 was isolated as a white powder (Figure 30) exhibiting negative optical rotation 
([𝛼]𝐷
24 -26.1º (c 0.33, MeOH)). Its IR spectrum showed absorption bands in the regions 1602, 
1692 and 3369 cm-1 (see appendix III) attributable to the aromatic ring, carbonyl and hydroxyl 
groups, respectively. In its UV spectrum, absorption maxima were observed at 304 (log 2.99), 
259 (log  3.92) and 216 (log  4.27) nm (see appendix IV). 
 
Figure 30: Chemical Structure of (2S)-Rhedynoside A (RH2). 
Table 7: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound 
RH2 in CD3OD (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBC¤ 
1 - 212.4, C - 
2 - 51.5, C - 
3a 
3b 
3.45 (d, J = 17.4) 
2.75 (d, J = 17.4) 
37.7, CH2 C: 2, 9, 10 
4 7.01 (s) 121.2, CH C: 6 
5 - 143.6, C - 
6 - 132.9, C - 
7 - 139.0, C - 
8 - 127.3, C - 
9 - 153.1, C - 
10 1.14 (s) 22.0, CH3 C: 1, 2, 3, 11 
11a 
11b 
4.13 (d, J = 9.4) 
3.48 (d, J = 9.4) 
75.0, CH2 C: 1´, 2, 3, 10 
12 4.79 (s) 69.6, CH2 C: 4, 5, 6, 12 
13 2.77 (t, J = 5.9) 26.6, CH2 C: 6 
14 4.00 (t, J = 5.9) 66.5, CH2 C: 6, 12 
15 2.54 (s) 13.0, CH3 C: 6, 7, 8 
1′ 4.21 (d, J1′, 2′ = 7.8) 104.7, CH C: 2´, 11 
2′ 3.03 (dd, J2′, 3′ = 8.9) 74.9, CH - 
3′ 3.29 (m) 78.1, CH C: 4´ 
4′ 3.24 (m) 71.5, CH - 
5′ 3.20 (m) 77.9, CH - 
6′a 
6′b 
3.78 (dd, J5′, 6′a = 1.5, J6′a, 6′b = 12.0) 
3.61 (dd, J5′, 6′b = 4.6) 
62.7, CH2 - 
¤ HMBC correlations are from proton(s) stated to the indicated carbon(s) 
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The positive mode FT-ICR-MS spectrum of RH2 (Figure 39) demonstrates a quasi-molecular 
ion peak at m/z 409.1866 [M+H]+ suggesting the molecular formula C21H28O8 (Calcd for 
C21H29O8: 409.1862). Compound RH2 exhibited 
1H and 13C NMR data closely resembling 
those of RH1. Comparison of the UV, IR and NMR spectroscopic data of RH2 (Table 7) with 
those of rhedynosin A (RH1) showed the following differences, the main one being the 
presence of an additional hexose sugar moiety having a signal for an anomeric-H at H 4.21 (d, 
J = 7.8 Hz) and remaining sugar proton signals at H 3.03-3.78. The 13C NMR spectrum of 
RH2 contained an anomeric carbon signal of a hexose moiety at C 104.7 and signals for the 
remaining five sugar carbons at δC 62.7 - 78.1, which were in good agreement with those 
reported for glycoside compounds (Fukuoka et al., 1983). This indicated that compound RH2 
was a glycoside of compound RH1. The coupling constant (J = 7.8 Hz) is consistent with trans 
3JH-H, showing that it is a β-hexoside and that the adjacent proton on the sugar is axial in the 
chair conformation of the pyranose ring. The 8.9 Hz coupling between H-2′ and H-3′ is also 
only consistent with a trans-diaxial coupling, showing that the OH at C-3′ is equatorial. Thus, 
the sugar must be glucose or galactose. Since the 1H NMR signals for H-3′ and H-4′ overlap in 
the spectrum of RH2, a sample was peracetylated, on an analytical scale, forming the 
tetraacetate. The introduction of the electron withdrawing groups shifts the signals for the ring 
protons H-2′, H-3′, H-4′ and H-6′ downfield and resolves them clearly (Figure 34, see method 
in section 2.5). The JH3′,H4′ coupling was determined by examination of the H-3′ and H-4′ 
signals and was found to be ca. 8 Hz. This value is only consistent with a trans-diaxial 
relationship between these protons in the chair conformation of the hexopyranose. Three trans-
diaxial relationships derived from the ring protons of a pyranose are indicating a glycosyl 
residue. To our knowledge, no L-glucose has been reported being isolated from a plant source 
yet. Thus, it is most likely that this glycosyl residue belongs to the D- series. Carbon resonances 
at δC 104.7, 78.1, 77.9, 74.9, 71.5 and 62.7 in the 13C NMR spectrum (Table 7 and Figure 35) 
provided further evidence for the presence of the glucopyranyl residue. The key HMBC and 
COSY correlations are shown in Figure 31. The linkage position of the sugar moiety to C-11 
of the aglycone was confirmed by an HMBC experiment, which shows correlations between 
the anomeric resonance H-1′ ( 4.21) and C-11 ( 75.0), and between H-11 ( 4.13 and 3.48) 
and the anomeric carbon C-1′ ( 104.7). The CD spectrum shows a plain positive n → π* 
component at ~330 nm that can be correlated with the configuration at C-2 being 2S 
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(Kuroyanagi et al., 1979a). Based upon the above evidence, the structure of RH2 was identified 
as rhedynosin A 11-O--D-glycoside and named rhedynoside A (Figure 30). 
 
 
Figure 31: Some of HMBC and COSY key correlations used in the structural 
identification of the compound RH2. 
 
Figure 32: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH2. 
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Figure 33: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH2 (2.7 – 4.3 ppm). 
 
Figure 34: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH2 after acetylation. 
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Figure 35: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH2. 
 
Figure 36: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH2. 
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Figure 37: 1H-13C HSQC NMR spectrum of compound RH2 in CD3OD. 
 
Figure 38: 1H-13C HMBC NMR spectrum of compound RH2 in CD3OD. 
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Figure 39: FT-ICR-MS spectrum of compound RH2 in [M+H]+ positive ion mode. 
A new natural product, compound RH3, was isolated as a yellow powder (Figure 40). In the 
accurate mass spectrum measured by positive mode FT-ICR-MS, a molecular ion peak similar 
to RH1 at m/z 247.0967 [M+H]+ (Calcd for C14H15O4: 247.0970) was obtained, indicating a 
molecular formula of C14H14O4 along with eight degrees of unsaturation (see appendix II). The 
IR bands were due to a hydroxyl, carbonyl and aromatic carbon-carbon double bond observed 
at 3419, 1715 and 1603 cm-1, respectively (see appendix III).  
 
Figure 40: Chemical Structure of Rhedynosin B (RH3). 
The 1H NMR spectrum (Table 8 and see appendix I) of RH3 closely resembles that of RH1 
but the 13C NMR spectrum, in combination with HMBC experiment, displays 14 carbon 
resonances instead of the 15 signals that appear in the spectrum of RH1. These signals were 
ascribed to two methyls, three methylenes, one methine, six quaternary carbons and two 
carbonyl functional groups (Table 8). The major differences in the NMR data for compound 
RH3 are: i) the absence of a methylene signal at  4.80 (CH2-12, 1H NMR) and ii) the 
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appearance of a quaternary carbon in the downfield region at C 165.012 (13C NMR) 
corresponding to an ester (see appendix I), thus indicating that the methylene group (CH2-12) 
of RH1 is oxidised and present as a carbonyl in RH3. This interpretation explains the 
downfield shift (H 8.05) of the methine signal (H-4) due to the influence of the carbonyl at 
position C-12. However, the HMBC and COSY experiments of compound RH3 were shown 
similar C-H correlations as for RH1, they displayed extra correlations used in structurally 
elucidation of RH3. 
Table 8: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of 
compound RH3 in CDCl3 (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBC* 
1 - 209.2, C - 
2 - 78.0, C - 
3 3.22 (s) 41.4, CH2 C: 1, 2, 6, 9, 10 
4 8.05 (s) 126.3, CH C: 5, 6, 12 
5 - 138.2, C - 
6 - 134.6, C - 
7 - 137.3, C - 
8 - 130.7, C - 
9 - 149.7, C - 
10 1.42 (s) 26.0, CH3 C: 1, 2, 3 
11 - - - 
12 - 165.0, C - 
13 3.05 (t, J = 6.0) 24.6, CH2 C: 5, 8, 14 
14 4.55 (t, J = 6.0) 66.9, CH2 C: 5, 12, 13 
15 2.64 (s) 13.7, CH3 C: 4, 6, 7, 8 
* HMBC correlations are from proton(s) stated to the indicated carbon(s) 
The main HMBC and COSY correlations are outlined in Figure 41. The HMBC spectrum 
confirmed the location of the carbonyl group. Furthermore, in the HMBC experiment (see 
appendix I) strong correlations were observed from both proton signals at H 8.05 (H-4) & 4.55 
(H-14) to the carbon signal at δC 165.0 (C-12). The other significant difference was the absence 
of CH2 signals at H 3.78 and H 3.62 (CH2-11) in the 1H NMR spectrum. The 13C NMR 
spectrum showed that the methylene signal from C-11 was absent and that the signal for C-2 
had moved downfield to C 78.0, showing the presence of an oxygen. While CD spectra were 
obtained for RH3, the absolute stereochemistry was not assignable as there was neither an X-
ray reference with hydroxyl substitution on C-2 nor a previous literature report of a CD 
                                                          
12 This carbon signal was assigned with HMBC experiment. 
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spectrum of a compound with a suitable chromophore core. Using this data, compound RH3 
was identified as a previously unreported natural product (new compound) and named 
rhedynosin B (Figure 40).  
 
Figure 41: 2D NMR key correlations including COSY and HMBC used in the structural 
identification of the compound RH3. 
Compound RH4 was obtained as a white powder with an optical rotation [𝛼]𝐷
24 +3.8º (Figure 
42). The negative mode mass spectrum showed a molecular ion peak at m/z 245.0821 [M-H]- 
(see appendix II), compatible with C14H13O4 (Calcd as 245.0814) and consequently indicated 
C14H14O4 as a molecular formula of RH4. In the IR spectrum, strong bands at νmax 1703 and 
3428 cm-1 were indicative of carbonyl and hydroxyl groups, respectively (see appendix III).  
 
Figure 42: Chemical Structure of Rhedynosin C (RH4). 
The maximum UV absorbances of RH4 appeared at 214, 258 and 306 nm (see appendix IV), 
and in agreement with 1-indanone compounds (Tanaka et al., 1982; Yoshihira et al., 1971). 
The 1H and 13C NMR spectroscopic data of RH4 are listed in Table 9. Analysis of the NMR 
and mass spectral data showed that RH4 is structurally similar to RH3. The major differences 
were detected by NMR spectroscopic data, for example the presence of two isolated methylene 
signals at H 5.40 (2H, s, H-12) and H 3.83 (2H, s, H-13) which appear as singlets and thus 
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indicated that the carbonyl group was at position C-14 in RH4. The chemical shift for CH2-12 
(H 5.40) also indicated a very electron-deficient environment, consistent with ArCH2OC=O. 
Table 9: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of 
compound RH4 in CD3OD (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBC‡ 
1 - 209.7, C - 
2 - 78.1, C - 
3a 
3b 
3.10 (d, J = 17.0) 
3.10 (d, J = 17.0) 
42.9, CH2 C: 1, 2, 9 
4 7.29 (s) 121.9, CH C: 8, 12 
5 - 140.5, C - 
6 - 136.9, C - 
7 - 137.8, C - 
8 - 131.3, C - 
9 - 152.1, C - 
10 1.36 (s) 25.2, CH3 C: 1, 2, 3 
11 - - - 
12 5.40 (s) 71.1, CH2 C: 4, 5, 8, 14 
13 3.83 (s) 32.8, CH2 - 
14 - 173.5, C - 
15 2.62 (s) 13.0, CH3 C: 7, 8 
‡ HMBC correlations are from proton(s) stated to the indicated carbon(s) 
The main HMBC correlations of RH4 which were not observed in compound RH3 are 
illustrated in Figure 43. The HMBC spectrum confirmed the assignments and connectivities, 
and also showed a cross peak between H-12 (H 5.40) and C-14 (C 173.5) (Figure 43 & see 
appendix I). The data provided further evidence for the carbonyl being present at the position 
C-14. Thus, the structure of RH4 was identified as a new compound and named rhedynosin C 
(Figure 42). However, the absolute configuration at position C-2 was not assignable with the 
CD spectroscopy and hence it remains undetermined. 
 
Figure 43: HMBC key correlations used in the structural identification of RH4. 
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Compound RH5 was obtained as a yellow solid (Figure 44). In the positive mode spectrum, 
pseudo-molecular ion peaks at m/z 269.0941 and m/z 271.0912 [M + H]+ in the pattern ratio 
3:1 are observed, indicate the presence of one chlorine atom and suggested a molecular formula 
of C14H18ClO3 (Calcd as 269.0944) (see appendix II). Proton and carbon NMR data of RH5 
are shown in Table 10.  
 
Figure 44: Chemical Structure of Rhedynosin D (RH5). 
Table 10: 1H (400 MHz) and 13C (100 MHz) NMR spectral 
data of compound RH5 in CDCl3 (δ in ppm, multiplicity, J in 
Hz). 
Position δH δC HMBC± 
1 - 208.9, C - 
2 - 77.8, C - 
3 3.15 (d, J = 2.8) 41.4, CH2 C: 2, 4, 9, 10 
4 7.39 (s) 124.0, CH C: 3, 6, 8, 12 
5 - 146.9, C - 
6 - 134.7, C - 
7 - 139.3, C - 
8 - 131.0, C - 
9 - 151.0, C - 
10 1.40 (s) 26.2, CH3 C: 1, 2, 3 
11 - - - 
12 4.84 (s) 63.8, CH2 C: 4, 5, 6 
13 3.21 (t, J = 8.0) 31.7, CH2 C: 5, 6, 7, 14 
14 3.62 (t, J = 8.0) 42.8, CH2 C: 6, 13 
15 2.67 (s) 14.0, CH3 C: 4, 5, 6, 7, 8 
± HMBC correlations are from proton(s) stated to the indicated carbon(s) 
 
The IR spectrum shows major absorption bands at 3418 cm-1 (OH), 1714 cm-1 (C=O) and 1602 
and 1447 cm-1 (aromatic C=C) (see appendix III). The UV spectrum exhibits UV signals at 
212, 215 and 303 nm (see appendix IV). The 1H NMR data (Table 10) of RH5 indicates a 
pentasubstituted benzene ring with a single aromatic proton signal at H 7.39 (1 H, s). Two 
coupled methylene groups at H 3.21 (2H, t, J = 8.0 Hz) and H 3.62 (2H, t, J = 8.0 Hz) indicate 
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an ArCH2CH2X system, with the chemical shift of the latter triplet suggesting that X = Cl. The 
remaining 1H NMR signals were in agreement with a pterosin-type structure (Fukuoka et al., 
1978; Kovganko et al., 2004; Kuraishi et al., 1985; Tanaka et al., 1982). The 13C NMR data of 
RH5 (see appendix I and Table 10) shows fourteen distinct carbon environments, confirming 
the presence of a pentasubstituted aromatic ring, including a low-field signal at C 208.9 ppm 
(C=O) assigned as the C-1 of a pterosin-type sesquiterpene skeleton. The distinctive COSY 
and HMBC correlations distinguishing RH5 from RH4 are displayed in Figure 45. The HMBC 
proton-carbon correlations confirmed a pterosin K side chain, a 2-chloroethyl group 
(CH2CH2Cl) attached to C-6 of benzene ring. A singlet methylene signal at H 4.84 was 
assigned as the hydroxymethylene (CH2OH) group attached to C-5 of the benzene ring. All 
assignments were confirmed by HMBC correlations and RH5 was thus identified as 
rhedynosin D (Figure 44). However, the absolute configuration in C-2 was not assigned by the 
CD spectroscopy and therefore it remains undetermined. 
 
Figure 45: COSY and HMBC key correlations used in the structural identification of 
RH5. 
Compound RH8 was obtained as a yellow gum (Figure 46), whose molecular formula, 
C14H17ClO3, was determined by a combination of a positive mode HR-ESI-MS at m/z 269.0941 
[M+H]+ (Calcd for C14H18ClO3: 269.0944) and NMR spectroscopic analysis. This molecular 
formula was exactly identical to that of RH5, designating RH8 as an isomer of RH5. The UV 
spectrum showed absorption bands at 218, 260 and 299 nm (see appendix IV). Table 11 shows 
the 1H and 13C NMR data of compound RH8. 
The IR, NMR and MS data of RH8 (see appendices I-III) were similar to those of RH5, with 
detailed exceptions which allowed identification of RH8. Differences were found in the NMR 
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signals for the positions C-12 and C-13 for these two compounds. The differences were 
concluded based on the following observations. First, in comparison with RH5, 1H NMR of 
compound RH8 displayed signal of protons in 12-position at up-field region while the chemical 
shifts of 13-position protons were shifted down-field indicating the presence of the electron 
withdrawing hydroxyl group (Figure 47). 
 
Figure 46: Chemical Structure of Rhedynosin G (RH8). 
Second, the 1H NMR spectrum of RH8 showed a methyl group resonating at H 2.55 that gave 
a proton-carbon correlation to the carbon resonating at C 22.0 in the HSQC spectrum and by 
HMBC experiment this was assigned as C-12. A methine group, resonating at H 5.45 (1 H, dd, 
J = 5.2, 8.7 Hz), that gave proton-carbon correlation to the carbon resonating at C 71.4 in the 
HSQC spectrum, was assigned as the C-13. This confirmed that the hydroxyl group, which had 
been at C-12 in RH5, was in position C-13 in RH8. 
Table 11: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound RH8 
in (CD3)2CO (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBC∆ 
1 - 208.5, C - 
2 - 77.4, C - 
3 3.05 (d, J = 9.5) 42.2, CH2 C: 2, 4, 5, 7, 8, 9, 10 
4 7.13 (s) 128.0, CH C: 3, 7, 8, 12 
5 - 145.7, C - 
6 - 134.6, C -  
7 - 138.5, C - 
8 - 131.1, C - 
9 - 151.9, C - 
10 1.32 (s) 25.5, CH3 C: 1, 2, 3 
11 - - - 
12 2.55 22.0, CH3 C: 4, 5, 7, 8 
13 5.45 (dd, J = 5.2, 8.7) 71.4, CH C: 5, 7, 14 
14a 
14b 
3.98 (dd, J13, 14a = 8.7, J14a, 14b = 11.2) 
3.81 (dd, J13, 14b = 5.2) 
48.1, CH2 C: 7, 13 
15 2.75 (s) 14.6, CH3 C: 4, 5, 6, 7, 8 
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∆ HMBC correlations are from proton(s) stated to the indicated carbon(s) 
Compound RH8 revealed more proton-carbon correlations in the HMBC experiment which 
were not shown by RH5. However, CD spectroscopy was applied, the stereochemistry of RH8 
in position C-2 was not assignable and thus it remains undetermined. Compound RH8 was thus 
identified as rhedynosin G (Figure 46). 
 
Figure 47: Up and down-field shifting of selected signals in 1H NMR of compounds RH5 
and RH8. 
 
Figure 48: COSY and HMBC key correlations used in the structural identification of 
RH8. 
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Compound RH7 was obtained as a pale yellow crystalline powder (Figure 49). From the 
molecular ion peak shown by a positive mode FT-ICR-MS at m/z 283.1098 [M+H]+ (Calcd for 
C15H20ClO3: 282.1023), the molecular formula of RH7 was concluded to be C15H19ClO3, 
suggesting an additional CH2 when compared to RH8. The UV, IR and NMR data were similar 
to those of RH8 (see appendices I, III and IV). However, an additional CH2 was evident from 
the NMR data of RH7, with two geminally coupled doublets H 3.79 (1 H, d, J = 10.7 Hz) and 
H 3.59 (1 H, d, J = 10.7 Hz), correlating through one-bond with a new carbon signal at C 68.1.  
 
Figure 49: Chemical Structure of Rhedynosin F (RH7). 
Table 12: 1H (400 MHz) and 13C (100 MHz) NMR spectral data of compound RH7 
in CDCl3 (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBCφ 
1 - 211.7, C - 
2 - 51.0, C - 
3a 
3b 
3.08 (d, J = 17.3) 
2.74 (d, J = 17.3) 
36.8, CH2 C: 2, 9, 10, 11 
4 7.11 (s) 127.5, CH C: 3, 6, 8, 12 
5 - 144.8, C - 
6 - 135.4, C - 
7 - 139.0, C - 
8 - 132.4, C - 
9 - 154.0, C - 
10 1.20 (s) 21.2, CH3 C: 2, 3, 11 
11a 
11b 
3.79 (d, J = 10.7) 
3.59 (d, J = 10.7) 
68.1, CH2 C: 2, 3, 10 
12 2.53 (s) 22.2, CH3 C: 4, 5, 6 
13 5.41 (dd, J = 3.5, 10.0) 71.5, CH C: 5, 6, 7, 14 
14a 
14b 
3.98 (dd, J13, 14a = 10.2, J14a, 14b =11.4) 
3.65 (dd, J13, 14b = 3.7) 
47.8, CH2 C: 13 
15 2.77 (s) 14.8, CH3 C: 4, 6, 7, 8, 10 
φ HMBC correlations are from proton(s) stated to the indicated carbon(s) 
The chemical shifts indicated that this new methylene was attached to the oxygen and thus the 
hydroxymethylene group was in position C-2. On the basis of the above mentioned evidence, 
the structure of RH7 was confirmed as rhedynosin F (Figure 49). The CD spectroscopy allowed 
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a S assignment of configuration at position C-2. Table 12 demonstrates the proton and carbon 
NMR data of compound RH7. 
Compound RH9 was isolated as an off-white powder and its mass spectrum in the negative ion 
mode FT-ICR-MS showed a molecular ion peak at m/z 297.0802 [M-H]- corresponding to a 
molecular formula of C14H17O5S (Calcd as 297.0797). The UV, IR, and NMR data of RH9 
were very similar to those of pterosin B (RH16) (Table 20 and see appendices I, III and IV).  
 
Figure 50: Chemical Structure of Rhedynosin H (RH9). 
Table 13: 1H (125 MHz) and 13C (500 MHz) NMR spectral data of 
compound RH9 in CD3OD (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBCπ 
1 - 208.8, C - 
2 2.63 (m) 43.7, CH C: 4, 5, 6, 7, 8, 10 
3a 
3b 
3.27 (m) 
2.59 (m) 
34.6, CH2 C: 2, 4, 8, 9 
4 7.16 (s) 126.9, CH C: 3, 6, 8, 12  
5 - 146.8, C - 
6 - 135.3, C - 
7 - 139.0, C - 
8 - 132.5, C - 
9 - 155.0, C - 
10 1.23 (d, J = 7.5) 16.9, CH3 C: 1, 2, 3 
11 - - - 
12 2.46 (s) 21.4, CH3 C: 4, 5, 6, 7, 8 
13 3.15 (t, J = 8.0) 29.3, CH2 C: 5, 6, 9, 14 
14 4.05 (t, J = 8.0) 67.4, CH2 C: 6, 13 
15 2.67 (s) 13.9, CH3 - 
π HMBC correlations are from proton(s) stated to the indicated carbon(s) 
The 1H and 13C NMR data of RH9 is shown in Table 13. This molecular formula and an 80 
amu difference in mass between RH9 (298 amu) and RH16 (218 amu) strongly suggested that 
the primary alcohol of RH16 had been sulfated in RH9, i.e. the OH group was replaced with 
the hydrogen sulfate substituent (HSO4
-). This was confirmed by a downfield shift of the proton 
Chapter Three Results and discussion 
 
66 
 
and carbon resonances for the adjacent methylene (CH2-14) to H 4.05 and C 67.4, 
respectively. Moreover, the HMBC cross peaks from H-14 (H 4.05) to each of C-6 (C 135.3) 
and C-13 (C 29.3), and from H-13 (H 3.15) to C-14 (C 67.4) verified the location of C-13 
and C-14. Sulfated monoesters are common in marine natural products (McKee et al., 1994; 
Uddin et al., 2011). Compound RH9 was subjected to CD spectroscopy, however no significant 
spectrum was observed. It is hypothesised that compound RH9 is racemised due to the presence 
of an acidic proton in the α-position to the carbonyl group. Therefore, the structure of RH9 was 
confirmed by full analysis of the data as rhedynosin H (Figure 50). 
Compound RH6 was obtained as an off-white powder (Figure 51). Its molecular formula 
(C15H18O4) was determined from the positive mode FT-ICR-MS which exhibited a molecular 
ion peak at m/z 263.1280 [M+H]+  (Calcd for C15H19O4: 263.1283). Table 14 exhibits the 
1H 
and 13C NMR data of RH6. The UV, IR and NMR data of RH6 were very similar to trans-
histiopterosin A (RH28) (Murakami et al., 1980) (see appendices I, III and IV). Two carbonyl 
resonances were evident in the 13C NMR spectrum, with the ketone signal at C 211.6 and a 
carboxylic acid signal at C 175.3. In the 1H NMR spectrum of RH6, an additional methyl 
signal is present, which was shown to be connected to C-2 by HMBC. Thus, two magnetically 
inequivalent methyl groups are attached to C-2, which resonate as singlets at H 1.05 and H 
1.19.  
 
Figure 51: Chemical Structure of (3S)-Rhedynosin E (RH6). 
The application of CD spectroscopy to compound RH6 showed a non-vibronic n → π* 
transition which was compared to the CD spectrum for RH19 reported by Kuroyanagi et al. 
(1979b) and assigned the configuration as S on C-3. Therefore, the structure of RH6 was 
confirmed as rhedynosin E (Figure 51). 
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Table 14: 1H (100 MHz) and 13C (400 MHz) NMR spectral data of 
compound RH6 in CD3OD (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBC# 
1 - 211.6, C - 
2 - 52.5, C - 
3 4.76 (s) 77.6, CH C: 4, 8, 9, 10 
4 7.39 (s) 126.0, CH C: 3, 6, 8, 12 
5 - 146.6, C - 
6 - 136.0, C - 
7 - 138.9, C - 
8 - 131.1, C - 
9 - 154.3, C - 
10 1.19 (s) 23.5, CH3 C: 1, 2, 3, 11 
11 1.05 (s) 20.7, CH3 C: 1, 2, 3, 10 
12 2,44 (s) 21.6, CH3 C: 4, 5, 6 
13 3.78 (s) 35.1, CH2 C: 5, 6, 7, 14 
14 - 175.3, C - 
15 2.61 (s) 14.2, CH3 C: 4, 5, 6, 7, 8 
# HMBC correlations are from proton(s) stated to the indicated carbon(s) 
 
Compound RH10 was obtained as a white crystalline product (Figure 52). An accurate mass 
spectrum of RH10 was recorded by a positive mode FT-ICR-MS, exhibited a molecular ion 
peak at m/z 415.1528 [M+H]+ and correlated to the molecular formula C20H28ClO7 (Calcd as 
415.1524). The 1H and 13C NMR data of RH10 is illustrated in Table 15. The UV, IR, and 
NMR data for RH10 were very similar to those reported for pterosin F (RH21) (Fukuoka et 
al., 1978; Kuroyanagi et al., 1979a) (see appendices I, III and IV), except for the presence of a 
sugar moiety in RH10 which was connected to the aglycone through C-2, as determined by the 
HMBC experiment. Careful study of the coupling constants around the hexopyranose in the 1H 
NMR spectrum suggested that the sugar was a glucose; J1′,2′ = 7.8 Hz, J2′,3′ = 8.0 Hz and J3′,4′ = 
8.9 Hz, consistent only with trans-diaxial arrangements of these protons. X-ray crystallography 
confirmed RH10 as rhedynoside B and assigned the configuration at C-2 as R (Figure 52-
Figure 53). The single crystal X-ray data is submitted to Cambridge X-ray data centre. The CD 
spectroscopy was applied to further confirm the stereochemistry of compound RH10 at 
position C-2, however no absorption bands were obtained in range of 300-360 nm. 
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Figure 52: Chemical Structure of (2R)-Rhedynoside B (RH10). 
Table 15: 1H (100 MHz) and 13C (400 MHz) NMR spectral data of compound 
RH10 in CD3OD (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBCᴪ 
1 - 207.3, C - 
2 - 84.1, C - 
3a 
3b 
3.45 (d, J = 17.4) 
3.08 (d, J = 17.4) 
40.9, CH2 C: 2, 8, 9, 10 
4 7.17 (s) 127.3, CH C: 3, 6, 8, 12 
5 - 147.2, C - 
6 - 136.7, C - 
7 - 139.6, C - 
8 - 131.5, C - 
9 - 152.3, C - 
10 1.44 (s) 23.7, CH3 C: 1, 2, 3 
11 - - - 
12 2.45 (s) 21.3, CH3 C: 4, 5, 6, 7, 8 
13 3.22 (t, J = 8.0) 33.0, CH2 C: 5, 6, 7, 14 
14 3.63 (t, J = 8.0) 43.1, CH2 C: 6, 13 
15 2.65 (s) 14.1, CH3 C: 4, 5, 6, 7, 8 
1′ 4.42 (d, J1′, 2′ = 7.8) 100.5, CH C: 2, 5´ 
2′ 3.16 (dd, J2′, 3′ = 8.0) 75.1, CH C: 3´ 
3′ 3.32++ 78.0, CH C: 4´ 
4′ 3.28 (dd ~ t, J3′, 4′ = 8.9)  71.3, CH C: 5´ 
5′ 3.12 (m) 77.7, CH - 
6′a 
6′b 
3.70 (dd, J5′, 6′a = 2.5, J6′a,6′b = 12.0)  
3.60 (dd, J5′, 6′b = 5.0) 
62.5, CH2 - 
++ Signal under solvent, confirmed by HSQC experiment. 
ᴪ HMBC correlations are from proton(s) stated to the indicated carbon(s) 
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Figure 53: Thermal ellipsoid plot of compound Rhedynoside B (RH10) with ellipsoids 
shown at 50% probability. N.B. Rhedynoside B crystallises as a hemihydrate with four 
molecules of Rhedynoside B and two molecules of water in the asymmetric unit. Only 
one molecule of the Rhedynoside B structure is shown here for clarity.  
Compound RH11 was obtained as an off-white crystalline powder (Figure 54). The mass 
spectrum showed a strong ion signal of [M-H]- at m/z 427.1531 (Calcd for C21H28ClO7: 
427.1524) in the negative mode FT-ICR-MS, indicating the molecular formula of C21H29ClO7 
with a molecular mass 14 Da higher than RH10. The 1H and 13C NMR data of RH11 are shown 
in Table 16. The UV, IR and NMR data of RH11 were similar to those of pterosin H (Hayashi 
et al., 1972; Padwa et al., 1996; Tanaka et al., 1982) with the exception that RH11 contained a 
sugar moiety (see appendices I, III and IV). Of particular interest was a pair of geminally 
coupled doublets in the 1H NMR spectrum at H 5.11 (1 H, d, J = 12.4 Hz) and H 4.78 (1 H, d, 
J = 12.4 Hz). These signals gave a one-bond H-C correlation with the 13C NMR signal at C 
70.2. The chemical shifts corresponded to an ArCH2O system. An HMBC experiment assigned 
this carbon signal being connected to C-12. Moreover, the HMBC also linked the sugar to this 
methylene. The 1H NMR spectrum of RH11 confirmed the sugar as a hexopyranoside and 
identified the configuration of the glycosidic bond as , with J1′,2′ = 7.7 Hz (also suggesting 
that the sugar was glucose or galactose). Peracetylation of the sugar separated the 1H NMR 
signals of the sugar sufficiently to provide a full diastereomeric assignment of the sugar as 
glucose (see the discussion for RH2 above). On the basis of this evidence, compound RH11 
was identified as rhedynoside C (Figure 54). 
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Figure 54: Chemical Structure of Rhedynoside C (RH11). 
Table 16: 1H (400 MHz) and 13C (100 MHz) spectral data of compound RH11 in 
CD3OD (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBC† 
1 - 211.2, C - 
2 - 46.9, C - 
3 2.93 (s) 42.7, CH2 C: 2, 4, 8, 9, 10 
4 7.50 (s) 126.5, CH C: 6, 8 
5 - 144.9, C - 
6 - 136.5, C - 
7 - 139.6, C - 
8 - 133.4, C - 
9 - 153.4, C - 
10 1.17 (s) 25.8, CH3 C: 1, 2, 3, 11 
11 1.17 (s) 25.8, CH3 C: 1, 2, 3, 10 
12a 
12b 
5.11 (d, J = 12.4) 
4.78 (d, J = 12.4) 
70.2, CH2 C: 4, 5, 6, 1´ 
13 3.26 (m) 32.5, CH2 C: 5, 6, 7, 14 
14 3.63 (m) 43.8, CH2 - 
15 2.66 (s) 13.7, CH3 C: 6, 7, 8 
1′ 4.40 (d, J = 7.7) 103.5, CH C: 12 
2′ 3.29 (m) 75.2, CH - 
3′ 3.31 (m) 78.2, CH - 
4′ 3.31 (m) 71.8, CH - 
5′ 3.36 (m) 78.2, CH - 
6′a 
6′b 
3.92 (dd, J5′, 6′a = 2.0, J6′a, 6′b = 12.0)  
3.70 (dd, J5′, 6′b = 4.0) 
62.9, CH2 - 
† HMBC correlations are from proton(s) stated to the indicated carbon(s) 
Compound RH12 (Figure 55), a novel natural product, was obtained as yellow powder with 
the negative optical rotation [𝛼]𝐷
25 -0.6 (c 0.33, MeOH). In the negative mode FT-ICR-MS, 
RH12 gave a quasi-molecular ion peak at m/z 413.1374 [M-H]-, appropriate for a molecular 
formula C20H26ClO7 (Calcd as 413.1367), and indicating that it was an isomer of RH10. Table 
17 demonstrates the proton and carbon NMR data of compound RH12. The UV, IR and NMR 
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data of RH12 were broadly similar to those of RH10 except that the point of attachment of the 
sugar was clearly different (see appendices I, III and IV). As for RH11, a diastereotopic 
methylene group was observed in the NMR spectra at H 5.10 (1 H, d, J = 12.3 Hz) & 4.78 (1 
H, d, J = 12.3 Hz) and C 70.2.  
 
Figure 55: Chemical Structure of Rhedynoside D (RH12). 
Table 17: 1H (400 MHz) and 13C (100 MHz) spectral data of compound RH12 in 
CD3OD (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBC¤ 
1 - 212.5, C - 
2 2.66 (m) 43.9, CH - 
3a 
3b 
3.33 (m) 
2.64 (m) 
34.9, CH2 C: 2, 9 
4 7.51 (s) 126.4, CH C: 3, 6, 8, 12 
5 - 144.7, C - 
6 - 136.4, C - 
7 - 139.1, C - 
8 - 134.4, C - 
9 - 154.7, C - 
10 1.25 (d, J = 7.2) 16.7, CH3 C: 1, 2, 3 
11 - - - 
12a 
12b 
5.10 (d, J = 12.3) 
4.78 (d, J = 12.3) 
70.2, CH2 C: 4, 5, 6, 1´ 
13 3.26 (t, J = 8.0) 32.5, CH2 C: 5, 6, 7, 14 
14 3.70 (t, J = 8.0) 43.8, CH2 - 
15 2.66 (s) 13.7, CH3 C: 4, 5, 6, 7, 8 
1′ 4.39 (d, J = 7.7) 103.5, CH C: 12, 3´, 5´ 
2′ 3.26 (m) 75.2, CH C: 1´, 3´, 5´ 
3′ 3.31 (m) 78.2, CH - 
4′ 3.31 (m) 71.8, CH - 
5′ 3.36 (m) 78.2, CH C: 4´ 
6′a 
6′b 
3.92 (dd, J5′, 6′a = 1.5, J6′a, 6′b = 11.5)  
3.69 (dd, J5′, 6′b = 3.0) 
62.9, CH2 - 
¤ HMBC correlations are from proton(s) stated to the indicated carbon(s) 
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Using the same rationale as for determination of the location of the sugar as for RH11, HMBC 
data confirmed that the sugar was attached through a glycosidic linkage to C-12. Examination 
of the 1H NMR coupling constants for protons around the hexopyranose in native and 
peracetylated forms demonstrated that it was -linked glucose. Also notable was the presence 
of only one methyl group at C-2, H 1.25 (3 H, d, J = 7.2 Hz), with the 13C NMR signal for C-
2 now reported as a methine. Compound RH12 was subjected to CD spectroscopy, but the 
absolute configuration in C-2 was not determined. It is assumed that RH12 is racemised due 
to the presence of an acidic proton in the α-position to the carbonyl group. The structure of 
RH12 was thus established as rhedynoside D (Figure 55). 
A novel compound RH13 was isolated as an off-white crystalline powder (Figure 56). Its 
molecular formula, C21H29ClO7, was deduced from the negative ion mode FT-ICR-MS at m/z 
427.1531 (Calcd for C21H28ClO7: 427.1524), indicating that it was another isomer of RH11. 
The spectroscopic NMR data (1H and 13C) of RH13 is displayed in Table 18. The UV, IR and 
NMR data for the aglycone of RH13 were very similar to those of (3R)-hydroxypterosin H 
(Tanaka et al., 1982) indicating that it has the same structure in the aglycone part (see 
appendices I, III and IV). A NOESY study of compound RH13 showed through-space 
correlations between H-1′ and H-3′ and between H-1′ and H-5′, confirming that these three 
protons are all axial and that the sugar is glucose. Singlet signals for three methyl groups were 
evident in the 1H NMR spectrum, with HMBC confirming that two methyl signals (H 1.28 and 
H 1.09) formed a geminal pair. The third (H 2.49) was in an ArMe environment and was 
confirmed by HMBC data to correspond to C-12. The signal for H-3 was identified as being at 
H 4.85, appropriate to ArCHO; thus, the glycoside was tentatively located at C-3. The HMBC 
correlations from H-3 (H 4.85, s) to C-1′ (C 105.9), and from H-1′ (H 4.58, d, J = 7.7 Hz) to 
C-3 (C 86.1) evidence that the glycosyl residue is connected through C-3 to the aglycone part 
(see appendix I). The application of CD spectroscopy to compound RH13 showed a non-
vibronic n → π* transition which is opposite to the transition observed for RH6. Based on the 
comparison of CD data of RH13 to that for RH19 reported by Kuroyanagi et al., 1979b, the 
absolute configuration of compound RH13 was assigned as R in position C-3. The reported 
compounds, 13-chloro-spelosin 3-O-β-D-glucopyranoside (Chen et al., 2015) and (2R,3R)-
pterosin L 3-O-β-D-glucopyranoside  (Chen et al., 2008), whose 1H and 13C NMR data are very 
similar to compound RH13, also show R configuration in position C-3. As a result of these 
observations, RH13 was identified as rhedynoside E (Figure 56). 
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Figure 56: Chemical Structure of (3R)-Rhedynoside E (RH13). 
Table 18: 1H (400 MHz) and 13C (100 MHz) spectral data of compound RH13 in 
CD3OD (δ in ppm, multiplicity, J in Hz). 
Position δH δC HMBC± 
1 - 211.2, C - 
2 - 52.6, C - 
3 4.85 (s) 86.1, CH C: 8, 9, 10, 1´ 
4 7.56 (s) 127.0, CH C: 7, 8, 12 
5 - 146.0, C - 
6 - 136.8, C - 
7 - 138.2, C - 
8 - 131.0, C - 
9 - 152.5, C - 
10 1.28 (s) 22.8, CH3 C: 1, 2, 3, 11 
11 1.09 (s) 22.0, CH3 C: 1, 2, 3, 10 
12 2.49 (s) 21.3, CH3 C: 4, 5, 7, 8 
13 3.24 (t, J = 8.0) 33.1, CH2 C: 5, 7, 14 
14 3.63 (t, J = 8.0) 43.0, CH2 C: 7 
15 2.65 (s) 14.1, CH3 C: 4, 7, 8 
1′ 4.58 (d, J = 7.7) 105.9, CH C: 3 
2′ 3.30 (m) 75.3, CH - 
3′ 3.36 (m) 78.0, CH - 
4′ 3.36 (m) 71.7, CH - 
5′ 3.42 (m) 78.3, CH C: 4´ 
6′a 
6′b 
3.93 (dd, J5′, 6′a = 1.5, J6′a, 6′b = 11.8)  
3.75 (dd, J5′, 6′b = 4.0) 
62.9, CH2 - 
± HMBC correlations are from proton(s) stated to the indicated carbon(s) 
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3.4. PHYSICO-CHEMICAL PARAMETERS OF NOVEL COMPOUNDS (RH1-RH13): 
(2S)-Rhedynosin A (RH1); Yellow powder; [𝛼]𝐷
24  -4.3º (c 0.33, CHCl3); UV (MeOH) max nm 
(log ): 211 (4.16), 241 (3.77), 258 (3.85), 306 (2.99); IR (film) νmax 3418, 3014, 2928, 1704, 
1605, 1446, 1380, 1048, 755, 666 cm-1; for 1H and 13C NMR spectroscopic data, see Table 6; 
FT-ICR-MS m/z 247.1330 [M+H]+ (Calcd for C15H19O3: 247.1334). 
(2S)-Rhedynoside A (RH2): White powder; [𝛼]𝐷
24 -26.1º (c 0.33, MeOH); UV (MeOH) max 
nm (log ): 216 (4.27), 259 (3.92), 304 (2.99); IR (film) νmax 3369, 2927, 1692, 1602, 1444, 
1378, 1075, 918 cm-1; for 1H and 13C NMR spectroscopic data, see Table 7; FT-ICR-MS m/z 
409.1866 [M+H]+ (Calcd for C21H29O8: 409.1862). 
Rhedynosin B (RH3): Yellow powder; [𝛼]𝐷
24 -12.8º (c 0.33, CHCl3); UV (MeOH) max nm (log 
): 209 (4.31), 260 (3.96), 313 (3.09); IR (film) νmax 3419, 3018, 2926, 1715, 1603, 1446, 1379, 
1290, 1196, 1096, 985, 856, 754, 666 cm-1; for 1H and 13C NMR spectroscopic data, see Table 
8; FT-ICR-MS m/z 247.0967 [M+H]+ (Calcd for C14H15O4: 247.0970). 
Rhedynosin C (RH4): White powder; [𝛼]𝐷
24 +3.8º (c 0.33, MeOH); UV (MeOH) max nm (log 
): 214 (3.24), 242 (2.97), 258 (2.94), 306 (2.51); IR (film) νmax 3428, 2924, 1703, 1608 1458, 
1379, 1260, 1034, 800 cm-1; for 1H and 13C NMR spectroscopic data, see Table 9; FT-ICR-MS 
m/z 245.0821 [M-H]- (Calcd for C14H13O4: 245.0814). 
Rhedynosin D (RH5): Yellow solid; [𝛼]𝐷
24 -19.1º (c 0.33, CHCl3); UV (MeOH) max nm (log 
): 215 (4.13), 259 (3.75), 303 (2.76); IR (film) νmax 3418, 2925, 1714, 1602, 1447, 1379, 1093, 
855, 756, 666 cm-1; for 1H and 13C NMR spectroscopic data, see Table 10; FT-ICR-MS m/z 
269.0941 [M+H]+ (Calcd for C14H18
35ClO3: 269.0944). 
(3S)-Rhedynosin E (RH6): Off-white powder; [𝛼]𝐷
24 -15.0º (c 0.33, MeOH); UV (MeOH) max 
nm (log ): 217 (4.35), 258 (4.02), 295 (3.13); IR (film) νmax 3419, 2932, 1699, 1600, 1465, 
1382, 1203, 1099, 995, 884 cm-1; for 1H and 13C NMR spectroscopic data, see Table 14; FT-
ICR-MS m/z 263.1280 [M+H]+ (Calcd for C15H19O4: 263.1283). 
(2S)-Rhedynosin F (RH7): Light yellow crystalline powder; [𝛼]𝐷
24 +15.4º (c 0.33, CHCl3); UV 
(MeOH) max nm (log ): 219 (4.27), 259 (3.87), 298 (2.92); IR (film) νmax 3417, 2929, 1698, 
1598, 1455, 1379, 1223, 1042, 923, 859, 755 cm-1; for 1H and 13C NMR spectroscopic data, 
see Table 12; FT-ICR-MS m/z 283.1098 [M+H]+ (Calcd for C15H20
35ClO3: 283.1101).  
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Rhedynosin G (RH8): Yellow gum; [𝛼]𝐷
24 +4.0º (c 0.33, MeOH); UV (MeOH) max nm (log ): 
218 (4.34), 260 (3.97), 299 (3.03); IR (film) νmax 3405, 2929, 1705, 1599, 1447, 1378, 1217, 
1094, 983, 887, 751 cm-1; for 1H and 13C NMR spectroscopic data, see Table 11; FT-ICR-MS 
m/z 269. 0941 [M+H]+ (Calcd for C14H18
35ClO3: 269.0944). 
Rhedynosin H (RH9): Off-white powder; [𝛼]𝐷
24 -28.0º (c 0.33, CHCl3); UV (MeOH) max nm 
(log ): 217 (4.71), 258 (4.37), 303 (3.55); IR (film) νmax 2919, 1704, 1601, 1456, 1377, 1325, 
1221, 1129, 1020, 970, 885, 756, 702 cm-1; for 1H and 13C NMR spectroscopic data, see Table 
13; FT-ICR-MS m/z 297. 0802 [M-H]- (Calcd for C14H17O5S: 297.0797). 
(2R)-Rhedynoside B (RH10): White crystalline compound; [𝛼]𝐷
24 -10.8º (c 0.33, MeOH); UV 
(MeOH) max nm (log ): 219 (4.48), 263 (4.12), 304 (3.11), nm; IR (film) νmax 3391, 2926, 
1703, 1601 1451, 1376, 1327, 1227, 1074, 918, 872 cm-1; for 1H and 13C NMR spectroscopic 
data, see Table 15; FT-ICR-MS m/z 415.1527 [M+H]+ (Calcd for C20H28
35ClO7: 415.1523). 
Rhedynoside C (RH11): Off-white crystalline powder; [𝛼]𝐷
25 -0.5º (c 0.33, MeOH); UV 
(MeOH) max nm (log ): 216 (4.43), 257 (3.98), 303 (2.93); IR (film) νmax 3391, 2927, 1699, 
1601, 1440, 1379, 1326, 1077, 918, 888 cm-1; for 1H and 13C NMR spectroscopic data, see 
Table 16; FT-ICR-MS m/z 427.1530 [M-H]- (Calcd for C21H28
35ClO7: 427.1524). 
Rhedynoside D (RH12): Yellow powder; [𝛼]𝐷
25 -0.6º (c 0.33, MeOH); UV (MeOH) max nm 
(log ): 216 (4.43), 256 (4.01), 303 (2.98); IR (film) νmax 3374, 2928, 1700, 1600, 1440, 1376, 
1312, 1163, 1075, 921, 890 cm-1; for 1H and 13C NMR spectroscopic data, see Table 17; FT-
ICR-MS m/z 413.1374 [M-H]- (Calcd for C20H26
35ClO7: 413.1367). 
(3R)-Rhedynoside E (RH13): Off-white crystalline powder; [𝛼]𝐷
25 +0.4º (c 0.33, MeOH); UV 
(MeOH) max nm (log ): 218 (4.40), 258 (3.92), 300 (2.63); IR (film) νmax 3390, 3018, 2928, 
1703, 1599, 1462, 1380, 1325, 1162, 1076, 898, 757 cm-1; for 1H and 13C NMR spectroscopic 
data, see Table 18; FT-ICR-MS m/z 427.1530 [M-H]- (Calcd for C21H28
35ClO7: 427.1524). 
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3.5. STRUCTURAL ELUCIDATION OF PREVIOUSLY REPORTED COMPOUNDS 
Table 19: Compound RH14 [(2S)-Rhedynosin I] 
IUPAC name 
(S)-7-(hydroxymethyl)-5,7-dimethyl-3,4,7,8-tetrahydrocyclopenta 
[g]isochromene-1,6-dione 
Sample ID RH14  
Sample quantity 6 mg 
Physical appearance Yellow gum   
Molecular formula C15H16O4 
Molecular Weight 260.2890 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 8.02 (1H, s, H-4), 4.55 (2H, t, J = 6.0 Hz, H2-14), 3.77 (1H, 
d, J = 10.6 Hz, Ha-11), 3.50 (1H, d, J = 10.6 Hz, Hb-11), 3.37 (1H, d, J = 17.3 Hz, Ha-3), 3.09 (2H, 
t, J = 6.0 Hz, H2-13), 2.89 (1H, d, J = 17.3 Hz, Hb-3), 2.64 (3H, s, H3-15), 1.12 (3H, s, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 210.6 (C-1), 167.4 (C-12), 153.4 (C-9), 139.8 (C-5), 138.2 (C-7), 
137.7 (C-6), 126.7 (C-4), 130.9 (C-8), 68.4 (C-14), 68.3 (C-11), 53.1 (C-2), 37.7 (C-3), 25.2 (C-13), 21.0 
(C-10), 13.2 (C-15). 
Compound RH14, obtained as a yellow gum, gave the molecular formula of C15H17O4 by HR-
ESI-MS at m/z 261.1123 [M+H]+ (Calcd for C15H17O4: 261.1127), with eight degrees of 
unsaturation. The 1H NMR spectrum of RH14 closely resembled that of RH1. The major 
difference was the absence of a methylene signal at  4.80 (CH2-12) in RH14. The presence 
of a downfield chemical shift at C 167.4, as a quaternary C-12, in the 13C NMR spectrum of 
RH14 indicated that the methylene group (CH2-12) of RH1 was oxidised to a carbonyl group 
in RH14. The HMBC of RH14 supported the presence of carbonyl at position C-12. Also, the 
appearance of carbonyl group at C-12 verified further with the accurate mass spectrum of 
RH14 which showed 14 Da more than of RH1. Thus, compound RH14 was confirmed as (S)-
7-hydroxymethyl-5, 7-dimethyl-3, 4, 7, 8-tetrahydrocyclopenta-[g]isochromene-1, 6-dione. 
CD spectroscopy allowed to assign the configuration of RH14 at position C-2 as 2S. This 
compound has previously been isolated  and identified along with 18 other compounds as a 
metabolism product of (2S)-pterosin A (RH15) in rat urine (Lee et al., 2012). This compound 
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isolated for the first time from plant material as opposed to mammalian metabolic products. In 
this thesis, hence rhedynosin I was suggested as a common name for compound RH14.  
Table 20: Compound RH16 [(2R)-Pterosin B] 
IUPAC name (R)-6-(2-hydroxyethyl)-2,5,7-trimethyl-2,3-dihydro-1H-inden-1-one 
Sample ID RH16  
Sample quantity 110 mg 
Physical appearance Yellow needles solid 
Molecular formula C14H18O2 
Molecular Weight 218.2960 g/mol 
 
NMR data 
1H NMR (400 MHz, CDCl3): δH ppm 7.09 (1H, s, H-4), 3.75* (1H, t, J = 7.5 Hz, Ha-13), 3.75* (1H, 
t, J = 7.5 Hz, Ha-14), 3.23 (1H, dd, J = 16.6, 7.7 Hz, Ha-3), 3.02* (1H, t, J = 7.5 Hz, Hb-13), 3.02* 
(1H, t, J = 7.5 Hz, Hb-14), 2.68 (3H, s, H3-15), 2.64 (1H, m, H-2), 2.58 (1H, dd, J = 17.4, 3.4 Hz, 
Hb-3), 2.43 (3H, s, H3-12), 1.27 (3H, d, J = 7.3 Hz, H3-10). 
13C NMR (101 MHz, CDCl3): δC ppm 210.6 (C-1), 152.6 (C-9), 144.5 (C-5), 137.9 (C-7), 135.0 (C-6), 132.1 
(C-8), 125.7 (C-4), 61.5 (C-14), 42.6 (C-2), 33.8 (C-3), 31.9 (C-13), 21.7 (C-12), 16.6 (C-10), 13.7 (C-15). 
* These data were confirmed from the HSQC experiment.
 
Compound RH16 was obtained as a yellow needles solid substance. It has a molecular formula 
of C14H18O2 which was determined on the basis of HR-ESI-MS (positive ion mode) at m/z 
219.1384 [M + H]+ (Calcd for C14H19O2: 219.1385). The 
1H NMR data of RH16 indicated a 
pentasubstituted benzene ring with a single aromatic proton signal at δH 7.09 (1H, s). Two 
coupled methylene groups at δH 3.02 (2H, t, J = 7.5 Hz) and δH 3.75 (2H, t, J = 7.5 Hz) 
suggested the attachment of an ethylene chain to the aromatic ring.  
The 1H NMR spectrum shows two singlets at δH 2.43 (s) and 2.68 (s) which are referred to the 
two methyl groups at positions C-5 and C-7, respectively. The only doublet signal at δH 1.27 
(d, J = 7.3 Hz) is due to the methyl group at C-2, while the multiplet signal at δH 2.64 (m) is 
assigned to H-2. The two signals appeared as doublet of doublet at δH 2.58 (dd, J = 17.4, 3.4 
Hz) and δH 3.23 (dd, J = 16.6, 7.7 Hz) are indicated the presence of two protons at position C-
3. The 1H NMR signals were all consistent with a C14 pterosin sesquiterpene structure (Fukuoka 
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et al., 1983; Kuraishi et al., 1985). The 13C NMR data of RH16 showed 14 distinct carbon 
signals, which were assigned by HSQC experiment to three methyls, three methylenes, two 
methines and six quaternary carbons including one benzene ring and one ketone group. The 
carbon signals also supported the presence of a pentasubstituted aromatic ring, including a low-
field signal at 210.61 ppm (C=O), as assigned to C-1 of a pterosin-type sesquiterpene skeleton 
(Fukuoka et al., 1983).  
The HMBC spectrum utilized to support the structure elucidation of compound RH16 which 
showed the proton-carbon correlations of H-3/C-1, H-3/C-2, H-3/C-4, H-3/C-5, H-3/C-9, H-
3/C-10, H-4/C-3, H-4/C-5, H-4/C-6, H-4/C-12, H-13/C-6, H-13/C-7, H-13/C-8, H-13/C-14, H-
14/C-6 and H-14/C-13, H-10/C-1, H-10/C-2, H-10/C-3, H-12/C-4, H-12/C-5, H-12/C-6, H-
12/C-7, H-12/C-8, H-12/C-9, H-12/C-14, H-15/C-4, H-15/C-5, H-15/C-6, H-15/C-7, H-15/C-
8, H-15/C-9 and H-15/C-14, and confirmed that the compound RH16 is a pterosin-type 
sesquiterpenoid. Moreover, the HMBC spectrum (see appendix I) exhibited cross peaks from 
H-15 to C-6, and H-12 to C-7, establishing the location of hydroxyethyl group at position C-6. 
The NMR data of RH16 thus showed signals typical of (2R)-pterosin B, and this was confirmed 
by comparison of its 1H and 13C NMR data with those reported in the literature (Fukuoka et al., 
1983, 1978; Kuroyanagi et al., 1979a). While CD spectroscopy has been applied to 
compound RH16 in order to determine and confirm its absolute configuration at position C-
2, the resulting spectrum did not show chirality which is thought to be caused by 
formation of the racemic mixture (Kuroyanagi et al., 1979b). 
(2R)-pterosin B is abundant in plant ferns and has been isolated from the young fronds of 
bracken,  P. aquilinum var. latiusculum (Yoshihira et al., 1978) and P. aquilinum var. caudatum 
(Castillo et al., 1997), the whole plants of Pteris ensiformis (Chen et al., 2013, 2008), Pteris 
setuloso-costulata and Histiopteris incisa (Murakami et al., 1980) and fronds of Pteris bella 
TAGAWA (Tanaka et al., 1982). This compound has been evaluated for its cytotoxicity toward 
human lung carcinoma, A549; breast carcinoma, MCF-7; human breast carcinoma, MDA-MB-
231; human liver cancer, Hep G2; human oral squamous carcinoma, Ca9-22; and human 
leukemia HL 60 cell lines. As a result, it showed selective activity against HL 60 (human 
leukemia) cell lines with the IC50 value of 8.7 µg/mL while it displayed no effect 
(pharmacological activity) against the other cell lines (Chen et al., 2008). (2R)-pterosin B along 
with pterosins F, I, O, Z and V have showed activities that induce abnormal development of 
urchin embryos, and they have also been found to have cytotoxic effect on ciliate, Paramecium 
caudatum (Kobayashi and Koshimizu, 1980). Recently, it has been identified that intra-
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articular injection of mice with pterosin B can effectively protect cartilage from osteoarthritis 
development and inhibit chondrocyte hypertrophy. Based on the histological study of the 
pellets, it has also been found that the addition of pterosin B in the medium had effect on the 
protection of chondrocytes from hypertrophy and mineralization (Yahara et al., 2016). 
Eventually, Yahara et al. state that “Collectively, our results suggest Sik3 (salt-inducible 
kinase) regulates the homeostasis of articular cartilage and is a target for the treatment of 
osteoarthritis, with pterosin B as a candidate therapeutic”. Furthermore, it is also patented that 
pterosin B enables to increase cartilage matrices production and prevent hypertrophy of human 
chondrocytes. Thus, pterosin B has been showed to be active in promoting the growth of 
hyaline cartilage in humans as it has been tested in vivo by administration of pterosin B into 
the knee articular cavity (Tsumaki et al., 2015). 
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Table 21: Compound RH31 [(2R)-Pteroside B] 
IUPAC name 
(R)-2,5,7-trimethyl-6-(2-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethyl)-2,3-dihydro-
1H-inden-1-one 
Sample ID RH31  
Sample quantity 203 mg 
Physical appearance Pale-yellow crystalline solid 
Molecular formula C20H28O7 
Molecular Weight 380.4370 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.13 (1H, s, H-4), 4.31 (1H, d, J = 7.8 Hz, H-1′), 3.89 (1H, dd, J = 
17.1, 8.3 Hz, Ha-14), 3.85 (1H, dd, J = 11.8, 1.9 Hz, Ha-6′), 3.66 (1H, dd, J = 11.7, 5.0 Hz, Hb-6′), 3.64 (1H, 
dd, J = 17.7, 9.1 Hz, Hb-14), 3.36 (1H, t, J = 8.3 Hz, H-3′), 3.30 (1H, m, H-4′), 3.27 (1H, m, H-5′), 3.24 (1H, 
dd, J = 16.9, 7.4 Hz, Ha-3), 3.19 (1H, dd, J = 7.2, 6.4 Hz, H-2′), 3.09 (2H, t, J = 8.0 Hz, H2-13), 2.64 (3H, s, 
H3-15), 2.61 (1H, m, H-2), 2.56 (1H, dd, J = 16.9, 4.5 Hz, Hb-3), 2.44 (3H, s, H3-12), 1.22 (3H, d, J = 7.2 
Hz, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 212.6 (C-1), 154.4 (C-9), 146.3 (C-5), 138.8 (C-7), 136.2 (C-6), 132.8 
(C-8), 126.8 (C-4), 104.4 (C-1′), 78.2 (C-3′), 78.0 (C-5′), 75.1 (C-2′), 71.6 (C-4′), 69.2 (C-14), 62.7 (C-6′), 
43.8 (C-2), 34.7 (C-3), 30.1 (C-13), 21.4 (C-12), 16.8 (C-10), 13.8 (C-15). 
Compound RH31 was obtained as a pale-yellow crystalline powder. The positive mode HR-ESI-
MS showed a quasimolecular ion peak at m/z 381.1907 [M+H]+, suggesting a molecular 
formula of C20H29O7 (Calcd for 381.1913). The 
1H and 13C NMR spectra of this compound 
(see appendix I and Table 21) showed signals that are similar to those of RH16 with the 
exception of signals for the glucose moiety and the downfield shift of the resonance at C-14 
(δc 69.16), suggesting it to be the site of glycosylation. The 1H NMR spectrum also exhibited 
the chemical shift of an anomeric proton at δH 4.31 (d, J = 7.8 Hz) and the other proton signals 
of the sugar moiety at H 3.19-3.85. Based on the coupling constant of the anomeric proton, 
the configuration of the sugar moiety was determined to be β-oriented indicating a β-glycosyl 
moiety.  
The 13C NMR spectrum of RH31 displayed twenty carbon signals, and the DEPTQ spectrum 
(see appendix I) showed that these comprised of three methyls, four methylenes, seven 
methines and six quaternary carbons. The anomeric carbon appeared at δc 104.42. In addition, 
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other signals for the glucose occurred at δc 75.12 (C-2′), 78.15 (C-3′), 71.56 (C-4′), 77.96 (C-
5′) and 62.67 (C-6′) which are typical signals for the glucose molecule (Fukuoka et al., 1983). 
This indicated that the compound RH31 was a glycoside of the compound RH16. The X-ray 
crystallography applied for the first time to compound RH31 (Figure 57) which confirmed the 
sugar moiety as D-glucose and also indicated that the absolute configuration of the compound 
at a chiral centre C-2 is R.  
 
Figure 57:  X-ray crystallographic structure of the compound RH31. 
Even though the CD spectrum measured in methanol for this compound, unpredictably no 
Cotton effect (n → π* transition at 300-360 nm) was observed. The absolute configuration of 
RH31 (Figure 57) was established based on X-ray diffraction analysis for its single crystals, in 
which the result is in agreement with the CD curve reported by Kuroyanagi et al. (1979b) for 
this compound. The single crystal X-ray data is deposited with Cambridge Crystallographic 
Data Centre. 
In the analysis of HMBC spectrum (see appendix I), it is noticed that the H-1′ (δH 4.31) was 
linked to C-14 (δC 69.16) and H2-14 (δH 3.64 and 3.89) was connected to C-1′ (δC 104.42), 
signifying that the β-D-glucose moiety was located at position C-14 of the pterosin skeleton. 
Thus, the absolute chemical structure of RH31 confirmed to be (2R)-pteroside B (synonym: 
pterosin B glycoside). The 1H and 13C NMR data (Table 21) of this compound are consistent 
with the reported literature values (Fukuoka et al., 1983, 1978). Compound RH31  has been 
isolated from P. aquilinum Kuhn var. latiusculum (Hikino et al., 1970) and the whole plant of 
Pteris multifida Poir. (Pteridaceae) (Ge et al., 2008).
Chapter Three Results and discussion 
 
82 
 
Table 22: Compound RH15 [(2S)-Pterosin A] 
IUPAC name 
(S)-6-(2-hydroxyethyl)-2-(hydroxymethyl)-2,5,7-trimethyl-2,3-
dihydro-1H-inden-1-one 
Sample ID RH15  
Sample quantity 160 mg 
Physical appearance Yellow crystalline solid 
Molecular formula C15H20O3 
Molecular Weight 248.3220 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.16 (1H, s, H-4), 3.71 (1H, d, J = 10.6 Hz, Ha-11), 3.61* 
(1H, t, J = 7.6 Hz, Ha-13), 3.61* (1H, t, J = 7.6 Hz, Ha-14), 3.46 (1H, d, J = 10.6 Hz, Hb-11), 3.23 
(1H, d, J = 17.1 Hz, Ha-3), 2.99* (1H, t, J = 7.6 Hz, Hb-13), 2.99* (1H, t, J = 7.6 Hz, Hb-14), 2.72 
(1H, d, J = 17.1 Hz, Hb-3), 2.65 (3H, s, H3-15), 2.44 (3H, s, H3-12), 1.09 (3H, s, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 212.9 (C-1), 154.1 (C-9), 146.2 (C-5), 138.8 (C-7), 136.4 
(C-6), 133.1 (C-8), 126.9 (C-4), 68.3 (C-11), 61.7 (C-14), 52.6 (C-2), 37.5 (C-3), 32.9 (C-13), 21.3 
(C-10), 21.3 (C-12), 13.9 (C-15). 
* These data were confirmed from the HSQC experiment. 
Compound RH15, isolated as a yellow crystalline solid, exhibited the molecular formula 
C15H21O3 by positive mode HR-ESI-MS (m/z 249.1489; Calcd for 249.1491), indicating six 
degrees of unsaturation in its structure. Comparison of the NMR spectral data of RH15 with 
those of RH16 revealed that they were quite similar to each other with some exceptions. The 
1H NMR spectrum exhibited that the tertiary proton at position C-2 in RH16 was replaced by 
a hydroxymethylene group in RH15. This fact was established based on the absence of a 
multiplet peak of H-2 (δH 2.64) and the appearance of H3-10 as a singlet (δH 1.09) in RH15.  
The DEPTQ spectrum also showed an extra methylene in addition of detecting C-2 as 
quaternary carbon. On the other hand, their mass values gave a difference of 30 amu which 
corresponds to the replacement observed. The correlations of H-11 (δH 3.46 and 3.71) with C-
2 (δC 52.16), C-3 (δC 37.50), and C-10 (δC 21.33) in HMBC spectrum of RH15 confirmed the 
above deduction. The CD spectrum of RH15 exhibited negative and positive vibronic 
components associated with the n → π* transition in the range of 320-360 nm (Figure 59). 
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Thus, compound RH15 was assigned to be 2S configuration (Kuroyanagi et al., 1979b) and 
confirmed by X-ray diffraction (Figure 58). The single crystal X-ray data is submitted to 
Cambridge Crystallographic Data Centre. Based on the above analysis and comparison of the 
NMR data (Table 22) with those reported in the literature (Hsu et al., 2013; Kovganko et al., 
2004; Lee et al., 2012), the structure of this compound was determined as (2S)-pterosin A 
(RH15).  
This compound has been isolated from the aerial part (frond) of the bracken-fern P. aquilinum 
L. (Hypolepidaceae) (Kovganko et al., 2004), fresh fronds of P. aquilinum var. caudatum 
(Castillo et al., 1997), the air-dried fronds of Microlepia substrigosa TAGAWA (Kuraishi et 
al., 1985) and the rhizomes of P. aquilinum var. latiusculum (Kuroyanagi et al., 1979a; 
Yoshihira et al., 1978), and it is reported to show no inhibition effect on sea urchin embryonic 
development and no cytotoxic effect against a ciliate, Paramecium caudatum (Kobayashi and 
Koshimizu, 1980).  
Interestingly, the therapeutic effect of pterosin A on diabetes has recently been 
investigated using several diabetic mouse models, and found that the oral administration 
of pterosin A can alleviate hyperglycemia and glucose intolerance in streptozotocin (STZ) 
and high-fat diet-fed (HFD) diabetic mice (Hsu et al., 2013). It has been concluded that 
pterosin A can significantly reverse the increased serum insulin and insulin resistance in 
diabetic mice. It has also been observed that pterosin A is capable of reducing the high 
serum levels of total cholesterol and LDL-cholesterol in STZ- and HFD-induced diabetic 
mice. Furthermore, it has also been noticed that pterosin A has the ability to improve 
glucose homeostasis and insulin resistance, i.e. it can recover the decreased body weight 
in STZ-diabetic mice and reduce the increased body weight in HFD-fed mice. Based on 
these findings, Hsu et al. (2013) have indicated that pterosin A may possibly be an 
alternative therapeutic for diabetes. 
 
Figure 58: X-ray crystallographic structure of the compound RH15. 
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Figure 59: The CD spectra of RH15 and RH30 in methanol illustrating the superposition 
of a longer wavelength positively signed vibronic progression and a shorter wavelength 
negatively signed vibronic progression.
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Table 23: Compound RH30 [(2S)-Pteroside A] 
IUPAC name 
(S)-2-(hydroxymethyl)-2,5,7-trimethyl-6-(2-(((2R,3R,4S,5S,6R) -
3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl) 
oxy)ethyl)-2,3-dihydro-1H-inden-1-one 
Sample ID RH30  
Sample quantity 10.2 mg 
Physical appearance Yellow-orange gum 
Molecular formula C21H30O8 
Molecular Weight 410.4630 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.16 (1H, s, H-4), 4.32 (1H, d, J = 7.8 Hz, H-1′), 3.90 (1H, 
m, Ha-14), 3.85 (1H, dd, J = 11.9, 1.5 Hz, Ha-6′), 3.71 (1H, d, J = 10.6 Hz, Ha-11), 3.66 (1H, dd, J 
= 11.7, 5.3 Hz, Hb-6′), 3.64 (1H, m, Hb-14), 3.46 (1H, d, J = 10.6 Hz, Hb-11), 3.34 (1H, m, H-3′), 
3.30 (1H, m, H-4′), 3.27 (1H, m, H-5′), 3.23 (1H, d, J = 17.2 Hz, Ha-3), 3.18 (1H, t, J = 8.7 Hz, H-
2′), 3.10 (2H, t, J = 8.0 Hz, H2-13), 2.72 (1H, d, J = 17.2 Hz, Hb-3), 2.66 (3H, s, H3-15), 2.45 (3H, 
s, H3-12), 1.09 (3H, s, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 212.88 (C-1), 154.2 (C-9), 146.4 (C-5), 138.9 (C-7), 136.1 
(C-6), 133.1 (C-8), 126.9 (C-4), 104.4 (C-1′), 78.2 (C-3′), 78.0 (C-5′), 75.1 (C-2′), 71.6 (C-4′), 69.2 
(C-14), 68.3 (C-11), 62.7 (C-6′), 52.6 (C-2), 37.5 (C-3), 30.1 (C-13), 21.4 (C-10), 21.3 (C-12), 
13.9 (C-15). 
Compound RH30 (10.2 mg) was obtained as a pale-yellow gum substance. It has a molecular 
formula of C21H30O8 which was established on the basis of positive mode HR-ESI-MS at m/z 
411.2019 [M + H]+ (Calcd for C21H31O8: 411.2019). The DEPTQ spectrum (see appendix I) 
showed 21 carbon signals, which consisted of three methyls, five methylenes, six methines and 
seven quaternary carbons. The comparison of the 1H and 13C NMR data (Table 23) with that 
of RH15 revealed close similarity except for the presence of signals for glucose moiety. Hence, 
the aglycone is suggested to be a pterosin A.  
The 1H NMR spectrum showed one anomeric proton at δH 4.32 (H-1′, d, J = 7.8 Hz), indicating 
a β-glycosyl moiety based on the coupling constant. Moreover, in the COSY spectrum (see 
appendix I), the correlation between the anomeric proton signal δH 4.32 (d, 7.8 Hz, H-1′) with 
δH 3.18 (t, 8.7 Hz, H-2′) assigned to position C-2′ was observed. The anomeric carbon appeared 
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at δc 104.44 and the remaining 13C NMR data for the glucose moiety occurred at δc 75.14 (C-
2′), 78.17 (C-3′), 71.58 (C-4′), 77.99 (C-5′) and 62.68 (C-6′) which are consistent with those of 
glucose.  
The attachment of the glucose unit at C-14 was apparent from the downfield shift of the 
resonance at C-14 (δc 69.20) and the H-1′ to C-14 HMBC connectivity (see appendix I). 
Comparison of the NMR values (Table 23) with those published (Fukuoka et al., 1983), 
identified pteroside A as the compound isolated. The absolute configuration of RH30 was 
determined from the CD spectrum (Figure 59), which showed a negative Cotton effect at 329 
nm in methanol, indicating the (2S)-configuration. This is in agreement with the reported CD 
curve for this compound (Kuroyanagi et al., 1979b). Accordingly, compound RH30 was 
confirmed to be (2S)-pteroside A.
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Table 24: Compound RH34 [(2S)-Pteroside A2] 
IUPAC name 
(S)-6-(2-hydroxyethyl)-2,5,7-trimethyl-2-((((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)-
2,3-dihydro-1H-inden-1-one 
Sample ID RH34  
Sample quantity 4.2 mg 
Physical appearance Pale-yellow gum 
Molecular formula C21H30O8 
Molecular Weight 410.4630 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.16 (1H, s, H-4), 4.20 (1H, d, J = 7.8 Hz, H-1′), 4.12 (1H, d, J = 9.4 
Hz, Ha-11), 3.77 (1H, dd, J = 12.0, 1.1 Hz, Ha-6′), 3.61 (1H, m, Hb-6′), 3.61 (2H, t, J = 7.8 Hz, H2-14), 3.48 
(1H, d, J = 9.4 Hz, Hb-11), 3.43 (1H, d, J = 17.0 Hz, Ha-3), 3.29 (1H, m, H-3′), 3.21 (1H, m, H-4′), 3.21 (1H, 
m, H-5′), 3.04 (1H, dd, J = 8.8, 8.1 Hz, H-2′), 2.99 (2H, t, J = 7.8 Hz, H2-13), 2.72 (1H, d, J = 17.0 Hz, Hb-
3), 2.64 (3H, s, H3-15), 2.44 (3H, s, H3-12), 1.13 (3H, s, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 212.4 (C-1), 154.1 (C-9), 146.4 (C-5), 138.9 (C-7), 136.4 (C-6), 132.6 
(C-8), 127.1 (C-4), 104.7 (C-1′), 78.1 (C-3′), 77.9 (C-5′), 75.0 (C-11), 74.9 (C-2′), 71.5 (C-4′), 62.7 (C-6′), 
61.7 (C-14), 51.4 (C-2), 37.5 (C-3), 32.9 (C-13), 22.1 (C-10), 21.3 (C-12), 13.9 (C-15). 
Compound RH34 (4.2 mg), obtained as a pale-yellow sticky compound, has a molecular 
formula of C21H30O8 as shown by high resolution mass spectrum HR-ESI-MS at m/z 411.2014 
[M + H]+ (Calcd for C21H30O8: 411.2019), and this indicating seven degrees of unsaturation in 
its structure. Similarly, when comparing the 1H NMR spectra of this compound with that of 
RH15, the presence of all the proton signals of RH15 can be observed with the exception of 
the signals for a glucose moiety. Hence, this observation suggests that the aglycone is a pterosin 
A. Based on the coupling constant of the anomeric proton showed by the 1H NMR spectrum at 
δH 4.20 (d, J = 7.8 Hz, H-1′), the sugar moiety configuration is assigned to be β-oriented 
indicating a β-glycosyl moiety. The COSY spectrum (see appendix I), also shows the coupling 
of H-1′ with H-2′ (δH 3.04), H-2′ with H-3′ (δH 3.29), H-4′ and H-5′ (δH 3.21) with Hb-6′ (δH 
3.61), Ha-3 (δH 3.43) with Hb-3 (δH 2.72), H-13 (δH 2.99) with H-14 (δH 3.61) and Ha-11 (δH 
4.12) with Hb-11 (δH 3.48).  
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The DEPTQ spectrum (see appendix I) revealed 21 signals equivalent to three methyls, five 
methylenes, six methines and seven quaternary carbons. The spectrum also showed an 
anomeric carbon at 104.72 (C-1′) and other signals for glucose (C-2′ to C-6′) were observed at 
range of δH 62.74-78.13 which are compatible with those of glucose. Moreover, the C-11 
site of glycoside resonated at higher field δC 75.03, thus showing a shielding effect and this 
indicated that the attachment of the sugar moiety was at C-11 through a C-O-C linkage. 
Likewise, the HMBC experiment (see appendix I), exhibited the correlation from the anomeric 
proton signal at δH 4.20 (H-1′) to δC 76.1 (C-3) confirming the site of linkage mentioned above. 
Accordingly, the structure of RH34 was confirmed as (2S)-pteroside A2 which is a positional 
isomer of compound RH30. The application of CD spectroscopy allowed to determine the 
absolute stereochemistry of RH34 as 2S at position C-2. 
This compound isolated for the first time from the rhizomes of P. aquilinum (L.) Kuhn subsp. 
aquilinum. Compound RH34 has been previously isolated by Castillo et al. (2003) from 
the young fronds of Pteridium caudatum (L.) Maxon (Synonym: P. aquilinum (L.) Kuhn 
var. caudatum). The 1H and 13C NMR data (Table 24) of this compound are consistent with 
the reported values published in the literature (Castillo et al., 2003).
Chapter Three Results and discussion 
 
89 
 
Table 25: Compound RH17 [(2R, 3R)-Pterosin C or trans-Pterosin C] 
IUPAC name 
(2R,3R)-3-hydroxy-6-(2-hydroxyethyl)-2,5,7-trimethyl-2,3-dihydro-
1H-inden-1-one 
Sample ID RH17  
Sample quantity 18 mg 
Physical appearance Pale-yellow crystalline powder 
Molecular formula C14H18O3 
Molecular Weight 234.2950 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.36 (1H, s, H-4), 4.69 (1H, d, J = 4.0 Hz, H-3), 3.61* (1H, 
t, J = 7.8 Hz, Ha-13), 3.61* (1H, t, J = 7.8 Hz, Ha-14), 3.01* (1H, t, J = 7.8 Hz, Hb-13), 3.01* (1H, 
t, J = 7.8 Hz, Hb-14), 2.65 (3H, s, H3-15), 2.48 (3H, s, H3-12), 2.43 (1H, m, H-2), 1.30 (3H, d, J = 
7.3 Hz, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 206.2 (C-1), 153.1 (C-9), 144.8 (C-5), 136.7 (C-7), 136.5 
(C-6), 130.9 (C-8), 124.2 (C-4), 74.4 (C-3), 60.1 (C-14), 53.1 (C-2), 31.5 (C-13), 19.9 (C-12), 12.5 
(C-15), 11.7 (C-10). 
* These data were confirmed from the HSQC experiment.
 
Compound RH17 was isolated as a pale-yellow crystalline powder, and its molecular formula 
was established as C14H18O3 by HR-ESI-MS as m/z 235.1329 [M + H]
+ (Calcd for C14H19O3: 
235.1334). The comparison of the 1H and 13C NMR data of RH17 (Table 25) with those of 
RH16 revealed close similarity except for the downfield shifts of the signals at H-3 (δH 4.69, 
d, J = 4.0 Hz) and position C-3 (δc 74.42), suggesting the presence of one hydroxyl group (OH) 
at position C-3, i.e. one of the protons at position C-3 replaced with an OH group. The HSQC 
spectrum (see appendix I), showed direct correlation between C-3 and H-3.  
The 1H NMR disclosed the existence of one carbinyl proton (δH 4.69, H-3), one methine proton 
(δH 2.43, H-2), one deshielded aromatic proton (δH 7.36, H-4), three methyl groups including 
two aromatic methyls appeared as singlet signals and one hydroxylethyl group. The structure 
was therefore deduced to be the 3-hydroxy derivative of pterosin B (RH16). The 1H and 13C 
NMR data of this compound are consistent with those reported in the literature (Ayer and 
McCaskill, 1981; Kuroyanagi et al., 1979a; Ng and McMorris, 1984). Ng and McMorris have 
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reported that can be distinguished between the cis and trans isomers from their NMR data. 
Thus, the trans-configuration of the methyl at C-2 and the hydroxyl (OH) at C-3 in RH17 was 
assigned by the vicinal coupling constant value (J2, 3 = 4.0 Hz) and the appearance of C2-
metheyl and C3-proton as doublets at δH 1.30 and δH 4.69, respectively (Ge et al., 2008; 
Murakami et al., 1985; Ng and McMorris, 1984).  
The absolute configuration of compound RH17 was established from its CD spectrum (Figure 
61), which revealed a strong negative Cotton effect at 330 nm in methanol, indicating the (2R, 
3R)-configuration, i.e. the OH group at C-3 is present in pseudo-axial conformation irrespective 
of the configuration at C-2 and the solvent (Kuroyanagi et al., 1979b, 1974b). Consequently, 
compound RH17 was assigned as (2R, 3R)-pterosin C. To further confirm the structure and the 
absolute stereochemistry of RH17, X-ray crystallographic study was conducted and ultimately 
the structure of RH17 confirmed as shown in Table 25. The single crystal X-ray data is 
submitted to Cambridge Crystallographic Data Centre. This compound has been isolated from 
the rhizomes of P. aquilinum var. latiusculum (Kuroyanagi et al., 1979a).  
 
Figure 60: X-ray crystallographic structure of the compound RH17. 
 
Figure 61: The CD spectra of RH17, RH18, and RH22 recorded in methanol. 
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Table 26: Compound RH18 [(2S, 3R)-Pterosin C or cis-Pterosin C] 
IUPAC name 
(2S,3R)-3-hydroxy-6-(2-hydroxyethyl)-2,5,7-trimethyl-2,3-dihydro-
1H-inden-1-one 
Sample ID RH18  
Sample quantity 20 mg 
Physical appearance White - pale yellow crystalline solid 
Molecular formula C14H18O3 
Molecular Weight 234.2950 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.37 (1H, s, H-4), 5.15 (1H, d, J = 6.6 Hz, H-3), 3.61* (1H, 
t, J = 7.8 Hz, Ha-13), 3.61* (1H, t, J = 7.8 Hz, Ha-14), 3.01* (1H, t, J = 7.8 Hz, Hb-13), 3.01* (1H, 
t, J = 7.8 Hz, Hb-14), 2.76 (1H, m, H-2), 2.65 (3H, s, H3-15), 2.48 (3H, s, H3-12), 1.17 (3H, d, J = 
7.5 Hz, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 210.4 (C-1), 155.2 (C-9), 146.3 (C-5), 138.5 (C-7), 138.1 
(C-6), 132.2 (C-8), 126.7 (C-4), 70.2 (C-3), 61.6 (C-14), 49.7 (C-2), 33.1 (C-13), 21.4 (C-12), 14.0 
(C-15), 10.7 (C-10). 
* These data were confirmed from the HSQC experiment.
 
Compound RH18 was obtained as a whit-pale yellow crystalline solid. The molecular formula 
of C14H18O3 established from the positive mode HR-ESI-MS at m/z 235.1327 [M + H]
+ (Calcd 
for C14H19O3: 235.1334), which is exactly identical to that of RH17 discussed above. The NMR 
spectral data of this compound were quite similar to those of RH17, except for the chemical 
shifts and coupling constant values due to H-2, H-3, and methyl-2 of the 1-indanone skeleton. 
The observed vicinal coupling constant value, J2, 3 = 6.6 Hz, indicated RH18 to be a cis-isomer, 
i.e. the larger coupling constant refers to the cis-isomer 1-indanone derivatives  (Ge et al., 2008; 
Ng and McMorris, 1984).  
The CD spectrum exhibited a negative Cotton effect at 330 nm in methanol (Figure 61), 
indicating that RH18 has R-configuration at C-3, regardless of the configuration at C-2 
(Kuroyanagi et al., 1979b, 1974b). In addition, for the first time the X-ray crystallography 
(Figure 62) was carried out which further confirmed the structure and the absolute 
stereochemistry of RH18 as shown in Table 26. The single crystal X-ray data is submitted to 
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Cambridge Crystallographic Data Centre. The structure of compound RH18 was therefore 
determined to be (2S, 3R)-pterosin C. The NMR data of RH18 are in a good agreement with 
those published in the literature (Kuroyanagi et al., 1979a; Ng and McMorris, 1984). The 
compound has been isolated from the fronds of P. aquilinum var. latiusculum (Fukuoka et al., 
1978; Kuroyanagi et al., 1979a). 
 
Figure 62: X-ray crystallographic structure of the compound RH18.
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Table 27: Compound RH28 [(2R, 3R)-Histiopterosin A = trans-Histiopterosin A] 
IUPAC name 
2-(1-hydroxy-2,4,6-trimethyl-3-oxo-2,3-dihydro-1H-inden-5-
yl)acetic acid 
Sample ID RH28  
Sample quantity 3 mg 
Physical appearance Yellow sticky 
Molecular formula C14H16O4 
Molecular Weight 248.2780 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.39 (1H, s, H-4), 4.71 (1H, d, J = 4.1 Hz, H-3), 3.78 (2H, s, 
H2-13), 2.62 (3H, s, H3-15), 2.47 (1H, m, H-2), 2.44 (3H, s, H3-12), 1.31 (3H, d, J = 7.3 Hz, H3-
10). 
13C NMR (101 MHz, MeOD): δC ppm 207.5 (C-1), 175.3 (C-14), 155.1 (C-9), 146.6 (C-5), 138.4 
(C-7), 135.9 (C-6), 132.3 (C-8), 125.5 (C-4), 75.9 (C-3), 54.8 (C-2), 35.3 (C-13), 21.6 (C-12), 14.2 
(C-15), 13.3 (C-10). 
Compound RH28 was isolated as a yellow sticky substance. The HR-ESI-MS data indicated a 
molecular formula of C14H16O4 based on the [M-H]
- ion signal at m/z 247.0968 (Calcd for 
C14H15O4: 247.0970). In Table 27, the full NMR signal assignments of compound RH28 are 
reported, as the 13C‑NMR data have not been published previously. The NMR data showed 
seven quaternary carbons; three methines; one methylene and three methyls, indicating that 
RH28 is an indanone-type sesquiterpenoid compound (Fukuoka et al., 1978; Ng and McMorris, 
1984; Yoshihira et al., 1971). The 1H and 13C NMR (Table 27) of RH28 were extremely similar 
with RH17 regarding 1-indanone skeleton part and also resembled closely those of RH20 in 
respect to the site chain located on position C-6. The molecular formula of RH28 and a 14 Da 
and 16 Da differences in mass between RH28 (248 amu) and RH17 (234 amu), and RH28 and 
RH20 (232 amu), respectively, suggested the oxidising of CH2-14 in RH17 to carbonyl group 
in RH28 and hence verified the above analysis. This was proved by the deshielded signals at 
H 3.78, C 35.3 and C 175.3 assigned to H-13, C-13 and C-14, respectively. Moreover, the 
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H-C cross peaks shown by HSQC, HMBS and COSY experiments (see appendix I) were also 
analogous to those of RH17 and RH20. 
Similar to the compound RH17, the small vicinal coupling constant value, J = 4.1 Hz, of H-3 
was observed and hence determined the trans-configuration of RH28 at positions C-2 and C-
3, this was confirmed by the signals resonated at δH 1.31 (CH3-2) and δH 4.71 (H-3) (Ge et al., 
2008; Murakami et al., 1985; Ng and McMorris, 1984). The compound RH28 exhibited a 
strong negative CD-curve in methanol at 337 nm (Figure 63), establishing the absolute 
configuration of RH28 at C-3 as 3R, regardless of the stereochemistry at position C-2 
(Kuroyanagi et al., 1979b, 1974b). These observations all together therefore confirmed the 
structure of the compound RH28 as (2R, 3R)-histiopterosin A (Table 27). trans-Histiopterosin 
A isolated for the first time from P. aquilinum (L.) Kuhn as it has been first obtained as a 
natural product from the fern, Histiopteris incisa (Murakami et al., 1980).  
The 1H NMR data of RH28 are in a good agreement with those published by Murakami et.al 
(1980) except for the chemical shift and coupling constant of H-3 which have not been 
mentioned in this publication. However, the positive CD value in methanol has been reported 
for histiopterosin A by Murakami et.al (1980), the absolute configuration has been left 
unambiguously as neither the stereochemistry of the compound was shown structurally nor was 
it written in text. In addition, the most important data of H-3 has not been recorded to decide 
on the absolute configuration at positions C-2 and C-3. Based on the CD results of the pterosin 
C type compounds reported by Kuroyanagi et al. (1979b), the positive value of the CD indicates 
(3S)-configuration for the reported histiopterosin A. Therefore, it is concluded that 
histiopterosin A reported by Murakami et al. (1980) may have either trans-configuration [(2S, 
3S) or (2R, 3R)] or cis-configuration [(2S, 3R) or (2R, 3S)] depending on the coupling constant 
of H-3 and the positive sign of its CD. 
 
Figure 63: The CD spectra of the compound RH28 recorded in methanol.   
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Table 28: Compound RH21 [(2R)-Pterosin F] 
IUPAC name (R)-6-(2-chloroethyl)-2,5,7-trimethyl-2,3-dihydro-1H-inden-1-one 
Sample ID RH21  
Sample quantity 10 mg 
Physical appearance White needles 
Molecular formula C14H17ClO 
Molecular Weight 236.7390 g/mol 
 
NMR data 
1H NMR (400 MHz, CDCl3): δH ppm 7.11 (1H, s, H-4), 3.54* (1H, t, J = 8.3 Hz, Ha-14), 3.54* (1H, 
t, J = 8.3 Hz, Ha-13), 3.25 (1H, dd, J = 16.8, 7.8 Hz, Ha-3), 3.02* (1H, t, J = 8.3 Hz, Hb-13), 3.02* 
(1H, t, J = 8.3 Hz, Hb-14), 2.68 (3H, s, H3-15), 2.65 (1H, m, H-2), 2.58 (1H, dd, J = 16.8, 4.1 Hz, 
Hb-3), 2.43 (3H, s, H3-12), 1.28 (3H, d, J = 7.3 Hz, H3-10). 
13C NMR (101 MHz, CDCl3): δC ppm 210.2 (C-1), 153.2 (C-9), 144.05 (C-5), 137.9 (C-7), 134.7 
(C-6), 132.5 (C-8), 126.1 (C-4), 42.7 (C-2), 42.2 (C-14), 34.0 (C-3), 32.4 (C-13), 21.3 (C-12), 16.6 
(C-10), 13.8 (C-15). 
* These data were confirmed from the HSQC experiment.
 
Compound RH21, a white needles, was obtained as a chlorine containing substance as the 
positive mode HR-ESI-MS showed the molecular formula of C14H17ClO at 237.1047 [M + H]
+ 
(Calcd for C14H18ClO: 237.1046). The 
1H and 13C NMR data of RH21 (Table 28) were closely 
resembling those of RH16 (pterosin B) (Table 20) in respect to the chemical shifts that 
appeared due to one aromatic-H at δH 7.11, one methine-H at δH 2.65, methylene protons on 
each positions C-3 and C-13 at δH 2.58 & 3.25 and δH 3.02, one secondary methyl at δH 1.28 
and two aromatic-methyls at δH 2.43 and 2.65 (Table 28 and see appendix I). The direct 
correlation between H-14 and C-14 is exhibited in the HSQC spectrum (see appendix I). The 
downfield shift of proton and carbon signals at position C-14 (δH 3.54 and δC 42.24) along with 
the molecular formula of RH21 suggested that the hydroxyl group of the hydroxyethyl group 
in RH16 was replaced with a chlorine atom. Additionally, the high resolution mass spectrum 
of RH21 showed quasi-molecular ion peaks at m/z 237.1047 and m/z 239.1014 [M+H]+ 
defining the pattern isotope ratio (3:1, 35Cl and 37Cl), which is consistent with a 
monochlorinated compound. 
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Comparison of the 1H and 13C NMR data of RH21 with those reported in literature (Fukuoka 
et al., 1983, 1978; Ng and McMorris, 1984) verified the structure of this compound as (2R)-
pterosin F (Table 28). CD spectroscopy was applied to confirm the absolute configuration of 
RH21, however, the spectrum showed no absorption peaks in the range of 300-360 nm. 
The compound has been isolated as a natural product from young leaves of P. aquilinum var. 
latiusculum (Yoshihira et al., 1978, 1971), young shoots of P. aquilinum (L.) Kuhn (Kobayashi 
and Koshimizu, 1980), Histiopteris incisa (Murakami et al., 1980), fronds of P. aquilinum 
subsp. wightiaunm (Tanaka et al., 1982) and fronds of Microlepia substrigosa TAGAWA 
(Kuraishi et al., 1985). (2R)-pterosin F has been reported to show toxicity as it totally inhibited 
the early embryonic development in sea urchin at a concentration of 12.5 µg/mL (Kobayashi 
and Koshimizu, 1980).
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Table 29: Compound RH22 [(2S, 3S)-Pterosin J or trans--Pterosin J] 
IUPAC name 
(2S,3S)-6-(2-chloroethyl)-3-hydroxy-2,5,7-trimethyl-2,3-dihydro-1H-
inden-1-one 
Sample ID RH22  
Sample quantity 5 mg 
Physical appearance White needles 
Molecular formula C14H17ClO2 
Molecular Weight 252.7380 g/mol 
 
NMR data 
1H NMR (400 MHz, CDCl3): δH ppm 7.36 (1H, s, H-4), 4.80 (1H, d, J = 2.2 Hz, H-3), 3.55 (2H, t, 
J = 8.2 Hz, H2-14), 3.21 (2H, t, J = 8.2 Hz, H2-13), 2.68 (3H, s, H3-15), 2.54 (1H, m, H-2), 2.47 
(3H, s, H3-12), 1.36 (3H, d, J = 7.3 Hz, H3-10). 
13C NMR (101 MHz, CDCl3): δC ppm 205.1 (C-1), 152.8 (C-9), 144.7 (C-5), 137.2 (C-7), 136.9 
(C-6), 131.9 (C-8), 124.7 (C-4), 75.7 (C-3), 54.0 (C-2), 42.1 (C-14), 32.5 (C-13), 21.4 (C-12), 14.1 
(C-15), 13.2 (C-10). 
Compound RH22, obtained as a white needles solid, was isolated as a monochlorinated 
compound and gave the molecular formula of C14H17ClO2 by a positive mode HR-ESI-MS m/z 
253.0992 (Calcd for C14H18ClO2: 253.0995 [M + H]
+ ), with six degrees of unsaturation. 
The NMR spectroscopic data of RH22 were very similar to those of RH17 regarding the 
chemical shifts and coupling constant values due to the three methyl groups, one ethylene, one 
aromatic-H and one methine-H of the 1-indanone skeleton as shown in Table 29, meanwhile 
the characteristic chemical shifts and coupling patterns were showed by the signals of the two 
methylene groups at δH 3.21 (2H, t, J = 8.2 Hz) and δH 3.55 (2H, t, J = 8.2 Hz) as those of 
RH21, establishing the presence of a chloroethyl group at position C-6. Similar to RH21, the 
high resolution mass spectrum of RH22 also demonstrated the isotope pattern (3:1) at m/z 
253.0992 and 255.0960 confirming the presence of one chlorine atom in the molecule (see 
appendix II). Thus, this compound was identified as pterosin J.    
The trans-configuration of pterosin J at positions C-2 and C-3 was ascertained on the basis of 
the small value of the vicinal coupling constant of H-3 (J = 2.2 Hz) and chemical shifts of the 
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secondary methyl (δH 1.36) and the carbinyl proton (δH 4.80) (Ge et al., 2008; Murakami et al., 
1985; Ng and McMorris, 1984). Finally, the absolute stereochemistry of RH22 was established 
as (2S, 3S)-configuration by its CD spectrum (Figure 61) which exhibited a strong positive 
Cotton effect at 332 nm in methanol (Kuroyanagi et al., 1979b, 1974b). Compound RH22 was 
therefore confirmed as (2S, 3S)-pterosin J as shown in Table 29. The NMR spectroscopic data 
of the compound are in consistent with those reported in the literature (Fukuoka et al., 1978; 
Ng and McMorris, 1984). It has been obtained from the young fronds of P. aquilinum var. 
latiusculum (Fukuoka et al., 1972; Yoshihira et al., 1978) and Histiopteris incisa (Murakami 
et al., 1980). 
Table 30: Compound RH19 [(3S)-Pterosin D] 
IUPAC name 
(S)-3-hydroxy-6-(2-hydroxyethyl)-2,2,5,7-tetramethyl-2,3-dihydro-
1H-inden-1-one 
Sample ID RH19  
Sample quantity 60 mg 
Physical appearance White amorphous solid 
Molecular formula C15H20O3 
Molecular Weight 248.3220 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.36 (1H, s, H-4), 4.74 (1H, s, H-3), 3.62* (1H, t, J = 7.5 Hz, 
Ha-13), 3.62* (1H, t, J = 7.5 Hz, Ha-14), 3.01* (1H, t, J = 7.5 Hz, Hb-13), 3.01* (1H, t, J = 7.5 Hz, 
Hb-14), 2.64 (3H, s, H3-15), 2.48 (3H, s, H3-12), 1.18 (3H, s, H3-11), 1.04 (3H, s, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 211.7 (C-1), 153.7 (C-9), 146.3 (C-5), 138.4 (C-7), 138.4 
(C-6), 131.2 (C-8), 126.1 (C-4), 77.5 (C-3), 61.6 (C-14), 52.4 (C-2), 33.1 (C-13), 23.5 (C-11), 21.4 
(C-12), 20.7 (C-10), 14.1 (C-15). 
* These data were confirmed from the HSQC experiment.
 
Compound RH19 was obtained as a white amorphous solid (Table 30). The HR-ESI-MS data 
indicated a molecular formula of C15H20O3 based on the [M + H]
+ ion signal at m/z 249.1482 
(Calcd for C15H21O3: 249.1491). The NMR spectroscopic data of RH19 were similar to those 
of RH17 in respect to the chemical shifts of the carbinyl proton, aromatic-H, the two aromatic 
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methyl groups and hydroxylethyl group, with some exceptions. The 1H NMR spectrum of 
RH19 revealed the existence of two singlets of a geminal dimethyl group resonated at δH 1.04 
and 1.18 instead of a doublet signal of the secondary methyl group (δH 1.30, d, J = 7.3 Hz) and 
a multiplet peak of the methine proton (δH 2.43, m) in RH17 (Figure 64). Moreover, the mass 
difference (14 Da) between RH17 (m/z 235.1329) and RH19 (m/z 249.1482) firmly suggested 
the replacement of H-2 in RH17 with a methyl group in RH19. The H-C correlations of H-
10/C-2, H-10/C-3, H-10/C-11, H-11/C-2, H-11/C-3 and H-11/C-10 showed by the HMBC 
experiment are also evident to exist two methyl groups on position C-2. In addition, the HSQC 
spectrum confirmed the direct proton-carbon link between δH 1.04 (H-10) and δC 20.73 (C-10), 
and between δH 1.18 (H-11) and δC 23.48 (C-11). 
 
Figure 64: 1H NMR spectra of compounds RH17 and RH19 showing the main 
differences occurred to the selected signals. 
The CD spectrum of RH19 showed a strong negative Cotton effect at 333 nm in methanol 
(Figure 65) confirming the configuration of the hydroxyl group at the position C-3 as 3S as it 
is stated that the OH group at position C-3 of pterosin D type compounds exists mainly in the 
pseudo-axial conformation regardless of the configuration at position C-2 whether it is opposite 
or the same (Kuroyanagi et al., 1979b). Comparison of the NMR data of RH19 are also 
consistent with those published (Kuroyanagi et al., 1979a; Ng and McMorris, 1984). From the 
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above evidence, the structure of RH19 was therefore confirmed as (3S)-pterosin D. It has been 
obtained from Hypolepis punctata (THUNB.) METT. (Murakami et al., 1976) and the 
rhizomes of P. aquilinum var. latiusculum (Kuroyanagi et al., 1979a). 
 
Figure 65: The CD spectrum of RH19 recorded in methanol.
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Table 31: Compound RH32 [(3S)-Pteroside D] 
IUPAC name 
(S)-3-hydroxy-2,2,5,7-tetramethyl-6-(2-(((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethyl)-
2,3-dihydro-1H-inden-1-one 
Sample ID RH32  
Sample quantity 4.9 mg 
Physical appearance Yellow amorphous solid 
Molecular formula C21H30O8 
Molecular Weight 410.4630 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.36 (1H, s, H-4), 4.74 (1H, s, H-3), 4.32 (1H, d, J = 7.8 Hz, H-1′), 
4.02 (2H, t, J = 7.8 Hz, H2-14), 3.81 (1H, dd, J = 11.9, 2.1 Hz, Ha-6′), 3.68 (1H, dd, J = 11.9, 5.2 Hz, Hb-6′), 
3.34 (1H, m, H-3′), 3.30 (1H, m, H-4′), 3.28 (1H, m, H-5′), 3.19 (1H, dd, J = 8.8, 8.0 Hz, H-2′), 3.13 (2H, t, 
J = 8.0 Hz, H2-13), 2.65 (3H, s, H3-15), 2.49 (3H, s, H3-12), 1.18 (3H, s, H3-10), 1.04 (3H, s, H3-11). 
13C NMR (101 MHz, MeOD): δC ppm 211.7 (C-1), 153.8 (C-9), 146.5 (C-5), 138.6 (C-7), 138.1 (C-6), 131.1 
(C-8), 126.1 (C-4), 104.4 (C-1′), 78.1 (C-3′), 78.0 (C-5′), 77.5 (C-3), 75.1 (C-2′), 71.3 (C-4′), 69.1 (C-14), 
62.7 (C-6′), 52.4 (C-2), 30.3 (C-13), 23.5 (C-10), 21.5 (C-12), 20.8 (C-11), 14.1 (C-15). 
Compound RH32 (Table 31), isolated as a yellow amorphous solid, was determined to have 
the molecular formula C21H30O8 (7 degrees of unsaturation) on the basis of positive mode HR-
ESI-MS analysis at m/z 411.2008 [M + H]+ (Calcd for C21H31O8: 411.2019). Twenty one carbon 
signals are shown by the DEPTQ spectrum (see appendix I), referring to the presence of four 
methyls, three methylenes, seven methines and seven quaternary carbons. The 1H and 13C NMR 
data of RH32 closely resemble those of RH19, except that RH32 has one more sugar unit. On 
the basis of this observation, pterosin D was therefore indicated to be the aglycone portion. The 
sugar moiety was assigned as a β-glycosyl based on the coupling constant value, J = 7.8 Hz, of 
the anomeric proton that resonated at δH 4.32 (H-1′). In addition, the chemical shifts and 
coupling constants of the sugar part were very similar to those of RH31. The strong correlation 
between the H-1′ (δH 4.32) and H-2′ (δH 3.18) was also shown by the COSY experiment (see 
appendix I). The characteristic carbon signals of the glucose moiety including the anomeric 
carbon (δc 104.41) were revealed by the 13C NMR spectrum in the range of δc 62.65 – 78.14.  
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The HMBC experiment shows apparent correlation from the anomeric-H (H-1′) to C-14, 
suggesting the attachment of the glucose moiety at position C-14. The C1′-O-C14 linkage is also 
evident from the chemical shifts of H-14 and C-14 appeared in the downfield region at δH 4.02 
and δc 69.07, respectively (see appendix I).  
The CD spectrum of the RH32 is similar to that of RH19, exhibiting the negative band at 333 
nm in methanol (Figure 66) and was consistent with the reported CD spectra of pterosin D type 
compounds (Kuroyanagi et al., 1979b). This result confirms the (3S)-configuration of RH32 
for the same reason as discussed above for RH19. The NMR spectroscopic data of RH32 
(Table 31) are very similar to those reported previously (Kuroyanagi et al., 1979a). Based on 
the above evidence, the structure of compound RH32 was thus elucidated and established as 
(3S)-pteroside D (Table 31). The  compound was first isolated in 1971 and 1979 from the 
rhizomes of Japanese bracken, P. aquilinum KUHN var. latiusculum UNDERWOOD 
(Pteridaceae) (Hikino et al., 1971; Kuroyanagi et al., 1979a). 
 
Figure 66: The CD spectrum of RH32 recorded in methanol.
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Table 32: Compound RH20 [(2R)-Pterosin E]  
IUPAC name (R)-2-(2,4,6-trimethyl-3-oxo-2,3-dihydro-1H-inden-5-yl)acetic acid 
Sample ID RH20  
Sample quantity 17 mg 
Physical appearance Yellow-orange needles 
Molecular formula C14H16O3 
Molecular Weight 232.2790 g/mol 
 
NMR data 
1H NMR (400 MHz, CDCl3): δH ppm 7.13 (1H, s, H-4), 3.78 (2H, s, H2-13), 3.25 (1H, dd, J = 16.6, 
7.6 Hz, Ha-3), 2.66 (3H, s, H3-15), 2.63 (1H, m, H-2), 2.59 (1H, dd, J = 17.3, 4.6 Hz, Hb-3), 2.39 
(3H, s, H3-12), 1.27 (3H, d, J = 7.3 Hz, H3-10). 
13C NMR (101 MHz, CDCl3): δC ppm 210.2 (C-1), 175.8 (C-14), 153.6 (C-9), 144.2 (C-5), 138.4 
(C-7), 132.1 (C-6), 131.1 (C-8), 125.7 (C-4), 42.4 (C-2), 33.7 (C-13), 33.7 (C-3), 21.3 (C-12), 16.4 
(C-10), 13.6 (C-15). 
Compound RH20 was obtained as a yellow-orange needles (Table 32). Its HR-ESI-MS 
spectrum gave a pseudo-molecular ion peak at m/z 231.1015 [M-H]- (Calcd for C14H15O3: 
231.1021) compatible with the molecular formula C14H16O3, requiring seven degrees of 
unsaturation. The 13C and HSQC NMR spectra of RH20 displayed resonances for 14 carbon 
signals: 3 methyls, 2 methylenes, 2 methines, and 7 quaternary carbons including 2 carbonyl 
carbons. The NMR spectral data of RH20 were similar to those of RH16 regarding the 1-
indanone skeleton, except the appearance of a singlet peak at δH 3.78 instead of the 2 doublet 
signals of the hydroxyethyl group.  
Furthermore, compound RH20 was 14 mass units and one degree of unsaturation more than 
RH16, indicating that one of the methylene group (H2-C14) of the side chain positioned on C-
6 in RH16 was oxidised to the carbonyl group in RH20. Hence, the singlet signal appeared at 
δH 3.78 was assigned to the methylene group located between the benzene ring and the carbonyl 
group. Moreover, the HMBC spectrum (see appendix I) showed cross peaks from H-13 (δH 
3.78) to each of C-5 (δC 144.20), C-7 (δC 138.37) and C-14 (δC 175.75), supporting the 
assignment of the singlet peak as a methylene group at 13-position. Thus, the deshielded 
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resonance peak assignable to position C-14 is observed at δC 175.75. From the above analyses, 
the structure of RH20 was confirmed to be pterosin E (Table 32). Despite that the CD 
spectroscopy was carried out in methanol to RH20 in order to determine the absolute 
stereochemistry, no Cotton effect was observed in the spectrum in range of 300-360 nm. 
Similarity and consistency were showed by the NMR data of RH20 when compared with those 
reported previously in the literature (Fukuoka et al., 1978; Nambudiry and Rao, 1974; Ng and 
McMorris, 1984), verifying the structure of this compound as (2R)-pterosin E (Table 32). It 
has been separated as a natural compound from young leaves of P. aquilinum var. latiusculum 
(Pteridaceae) (Yoshihira et al., 1978, 1971) and Histiopteris incisa (Murakami et al., 1980).  
Table 33: Compound RH23 [(2S)-Pterosin K] 
IUPAC name 
(S)-6-(2-chloroethyl)-2-(hydroxymethyl)-2,5,7-trimethyl-2,3-
dihydro-1H-inden-1-one 
Sample ID RH23  
Sample quantity 3 mg 
Physical appearance White sticky  
Molecular formula C15H19ClO2 
Molecular Weight 266.7650 g/mol 
 
NMR data 
1H NMR (400 MHz, CDCl3): δH ppm 7.12 (1H, s, H-4), 3.78 (1H, d, J = 10.7 Hz, Ha-11), 3.60 (1H, 
d, J = 10.7 Hz, Hb-11), 3.54* (1H, t, J = 8.7 Hz, Ha-13), 3.54* (1H, t, J = 8.7 Hz, Ha-14), 3.19* (1H, 
t, J = 8.7 Hz, Hb-13), 3.19* (1H, t, J = 8.7 Hz, Hb-14), 3.06 (1H, d, J = 17.1 Hz, Ha-3), 2.75 (1H, 
d, J = 17.1 Hz, Hb-3), 2.67 (3H, s, H3-15), 2.43 (3H, s, H3-12), 1.22 (3H, s, H3-10). 
13C NMR (101 MHz, CDCl3): δC ppm 211.9 (C-1), 153.0 (C-9), 144.8 (C-5), 138.3 (C-7), 135.0 
(C-6), 131.9 (C-8), 126.3 (C-4), 68.3 (C-11), 50.8 (C-2), 42.2 (C-14), 37.0 (C-3), 32.4 (C-13), 21.4 
(C-12), 21.2 (C-10), 13.9 (C-15). 
* These data were confirmed from the HSQC experiment.
 
Compound RH23 (Table 33), obtained as a white sticky substance, was identified as a chlorine-
containing compound and possessed the molecular formula of C15H19ClO2 which was deduced 
from the HR-ESI-MS m/z 267.1151 (Calcd. for C15H20ClO2: 267.1152 [M+H]
+, indicating six 
degrees of unsaturation. Analysis of the 1H and 13C NMR data suggested a molecular skeleton 
Chapter Three Results and discussion 
 
105 
 
of pterosin compounds. The close similarity was clearly observed in the 1D and 2D NMR 
spectra of RH29 and RH15 (see appendix I) except for the presence of a chlorine group at 
position C-14 in RH23 instead of a hydroxyl group as in RH15. This was supported by its mass 
spectrum which showed a ratio of (3:1) typical for chlorine isotopes (35Cl: 37Cl) of natural 
products. Furthermore, the coupling constant values and the chemical shifts of the ethylene 
protons (-CH2-CH2-) in RH23 were very similar to those of chloroethyl group as in pterosins 
F (RH21) and J (RH22), confirming the existence of the chlorine atom in the molecule at 
position C-14. From the above conclusion, the structure of RH23 was established to be pterosin 
K as shown in Table 33.  
This compound was determined to have 2S configuration, as its CD curve exhibited a negative 
Cotton effect at 329 nm for the n → π* absorption band (Figure 67). This result is in a good 
agreement with the CD data provided previously for pterosin K (Kuroyanagi et al., 1979b). 
Thus, the absolute configuration of RH23 was deduced as (2S)-pterosin K (Table 33).  
The NMR data of RH23 were identical to those published in the literature (Castillo et al., 2003, 
1997; Fukuoka et al., 1978; Ng and McMorris, 1984). (2S)-pterosin K has been achieved as a 
natural product from methanol extract of young leaves of P. aquilinum KUHN var. latiusculum 
UNDERWOOD (Pteridaceae) (Fukuoka et al., 1972; Kuroyanagi et al., 1979a; Yoshihira et 
al., 1978) and fresh fronds of P. aquilinum var. caudatum  (Castillo et al., 1997).  
 
Figure 67: The CD spectrum of RH23 in methanol showing positive (longer wavelength) 
and negative (shorter wavelength) signed vibronic progressions.
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Table 34: Compound RH35 [(2S)-Pteroside K] 
IUPAC name 
(S)-6-(2-chloroethyl)-2,5,7-trimethyl-2-((((2R,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)-
2,3-dihydro-1H-inden-1-one 
Sample ID RH35  
Sample quantity 30 mg 
Physical appearance White crystalline solid 
Molecular formula C21H29ClO7 
Molecular Weight 428.9060 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.19 (1H, s, H-4), 4.20 (1H, d, J = 7.8 Hz, H-1′), 4.12 (1H, d, J = 9.4 
Hz, Ha-11), 3.77 (1H, dd, J = 11.8, 1.6 Hz, Ha-6′), 3.61* (1H, t, J = 8.0 Hz, Ha-14), 3.61* (1H, m, Ha-13), 
3.61 (1H, m, Hb-6′), 3.48 (1H, d, J = 9.4 Hz, Hb-11), 3.44 (1H, d, J = 17.2 Hz, Ha-3), 3.29 (1H, m, H-3′), 
3.21* (1H, t, J = 8.0 Hz, Hb-13), 3.21* (1H, m, Hb-14), 3.21 (1H, m, H-5′), 3.21 (1H, m, H-4′), 3.04 (1H, dd, 
J = 8.9, 7.8 Hz,  H-2′), 2.73 (1H, d, J = 17.2 Hz, Hb-3), 2.65 (3H, s, H3-15), 2.45 (3H, s, H3-12), 1.13 (3H, 
s, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 212.2 (C-1), 154.7 (C-9), 146.2 (C-5), 139.0 (C-7), 136.1 (C-6), 132.8 
(C-8), 127.4 (C-4), 104.7 (C-1′), 78.1 (C-3′), 77.9 (C-5′), 75.0 (C-11), 74.9 (C-2′), 71.5 (C-4′), 62.7 (C-6′), 
51.4 (C-2), 43.1 (C-14), 37.7 (C-3), 33.0 (C-13), 22.0 (C-10), 21.2 (C-12), 13.9 (C-15). 
* These data were confirmed from the HSQC experiment. 
Compound RH35 (Table 34), achieved as a white crystalline solid, showed the molecular 
formula C21H29ClO7, as determined by the positive ion mode HR-ESI-MS at m/z 429.1671 
[M+H]+ (Calcd for C21H30ClO7: 429.1680). This molecular formula revealed 7 equivalents of 
unsaturation, one more than RH23. The 1H and 13C NMR data of RH35 were closely related 
to those of (2S)-pterosin K (RH23) regarding the aglycone part except the presence of signals 
of an additional sugar unit.  
The DEPTQ experiment showed resonances for exactly 21 carbons including characteristic 
signals of sugar moiety. The 14 protonated carbons were assigned by HSQC spectrum (see 
appendix I). From the coupling constant value, J = 7.8 Hz, of the anomeric proton (δH 4.20), 
the sugar moiety was considered to be a β-glycosyl. Further, the 1H NMR spectrum showed 
signals and coupling constants of the sugar moiety that were consistent with those of RH30 
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and RH31. This is evident from the 1H-1H COSY cross peaks of H-1′ (δH 4.20)/H-2′ (δH 3.04), 
H-3′ (δH 3.29)/H-2′ (δH 3.04), H-6′ (δH 3.77 and 3.60)/H-4′ and H-5′ (δH 3.21) and Ha-6′ (δH 
3.77)/Hb-6′ (δH 3.60). The significant downfield shift of Ha-11 (δH 4.11) and C-11 (δC 74.99) 
of the aglycone suggested the linkage site of sugar moiety at position C-11, which was further 
supported by the key HMBC correlations from the anomeric proton (δH 4.20) to C-11 (δC 74.99) 
and from Ha-11 (δH 4.11) and Hb-11 (δH 3.48) to the anomeric carbon (δC 104.70).  
The CD spectrum of RH35 was measured in methanol as shown in Figure 68. The spectrum 
illustrates a positive Cotton effect sign at 325 nm similar to that obtained by Kuroyanagi et al. 
(1979b) for the same compound, confirming the absolute configuration at the chiral center of 
C-2 as 2S. An X-ray diffraction analysis of a single crystal was performed for the first time, 
which confirmed the stereochemistry of compound RH35 and also indicated the sugar unit as 
D-glucose. The X-ray structure (Figure 69) supports the CD result as it indicates the absolute 
configuration of RH35 as 2S. The single crystal X-ray data is submitted to Cambridge 
Crystallographic Data Center. Based on the above information, the structure of RH35 was 
established as (2S)-pterosin K β-D-glucopyranoside, called (2S)-pteroside K (Table 34). By 
comparison, the NMR data of RH35 showed similarity with those published before in the 
literature (Kuroyanagi et al., 1979a). It was first isolated from the underground parts of P. 
aquilinum var. latiusculum by Kuroyanagi et al. (1979a). 
          
Figure 68: CD spectra recorded in methanol of the: a) isolated compound RH35 and b) 
(2S)-pteroside K achieved by Kuroyanagi et al (1979b). 
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Figure 69: X-ray crystallographic structure of the compound RH35. 
Table 35: Compound RH24 [(2S)-Pterosin N] 
IUPAC name 
(S)-2-hydroxy-6-(2-hydroxyethyl)-2,5,7-trimethyl-2,3-dihydro-1H-
inden-1-one 
Sample ID RH24  
Sample quantity 15.4 mg 
Physical appearance White crystalline solid  
Molecular formula C14H18O3 
Molecular Weight 234.2950 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.13 (1H, s, H-4), 3.62* (1H, t, J = 7.8 Hz, Ha-13), 3.62* (1H, 
t, J = 7.8 Hz, Ha-14), 3.09 (1H, d, J = 16.8 Hz, Ha-3), 3.01 (1H, d, J = 16.8 Hz, Hb-3), 2.99* (1H, 
t, J = 7.8 Hz, Hb-13), 2.99* (1H, t, J = 7.8 Hz, Hb-14), 2.64 (3H, s, H3-15), 2.44 (3H, s, H3-12), 
1.33 (3H, s, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 209.9 (C-1), 151.2 (C-9), 146.9 (C-5), 139.4 (C-7), 137.0 
(C-6), 130.8 (C-8), 127.0 (C-4), 78.1 (C-2), 61.7 (C-14), 42.8 (C-3), 32.9 (C-13), 25.4 (C-10), 21.3 
(C-12), 14.0 (C-15). 
* These data were confirmed from the HSQC experiment.
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Compound RH24 was isolated as a white crystalline solid, whose molecular formula was 
established as C14H18O3 based on a quasimolecular ion peak at m/z 235.1328 [M+H]
+ (Calcd 
for C14H19O3: 235.1334) in the positive HR-ESI-MS measurements. Analysis of the NMR 
spectroscopic data of RH24 (Table 35) suggested high structural similarity with pterosin B 
(RH16) regarding the signals that appeared at δH 7.13 (H-4, s), δH 3.62 (H-14, t, J = 7.8 Hz), 
δH 2.99 (H-13, t, J = 7.8 Hz), δH 2.64 (H-15, s) and δH 2.44 (H-12, s), except that the proton at 
position C-2 in pterosin B was replaced by a hydroxyl group in RH24. This variation was 
deduced from some facts: first, the carbon signals of C-2 and C-10 were strongly shifted 
downfield to δC 78.13 and δC 25.43, respectively, due to the strong influence of hydroxyl group 
at position C-2; second, the secondary methyl at position C-2 appeared as a singlet peak instead 
of a doublet signal at δH 1.33 (CH3-2), and the multiplet peak of H-2 in RH16 was absent in 
compound RH24; third, the signals of the methylene group at C-3 appeared as two doublets at 
a slightly lower field (δH 3.01 , d, J = 16.8 Hz and 3.09, d, J = 16.8 Hz). These observations 
were evident for the above analysis. Therefore, compound RH24 was deduced as pterosin N.  
The CD spectrum of this compound did not show any absorption bands around 300-360 nm 
typical for pterosin B type compounds (Kuroyanagi et al., 1979b). The 1H and 13C NMR 
spectral data of RH24 are consistent with those reported previously (Fukuoka et al., 1983, 
1978; Kuroyanagi et al., 1974a; Wu et al., 2014). On the basis of the above detailed spectral 
analysis, the compound RH24 was elucidated as (2S)-pterosin N (Table 35). It has been 
isolated from Histiopteris incisa and Pteris oshimensis (Murakami et al., 1974), young leaves 
of P. aquilinum van. Latiusculum  (Kuroyanagi et al., 1974a) and Pteris setuloso-costulata 
(Murakami et al., 1980).
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Table 36: Compound RH25 [(2S)-Pterosin P] 
IUPAC name 
(S)-6-(2-hydroxyethyl)-5-(hydroxymethyl)-2,7-dimethyl-2,3-dihydro-
1H-inden-1-one 
Sample ID RH25  
Sample quantity 4 mg 
Physical appearance Colourless needles 
Molecular formula C14H18O3 
Molecular Weight 234.2950 g/mol 
 
NMR data 
1H NMR (400 MHz, CDCl3): δH ppm 7.32 (1H, s, H-4), 4.73 (2H, s, H2-12), 3.91 (2H, t, J = 6.0 
Hz, H2-14), 3.29 (1H, dd, J = 17.4, 8.5 Hz, Ha-3), 3.09 (2H, t, J = 6.0 Hz, H2-13), 2.67 (3H, s, H3-
15), 2.64 (1H, m, H-2), 2.63 (1H, dd, J = 17.4, 3.5 Hz, Hb-3), 1.28 (3H, d, J = 7.2 Hz, H3-10). 
13C NMR (101 MHz, CDCl3): δC ppm 210.7 (C-1), 152.6 (C-9), 145.7 (C-5), 138.5 (C-7), 135.8 
(C-6), 133.7 (C-8), 125.2 (C-4), 64.1 (C-12), 61.7 (C-14), 42.8 (C-2), 34.1 (C-3), 30.7 (C-13), 16.6 
(C-10), 14.0 (C-15). 
Compound RH25 (4 mg) was isolated as colourless needles (Table 36). Its HR-ESI-MS 
exhibited a [M+H]+ peak at m/z 235.1330, suggesting a molecular formula of C14H18O3 (Calcd 
for C14H19O3: 235.1334). This molecular formula highlighted a difference of one oxygen atom 
as compared to that of RH16. The DEPTQ spectrum of RH25 (see appendix I) showed 14 
carbon signals including one carbonyl carbon. Study of the NMR spectroscopic data of RH25 
indicated a structural resemblance with pterosin B (RH16), except that the methyl group at 
position C-12 in RH16 was substituted by hydroxymethyl (CH2OH) group in RH25. The 
downfield shift noticed for the signals of methylene-12 (H 4.73) and C-12 (C 64.1), and this 
firmly confirmed the attachment of the CH2-12 to the hydroxyl group. The resonance of H-4 at 
a lower field (H 7.32) and the 16 Da difference in mass between RH16 (218 amu) and RH25 
(234 amu) were also evident for the above variation. Based on the above observations and by 
comparison of the NMR data with those reported in the literature (Kuraishi et al., 1985; 
Kuroyanagi et al., 1979a; Ouyang et al., 2010), the structure of RH25 (Table 36) was assigned 
to (2S)-pterosin P.  
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In order to confirm the configuration at the chiral center of C-2, a CD spectroscopy was 
undertaken. Unluckily, the CD spectrum of RH25 showed no Cotton effect for n → π* 
transition at 300-360 nm.  (2S)-pterosin P has been isolated from various plant ferns, for 
instance, the rhizomes of P. aquilinum var. latiusculum (Kuroyanagi et al., 1979a), the fronds 
of Microlepia strigosa (THUNB.) PRESL ( (Kuraishi et al., 1985) and the aerial parts of Pteris 
multifida Poir (Ouyang et al., 2010). The compound has been assessed by Ouyang et al. (2010) 
for its cytotoxicity against four human cancer cell lines (A549, LOVO, PANC-1, and NCI-
H446), and the results showed no significant inhibitory activity of pterosin P against all the 
cancer cell lines.  
Table 37: Compound RH26 [Pterosin Z] 
IUPAC name 6-(2-hydroxyethyl)-2,2,5,7-tetramethyl-2,3-dihydro-1H-inden-1-one 
Sample ID RH26  
Sample quantity 14 mg 
Physical appearance White amorphous solid 
Molecular formula C15H20O2 
Molecular Weight 232.3230 g/mol 
 
NMR data 
1H NMR (400 MHz, CDCl3): δH ppm 7.08 (1H, s, H-4), 3.76* (1H, t, J = 7.5 Hz, Ha-13), 3.76* (1H, 
t, J = 7.5 Hz, Ha-14), 3.02* (1H, t, J = 7.5 Hz, Hb-13), 3.02* (1H, t, J = 7.5 Hz, Hb-14), 2.85 (2H, 
s, H2-3), 2.69 (3H, s, H3-15), 2.44 (3H, s, H3-12), 1.19 (3H, s, H3-10), 1.19 (3H, s, H3-11). 
13C NMR (101 MHz, CDCl3): δC ppm 212.4 (C-1), 151.5 (C-9), 144.6 (C-5), 138.5 (C-7), 134.9 
(C-6), 131.3 (C-8), 126.0 (C-4), 61.8 (C-14), 45.7 (C-2), 41.9 (C-3), 32.0 (C-13), 25.7 (C-10), 25.7 
(C-11), 21.5 (C-12), 13.9 (C-15). 
* These data were confirmed from the HSQC experiment.
 
Compound RH26, isolated as a white amorphous solid, was determined to have the molecular 
formula C15H20O2 (6 degrees of unsaturation) on the basis of HR-ESI-MS analysis which 
showed a quasi-molecular ion peak at m/z 233.1537 [M+H]+ (Calcd. For C15H21O2: 233.1542). 
The molecular formula of RH26 indicated one carbon atom and two protons more than RH16. 
The DEPTQ and 13C NMR spectra (see appendix I) of compound RH26 showed 14 signal 
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peaks, representing 15 carbon atoms and including 4 methyl signals. Both C-10 and C-11 
resonated at δC 25.73 and appeared as one big signal. Comparison of the 13C NMR data of 
RH26 with those of RH16 revealed that they were quite similar. The 1H NMR spectrum of 
RH26 disclosed a chemical shift of an equivalent geminal-dimethyl group instead of the 
secondary methyl group at position C-2, i.e. one proton at position C-2 in RH16 was replaced 
by an additional methyl group in RH26. The 1H NMR data (Table 37) of RH26 showed two 
singlet signals at δH 1.19 and δH 2.85 assignable to the two tertiary methyls and methylene at 
C-3, respectively, contrary to the multiplet (H-2), doublet of doublet (H-3) and doublet (CH3-
2) signals revealed by the 1H NMR spectrum of RH16 (Figure 70). The direct HSQC 
correlations from H-10 to C-10 and H-11 to C-11 were evident for the presence of the two 
geminal methyls at position C-2. In addition, the HMBC cross peaks of H-10 and H-11(δH 1.19, 
s) with C-2 (δC 45.72) and C-3 (δC 41.88), H-10 with C-11 and H-11 with C-10, further 
confirmed the above argument. By comparison of the NMR data of RH26 with the literature 
values (Fukuoka et al., 1983, 1978; Neeson and Stevenson, 1988; Padwa et al., 1996) and based 
on the above evidence, the compound RH26 was established as pterosin Z.  
It has been previously reported from fronds of P. aquilinum var. caudatum (Castillo et al., 
1997), Microlepia substrigosa TAGAWA, Microlepia speluncae (L.) MOORE and Microlepia 
trapeziformis (ROXB.) KUHN (Kuraishi et al., 1985), fronds of P. aquilinum subsp. 
wightiaunm (Tanaka et al., 1982), young shoots of P. aquilinum (L.) Kuhn (Kobayashi and 
Koshimizu, 1980), aerial parts of Pityrogramma calomelanos (Bardouille et al., 1978), leaves 
of a fern Hypolepis punctata Mett. (Hayashi et al., 1972) and fronds of P. aquilinum var. 
latiusculum  (Saito et al., 1975; Yoshihira et al., 1978, 1971). Pterosin Z has been shown to 
have smooth muscle relaxant activity against calcium contractions, with an EC50 value of 1.3 
× 10-6 M (Sheridan et al., 2009, 1999). It has been reported that pterosin Z showed cytotoxic 
effect on a ciliate, Paramecium caudatum, along with inhibitory effect on sea urchin embryo 
at the early development stages (Kobayashi and Koshimizu, 1980). Moreover, pterosin Z has 
been found to have the effect of promoting cartilage growth in humans and showed to be 
effective in inhibiting chondrocyte hypertrophy as well (Tsumaki et al., 2015).    
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Figure 70: Combined 1H NMR spectra showing the main variation between RH16 and 
RH26. 
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Table 38: Compound RH33 [Pteroside Z] 
IUPAC name 
2,2,5,7-tetramethyl-6-(2-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethyl)-2,3-dihydro-
1H-inden-1-one 
Sample ID RH33  
Sample quantity 47 mg 
Physical appearance Yellow-orange gum 
Molecular formula C21H30O7 
Molecular Weight 394.4640 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.13 (1H, s, H-4), 4.32 (1H, d, J = 7.8 Hz, H-1′), 3.91 (1H, dd, J = 
17.1, 8.5 Hz, Ha-14), 3.85 (1H, dd, J = 11.8, 1.6 Hz, Ha-6′), 3.66 (1H, dd, J = 11.8, 5.3 Hz, Hb-6′), 3.65 (1H, 
dd, J = 17.1, 7.8 Hz, Hb-14), 3.35 (1H, t, J = 8.4 Hz, H-3′), 3.29 (1H, m, H-4′), 3.27 (1H, m, H-5′), 3.19 (1H, 
t, J = 8.3 Hz, H-2′), 3.11 (2H, t, J = 8.0 Hz, H2-13), 2.87 (2H, s, H2-3), 2.65 (3H, s, H3-15), 2.45 (3H, s, H3-
12), 1.16 (3H, s, H3-10), 1.16 (3H, s, H3-11). 
13C NMR (101 MHz, MeOD): δC ppm 214.5 (C-1), 153.1 (C-9), 146.5 (C-5), 139.3 (C-7), 136.4 (C-6), 131.8 
(C-8), 127.0 (C-4), 104.5 (C-1′), 78.2 (C-3′), 78.0 (C-5′), 75.2 (C-2′), 71.6 (C-4′), 69.2 (C-14), 62.7 (C-6′), 
46.7 (C-2), 42.6 (C-3), 30.1 (C-13), 25.8 (C-10), 25.8 (C-11), 21.4 (C-12), 13.9 (C-15). 
Compound RH33 (47 mg) was isolated as a yellow-orange gum material (Table 38). It was 
characterized by NMR spectroscopic studies and HR-ESI-MS. Its positive HR-ESI-MS 
spectrum indicated a pseudo-molecular ion peak at m/z 395.2060 [M+H]+ suggesting a 
molecular formula of C21H30O7 (Calcd for C21H31O7: 395.2070), and indicating the 
presence of 7 degrees of unsaturation in the molecule.  
The 1H and 13C NMR spectroscopic data of RH33 (Table 38) were found to be similar to 
those of RH26 except for the presence of identical and characteristic signals for a sugar 
moiety. The aglycone part was therefore determined as a pterosin Z. The coupling constant, J 
= 7.8 Hz, of the anomeric proton resonated at δH 4.32 (d, H-1′) confirmed the β-configuration 
for the sugar residue, indicating β-glycosyl moiety. Further, the presence of glucose as a β-D-
glucopyranoside was confirmed based on data similarity between glucose signals and those for 
(2S)-pteroside A (RH30) and (2R)-pteroside B (RH31). The COSY spectrum showed the 1H-
1H cross peaks between H-1′ (δH 4.32)/H-2′ (δH 3.19), H-2′ (δH 3.19)/H-3′ (δH 3.35), H-5′ (δH 
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3.27)/Ha-6′ (δH 3.85), H-5′ (δH 3.27)/Hb-6′ (δH 3.66) and Ha-6′ (δH 3.85)/Hb-6′ (δH 3.66) 
assignable for the glucose moiety. The 13C NMR data (Table 38) and DEPTQ spectrum (see 
appendix I) revealed carbon resonances for the glucose including the anomeric carbon (δc 
104.45), which are in good agreement with those of glucose.  
The location of the attachment of the glucose to the aglycone at C-14 was evident from 
the downfield chemical shifts resonated at δH 3.91 (Ha-14) and δC 69.21 (C-14). This 
attachment was confirmed by HMBC spectrum (see appendix I), by which HMBC cross 
peaks from the anomeric proton H-1′ (δH 4.32) of the sugar moiety to the C-14 (δC 69.21) 
and from Hb-14 (δH 3.91) to the anomeric carbon C-1′ (δC 104.45) were observed 
confirming the above mentioned link. On the basis of these evidence and by comparison of 
the NMR data with those reported before (Hikino et al., 1971; Kuroyanagi et al., 1979a), the 
structure of RH33 was concluded to be pteroside Z as shown in Table 38. The NMR spectral 
data of RH33 are consistent with those previously published by Hikino et al. (1971) and 
Kuroyanagi et al (1979a). This glycoside has been obtained for the first time from the rhizomes 
of P. aquilinum KUHN var. latiusculum UNDERWOOD (Pteridaceae) (Hikino et al., 1971; 
Kuroyanagi et al., 1979a).
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Table 39: Compound RH27 [(2S)-2-Hydroxymethylpterosin E] 
IUPAC name 
(S)-2-(2-(hydroxymethyl)-2,4,6-trimethyl-3-oxo-2,3-dihydro-1H-
inden-5-yl)acetic acid 
Sample ID RH27  
Sample quantity 14.7 mg 
Physical appearance Yellow sticky 
Molecular formula C15H18O4 
Molecular Weight 262.3050 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.19 (1H, s, H-4), 3.76 (2H, s, H2-13), 3.72 (1H, d, J = 10.7 
Hz, Ha-11), 3.46 (1H, d, J = 10.7 Hz, Hb-11), 3.26 (1H, d, J = 17.2 Hz, Ha-3), 2.74 (1H, d, J = 17.2 
Hz, Hb-3), 2.61 (3H, s, H3-15), 2.40 (3H, s, H3-12), 1.10 (3H, s, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 212.8 (C-1), 174.9 (C-14), 154.8 (C-9), 146.5 (C-5), 139.3 
(C-7), 133.8 (C-6), 133.0 (C-8), 126.8 (C-4), 68.2 (C-11), 52.7 (C-2), 37.5 (C-3), 35.0 (C-13), 21.5 
(C-12), 21.3 (C-10), 14.0 (C-15). 
Compound RH27 was obtained as a yellow sticky material (Table 39). The negative mode 
HR-ESI-MS data showed a quasimolecular ion peak at m/z 261.1126 [M-H]-, suggesting 
a molecular formula of C15H18O4 (Calcd for C15H17O4: 261.1127), hence it required one 
more degree of unsaturation than RH15. This molecular formula also indicated that RH27 
has one oxygen more and two hydrogens less than RH15. The DEPTQ spectrum of RH27 
revealed resonances for 15 carbons including 2 carbonyl carbons. It is found that the NMR 
spectral data of this compound closely resembled those of compound RH15 in relation to 
signals belonging to the skeleton of 1-indanone, and were very similar to those of RH20 
regarding the signals of the side chain linked at position C-6. Based on this information, the 
compound is suggested to have an analogous structure as pterosin A.  
The 1H NMR spectrum showed the major difference between RH27 and RH15 due to the 
downfield shift of signals δH 3.76 (H-13, s) and δC 174.85 (C-14) attributed to the methylene 
and carboxylic group of the side chain, respectively, indicating that the CH2-14 in RH15 was 
oxidised to carbonyl group in RH27. This was evident from the 14 Da difference in mass 
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between these two compounds, the absence of CH2-14 signal and the appearance of a singlet 
peak of CH2-13 in RH27 in comparison with those of RH15. Further analysis of its HMBC 
spectrum (see appendix I) revealed key correlations from H-13 (δH 3.76) to each of C-14 (δC 
174.85), C-5 (δC 146.45), C-6 (δC 133.84) and C-7 (δC 139.25) confirming the above variation 
and hence the presence of the -CH2COOH group as a side chain at position C-6. Thus, 
compound RH27 was established as 2-hydroxymethylpterosin E.  
In order to establish the stereochemistry of RH27 at position C-2, the CD spectrum of RH27 
was studied (Figure 71). Similar to compound RH15, the spectrum of RH27 in methanol 
exhibited Cotton effects around 320-360 nm ascribed to the n → π* transition, confirming the 
absolute configuration of RH27 as 2S (Kuroyanagi et al., 1979b). The NMR spectral data of 
RH27 were in a good agreement when compared with those stated in the literature (Lee et al., 
2012). The compound was therefore structurally confirmed to be (2S)-2-hydroxymethyl 
pterosin E as shown in Table 39. The isolation of this compound was reported as a natural 
product from P. aquilinum (L.) Kuhn for the first time, as the compound has been previously 
obtained by Lee et al. (2012) as a major metabolite product from the metabolism of (2S)-
pterosin A in rats. 
 
Figure 71: The CD spectra of the compounds RH27 and RH29 recorded in methanol.  
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Table 40: Compound RH29 [(2S)-12-Hydroxypterosin A] 
IUPAC name 
(S)-6-(2-hydroxyethyl)-2,5-bis(hydroxymethyl)-2,7-dimethyl-2,3-
dihydro-1H-inden-1-one 
Sample ID RH29  
Sample quantity 4 mg 
Physical appearance Pale-yellow solid 
Molecular formula C15H20O4 
Molecular Weight 264. 3210 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.44 (1H, s, H-4), 4.75 (2H, s, H2-12), 3.72 (1H, d, J = 10.6 
Hz, Ha-11), 3.66 (2H, t, J = 7.4 Hz, H2-14), 3.47 (1H, d, J = 10.6 Hz, Hb-11), 3.29 (1H, d, J = 17.2 
Hz, Ha-3), 3.00 (2H, t, J = 7.4 Hz, H2-13), 2.77 (1H, d, J = 17.2 Hz, Hb-3), 2.66 (3H, s, H3-15), 
1.10 (3H, s, H3-10). 
13C NMR (101 MHz, MeOD): δC ppm 213.0 (C-1), 154.2 (C-9), 148.5 (C-5), 139.0 (C-7), 135.7 
(C-6), 134.1 (C-8), 124.4 (C-4), 68.3 (C-11), 63.6 (C-12), 62.1 (C-14), 52.7 (C-2), 37.7 (C-3), 31.9 
(C-13), 21.3 (C-10), 13.8 (C-15). 
Compound RH29 was isolated as a pale-yellow amorphous solid. The positive mode HR-ESI-
MS exhibited a pseudo-molecular ion peak at m/z 265.1435 [M+H]+ (Calcd for C15H21O4: 
265.1440), indicating the molecular formula C15H20O4, possessing one oxygen atom more than 
RH15 whilst having the same equivalent of unsaturation as RH15. The NMR spectroscopic 
data of RH29 (Table 40) were quite similar to those of RH15. Comparing the NMR data 
between RH29 and RH15 (Table 40 & Table 22) assigned the replacement of the methyl group 
at position C-5 in RH15 by a hydroxymethylene group in RH29. This variation was apparent 
from the mass spectrum of RH29 (264 amu) which demonstrated a 16 Da difference in mass 
with that of RH15 (248 amu).  
The HSQC spectrum exhibited the direct cross peak between H-12 and C-12. In the 1H and 13C 
NMR data of RH29 (Table 40), the significant low field chemical shifts of H-12 (δH 4.75) and 
C-12 (δC 63.57) were observed confirming the above mentioned replacement at position C-5. 
This was verified by detailed analysis of 2D NMR data of compound RH29. The HMBC 
experiment demonstrated correlations from H-12 (δH 4.75) to each of C-4 (δC 124.41), C-5 (δC 
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148.53), C-6 (δC 135.69); indicated that the hydroxymethylene group (CH2OH) was linked to 
the position C-5. On the basis of these observations, compound RH29 was elucidated as 12-
hydroxypterosin A (Table 40).  
The absolute configuration of RH29 at position C-2 was determined by an intensive study of 
its CD spectrum (Figure 71). The spectrum was obtained in methanol which showed close 
similarity with that of RH27 and RH15 in relation to display the Cotton effects (n → π* 
transition) around 320-360 nm, thus the stereochemistry of RH29 was confirmed to be 2S 
(Kuroyanagi et al., 1979b). The NMR data of RH29 showed resemblance when compared with 
the literature values (Lee et al., 2012). Consequently, the chemical structure of compound 
RH29 was confirmed as (2S)-12-hydroxypterosin A (Table 40). This compound isolated and 
characterised here for the first time as a natural product from P. aquilinum (L.) Kuhn. It has 
been first obtained as a metabolite product from an in vivo study on the metabolism of (2S)-
pterosin A in rats (Lee et al., 2012).
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Table 41: Compound RH36 [(5-(β-hydroxy)ethyl-2, 2, 4, 6-tetramethyl-1, 3-indandione] 
IUPAC name 5-(2-hydroxyethyl)-2,2,4,6-tetramethyl-1H-indene-1,3(2H)-dione 
Sample ID RH36  
Sample quantity 4 mg 
Physical appearance Pale-yellow solid 
Molecular formula C15H18O3 
Molecular Weight 246.3060 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 7.64 (1H, s, H-4), 3.70 (2H, t, J = 7.4 Hz, H2-14), 3.12 (2H, t, J = 7.4 
Hz, H2-13), 2.78 (3H, s, H3-12), 2.56 (3H, s, H3-15), 1.20 (3H, s, H3-10), 1.20 (3H, s, H3-11). 
13C NMR (101 MHz, MeOD): δC ppm 203.2 (C-1), 202.7 (C-3), 147.7 (C-9), 147.2 (C-5), 140.3 (C-7), 136.0 
(C-6), 135.4 (C-8), 123.3 (C-4), 61.3 (C-14), 51.0 (C-2), 33.7 (C-13), 21.5 (C-12), 20.8 (C-10), 20.8 (C-11), 
14.6 (C-15). 
Compound RH36 was obtained as a pale-yellow solid (Table 41). The molecular formula of 
RH36 was found to be C15H18O3 from its positive mode HR-ESI-MS at m/z 247.1329 [M+H]
+ 
(Calcd for C15H19O3: 247.1334), indicating 7 degrees of unsaturation, one more than compound 
RH26. The 1H and 13C NMR spectral data of RH36 (Table 41) are very similar to those of 
RH26 except for the large downfield shift of the C-3 signal (δC 202.71) and deshielding of the 
aromatic proton (H-4) resonated at δH 7.64, suggesting the replacement of the methylene (2H-
3) in RH26 with a carbonyl group in RH36. This variation was evident from the absence of 
the methylene singlet signal (δH 2.85, s, H-3) in RH36, and was verified with the 14 Da 
difference in mass between RH26 (232 amu) and RH36 (246 amu). Depended upon the NMR 
data comparison of RH36 with those reported in the past (Fukuoka et al., 1978; Ng and 
McMorris, 1984) and from the above information, compound RH36 was thus concluded to be 
5-(β-hydroxy)ethyl-2, 2, 4, 6-tetramethyl-1, 3-indandione.  
Here, the isolation of this compound as a natural product from the rhizomes of P. aquilinum 
(L.) Kuhn has been reported for the first time. The compound has been prepared previously 
based on oxidation reaction of pterosin D with chromic anhydride and pyridine in order to 
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confirm the location of hydroxyl group at position C-3 in pterosin D (Fukuoka et al., 1978). It 
has also been achieved by Ng and McMorris in 1984 by treatment of 5-(β-methoxy)ethyl-2, 2, 
4, 6-trimethyl-1, 3-indandione with 48% hydrobromic acid in glacial acetic acid. 
Table 42: Compound RH37 [Ptaquiloside] 
IUPAC name 
(2'R,3a'R,4'S,7a'R)-4'-hydroxy-2',4',6'-trimethyl-7a'-(((2S,3R, 
4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-
2-yl)oxy)-1',3a',4',7a'-tetrahydrospiro[cyclopropane-1,5'-inden]-
3'(2'H)-one 
Sample ID RH37  
Sample quantity 21 mg 
Physical appearance Colourless amorphous material 
Molecular formula C20H30O8 
Molecular Weight 398.4520 g/mol 
 
NMR data 
1H NMR (400 MHz, MeOD): δH ppm 5.77 (1H, s, H-4), 4.60 (1H, d, J = 7.7 Hz, H-1′), 3.90 (1H, dd, J = 
11.9, 1.4 Hz, Ha-6′), 3.66 (1H, dd, J = 11.9, 5.4 Hz, Hb-6′), 3.37 (1H, m, H-3′), 3.29 (1H, m, H-5′), 3.29 (1H, 
m, H-4′), 3.20 (1H, dd, J = 9.0, 7.8 Hz, H-2′), 2.65 (1H, d, J = 1.3 Hz, H-8), 2.50 (1H, dd, J = 12.3, 8.1 Hz, 
Ha-3), 2.23 (1H, m, H-2), 1.93 (1H, t, J = 12.7 Hz, Hb-3), 1.53 (3H, d, J = 0.7 Hz, H3-12), 1.29 (3H, s, H3-
15), 1.07 (3H, d, J = 6.9 Hz, H3-10), 0.88 (1H, m, Ha-14), 0.84 (1H, m, Ha-13), 0.69 (1H, ddd, J = 9.3, 5.2, 
4.1 Hz, Hb-14), 0.48 (1H, ddd, J = 9.3, 5.4, 4.1 Hz, Hb-13). 
13C NMR (101 MHz, MeOD): δC ppm 212.6 (C-1), 144.5 (C-5), 123.2 (C-4), 99.3 (C-1′), 82.1 (C-9), 78.2 
(C-3′), 77.8 (C-5′), 75.2 (C-2′), 71.9 (C-7), 71.9 (C-4′), 62.8 (C-6′), 62.5 (C-8), 45.2 (C-2), 45.2 (C-3), 30.1 
(C-6), 27.0 (C-15), 19.5 (C-12), 13.6 (C-10), 10.6 (C-13), 5.9 (C-14). 
Compound RH37 (Table 42), a colourless amorphous powder, was obtained as an unstable 
compound. It gave a quasimolecular ion peak in the negative mode HR-ESI-MS at m/z 
397.1879 [M-H]-, consistent with the molecular formula C20H30O8 (Calcd for C20H29O8: 
397.1862). From the 1H NMR spectrum of RH37, a doublet peak at δH 1.07 alongside two 
singlet signals at δH 1.29 and δH 1.53 were observed corresponding to three methyls at 
positions C-10, C-15 and C-12, respectively, for which the latter (δH 1.53) showed a long 
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range coupling to the aromatic proton (δH 5.77) at position C-4. Surprisingly, a doublet 
signal (J = 1.3 Hz) was observed for an isolated hydrogen at position C-8. 
A total of twenty carbon signals were exhibited by its DEPTQ spectrum including 
characteristic resonances for sugar moiety. The spectrum showed the presence of an 
anomeric carbon signal at δC 99.31 and a ketone at δC 212.62. The DEPTQ spectrum also 
indicated the presence of three methyls, four methylenes and eight methine groups along 
with carbon signals corresponding to five quaternary carbon atoms. The connectivity of 
the quaternary carbons was determined by HMBC spectrum.  
The assignment of all the protonated carbon signals were performed by HSQC 
experiment. The HSQC spectrum signified that the chemical shifts resonated at  δH 0.48 
and 0.84 were attached to the carbon at δC 10.57 (C-13), and also showed the direct 
correlations from δH 0.69 and 0.88 to δC 5.88 (C-14). This supported the presence of one 
cyclopropane ring in the molecule. 
The hydrogen connectivities were established by COSY experiment. The cross-peaks H-
2/H-10, H-2/Ha-3, H-2/Hb-3, Ha-3/Hb-3 and H-2/H-10 were observed in the spectrum. The 
spectrum also exhibited correlations H-1′/H-2′, H-4′/Ha-6′, H-4′/Hb-6′, H-5′/Ha-6′, H-
5′/Hb-6′ and Ha-6′/Hb-6′ associated with glucose moiety and cross-peaks related to the 
cyclopropane ring [Ha-13 (δH 0.84)/Hb-14 (δH 0.69), Hb-13 (δH 0.48)/Ha-14 (δH 0.88) and 
Hb-13 (δH 0.48)/Hb-14 (δH 0.69)] which proved that no proton was attached to position C-
6 except the cyclopropane ring. This fact was confirmed by HMBC experiment (see 
appendix I) which demonstrated key correlations from Ha-13 (δH 0.84) and Ha-14 (δH 
0.88) to each of C-5 (δC 144.49), C-6 (δC 30.09) and C-7 (δC 71.93). The position of the 
double bond between C-4 and C-5 was derived from the cross-peak between H-4 (δH 5.77) 
and H-12 (δH 1.53).  
The 1H NMR data (Table 42) showed a doublet signal for an anomeric proton resonated 
at δH 4.60, indicating the presence of a sugar moiety in the molecule. Based on the H-
l′/H-2′ coupling constant of 7.7 Hz and comparison with that of RH30-RH35, the 
configuration of sugar unit was suggested to be β-oriented indicating a β-glycosyl moiety. 
The location of the glycosidic linkage (C-O-C) at position C-9 was confirmed by the 
HMBC experiment which revealed a strong correlation from the anomeric proton signal 
(δH 4.60, 1H, d, J = 7.7 Hz) to the carbon signal resonated at δC 82.05 (C-9). In the COSY 
spectrum, the existence of spatial cross peaks H-4/H-8, H-8/H-15, H-8/H-4′ along with 
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H-4/H-12 indicates that the glucose moiety, H-8 and methyl-15 are all face to same 
direction, i.e. they all have β-orientation. Based on the spectral data discussed above, the 
structure of RH37 was fully established to be ptaquiloside as shown in Table 42.  
The NMR spectroscopic data of RH37 were identical with those given in the literature 
for the norsesquiterpene glycoside, called ptaquiloside (Castillo et al., 1997; Fletcher et 
al., 2010; Niwa et al., 1983; Oelrichs et al., 1995; Ojika et al., 1987). Ptaquiloside has 
been isolated previously from variety of fern, for example, P. aquilinum var. latiusculum  
(Niwa et al., 1983; Ojika et al., 1987), Pteris cretica and Histiopteris incisa (Saito et al., 1990), 
P. aquilinum var. revolutum (Oelrichs et al., 1995), fresh fronds of P. aquilinum var. 
caudatum  (Castillo et al., 1998, 1997), P. aquilinum (L.) Kuhn (Rasmussen et al., 2005) 
and Australian bracken P. esculentum (Fletcher et al., 2010).
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Table 43: Compound RH38 [5-Hydroxyisocalamenene] 
IUPAC name 8-isopropyl-3,5-dimethyl-5,6,7,8-tetrahydronaphthalen-1-ol 
Sample ID RH38  
Sample quantity 4 mg 
Physical appearance Yellow sticky 
Molecular formula C15H22O 
Molecular Weight 218.3400 g/mol 
 
NMR data 
1H NMR (500 MHz, CDCl3): δH ppm 6.58 (1H, s, H-8), 6.43 (1H, s, H-6), 4.57 (1H, s, OH-5), 3.06 (1H, m, 
H-1), 2.45 (1H, m, H-4), 2.24 (3H, s, H3-15), 2.01 (1H, m, H-11), 1.78 (2H, m, H2-3), 1.50 (2H, m, H2-2), 
1.20 (3H, d, J = 7.0 Hz, H3-14), 0.98 (3H, d, J = 6.8 Hz, H3-13), 0.82 (3H, d, J = 6.8 Hz, H3-12). 
13C NMR (125 MHz, CDCl3): δC ppm 153.1 (C-5), 141.3 (C-9), 135.2 (C-7), 126.1 (C-10), 123.1 (C-8), 
113.5 (C-6), 43.2 (C-4), 33.3 (C-11), 27.3 (C-2), 26.7 (C-1), 22.3 (C-13), 21.3 (C-14), 21.2 (C-15), 19.8 
(C-12), 19.2 (C-3). 
Compound RH38 was obtained as a yellow sticky material, and its molecular formula was 
confirmed as C15H22O by a negative ion mode HR-ESI-MS [M-H]
- at 217.1590 (Calcd for 
C15H21O: 217.1592), implying 5 degrees of unsaturation. The 
1H and 13C NMR data (Table 43) 
along with coupling constant values were verified and confirmed with COSY, HSQC, HMBC, 
and HSQC-TOCSY experiments. The signals of NMR spectra of RH38 (see appendix I) 
suggest that it does not possess features of 1-indanone compounds. From 1H NMR data, 
molecular formula and equivalents of unsaturation, it was clear that the compound RH38 
contained an aromatic ring and a cyclohexane ring.  
By comparison with the literature values, the NMR data of RH38 showed close similarity with 
those reported for 5-hydroxycalamenene (Figure 73) (Tanaka and Adachi, 1990) with some 
exceptions. The main difference was apparent from the multiplicity of the two aromatic proton 
signals, resonated at 6.43 ppm and 6.58 ppm, in which they both appeared as singlets in RH38 
(Figure 72) instead of doublets in 5-hydroxycalamenene. This indicated that the aromatic 
hydrogens were in meta-position, i.e. the aromatic protons in RH38 were separated by a 
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quaternary carbon atom (C-7) holding a methyl group, while they are adjacent protons in 5-
hydroxycalamenene.  
 
Figure 72: The expanded 1H NMR (500 MHz) spectrum of RH38 in CDCl3. 
 
Figure 73: Chemical structures of 5, 7 and 8-hydroxycalamenes. 
The 1H NMR spectrum showed the characteristic chemical shifts at 0.82 ppm (d, J = 6.8 Hz), 
0.98 ppm (d, J = 6.8 Hz) and 2.01 ppm (m) compatible with those of an isopropyl group. The 
key HMBC cross peaks from H-11 to C-4 and C-13, H-12 to C-4, C-11 and C-13, H-13 to C-
4, C-11 and C-12, H-14 to C-2 and C-10, and H-15 to C-6, C-7 and C-8 were evidence of the 
connection (presence) of the isopropyl group at position C-4, secondary methyl at position C-
1 and aromatic methyl group at position C-7. The above analysis was further confirmed from 
the key 1H-1H COSY correlations H-1/H-14, H-2/H-3, H-3/H-4, H-4/H-11, H-11/H-12, H-
11/H-13, H-6/H-15 and H-8/H-15 which verified the presence of the (CH3)2CH-, secondary-
methyl and aromatic-methyl groups at positions C-4, C-1 and C-7, respectively. The 
stereochemistry of RH38 at positions C-1 and C-4 remains unknown as no CD spectrum was 
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recorded of RH38. From the above evidence, the chemical structure of compound RH38 was 
established to be 5-hydroxyisocalamenene as illustrated in Table 43. 
5-Hydroxyisocalamenene (RH38), a phenolic sesquiterpenoid, has been synthesised from m-
cresol (Tanaka and Adachi, 1989). In this thesis, the isolation of this compound along with its 
NMR spectroscopic data have been reported for the first time as no NMR data have been 
documented previously. Several isomers of compound RH38 have been described previously, 
for instance, 5, 7 and 8-hydroxycalamenenes have been naturally isolated from the essential oil 
of liverwort Bazzania tricrenata (Konečný et al., 1985; Tanaka and Adachi, 1990), and 7-
hydroxycalamenene has also been synthesised by Krause and Bohlmann in 1987. 
3.6. STRUCTURAL RELATIONSHIPS BETWEEN NEW AND KNOWN PTEROSINS AND 
PTEROSIDES 
Rhedynoside B (RH10) is the first example of a pteroside bearing the glucose moiety at the 
position C-2 and hence being directly attached to the five membered ring in α-position to the 
keto group. In addition, this is also the first report of glycosylation at C-12 with the 12-O-β-D-
glucopyranoside substituted pterosins: rhedynosides C (RH11) and D (RH12). 
Most previously reported pterosides have had the sugar moiety at the following positions: C-
11, for example, pterosides A2 and K (Castillo et al., 2003; Kuroyanagi et al., 1979a); C-14, 
such as pterosides A, B, C, D, P and Z (Hikino et al., 1972, 1971; Kuroyanagi et al., 1979a) or 
C-3, e.g. 13-chloro-spelosin 3-O-β-D-glucopyranoside (Chen et al., 2015), (2R, 3R)-pterosin L 
3-O-β-D-glucopyranoside (separated from Ceratopteris thalictroides) (Chen et al., 2008) and 
(2S, 3S)-pterosin C 3-O-β-D-glucoside (wallichoside) (isolated from Pteris ensiformis) 
(Sengupta et al., 1976) (see Figure 74). Furthermore, rhedynosin A (RH1) and rhedynoside A 
(RH2) are novel compounds, being the first examples of a six-membered cyclic ether 
containing pterosin and pteroside. 
For the first time rhedynosin C (RH4) was isolated from the rhizomes of P. aquilinum (L.) 
Kuhn as a new cyclic lactone pterosin with a keto group at position C-14. However, another 
cyclic lactone pterosin, (S)-12-hydroxy-2-hydroxymethylpterosin E 14, 12-lactone, with one 
extra methylene has been reported as a metabolic product of (2S)-pterosin A in rat urine via 
oral administration (100 mg/kg)  (Lee et al., 2012). 
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Figure 74: Structural similarity between the novel compound RH13 and the reported 
glycosides from the literature. 
Other metabolites of (2S)-pterosin A were compounds RH14, RH27 and RH29, which have 
been isolated for the first time from plant material. Compound RH14 was suggested to be 
named as “rhedynosin I”. Moreover, (2S)-pteroside A2 and trans-histiopterosin A are being 
reported for the first time from the rhizomes of subsp. aquilinum of bracken, as they have 
previously been isolated from the young fronds of P. aquilinum (L.) Kuhn var. caudatum 
(synonym: Pteridium caudatum L. Maxon) (Castillo et al., 2003) and Histiopteris incisa 
(Murakami et al., 1980), respectively.  
More interestingly, for the first time a novel sulfated-pterosin, rhedynosin H (RH9), was 
isolated from belowground rhizomes of P. aquilinum (L.) Kuhn. Previously, (2R, 3S)-sulfated 
pterosin C and (2S, 3S)-sulfated pterosin C have been reported from the methanolic extract of 
the aerial parts of Acrostichum aureum (Uddin et al., 2011). These sulfated pterosins have one 
extra hydroxyl group at position C-3 (Figure 75). 
In addition, rhedynosins B (RH3) and I (RH14) exhibit close similarity with 
Deoxypterolactone A (Figure 76) which has been obtained as an oxidation product from 
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the reaction of calamelanolactone with Jones reagent13 (Bardouille et al., 1978). 
Echinolactone D, an illudalane sesquiterpenoid, is also structurally similar to compounds 
RH3 and RH14 (Figure 76). This compound has been isolated from the cultured mycelia 
of the basidiomycetous fungus Echinodontium japonicum (Suzuki et al., 2006). 
 
Figure 75: Chemical structural similarity between a new compound RH7 and reported 
sulfated pterosins in the literature. 
 
Figure 76: Structural similarity of rhedynosins B and I with reported compounds in the 
literature. 
                                                          
13 The Jones Reagent is a solution of chromium trioxide (CrO 3) in diluted sulfuric acid that can be used 
safely for oxidations of organic substrates in acetone. 
 Reference: http://www.organic-chemistry.org/chemicals/oxidations/jones-reagent.shtm. 
 
Chapter Three Results and discussion 
 
129 
 
There is also similarity between the new compound, rhedynosin D, and setulosopterosin which 
has previously reported by Murakami et al in 1980 (Figure 77). 
 
Figure 77: Structural similarity between the new compound, rhedynosin D, and 
setulosopterosin from the literature. 
Additionally, the two new compounds, rhedynosins F (RH7) and G (RH8), are very similar to 
(2S)-13-hydroxypterosin A which has been isolated from the whole plants of Pteris ensiformis 
(Chen et al., 2013). The hydroxyl group of (2S)-13-hydroxypterosin A at position C-14 has 
been replaced with a chlorine atom in both rhedynosins F and G (Figure 78). 
 
Figure 78: Similarity between chemical structures of two novel compounds, RH7 and 
RH8, and a published pterosin in the literature.  
The absolute stereochemistry of the novel compound rhedynoside B (RH10) was determined 
by single crystal X-ray diffraction analysis (Figure 52-Figure 53). The 2S configurations of 
compounds RH15 and RH35 were assigned by their CD spectra (Figure 59 & Figure 68) which 
coincide with those reported in the literature (Kuroyanagi et al., 1979b), and consequently 
confirmed by X-ray crystallography (Figure 58 & Figure 69). The n → π* CD components of 
compounds RH17 and RH18 exhibit a strong negative Cotton effect around 330 nm (Figure 
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61) which is in agreement with the reported CD data. Thus the configurations of RH17 and 
RH18 were determined to be 2R, 3R and 2S, 3R, respectively (Kuroyanagi et al., 1979b),  and 
again this was confirmed with X-ray diffraction (Figure 60-Figure 62). X-ray data for the 
known compound (2R)-pteroside B (RH31) confirmed the absolute configuration determined 
previously by CD spectroscopy (Figure 57) (Hikino et al., 1970; Kuroyanagi et al., 1979b) 
Both cis and trans motifs at C2-C3 were identified in compounds RH17, RH18, RH22 and 
RH28 (Table 25-Table 27Table 26 & Table 29). The position C-2 adjacent to the keto group 
readily epimerises if there is simply a methyl substituent. As a result, at this stage it was not 
possible to assign and/or confirm the absolute configurations for compounds RH9, RH12, 
RH16, RH20, RH21 and RH25 using the CD spectroscopy.  A hydroxymethyl group at C-2 
is apparently optically stable as in compounds RH1, RH2, RH7, RH14, RH15, RH23, RH27, 
RH29, RH30, RH34 and RH35. Epimerisation may well be inhibited through intermolecular 
hydrogen bonding in these compounds (Kuroyanagi et al., 1979b).  
Finally, the yield and concentrations of all isolated compounds (mg/kg dry weight) are shown 
in Table 44. Also, details of previously reported pterosins and pterosides including source of 
their isolation and related references from 1970 up to date are summarised and given in Table 
45.  
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Table 44: Yield and concentration of minor and major isolated compounds. 
Compound’s name (sample ID) 
Weight  
(mg) 
Concentration 
(mg/kg dry weight) 
Minor 
components 
Major 
components 
(2S)-Rhedynosin A (RH1) 6.0 1.7   
(2S)-Rhedynoside A (RH2) 11.0 3.1   
Rhedynosin B (RH3) 5.8 1.7   
Rhedynosin C (RH4) 2.6 0.7   
Rhedynosin D (RH5) 4.5 1.3   
(3S)-Rhedynosin E (RH6) 6.0 1.7   
(2S)-Rhedynosin F (RH7) 4.1 1.2   
Rhedynosin G (RH8) 13.0 3.7   
Rhedynosin H (RH9) 3.0 0.9   
(2R)-Rhedynoside B (RH10) 11.6 3.3   
Rhedynoside C (RH11) 3.2 0.9   
Rhedynoside D (RH12) 9.1 2.6   
(3R)-Rhedynoside F (RH13) 3.8 1.1   
(2S)-Rhedynosin I (RH14) 6.0 1.7   
(2S)-Pterosin A (RH15) 160.0 45.7   
(2R)-Pterosin B (RH16) 110.0 31.4   
trans-Pterosin C (RH17) 18.0 5.1   
cis-Pterosin C (RH18) 20.0 5.7   
(3S)-Pterosin D (RH19) 60.0 17.1   
(2R)-Pterosin E (RH20) 17.0 4.9   
(2R)-Pterosin F (RH21) 10.0 2.9   
trans-Pterosin J (RH22) 5.0 1.4   
(2S)-Pterosin K (RH23) 3.0 0.9   
(2S)-Pterosin N (RH24) 15.4 4.4   
(2S)-Pterosin P (RH25) 4.0 1.1   
Pterosin Z (RH26) 14.0 4.0   
(2S)-2-Hydroxymethylpterosin E (RH27) 14.7 4.2   
trans-Histiopterosin A (RH28) 3.0 0.9   
(2S)-12-Hydroxypterosin A (RH29) 4.0 1.1   
(2S)-Pteroside A (RH30) 10.2 2.9   
(2R)-Pteroside B (RH31) 203.0 58.0   
(3S)-Pteroside D (RH32) 4.9 1.4   
Pteroside Z (RH33) 47.0 13.4   
(2S)-Pteroside A2 (RH34) 4.2 1.2   
(2S)-Pteroside K (RH35) 30.0 8.6   
5-(β-hydroxy)ethyl-2, 2, 4, 6-
tetramethyl-1, 3-indandione (RH36) 
4.0 1.1   
Ptaquiloside (RH37) 21.0 6.0   
5-hydroxycalamenene (RH38) 4.0 1.1   
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Table 45: Previous description and source details for previously reported pterosins and 
pterosides. 
Compounds Derived from References 
(2S)-Rhedynosin I (RH14) Isolated as a metabolite of (2S)-pterosin A from rat urine  (Lee et al., 2012) 
(2S)-pterosin A (RH15) 
Aerial part of bracken-fern P. aquilinum  (Kovganko et al., 2004) 
P. aquilinum var. caudatum (Pteridaceae)  (Castillo et al., 1997) 
Microlepia substrigosa TAGAWA  (Kuraishi et al., 1985) 
Rhizomes of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
Young fronds of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; 
Yoshihira et al., 1978) 
(2R)-pterosin B (RH16) 
The whole plant of Pteris ensiformis (Chen et al., 2013, 2008) 
Aerial parts of Pteris semipinnata L. (Pteridaceae) (Zhan et al., 2010) 
The whole plant of Pteris multifidi Poir (Pteridaceae) (Ge et al., 2008) 
P. aquilinum var. caudatum (Pteridaceae) (Castillo et al., 1997) 
Microlepia strigosa (THUNB.) PRESL (Kuraishi et al., 1985) 
Pteris bella TAGAWA (Tanaka et al., 1982) 
Pteris setulosocostulata and Histiopteris incisa (Murakami et al., 1980) 
Rhizomes of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
Young fronds of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; 
Yoshihira et al., 1978) 
Methanol extract of air-dried young leaves of bracken, P. aquilinum KUHN var. 
latiusculum UNDERWOOD (Pteridaceae) 
(Yoshihira et al., 1971) 
(2R, 3R)-pterosin C (RH17) 
Rhizomes of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
P. aquilinum var. latiusculum (Kuroyanagi et al., 1979b) 
Methanol extract of air-dried young leaves of bracken, P. aquilinum KUHN var. 
latiusculum UNDERWOOD (Pteridaceae)  
(Yoshihira et al., 1971) 
(2S, 3R)-pterosin C (RH18) 
P. aquilinum var. latiusculum 
(Fukuoka et al., 1978; 
Kuroyanagi et al., 1979a, 
1979b; Yoshihira et al., 
1978) 
It was obtained from enzymatic hydrolysis of pteroside C  (Hikino et al., 1972) 
Methanol extract of air-dried young leaves of bracken, P. aquilinum KUHN var. 
latiusculum UNDERWOOD (Pteridaceae)  
(Yoshihira et al., 1971) 
(3S)-pterosin D (RH19) 
Microlepia speluncae (L.) MOORE  
Microlepia strigosa (THUNB.) PRESL 
(Kuraishi et al., 1985) 
Dicksonia gigantea KARST. (1984, p.4620) (Satake et al., 1984) 
P. aquilinum subsp. wightianum (Tanaka et al., 1982) 
Coniogramme japonica  (Murakami et al., 1980) 
Young fronds of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; 
Yoshihira et al., 1978) 
Hypolepis punctate (Thunb.) (Murakami et al., 1976) 
Methanol extract of air-dried young leaves of bracken, P. aquilinum KUHN var. 
latiusculum UNDERWOOD (Pteridaceae) 
(Yoshihira et al., 1971) 
(2R)-pterosin E (RH20) 
Histiopteris incisa (Murakami et al., 1980) 
Young fronds of bracken fern, P. aquilinum var. latiusculum (Pteridaceae)  
(Fukuoka et al., 1978; 
Yoshihira et al., 1978) 
Methanol extract of air-dried young leaves of bracken, P. aquilinum KUHN var. 
latiusculum UNDERWOOD (Pteridaceae) 
(Yoshihira et al., 1971) 
(2R)-pterosin F (RH21) 
Microlepia substrigosa TAGAWA 
Microlepia strigosa (THUNB.) PRESL 
(Kuraishi et al., 1985) 
P. aquilinum subsp. wightianum (Tanaka et al., 1982) 
Histiopteris incisa (Murakami et al., 1980) 
Rhizomes of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
Young fronds of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; 
Yoshihira et al., 1978) 
Methanol extract of air-dried young leaves of bracken, P. aquilinum KUHN var. 
latiusculum UNDERWOOD (Pteridaceae) 
(Yoshihira et al., 1971) 
(2S, 3S)-pterosin J (RH22) 
Histiopteris incisa (Murakami et al., 1980) 
P. aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979b) 
Young fronds of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; 
Yoshihira et al., 1978) 
Methanol extract of air-dried young leaves of bracken fern, P. aquilinum var. latiusculum (Kuroyanagi et al., 1974b) 
(2S)-pterosin K (RH23) 
P. aquilinum var. caudatum (Pteridaceae)  (Castillo et al., 1997) 
P. aquilinum var. latiusculum (Fukuoka et al., 1983) 
Rhizomes of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
P. aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979b) 
Young fronds of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; 
Yoshihira et al., 1978) 
Methanol extract of air-dried young leaves of bracken fern, P. aquilinum var. latiusculum (Kuroyanagi et al., 1974b) 
(2S)-pterosin N (RH24) 
P. aquilinum var. latiusculum (Fukuoka et al., 1983) 
Young fronds of bracken fern, P. aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; 
Yoshihira et al., 1978) 
Methanol extract of air-dried young leaves of bracken fern, P. aquilinum var. latiusculum  (Kuroyanagi et al., 1974a) 
(2S)-pterosin P (RH25) 
The aerial parts of Pteris multifida Poir. (Pteridaceae) (Ouyang et al., 2010) 
Microlepia strigosa (THUNB.) PRESL (Kuraishi et al., 1985) 
Rhizomes of bracken fern, P. aquilinum var. latiusculum (Pteridaceae)  (Kuroyanagi et al., 1979a) 
P. aquilinum var. latiusculum (Pteridaceae)  (Kuroyanagi et al., 1979b) 
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Continuation of Table 45. 
Compounds Derived from References 
Pterosin Z (RH26) 
Pteridium aquilinum var. caudatum (Pteridaceae) (Castillo et al., 1997) 
Microlepia speluncae (L.) MOORE 
Microlepia trapeziformis (ROXB.) Kuhn 
Microlepia substrigosa TAGAWA 
(Kuraishi et al., 1985) 
Pteridium aquilinum var. latiusculum (Fukuoka et al., 1983) 
Fronds of Pteridium aquilinum subsp. wightianum (Tanaka et al., 1982) 
Methanol extract of the young shoots of bracken fern, Pteridium aquilinum (L.) Kuhn (Kobayashi and Koshimizu, 1980) 
Pityrogramma cabmelanos (Bardouille et al., 1978) 
Young fronds of bracken fern, Pteridium aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; Yoshihira et 
al., 1978) 
Hypolepis punctata Mett. (Hayashi et al., 1972) 
Methanol extract of air-dried young leaves of bracken, Pteridium aquilinum KUHN 
var. latiusculum UNDERWOOD (Pteridaceae) 
(Yoshihira et al., 1971) 
(2S)-2-Hydroxymethyl 
pterosin E (RH27) 
Isolated as a major metabolite of (2S)-pterosin A from rat urine (Lee et al., 2012) 
(2R, 3R)Histopterosin A 
(RH28) 
Histiopteris incisa (Murakami et al., 1980) 
(2S)-12-Hydroxypterosin A 
(RH29) 
Isolated as a metabolite of (2S)-pterosin A from rat urine (Lee et al., 2012) 
(2S)-pteroside A (RH30) 
Pteridium aquilinum var. latiusculum (Fukuoka et al., 1983) 
Rhizomes of bracken fern, Pteridium aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
Young fronds of bracken fern, Pteridium aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; Yoshihira et 
al., 1978) 
Japanese bracken, Pteridium aquilinum KUHN var. latiusculum UNDERWOOD 
(Pteridaceae) 
(Hikino et al., 1972) 
Japanese bracken, Pteridium aquilinum KUHN var. latiusculum UNDERWOOD 
(Pteridaceae) 
(Hikino et al., 1970) 
(2R)-pteroside B (RH31) 
The whole plant of Pteris multifidi Poir (Pteridaceae) (Ge et al., 2008) 
Pteridium aquilinum var. latiusculum (Fukuoka et al., 1983) 
Methanol extract of the young shoots of bracken fern, Pteridium aquilinum (L.) Kuhn (Kobayashi and Koshimizu, 1980) 
Rhizomes of bracken fern, Pteridium aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
Young fronds of bracken fern, Pteridium aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; Yoshihira et 
al., 1978) 
Japanese bracken, Pteridium aquilinum KUHN var. latiusculum UNDERWOOD 
(Pteridaceae) 
(Hikino et al., 1970) 
(3S)-pteroside D (RH32) 
Rhizomes of bracken fern, Pteridium aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
young fronds of bracken fern, Pteridium aquilinum var. latiusculum (Pteridaceae) 
(Fukuoka et al., 1978; Yoshihira et 
al., 1978) 
Japanese bracken, Pteridium aquilinum KUHN var. latiusculum UNDERWOOD 
(Pteridaceae) 
(Hikino et al., 1971) 
Pteroside Z (RH33) 
Rhizomes of bracken fern, Pteridium aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
Pteris wallichiana AGARDH (Aoyama et al., 1977) 
Japanese bracken, Pteridium aquilinum KUHN var. latiusculum UNDERWOOD 
(Pteridaceae) 
(Hikino et al., 1971) 
(2S)-pteroside A2 (RH34) Young fronds of Pteridium caudatum L. Maxon (Syn. P. aquilinum var. caudatum) (Castillo et al., 2003) 
(2S)-pteroside K (RH35) Rhizomes of bracken fern, Pteridium aquilinum var. latiusculum (Pteridaceae) (Kuroyanagi et al., 1979a) 
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3.8. PROOF AND CONFIRMATION OF SULFATE AND CHLORINE-CONTAINING 
COMPOUNDS USING HPLC-ESI-MSN METHOD 
In this research, a moderately polar organic solvent “chloroform” was selected to start the 
extraction of the bracken rhizomes. This resulted in the isolation of a number of pterosins and 
pterosides along with ptaquiloside. These isolated pterosins and pterosides from bracken 
rhizomes showed surprising structural diversity, which even encompassed chloride and sulfate 
substituents. The biosynthesis of pterosin B is thought to be derived from the sesquiterpenoid 
biosynthetic pathway established by using the incorporation of radiolabelled mevalonate. 
Specifically, Hikino et al. (1976) suggested pterosin B (RH16) to be derived from mevalonic 
acid via farnesyl pyrophosphate and humulene. It is hypothesised that at least compounds RH9 
and RH12 derive from ptaquiloside degradation in planta as the major ptaquiloside degradation 
product, pterosin B (RH16), originates from a nucleophilic addition of present nucleophiles for 
example hydroxide ion (OH-) and hydroxide ion (Cl-). The less abundant nucleophiles in planta 
Cl- and SO4
2- can also act by a similar mechanism to yield the chlorinated rhedynosins D 
(RH5), F (RH7) & G, rhedynosides B (RH10), C (RH11), D (RH12) & E (RH13), pterosins 
F (RH21), J (RH22) & K (RH23) and pteroside K (RH35).  
It seems more likely that chlorinated compounds may produce from the reactions involve 
chlorinated solvents such as chloroform. This may take place, for instance, during organic 
synthesis of biologically active compounds. From this perspective, it is necessary and 
important to confirm the existence of compounds which possess chlorine and sulfate groups in 
the plant extract. In order to investigate this purpose, a non-chlorinated organic solvent 
“methanol” was used to prepare a crude extract from ground bracken rhizomes. The methanolic 
extract was then analysed by HPLC-ESI-MSn. This analysis was used to indicate and confirm 
that the isolated pterosins and pterosides containing chlorine or sulfate group were present in 
the extract itself rather than synthesis of these compounds as a result of their reactions with 
chloroform during extraction and chromatographic isolation process. 
The results of HPLC/ESI-MSn analysis of the methanolic crude rhizome extract confirmed the 
presence of the above mentioned chlorinated and sulfated compounds. Both negative molecular 
ions (427 and 429 Da) of compounds RH11, RH13 and RH35 showed a constant neutral loss 
of 162 Da to give ions at m/z 265 and 267, respectively, which corresponded to the loss of an 
O-linked hexose moiety (glucose) (Felipe et al., 2014; Levandi et al., 2014; Qu et al., 2004; 
Scholz et al., 2005) (Figure 79-Figure 83). The presence of only one sulfated metabolite 
amongst the group of reported pterosins suggests that it is rather a degradation product than a 
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compound of biosynthetic origin. The other reported sulfated pterosins (Uddin et al., 2011) 
occurred as both trans and cis isomers at C2-C3. The origin of these sulfated compounds is 
also suggested to be from degradation of ptaquiloside rather than through direct biosynthesis 
(Yamada et al., 2007).  
 
Figure 79: Reverse phase HPLC-ESI-MS total ion current (TIC) chromatogram of 
methanolic crude extract of bracken rhizomes in the negative ion mode. 
 
Figure 80: HPLC-ESI–MS/MS base peak chromatogram of methanolic crude extract of 
bracken rhizomes in the negative ion mode.  
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Figure 81: HPLC/ESI–MS/MS total ion current chromatogram of a selected peak 
(relative retention time (RRt) = 9.15 min) of methanolic crude extract of bracken 
rhizomes in the negative ion mode. 
 
Figure 82: HPLC/MS identification of the sulfated-pterosin (RH9) in methanolic crude 
extract of bracken rhizomes. HPLC/MS spectrum showing [M-H]- (297.14 amu) in the 
negative ion mode at RRt of 9.90 min for compound (RH9).  
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Figure 83: Further HPLC/MS/MS identification of the chlorinated compounds (RH11, 
RH13 and RH35) (loss of 162 amu) in methanol extract of bracken rhizomes. TIC of 
compounds at RRt of 18.8 min: (A) with 35Cl isotope; (B) with 37Cl isotope. HPLC/MS/MS 
spectrum showing [M-H-Glc]- (265 amu) in the negative mode at RRt of 18.8 min for (C) 
35Cl-compounds and (D) 37Cl-compounds. 
 
D 
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CHAPTER FOUR 
4. BIOLOGICAL ACTIVITY ASSESSMENT OF PTEROSINS AND PTEROSIDES IN 
BRACKEN  
The aim of this chapter is to investigate whether the isolated pterosins and pterosides show any 
significant biological activity towards different test species. The traditional use of bracken 
suggests that pterosins or pterosides maybe biologically active on their own as this has been 
documented in the scientific literature (details chapter 1 and chapter 3). 
4.1. EXPERIMENTAL PART OF BIOASSAYS 
4.1.1. ALAMAR BLUE ASSAY TO DETERMINE DRUG SENSITIVITY OF AFRICAN 
TRYPANOSOMES IN VITRO14 
A modification of the microplate Alamar blue assay was used to test the antitrypanosomal 
activity of 21 pterosins and pterosides (RH2, RH8, RH10, RH12, RH14-RH21, RH24, RH26 
–RH27 and RH30 –RH35) against the blood stream form of the Trypanosoma brucei brucei 
S427. The solutions of these compounds were prepared as 10 mg/mL stock solutions in DMSO 
(100%). The test solutions (200 μg/ml) were prepared by pipetting 4 μl of 10 mg/ml test stock 
solution and adding 196 μl HMI-9 medium (%10 fetal calf serum (FCS)) (Invitrogen) into each 
well. 100 μl of the test solution (HMI-9 medium) was pipetted in duplicate into the first column 
of a 96-well microplates (polyethylene storage plate) and the serial 1:1 dilutions were carried 
out using a multi-channel pipette from columns 2 to 11 (Table 46). DMSO at a concentration 
range of 0.001–1% and suramin15 over a concentration range of 0.008–1 μM were included as 
negative and positive controls. A sterility check was conducted by using 90μl of the diluted 
bacterial inoculum to all the assay plates with the exception of well A1. The microplates were 
incubated at 37 ºC in a humidified 5% CO2 atmosphere for 48 hours. Thereafter, 10% alamar 
blue™ was added to each well and the microplates were incubated for a further 24 hours. 
Fluorescence was determined using a microplate fluorometer at an excitation wavelength of 
560 nm and an emission wavelength of 590 nm. Percentages of control values were calculated 
and the MIC was determined as the lowest compound concentration with <5 % of the control 
values.  
                                                          
14 Biological activity tests against T. brucei and M. marinum were undertaken by Carol Clements. Strathclyde 
Institute of Pharmacy and Biomedical Sciences in collaboration. 
15 Suramin is an antiparasitic drug developed by Oskar Dressel and Richard Kothe of Bayer, Germany in 1916. It 
has been shown to have potent antineoplastic properties. 
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Table 46: Final assay concentrations µg/ml. +ve control 
 1 2 3 4 5 6 7 8 9 10 11 12 
A control 100 50 25 12.5 6.25 3.1 1.55 0.78 0.34 0.17 1.0µM suramin 
B control 100 50 25 12.5 6.25 3.1 1.55 0.78 0.34 0.17 0.5µM suramin 
C control 100 50 25 12.5 6.25 3.1 1.55 0.78 0.34 0.17 0.25µM suramin 
D control 100 50 25 12.5 6.25 3.1 1.55 0.78 0.34 0.17 0.125µM suramin 
E control 100 50 25 12.5 6.25 3.1 1.55 0.78 0.34 0.17 0.062µM suramin 
F control 100 50 25 12.5 6.25 3.1 1.55 0.78 0.34 0.17 0.031µM suramin 
G control 100 50 25 12.5 6.25 3.1 1.55 0.78 0.34 0.17 0.015µM suramin 
H control 
equivalent 
solvent 
control 
e.g. DMSO 
         0.008µM suramin 
4.1.2. ANTIMICROBIAL ASSAY - M. MARINUM ATCC.BAA535  
A modification of the microplate Alamar blue method for susceptibility testing of fast growing 
species of Mycobacterium was used. Mycobacterium marinum ATCC.BAA535 from the 
thawed stock cryoculture was streaked onto Columbia (5% horse blood) agar slopes and 
incubated at 31 oC for 5 days. A loopful of the culture was then transferred to a sterile universal 
container containing 10 mL of sterile 0.9% NaCl and glass beads. The bacterial suspension was 
mixed vigorously and allowed to settle. One millilitre of the supernatant was added to a fresh 
tube containing 10 mL sterile MHB (Mueller Hinton broth) saline that had previously been 
used to Zero the turbidity meter. The turbidity of the solution was adjusted to be the same as a 
0.5 McFarland standard. A few drops of Tween 80 0.02% were filter sterilized and added to 
homogenise the suspension. This was then shaken and the inoculum diluted 1 in 1000 with 
MHB for use in the assay. Samples were dissolved in a sufficient quantity of DMSO to reach 
a concentration of 10 mg/mL or 1 mg/100 μL. For the initial screen, the 10 mg/mL stock 
solutions of the samples were diluted to 1000 μg/mL using MHB. Then 20 μL of each extract 
was placed in each well and 80 μL of MHB was added. DMSO was added as the negative 
control at a concentration range of 1 to 0.002% and gentamycin as positive control at a range 
of 100 to 0.78 μg/mL. Then one hundred microlitres of the bacterial suspension were added to 
the wells. The plates were sealed and incubated at 31 oC for 5 days before the addition of 10 μl 
of Alamar blue. The plates were again sealed and incubated at the same temperature for 24 
hours after which fluorescence was determined using the Wallac Victor microplate reader in 
fluorescence mode (Excitation 530 nm; Emission 590 nm). The results were calculated as 
percentages. The conditions used in M. marinum ATCC.BAA535 assay can be summarised as 
shown in Table 47.  
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Table 47: Conditions of M. marinum ATCC.BAA535 assay. 
Bacterium M.marinum ATCC.BAA535 
Incubation temperature (ᵒC) 31 
Incubation time (CA slope) 5 days 
Inoculum suspension density 0.5 McFarland standard then 1 in 10 dilution 
Positive control 
Gentamycin 50 mg/ml stock then 1 in 50 dil. 
1:1 serial dilution, then 20µl in 200µl in assay 
plate 
Positive control range/ usual MIC 100 to 0.78µg/ml MIC 6.25µg/ml 
Assay Incubation time  5 days 
Incubation time until Fluorescence determined 24 hours 
The same method was used for Klebsiella pneumonia (strains ATCC 13883 and BAA 2146 
NDM-1) and Methicillin resistant staphylococcus aureus (MRSA) (strains 16 and 106) except 
that a loopful of each bacterial strain was streaked on to individual Columbia 5% horse blood 
agar slopes and were incubated at 37 oC for 20 hours. 
4.1.3. ANTIFUNGAL ASSAY16 
Five strains of C. albicans harbouring a range of ERG3 and ERG11 mutations (Table 48), and 
representing different anti-fungal resistance spectra were selected to analyse the potential toxic 
properties of 21 pterosins and pterosides (RH2, RH8, RH10, RH12, RH14-RH21, RH24, 
RH26 –RH27 and RH30 –RH35). The 5 strains were SC514 (wild type), CA12, CA488, 
CA490 and CA1008. A description of the mutations present in each strain is detailed in Table 
48. All C. albicans strains were cultured on YPD (1% yeast extract, 2% peptone, and 1% 
dextrose) agar plates at 30 °C. For routine growth, yeast strains were grown with rotary shaking 
at 37 °C in RPMI-1640 + 2% glucose media. The plated cultures of C. albicans were grown 
for 24 hours at 30 °C. Isolated colonies were then selected from this plated culture, transferred 
to 0.85% Saline and cell density determined by haemocytometer counts. Cell suspensions at a 
density of 1.5 x 103 cells/mL were prepared in RPMI-1640 media, and 100 µL of inoculate 
transferred to each well of 96 well flat-bottomed plate. Working stocks of the 21 pterosins and 
pterosides were prepared in RPMI-1640 media at concentrations of 40 µg/mL and 80 µg/mL 
and 100 µL added to each of triplicate wells to give final concentrations of 20 µg/mL and 40 
μg/ml, respectively. Thus, each plate consisted of a specific yeast strain with each compound 
assessed in triplicate. Plates were incubated with shaking at 37 °C for 24 hours and then the 
                                                          
16 Undertaken by Prof Steve Kelly’s Group, University of Swansea in collaboration.  
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cell growth assessed by microscopy with a 10x objective. The experiments were performed in 
duplicate. 
Table 48: Candida albicans strains. 
Strain ERG3 Mutation ERG11 Mutation 
SC514 - - 
CA12 W332R - 
CA488 H243N; T330A; A351V D225G; E266D; E391G; V488I 
CA490 D147G; T330A; A351V 
F72S; T229A; E266D; N440S;  
V488I; R523G 
CA1008 
K97E; L193P; V237A;  
A351V; A353T 
E266D 
 
4.1.4. AGROCHEMICAL RELEVANT ASSAYS17 
4.1.4.1. FUNGICIDE ASSAYS 
Eighteen selected pterosins and pterosides (RH2, RH8, RH10, RH12, RH15 – RH21, RH24, 
RH26 – RH27, RH30 – RH31, RH33 and RH35) were evaluated in mycelial growth tests in 
artificial media against Pythium dissimile, Alternaria solani, Botryotinia fuckeliana and 
Gibberella zeae, at rates of 20 ppm.  
Test species Media Rate (ppm) 
Pythium dissimile Semi-solid 20 
Alternaria solani Semi-solid 20 
Botryotinia fuckeliana (Botrytis cinerea) Semi-solid 20 
Gibberella zeae (Fuscarium graminearum) Semi-solid 20 
The compounds were also evaluated against several pathogens on leaf-piece assays at the rate 
of 100 ppm for Uromyces viciae-fabae on bean and Zymoseptoria tritici on wheat, and at the 
rate of 200 ppm for Phytophthora infestans on tomato. The compounds were applied prior to 
inoculation with the pathogens. Mycelial growth or disease inhibition was assessed visually 
and scored using a 3 band system (0, 55 and 99 where 99 = total inhibition of hyphal growth / 
disease development, 55 = partial inhibition, 0 = no inhibition), 4-14 days after inoculation 
depending on the assay.  
                                                          
17 Undertaken at Syngenta, UK. 
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Test species Host Rate (ppm) 
Zymoseptoria tritici Wheat 100 
Phytophthora infestans Tomato 200 
Uromyces viciae-fabae Bean 100 
4.1.4.2. HERBICIDE ASSAYS  
The pterosins and pterosides (18 compounds) were tested for herbicidal activity against 
Arabidopsis thaliana at 10 ppm and Poa annua at 32 ppm. Test plates were stored for seven 
days in a controlled environment cabinet. They were scored as 0 or 99, where 99 = significant 
herbicidal effect, and 0 = no effect.  
Test species Treatment timing Rate (ppm) 
Arabidopsis thaliana Pre-emergence 10 
Poa annua Pre-emergence 32 
4.1.4.3. INSECTICIDE ASSAYS 
The 18 pterosins and pterosides were tested for activity against an aphid species at 1000 ppm 
on a leaf-piece based assay, and against Plutella xylostella and Diabrotica balteata at 500 ppm 
in artificial diet assays. Chemicals were applied to feeding aphids, or prior to infestation with 
P. xylostella and D. balteata larvae. Mortality was assessed relative to control wells using a 2 
band system (0 or 99 where 99 = significant mortality, 0 = no effect), 3-6 days after the 
treatments depending on the assay.  
Test species Treatment type Media Rate (ppm) 
Aphid species Feeding / contact Leaf disc 1000 
Plutella xylostella Feeding / contact Artificial diet 500 
Diabrotica balteata Feeding / contact Artificial diet 500 
Positive controls: In addition to the test compounds, positive control compounds were 
included in each test: azoxystrobin and prochloraz for fungicide assays, thiamethoxam and 
indoxacarb for insecticide assays and norflurazon for herbicide assays. For all screens, data 
were recorded for replicates and averaged.  
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4.1.5. ANTI-SCHISTOSOMAL SCREENING18 
Cercaria from Schistosoma mansoni were shed from Biomphalaria snails upon exposure to 
light and were subsequently mechanically transformed to obtain schistosomula. Solutions of 
the test compounds were dissolved in DMSO to obtain a working concentration of 1.6 mM and 
added to a stock plate. Basch culture media (80 μL) and approximately 120 schistosomula were 
pipetted into a 384 well plate (known as the master plate), and compounds were transferred 
from the stock plate to the master plate using the Biomek platform (Beckman Coulter) to give 
a final concentration of 10 μM within each well. On each plate two controls were used- 
Auranofin which completely kills the parasite (positive control) and DMSO (negative control). 
Each plate also contained the currently used drug for treating the disease- Praziquantel. All 
control compounds were run at a concentration of 10 μM. The plates were then incubated at 37 
ºC for 72 hours in an incubator containing 5% CO2 after which the Biomek platform was used 
to re-suspend the schistosomula mixture. The 384 well plate was then imaged for both 
phenotype and motility using the Molecular Devices ImageXpress XL microscope. Phenotype 
was imaged at 10x objective in four well locations and combined into one image tile. Motility 
was imaged at 10x objective over six seconds, five times and displayed as a video. 
The data generated from the images were analysed using Pipeline pilot to quantify the effect 
of the test compounds in comparison to the control compounds. Any compound that falls within 
the ‘hit’ area has had an effect on both motility and phenotype of the parasites within the 
Schistosomula life cycle stage of the parasite. 
4.1.6. ASSESSMENT OF EFFECT OF COMPOUNDS ON GLUCOSE TRANSPORT ACROSS CELL 
MEMBRANES19 
4.1.6.1. GLUCOSE TRANSPORT INHIBITOR CELL SCREENING ASSAY 
Differentiated cell monolayers were washed gently in Dulbecco's Phosphate Buffered Saline 
containing CaCl2 & MgCl2 (PBS(+) (Invitrogen) and the inserts transferred to a new Corning
® 
HTS Transwell®-96 well receiver plate (Sigma). The cells were incubated with fresh PBS(+) 
(75 μl per insert & 225 μl per well) for 60 mins at 37 oC, 5% CO2.  The PBS(+) was gently 
aspirated and replaced with 75 μl per insert of either 5mM D-Glucose (Sigma) ± test active or 
                                                          
18 Undertaken by Prof Karl Hoffman and Dr Helen Whiteland, IBERS, Aberystwyth University. Funded by 
National Research Network. 
19 Undertaken by Mark Fowler and Mark Berry from Strategic Science Group, Unilever R & D Colworth, Bedford, 
UK. 
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25 mM D-Glucose ± test active in triplicate and 225 μl per well of PBS(+) quickly added to 
each well.  The 5 mM glucose wells and the 45 mM glucose wells were incubated at 37 oC, 5% 
CO2 for 15 mins and 30 mins, respectively. Details of all the actives tested can be found in 
Table 49. The cell inserts were transferred to a new receiver plate, the supernatant gently 
aspirated from the cells and replaced with 100 μl of 100 μM of Lucifer Yellow (Sigma) solution 
to confirm the integrity of the monolayers.  225 μl of PBS(+) was added to each well and 
incubated at 37 oC, 5% CO2 for 1 hr.  The cell inserts were then discarded and the permeability 
of the membranes to Lucifer Yellow checked by measuring the fluorescence of the samples at 
485 nm (excitation) & 530 nm (emission) on a Spectramax Gemini EM fluorescence microplate 
reader.  
4.1.6.2. GLUCOSE TRANSPORT ASSAY 
The amount of glucose transported across the cell monolayers was measured using a 
glucose assay based on Invitrogen’s Amplex Red Glucose/Glucose oxidase Assay Kit. 
Briefly, 50 μl of each sample was transferred to a black sided / clear bottom 96-well plate 
(Greiner Bio-One) to which 100 μl of reaction buffer [0.5 μl 10 mM Ampliflu Red, 1 μl 
10U/ml HRP, 1 μl 100U/ml Glucose Oxidase and 97.5 μl Phosphate Buffered Saline 
(PBS) (all Sigma)] was added.  After incubation for 10 minutes at room temperature, the 
fluorescence of the samples was measured at 530 nm (excitation) & 590 nm (emission) 
on a Spectramax Gemini EM fluorescence microplate reader and the glucose 
concentration extrapolated from a standard curve.  
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4.2.   RESULTS AND DISCUSSION 
The compounds tested for biological screening were isolated from bracken rhizomes. 
These compounds are thought to be produced either from biochemical pathways or more 
likely they are derived from the degradation of ptaquiloside in planta. They have been 
found to have, for instance, antibacterial,  antimicrobial (Kobayashi et al., 1975) and 
antispasmodic activity (Sheridan et al., 1999). Cellular uptake of 3H-labelled DNA, RNA 
and protein precursors were inhibited by pterosin B (Saito et al., 1976). In this project, 
some biological activity screens were performed for a group of compounds as discussed 
and listed below. Hereafter, depending on the inhibition percentages of the tested 
compounds against bacterial and pesticidal growth, the activity of each compound in all 
the biological tests (except for glucose transport assay) is considered as the following: 
moderate-high for 55-85% inhibition, moderate for 45-55%, mild-moderate for 40-45% 
and mild (low) for less than 40%. 
4.2.1. GLUCOSE TRANSPORT ASSAY: 
Hsu et al. (2014) patented the use of pterosins and pterosides, including 84 distinct 
compounds of natural and synthetic origin. Their biological activity for treating diabetes 
and obesity was investigated predominantly with (2S)-pterosin A, but claimed for all 
described compounds. On this basis, it was decided to evaluate whether pterosins or 
pterosides were more active. Hence a selection of pterosins (RH15 - RH17) and their 
associated glycosides (RH30, RH31 and RH33) were assessed for their anti-diabetic 
activity specifically against two types of glucose transporters, SGLT1 and GLUT2, using 
an intestinal glucose uptake assay in vitro, however, they were found to be inactive at 300 
µM. This finding does not support the patented observation of Hsu et al. (2014) who claimed 
anti-diabetic activity for extracts of bracken against STZ-induced disease in mice at 100 
mg/Kg/d for 14 days by activating GLUT4. This discrepancy could have multiple origins, 
including the dosing schedule and activity in the latter assay through a mechanism other than 
through SGLT1 and GLUT2 transporters. 
Table 49 shows the percentage of inhibition of each compound (test active) against the 
transport of glucose across a differentiated Caco-2 cell monolayer, i.e. it represents the 
preliminary results of glucose transport assay of (2S)-pterosin A, (2R)-pterosin B and (2R, 3R)-
pterosin C, and (2S)-pteroside A, (2R)-pteroside B and pteroside Z, along with positive 
controls, phloridzin and phloretin. At the lower concentration of D-glucose (5 mM), the early 
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transport of glucose across the cell monolayer is predominantly performed through the high 
affinity, low capacity SGLT1 glucose transporter. At higher D-glucose concentrations, the 
SGLT1 transporter becomes saturated and consequently the majority of glucose transport 
across the monolayer is driven by the low affinity, high capacity GLUT2 glucose transporter 
(Kellett and Brot-Laroche, 2005). Each compound (active) was tested at low and high 
concentrations of glucose (5 mM D-glucose for 15 minutes and 25 mM D-glucose for 30 
minutes). The compounds were classed as SGLT1 inhibitors if they exhibited a greater than 
20% inhibition of glucose transport at 5 mM D-glucose and a corresponding less than 20% 
inhibition at 25 mM D-glucose.  Actives that were able to inhibit glucose transport by greater 
than 20% in both conditions were classed as GLUT2 inhibitors. This approach was qualified 
through the use of the widely recognised specific inhibitors of both SGLT1 and GLUT2, 
namely phloridzin and phloretin respectively. In general, (2S)-pterosin A, (2R)-pterosin B, (2R, 
3R)-pterosin C and pteroside Z showed some slight inhibition against both glucose 
transporters.  The patterns of inhibition at low and high concentrations of glucose suggests that 
these pterosins and pterosides are very weak GLUT2 inhibitors.  Neither glycosides A and B 
demonstrated significant SGLT1 inhibition. Overall, it is concluded that pterosins have 
negligible inhibitory effect on the main glucose transporters found in the intestine.  
Table 49: Results of pterosins and pterosides tested for SGLT1 and GLUT2 inhibition 
activity in Caco-2 cells using 5 mM D-glucose (15 min) and 25 mM D-glucose (30 
min), respectively.    
Test Active a Solvent 
% Inhibition of glucose transport 
Class b 5 mM Glucose 25 mM Glucose 
Ave. S.D. Ave. S.D. 
Phloridzin c DMSO 35.50 1.71 16.03 2.32 SGLT1 
Phloretin c DMSO 85.89 0.95 81.33 2.71 GLUT2 
(2S)-pterosin A DMSO 12.93 5.14 4.97 1.98 None 
(2R)-pterosin B DMSO 22.10 3.19 8.49 3.21  SGLT1 
(2R, 3R)-pterosin C DMSO 14.41 5.10 3.03 3.00 None 
(2S)-pteroside A DMSO 6.69 5.16 -1.89 3.19 None 
(2R)-pteroside B DMSO 3.50 3.91 -4.63 3.53 None 
Pteroside Z DMSO 14.27 4.93 4.35 4.82 None 
a – All actives tested at 300 µM 
b – Based on SGLT1 inhibitors having ≥ 20 inhibition of glucose transport at 5 mM D-glucose and ≤ 
20 inhibition at 25 mM D-glucose, and GLUT2 inhibitors having ≥ 20 inhibition at both 5 mM and 25 
mM glucose levels 
c – Positive control 
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4.2.3. ALAMAR BLUE ASSAY (ANTITRYPANOSOMAL ACTIVITY)  
The antitrypanosomal activity of 12 pterosins and 9 pterosides were tested against 
Trypanosoma brucei brucei which was conducted by Dr Carol Clements. The results are 
presented in Table 50. This assay was applied for the first time for pterosins and pterosides 
as no pterosins have been examined for antitrypanosomal activities and documented in the 
literature. It was noticed that the novel compound, rhedynosin G (RH8), showed highest 
activity when tested against blood stream Trypanosoma brucei brucei at a rate of 20 μM 
resulting in 79% inhibition, while all other tested compounds (except for RH12 and RH32 
which showed negative value) were found to be almost inactive as they displayed mild 
inhibition ranged between 4.5% – 37.5% at a rate of 20 µM against this type of bacterium. 
It is proposed that the activity of RH8 might be related to the feature of its structure due to the 
presence of keto group at C-1 and active functional groups, chlorine and two free hydroxyl 
groups at positions C-14, C-13 and C-2, respectively.  
4.2.4. ANTIBACTERIAL ACTIVITY 
This biological test was conducted by Dr Carol Clements. In general, 21 pterosins and 
pterosides were screened for antibacterial activity against five different bacterial strains. 
The compound RH35 ((2S)-pteroside K) was found to have a mild – moderate inhibition of 
44.1% against M. marinum (an indicator species for activity against tuberculosis) at a rate of 
100 µM, while the rest of the tested compounds showed low inhibition at the same rate against 
M. marinum. According to preliminary antibacterial screening, compounds RH2, RH8, 
RH20, RH30 and RH34 were found to be moderately active at a rate of 100 µM against 
Klebsiella pneumonia BAA 2146 compared to RH27 and RH33 (mild – moderate inhibition, 
41.1-43.8%) and the other tested compounds which displayed low inhibition (< 40%) against 
this bacterium. Moreover, these compounds all showed low activity at the same rate against 
Klebsiella pneumonia ATCC 13883 except (2S)-pterosin D (RH19) (moderate inhibition, 
46.6%) and rhedynosins B and D (RH10 and RH12) (moderate inhibition, 40.1% and 
40.5%, respectively). Also the tested pterosins and pterosides exhibited very low 
antibacterial activity when they tested against methicillin-resistant staphylococcus aureus 
(MRSA) strains 16 and 106 at a rate of 100 µM. 
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4.2.6. AGROCHEMICAL RELEVANT ASSAYS 
A number of selected pterosins and pterosides (18 compounds) were screened to evaluate their 
fungicidal and insecticidal activity on both artificial media and leaf-piece based assays in order 
to determine their potential activity as agrochemicals. Table 51 lists a summary of the 
agrochemical relevant assays tested on pterosins and pterosides. According to the initial results, 
only the 2 compounds, trans-pterosin C (RH17) and pterosin N (RH24), displayed moderate 
activity at the concentration of 10 µg/mL against Arabidopsis thaliana on the herbicide assay, 
meanwhile all the tested compounds were found to be inactive when tested against Poa annua 
at the concentration of 32 µg/mL. Additionally, none of the compounds produced any 
significant activity in the fungicide assay against 4 kinds of pathogens (Phytophthora 
infestans, Alternaria solani, Botryotinia fuckeliana and Gibberella zeae) nor in the 
insecticide assay against aphid species, Plutella xylostella and Diabrotica balteata. At the 
same time, the fungicidal results showed that the compounds RH15 and RH35 showed low 
(49%, 100 µg/mL) and very low (27%, 100 µg/mL) fungicidal activity against Uromyces 
viciae-fabae. Moreover, moderate inhibition was recorded for the pterosins RH16 (51%, 100 
µg/mL) and RH20 (55%, 20 µg/mL) against Zymoseptoria tritici and Pythium dissimile, 
respectively. Three other pterosins (RH17, RH24 and RH33) also showed very low potential 
activity (18-33%, 100 µg/mL) against Zymoseptoria tritici with all of the eighteen compounds 
failing to pass the selection criteria for progression of higher tier screens and therefore these 
were not selected as potential fungicides. 
4.2.7. ANTIFUNGAL ACTIVITY 
The aim of this biological test was to study the anti-fungal activity of 21 pterosins and 
pterosides by testing them for toxicity in the clinically important yeast species Candida 
albicans. This was conducted by Professor Steve Kelly’s group. All the compounds were 
tested in triplicate against five strains of the yeast species Candida albicans. The results 
showed that the compounds were ineffective against the five C. albicans strains as no 
growth inhibition was observed in any of the five C. albicans strains analysed after 
treatment with all of the 21 compounds at 20µg/mL or at the higher concentration of 
40µg/mL. These negative results illustrate that C. albicans has no susceptibility to any of 
the 21 pterosins and pterosides tested (Table 50).  
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Table 50: Summary of biological assay results for the selected pterosins and pterosides. 
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RH2 7.0 31.0 35.0 54.8 5.2 10.0 – – – – – 
R
e
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s 
(a
s 
%
 i
n
h
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) 
RH8 79.0 -6.0 37.3 45.1 4.4 4.3 – – – – – 
RH10 9.0 9.4 40.1 33.7 5.2 8.5 – – – – – 
RH12 -0.7 37.5 40.5 39.9 2.4 4.8 – – – – – 
RH14 37.5 9.1 29.0 15.7 2.2 1.1 – – – – – 
RH15 9.6 33.3 27.4 18.0 2.5 5.5 – – – – – 
RH16 14.9 2.5 28.4 30.0 6.2 6.6 – – – – – 
RH17 10.2 -3.7 32.4 30.6 7.5 7.0 – – – – – 
RH18 4.5 -9.7 41.3 25.3 8.3 7.6 – – – – – 
RH19 10.6 -12.1 46.6 27.9 5.0 8.3 – – – – – 
RH20 5.2 12.9 42.5 52.7 3.9 4.1 – – – – – 
RH21 16.6 -8.0 22.6 19.8 -1.4 -0.1 – – – – – 
RH24 33.6 14.3 22.9 11.6 0.1 1.4 – – – – – 
RH26 18.0 3.9 30.7 31.4 2.2 6.1 – – – – – 
RH27 11.5 -6.0 44.3 41.1 6.2 6.1 – – – – – 
RH30 20.6 11.9 37.8 48.2 3.8 6.5 – – – – – 
RH31 12.2 13.5 41.0 29.8 2.6 1.9 – – – – – 
RH32 -2.7 11.4 38.6 23.8 3.0 16.0 – – – – – 
RH33 30.7 6.2 40.2 43.8 6.7 5.8 – – – – – 
RH34 5.4 -11.4 44.4 51.9 2.1 8.2 – – – – – 
RH35 4.7 44.1 34.3 30.6 5.0 3.6 – – – – – 
Rate 20 μM 100 μM 20 mg/mL and 40 mg/mL  
Note:         = Moderate-high activity;         = Moderate activity;         = Mild-moderate activity; – = No activity; MRSA =  Methicillin resistant staphylococcus 
aureus. 
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Table 51: Summary of biological assay results for the selected pterosins and pterosides. 
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RH2 – – – – – – – – – – – – 
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%
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RH8 – – – – – – – – – – – – 
RH10 – – – – – – – – – – – – 
RH12 – – – – – – – – – – – – 
RH15 – – 49 – – – – – – – – – 
RH16 – 51 – – – – – – – – – – 
RH17 – 18 – – – – – 49 – – – – 
RH18 – – – – – – – – – – – – 
RH19 – – – – – – – – – – – – 
RH20 – – – 55 – – – – – – – – 
RH21 – – – – – – – – – – – – 
RH24 – 18 – – – – – 49 – – – – 
RH26 – - – – – – – – – – – – 
RH27 – 33 – – – – – – – – – – 
RH30 – – – – – – – – – – – – 
RH31 – – – – – – – – – – – – 
RH33 – – – – – – – – – – – – 
RH35 – – 27 – – – – – – – – – 
Rate 200 ppm 100 ppm 20 ppm 10 ppm 32 ppm 1000 ppm 500 ppm  
Note:         = Low activity;          = Very low activity; – = No activity. 
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4.2.8. ANTI-SCHISTOSOMAL SCREENING 
Bracken has traditionally been used as an antihelminthic (Marrs and Watt, 2006), hence the 
pterosins and pterosides were used in a motility assay for the intestinal flatworm Schistosoma 
mansoni a vector transferring schistosomiasis. No studies have been conducted so far to 
examine the anti-schistosomal properties of pterosins and pterosides both in vivo and in vitro. 
Thus, in order to investigate the bioactivity of pterosins and pterosides, 20 compounds (RH2, 
RH8, RH10, RH12, RH14-RH21, RH24, RH26 –RH27 and RH30 –RH34) along with the 
current anti-schistosomal drug praziquantel (PZQ) were tested for their schistosomicidal 
activity against Schistosoma mansoni at early stage of its life cycle, known as the schistosomula 
stage, at which a parasitic schistosome enters the blood vessels of its host. The preliminary 
results of the test (Figure 84) showed that none of the tested compounds were active against 
the parasite used as they displayed lower negative scores on both the phenotype and motility 
axes.  
Compound ID Phenotype score Motility score 
RH2 -0.1055 0.1705 
RH8 0.0151 0.16 
RH10 -0.0681 -0.1285 
RH12 -0.1178 -0.0337 
RH14 -0.0986 -0.0248 
RH15 -0.137 0.0343 
RH16 -0.0148 0.0728 
RH17 -0.1112 -0.0154 
RH18 -0.1363 -0.0387 
RH19 -0.0773 0.1586 
RH20 -0.1128 -0.0087 
RH21 -0.0798 0.1206 
RH24 -0.0592 0.0495 
RH26 -0.0581 -0.0306 
RH27 -0.0696 0.1074 
RH30 -0.1161 -0.0709 
RH31 -0.0721 0.2319 
RH32 -0.0781 0.0513 
RH33 -0.0859 0.0181 
RH34 -0.1249 0.1992 
DMSO -0.0908 -0.0346 
AUR -0.6426 -0.9184 
PZQ -0.394 -0.7506 
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Figure 84: Tabular and graphical representation of the anti-schistosomal activity score 
of a selection of pterosins and pterosides in comparison to the current anti-schistosomal 
drug and controls. 
Overall, while the biological activity of the different pterosins and pterosides was investigated, 
only compound RH8 showed relatively high activity against Trypanosoma brucei brucei and 
moderate effects were recorded for only a few pterosins against Klebsiella pneumonia ATCC 
13883, Uromyces viciae-fabae, Zymoseptoria tritici, Pythium dissimile and Arabidopsis 
thaliana, while no biological effects were recorded for the 5 strains of C. albicans. This was 
unexpected because of reported traditional use and patented applications of pterosins. There 
are a number of contributing factors for the observations. Concentration always needs to be 
considered for biological activity, as mostly the concentrations utilised reflect the best available 
treatment at the moment. It seems that none of the individual pterosins or pterosides would be 
sufficiently biologically active to justify further investigations in the areas studied. On the other 
hand, traditional use, for example, is not based on isolated compounds, rather it employs whole 
plant material or crude extracts. The same can be applied to bracken as a food or fodder crop. 
Because of the structural similarities of pterosins and pterosides with ptaquiloside, all are most 
likely present is crude extracts. Hence the biological activities traditionally associated with 
bracken and recently with pterosins, may in fact derive from ptaquiloside.   
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CHAPTER FIVE 
5. SEASONAL VARIATION AND QUANTIFICATION OF PTEROSIN B AND 
PTEROSIDE B IN BRACKEN SAMPLES 
5.1. INTRODUCTION 
Because ptaquiloside is an unstable compound, so analysis, identification and determination 
has taken a long time to be developed. Some attempts have so far been made in order to develop 
a successful separation of ptaquiloside and then its quantification methods (Burkhalter et al., 
1996; Niwa et al., 1983; Oelrichs et al., 1995; Ojika et al., 1985). Eventually, this problem has 
been tackled during sample preparation by transforming ptaquiloside into the stable compound, 
pterosin B. Consequently the concentration of pterosin B was quantified which is equivalent to 
the ptaquiloside concentration (Rasmussen et al., 2003b). In 1991, a simple high-performance 
liquid chromatography (HPLC-UV) method was described by Agnew and Lauren for the 
quantification of ptaquiloside in bracken. In this method, aqueous extraction has used to 
prepare the samples and polyamide resin column utilized to clean-up the sample solutions. An 
alternative method has also been mentioned to analyse ptaquiloside based on the base-acid 
conversion of ptaquiloside to pterosin B, followed by HPLC-UV analysis (Agnew and Lauren, 
1991). 
The most common method for carrying out quantification is by using HPLC with external 
standards. Generally, the indirect method is used to quantify the concentration of 
ptaquiloside. Before the analysis, ptaquiloside is converted to pterosin B in acidic or alkaline 
medium or by heat treatment. It is more preferable to use indirect method for determination 
of ptaquiloside which has the following advantages: a) pterosin B is a stable compound while 
ptaquiloside is quite unstable, b) the UV response of pterosin B is much higher than 
ptaquiloside (5-6 times greater). Subsequently, the limit of detection will be decreased 
during sample analysis with a UV detection source, and this may overcome the difficulties 
linked with the handling of ptaquiloside (Agnew and Lauren, 1991; Aranha et al., 2014). 
Various analytical techniques have so far been developed in order to determine the 
amount of pterosin B and ptaquiloside in different sample matrices, but HPLC-UV 
method being the most popular. These analytical methods have been used to analyse and 
quantify the concentrations of pterosin B and/or ptaquiloside in bracken extract (Alonso-
Amelot et al., 1992a), soil (Rasmussen et al., 2005), groundwater (Jensen et al., 2008), 
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biological samples (Fletcher et al., 2011) and milk (Alonso-Amelot et al., 1998; 
Francesco et al., 2011). 
Table 52 shows the summary of different analytical methods which have so far been used 
for determination of pterosin B and ptaquiloside in the literature.   
A developed HPLC-UV method has been used to estimate the contents of pterosins B and 
ptaquiloside quantitatively, for example, in the extracts of fronds and rhizomes of 
bracken, P. aquilinum var. caudatum, from Northern South America (Alonso-Amelot et 
al., 1992a) and in milk from cows fed bracken in Venezuela (Alonso-Amelot et al., 1998; 
Rasmussen et al., 2003b). 
Using the mass spectrometry method offers the advantage of confirming the structure of the 
compound. It has been found that the most suitable analogues for the detection of ptaquiloside 
derivatives by mass spectrometry are pterosin B and bromopterosin. Recently, the mass 
spectrometric system has been effectively applied. This approach is depended on the 
ptaquiloside conversion to bromopterosin or methoxypterosin subsequent with gas 
chromatography-mass spectrometry (GC-MS) and stable isotope dilution tests utilizing 
deuterated bromopterosin as internal standard (Attya et al., 2012). A sensitive liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method has recently been published 
for the quantification of pterosin B and ptaquiloside in groundwater and soil samples, based on 
the transformation of ptaquiloside to pterosin B  (Bonadies et al., 2004; Francesco et al., 2011; 
Jensen et al., 2008).
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Table 52: Various analytical methods for determination of pterosin B and ptaquiloside in different sample matrices.    
Analytical 
instrument 
UV detection 
(nm) 
Matrix Compound 
Concentration 
range (ng/mL) 
Recovery (%) LOD a (ng/mL) LOQ a (ng/mL) References 
HPLC-UV 260 
Bracken fronds 
Pterosin B 
Ptaquiloside 
0.54-0.79 b 
1.78-1.96 b 
- 
- 
- 
- 
- 
- 
(Alonso-Amelot et 
al., 1992a; Aranha et 
al., 2014) 
Bracken rhizome 
Pterosin B 
Ptaquiloside 
3.1-4.4 × 10-3 b 
2.0-7.5 × 10-3 b 
- 
- 
- 
- 
- 
- 
Bracken crosiers 
Pterosin B 
Ptaquiloside 
0.69-0.80 b 
1.88-2.34 b 
- 
- 
- 
- 
- 
- 
HPLC-UV 220 Bracken extract 
Pterosin B c 
Ptaquiloside 
- 
- 
89 
95 
5 d 
30 d 
- 
- 
(Agnew and Lauren, 
1991) 
LC-MS 
 
- 
 
Plasma 
Pterosin B 
Ptaquiloside 
5.5-250 
5-500 
75 
71 
1.1 
0.35 
3.7 
1.2 
(Aranha et al., 2014) Urine 
Pterosin B 
Ptaquiloside 
5.5-250 
10-500 
82 
88 
1.0 
1.6 
3.3 
5.2 
Milk 
Pterosin B 
Ptaquiloside 
6.85-137 
10-250 
63 
77 
1.6 
1.7 
5.3 
5.8 
LC-MS/MS - 
Soil 
Pterosin B 
Ptaquiloside 
0.3-60 
0.5-100  
84-91 
48-71 
0.15 (0.60 e) 
0.19 (0.76 e) 
- 
- 
(Jensen et al., 2008) 
Groundwater 
Pterosin B 
Ptaquiloside 
- 
- 
84-89 
52-66 
8 × 10-3  
14 × 10-3  
- 
- 
HPLC-UV 220 
Blood plasma Ptaquiloside - 81 40  100  (Fletcher et al., 
2011) Tissue Ptaquiloside - - 20  40  
HPLC-UV 260 Milk Pterosin B c - 91 500  - 
(Alonso-Amelot et 
al., 1998) 
GC-MS - Milk Bromo-pterosin c 3-20  79 0.3  0.4  
(Francesco et al., 
2011) 
a LODs and LOQs have been measured for the analytical instrument methods used in the experiment. 
b mg/g dry weight.  
c Ptaquiloside converted.  
d µg/g dry weight.  
e ng/g fresh weight. 
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5.2. MATERIALS AND METHODS 
5.2.1. GENERAL EQUIPMENT 
The analytical miller (Type: Retsch cyclone mill) was purchased from Retsch GmbH, 
Germany. A Jenway Model 3510 pH meter (Bibby Scientific, UK) was used to measure the 
pH of water samples. HeraeusTM MegafugeTM 16R refrigerated centrifuge from Thermo Fisher 
Scientific was used for the purpose of centrifugation of the water extract samples. A tabletop 
shaker (model: MaxQ 2000 Shaker-Analog) was purchased from Thermo Scientific and 
utilized to shake the samples at speed of 350 rpm. The Stuart® SBH 200D/3 Block Heater was 
purchased from Bibby Scientific Ltd., Staffordshire, UK. 
5.2.2. SAMPLE COLLECTIONS 
5.2.2.1. PLANT AND SOIL SAMPLES 
Bracken plants and soil samples used in this study were collected from the location N 53o 07′ 
and W 04o 08′ at a height of 250 m above sea level in the Snowdonia National Park (Llanberis, 
Wales-United Kingdom). The site area belongs to the upland vegetation type U20a (Pteridium 
aquilinum-Gallium saxatile community U20, Anthoxanthum odoratum sub-community U20a) 
(Thoss et al., 2012). This community is widespread in the British uplands. It is one of the 
common vegetation types in many parts of England, Wales and the south and west of Scotland. 
The most dominant vegetation exist in this community is bracken with a height of up to 1.5 m. 
Also a short and very common grassy sward is present underneath the fronds of bracken 
including Agrostis capillaris, Festuca ovina, Galium saxatile, Holcus lanatus, Potentilla 
erecta, Rumex acetosa, Viola riviniana, and small flowerless green plants such as Hypnum 
jutlandicum, Rhytidiadelphus squarrosus and Scleropodium purum. The site is categorised as 
rough grazing for agricultural purposes. It is typical of the zone where the farmed lowlands 
adjoin the unenclosed highlands with infertile and well-drained soils (Averis et al., 2004; Thoss 
et al., 2012) (Figure 85). The site encompasses approximately 1000 m2 (ca. 25m × 40m) with 
mostly bracken (P. aquilinum (L.) Kuhn) and bluebell (Hyacinthoides non-scripta (L.) 
Chouard ex Rothm) coverage. The site zone was gridded and divided into 144 quadrants. 
Bracken (rhizomes, fronds and stems) and soil samples were collected between March 2014 
and August 2015. A stainless steel (5 mm thickness) square hollow section (20 × 20 × 30 cm, 
W × L × H) was used for sampling. 
In 2014, two quadrants were sampled in duplicate on each sampling occasion during the main 
growing stages of Bluebell plants, while samples collected in 2015 comprised of one core per 
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sampling occasion. Thus, the lifecycle of Bluebell plant (growth pattern) was used as a base 
for collection of bracken and soil samples as follow:  
a) Weekly: from leaf emergence to end of flowering (March 2014 to mid-June 2014). 
b) After seed ripening until dormancy i.e. until bracken senescence:  
i. Fortnightly (June 2014 to August 2014). 
ii. Monthly (September 2014 to November 2014). 
c) Once every six weeks throughout the winter (December 2014 to end of January 2015). 
d) Once every three weeks until bluebell shoot emergence in March 2015.   
e) Fortnightly (March 2015 to August 2015). 
To diminish the effect of daytime variation, samples were collected always at the same time 
from 9:00 am to 11:00 am. 
  
 
Figure 85: A, Sampling site location and B, aerial view of the sampling site with 
bracken vegetation and bluebell flowers. 
A 
B 
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5.2.2.2. WATER SAMPLES 
In this experiment, in order to identify and quantify trace amounts of pterosin B and 
pteroside B in water, three types of water samples were chosen for validating the 
developed SPE-HPLC-UV method. The samples were tap water, groundwater (Well 
water) and surface water. All the samples were collected from the local regions 
surrounded by bracken in North of Wales - UK. Tap water sample was obtained in Bangor 
from the laboratory in chemistry building. The surface waters were collected in three 
different areas in Llanberis 1) at the bracken field site, 2) somewhere down the bracken 
field site and 3) the same hillside and elevation but different watershed. The groundwater 
sample was taken from a private water supply (Well water) with bracken on watershed 
and geological chalk areas in Anglesey. Table 53 shows the acidity degree (pH) of water 
samples measured by using a pH meter. All environmental water samples were stored at 
room temperature in the lab for two weeks and then analysed.  
Table 53: The pH value of water samples 
Water samples Location pH measurement 
Private water supply (Well water) Anglesey 7.50 
Surface water (unfiltered)  Llanberisa 7.10 
Surface water (filtered)  Llanberisa 7.50 
Surface water (below field side) Llanberisb 7.38 
Surface water (pale-yellow colour) Llanberisc 6.0 
Tap water  Chemistry building in Bangor 7.50 
a 
The samples were taken from a private water supply that abstracts surface water above the bracken field side. 
b 
The sample was taken somewhere below the bracken field side. 
c 
The sample was taken at similar elevation and vegetation as the field side but used a different watershed. 
 
5.2.3. PRE-TREATMENT OF PLANT AND SOIL SAMPLES: 
5.2.3.1. BRACKEN PLANT SAMPLES 
Bracken samples were manually processed in the laboratory and separated from the rest of the 
core. The rhizomes were separated and thoroughly cleaned from the soil with a spatula, 
meanwhile the fronds were divided into stems and leaves (called pinna) (Figure 86), in which 
they were used for SPE-HPLC-UV quantification of pterosin B and pteroside B.  
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Figure 86: Main parts of bracken fern (Pteridium aquilinum (L.) Kukn), A: fronds; B: 
rhizomes and crosiers. 
The samples were then air-dried at room temperature in the laboratory for a week. On each 
sampling occasion, fresh and dry weights were also recorded. The percentage of dry matter 
content (𝐷𝑤%) and water (𝑊%) were calculated from the fresh weight (𝐹𝑤) and dry weight 
(𝐷𝑤) using Equations 1 and 2, respectively.  
𝐷𝑤% =  
𝐷𝑤
𝐹𝑤
 × 100                                  (1) 
 
𝑊% =
𝐹𝑤 − 𝐷𝑤
𝐹𝑤
 × 100                          (2) 
 
The air-dried plant samples were ultimately ground and milled into a homogeneous particles 
using a Retsch cyclone mill and passed through a 1 mm sieve in order to obtain a representative 
sample for analysis. The milled samples were placed in tightly sealed plastic bags and stored 
at 4 °C in the refrigerator until the day of analysis. 
5.2.3.2. SOIL SAMPLES20 
The soil core samples were processed in the laboratory and thoroughly separated from the 
plants by hand. Soil samples were air dried, ground in a porcelain mortar, passed through a 2 
mm sieve and combined to form a composite sample for each sampling occasion. The samples 
were kept at room temperature in the laboratory until analysis. The top soil of the samples was 
used for the purpose of quantification and seasonal variation of pterosin B and pteroside B. 
                                                          
20 Soil samples were prepared by Victor Ebuele, PhD student, who has also been supervised by Dr Vera Thoss. 
A 
 
B 
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5.2.3.3. WATER SAMPLES 
The pH of the water samples was measured in the lab (see Table 53). The samples were 
prepared for SPE-RP-HPLC analysis by filtering them utilizing Wattman No. 1 filter paper. 
5.2.4. PREPARATION OF SOLID PHASE EXTRACTION (SPE) CARTRIDGES21  
SPE cartridges (500 mg Discovery® DSC-18Lt, 52615-U Supelco, Volume 6 mL) were 
supplied by Sigma Aldrich and contained silica gel based material (C18-
trimethyl(octadecyl)silane). The cartridges were preconditioned with 3 ml of methanol and 
washed with 3 ml of water in order to activate and prepare them for loading the plant and 
soil supernatants or water samples. 
5.2.5. REAGENTS AND STANDARDS 
All solvents used in this experiment including water, methanol and acetonitrile were 
HPLC grade and purchased from Fisher Scientific, UK, while formic acid (HPLC-grade) 
was supplied by Sigma Aldrich, UK. Standard compounds, pterosin B and pteroside B, were 
isolated from the chloroform extract of bracken rhizomes in the lab (see chapter two and 
three), and they were used for monitoring seasonal changes of pterosin B and pteroside B 
and/or quantification purpose in bracken, soil and water samples. Methanol was selected 
as the most suitable solvent for preparation of the solutions of standard compounds. 
5.2.6. PREPARATION OF STANDARD SOLUTIONS 
A stock standard solution of 100 mg/L of each compounds (pterosin B and pteroside B) 
was freshly prepared by dissolving an accurate weight of 1 mg of each compound with 
methanol. The solution was transferred into a 10-mL volumetric flask and then filled with 
methanol up to the etched line. All the standard solutions were kept at 5 °C in the 
refrigerator and protected from light. The methanolic solutions of a series of working 
standards, for example 0.2-1, 1-5 and 10-60 µg/mL (see Table 55), were prepared daily 
by diluting each stock standard solution with methanol and then they were injected into 
the HPLC instrument to make a calibration curve. All the glassware employed in this 
experiment was cleaned well with water and then rinsed three times with methanol.  
 
                                                          
21 The SPE cartridges have only been used twice. 
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5.2.7. SAMPLE PREPARATION AND EXTRACTION PROCEDURE BY SPE METHOD:  
5.2.7.1. PLANT AND SOIL SAMPLES 
A 4-digit balance was used for weighing 100 mg of milled bracken samples [rhizomes, fronds 
(pinna) and stems] and 5.00 g of soil samples into a 50 mL disposable centrifuge tube, and then 
10 mL (plant samples) or 25 mL (soil samples) of water was added. Samples were shaken for 
2 hr on a tabletop shaker at a speed of 350 rpm. The extract solutions were filtrated using 
qualitative filter paper (150 mm, Fisher Scientific) and then centrifuged with tabletop 
centrifuge machine at room temperature for 30 minutes at a speed of 5000 rpm.  
The sample supernatants were passed through the activated cartridges at a flow-rate of 1-2 ml 
min-1. To remove undesired polar compounds, the loaded SPE cartridges were washed with 
15% (5 mL) and 50% methanol-water (1 mL, method A; 4 mL method B, see below), 
respectively. Subsequently, the less polar fraction which contained the target analytes (third 
fraction) was eluted with an optimal volume 4 mL of methanol:water (v/v, 80:20). In order to 
pre-concentrate this fraction, the eluent was evaporated to dryness under a stream of nitrogen 
at 40 °C using the block-heater, and the temperature was constantly set at 40 °C to avoid any 
deterioration may occur to the pterosin compounds. It was then redissolved with 1 ml of 
MeOH and transferred to a HPLC vial. Afterward, the prepared sample along with standard 
solutions were submitted to the HPLC system for analysis. 
5.2.7.2. METHOD A: 
In method A, 15% aqueous solution of methanol (5 mL) was passed through the cartridges 
followed by 1 mL of 50% methanol:water to remove of undesired analytes. The third fraction 
which contained pterosin B and pteroside B was then collected with 4 mL of 80% 
methanol:water. This method was applied for quantification of: 
a) Pterosin B in soil, water and all plant samples except rhizomes. 
b) Pteroside B in all bracken (rhizomes, fronds and stems), soil and water samples. 
5.2.7.3. METHOD B: 
The concentration of pteroside B was higher than pterosin B in bracken rhizome samples while 
frond and stem samples contained almost equivalent amounts of pterosin B and pteroside B, as 
a result the peak height of pterosin B nearly disappeared in the chromatograms of rhizome 
samples. In order to obtain a better peak shape of pterosin B in rhizome samples, the volume 
of the second eluent (%50 methanol:water) was re-optimized. The maximum concentration of 
pterosin B with an obvious peak was obtained from the third fraction when 4 ml of %50 
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methanol:water used in the second eluent. Therefore, in method B, 15% (5 mL) and 50% (4 
mL) of methanol-water were used as first and second wash steps to remove unwanted polar 
compounds, respectively. Pterosin B was then eluted with 4 mL of 80% methanol: water. This 
method was only used for quantification of pterosin B in bracken rhizome samples. 
5.2.7.4. WATER SAMPLES 
After treatment of the samples as described above, they were considered as a supernatant and 
directly loaded on the SPE cartridges. The fractions were collected based on using method A. 
5.2.8. RP-HPLC-UV INSTRUMENTATION AND CONDITIONS  
5.2.8.1. RP-HPLC-UV INSTRUMENT 
The samples and standard compounds were injected automatically into a DIONEX UltiMate 
3000 HPLC system from Thermo Scientific equipped with a binary gradient pump, 
autosampler and diode array detector (DAD) monitoring 190-400 nm (UV-Vis range). The 
HPLC system was equipped with a Waters Spherisorb® ODS2 (C18) reverse phase analytical 
column (4.6 mm ID × 250 mm L) with a spherical particle size of 5 µm (purchased from 
Waters, UK). 
5.2.8.2. RP-HPLC-UV CONDITIONS 
The reverse phase C18 HPLC column was used and kept at 25 °C during sample analysis. The 
mobile phase consisted of a binary solvent system using water (solvent A) and acetonitrile 
(solvent B). The solvents were acidified with 0.1% formic acid. The elution gradient program 
started with 80% eluent A and 20% eluent B at a flow rate of 1.0 mL/min, and these percentages 
were maintained for 2 min, and then eluent B was ramped linearly to 100% in 14 min. This 
percentage (100% eluent B) was continued for 1 min, and then was declined to 20% eluent B 
within 1 min and then again maintained for 2 min to flush the column. A sample volume of 20 
µL was injected with the total run time of 20 min. Absorption spectral data of the main peaks 
were monitored concurrently and recorded with DAD at 254 nm. The Chromeleon 7 Software 
was used to control and process chromatographic data and analysis in terms of gradient setting, 
data acquisition and auto-sampler.  Table 54 shows summary of the optimum conditions of the 
developed HPLC method. 
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Table 54: The optimised conditions of RP-HPLV-UV method  
Column Waters Spherisorb® ODS-2 C18 (250mm × 4.6mm, 5µm) 
Mobile phase Acetonitrile and water (acidified with 0.1% Formic acid) 
Gradient 
20% ACN (2 min), 20-100% ACN (14 min), 100% ACN (1 min), 
100-20% ACN (1 min), 20% ACN (2 min). 
Flow rate 1 mL/min  
UV detection 254 nm 
Column temperature 25 °C 
Injection volume 20 µL 
 
5.2.8.3. LINEAR RANGE AND SENSITIVITY OF THE RP-HPLC-UV METHOD  
The standard calibration curves in bracken tissues, soil and water samples were linear over the 
pterosin B concentration ranges from 0.2 to 70 µg/mL (stems and fronds), from 0.2 to 30 µg/mL 
(rhizomes), from 0.2 to 2 µg/mL (soil) and from 0.2 to 1 µg/mL (water), while the samples 
showed linearity for pteroside B in the range of concentrations from 0.5 to 30 µg/mL (stems 
and fronds), from 0.5 to 300 µg/mL (rhizomes), from 0.2 to 1 µg/mL (soil and water) (Table 
55). The detection and quantification limits (LOD & LOQ), linear regression equations and 
correlation coefficients (r) for bracken (rhizomes, stems and fronds), soil and water samples 
are given in Table 55. All the linear equations were obtained over a wide concentration range 
in accordance with the levels of pterosin B and pteroside B found in the bracken, soil and water 
samples. The RP-HPLC method was linear in all cases (r > 0.99). 
5.2.9. PRECISION, ACCURACY AND RECOVERY  
For bracken stem samples, precision, accuracy and recovery experiments for pterosin B and 
pteroside B were performed. A 100 µL (V1) of three different concentrations of each standard 
solution (pterosin B and pteroside B) (C1 = 10, 50 and 100 mg/L) were spiked separately to 10 
mL of HPLC-grade water containing 100 mg of powdered bracken stem sample. The extract 
solution of unspiked and spiked bracken stem samples were then processed following the 
developed SPE-HPLC-UV method. Triplicate analysis were performed for spiked and 
unspiked bracken stem samples. A final volume of 1000 µL (V2) of each samples were 
subjected to HPLC-UV for analysis.  
C1 × V1 = C2 ×  V2                (3) 
Where: C1 = concentration of spiked standard solution; V1 = spiked volume of standard solution 
= 100 µL; C2 = concentration of analytes in final volume (V2) of 1000 µL. 
Therefore: 
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C1 ×  100 = C2 ×  1000                (4) 
The spiked amount of each compound (pterosin B and pteroside B) was calculated based on 
using Equation 5 (see data below). 
Spiked volume 
V1 (µL) 
Spiked concentration 
C1 (mg/L) 
Final volume 
V2 (µL) 
Analytes concentration in final volume 
C1 (mg/L) 
100 10 1000 1 
100 50 1000 5 
100 100 1000 10 
The inter-day precision and accuracy were calculated by determining three replicates for 
bracken stem sample. Percent recovery was determined by comparison of the recovered amount 
to the spiked amount and using Equation 5 (see Table 56). 
% Recovery =  
Amount recovered (
mg
L
)
Amount spiked (
mg
L
)
 × 100                  (5) 
In addition, in order to perform the recovery study of both analytes in the unspiked and spiked 
bracken stem samples, a series of standard solutions (0.5, 1, 5, 10, 15, 20 and 25 mg/L) of each 
compound (pterosin B and pteroside B) were freshly prepared and subjected to HPLC-UV 
instrument along with the sample solutions.  
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5.3. RESULTS 
A simple, accurate and reproducible RP-HPLC-UV method was developed and carried out to 
quantify and identify pterosin B and pteroside B in bracken rhizomes, fronds, stems, soil and 
water samples. Sample preparation for HPLC analysis were processed in duplicate through the 
methods A and B.  
5.3.1. WATER EXTRACTION PROCEDURE 
5.3.1.1. PRELIMINARY METHOD: 
During method optimisation, a 100 mg of plant material (stem) was accurately weighed 
and extracted with HPLC-grade water (15 mL), and then shaken for half an hour. It was 
then filtrated and the solution was centrifuged for 30 minutes. The supernatant was passed 
through a preconditioned SPE-cartridge. Three fractions were collected into 25-mL glass 
vials by passing 3 mL of 25%, 60% and 80% MeOH/ H2O through the cartridges, 
respectively. These fractions were dried on the block-heater at 40 °C under the stream of 
nitrogen. The dried fractions were redissolved in MeOH (1 ml) and transferred to labelled 
HPLC-vials. The solution of samples and standard compounds were then analysed with 
HPLC. The results displayed that the first fraction did not contain the target compounds, 
at the same time the peaks of desired components were observed in the chromatograms 
of fractions 2 and 3. Therefore, at this early stage the first fraction was used as a wash 
step and discarded as it only contained unwanted polar compounds.  
5.3.1.2. OPTIMIZATION OF THE METHOD 
To develop and improve the preliminary method, the following parameters were taken 
into account for optimization: 
a) Extraction time. 
b) Extraction volume of water. 
c) Percentage and volume of first and second fractions. 
d) Volume of third fraction. 
To figure out the effect of extraction time and obtain the highest concentration of the 
analyte (peak area), seven bracken stem samples (n1-n7) (100 mg each) were studied using 
the preliminary procedure in which the samples were shaken for 0.5, 1, 2, 3, 4, 5 and 15 
hrs (overnight), respectively. Figure 87 shows that up to an hour the extraction of the 
analytes was obviously not completed, while shaking for 2 hr is sufficient to extract the 
entire amount of pterosin B and pteroside B present in the samples. Figure 87 illustrates 
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that the extraction times of 2, 3, 4 and 5 hours give approximately the same peak areas 
for both analytes, while their peak areas decline dramatically when the solutions shake 
overnight for 15 hr. This might have been due to microbial degradation which changed 
the chemical composition of the extract. Therefore, 2 hr was used as an optimum value 
in the improvement of the subsequent parameter. 
 
Figure 87: Effect of extraction time on the peak areas of pterosin B and pteroside B.  
Under above experimental conditions, various volumes of water (5, 10, 15, 20 and 25 mL) 
were examined in order to obtain the optimal value of the extraction volume. As shown in 
Figure 88, the peak areas of the target components increase with increasing the extraction 
volume of water from 5-10 mL, and then the effect of the volume of water (from 10-25 mL) 
remains nearly constant. Based on this result, the volume of 10-mL was chosen to be the 
optimum for the extraction process, and this volume was fixed and used in the optimisation of 
the next variable. 
Degree of polarity of solvent system may play a great role in development of analytical 
methods. From this point of view and using the above conditions, different percentages of 
methanol (5, 10, 15, 20 and 25%) in the first fraction were studied. Figure 89 illustrates that 
the sensitivity of the method reaches the maximum at %15 methanol, and afterward the trend 
continues as a straight line from 15% to 25% methanol. Therefore, 15% of methanol was 
selected as an optimal percentage of the 1st fraction in this study.  
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Figure 88: Effect of extraction volume of water on the peak areas of pterosin B and 
pteroside B. 
 
Figure 89: Effect of percentage of methanol (1st fraction) on the peak areas of pterosin 
B and pteroside B. 
Further improvement of the method was performed based on the conditions mentioned above. 
The influence of different volumes of %15 methanol (1, 2, 3, 4, 5 and 6 mL) in collection of 
the 1st fraction was examined. As it is clear from Figure 90, the peak areas of both components 
rise gradually with increasing the volume of methanol and reach a peak at 5 mL, and afterward 
with using 6 mL of methanol the trend keeps steady. Therefore, 5 mL of methanol was denoted 
as an optimum volume and used in development of the method in a subsequent stage of the 
experiment. 
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Figure 90: Effect of volume of methanol (15%, 1st fraction) on the peak areas of 
pterosin B and pteroside B. 
Following the preliminary method and using the optimum value of the above variables, 
different volumes of 50% methanol in second fraction (1, 2, 3, 4, 5 and 6 mL) were tested in 
order to further develop the method. It was realised that this variable has a great impact in 
improving the method. Figure 92 exhibits that there is an inverse proportional between the peak 
areas of the analytes and the volume of 50% methanol (2nd fraction), in which the graph shows 
a gradual drop down of the peak areas with increasing the volume from 1 mL to 6 mL. Thus, 
volume of 1 mL 50% methanol (2nd fraction) was indicated as an optimal volume which gave 
the maximum peak areas. This volume was then fixed in the method and used in next 
optimization step. 
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Figure 91: Effect of percentage of methanol (2nd fraction) on the peak areas of pterosin 
B and pteroside B. 
 
Figure 92: Effect of volume of methanol (50%, 2nd fraction) on the peak areas of 
pterosin B and pteroside B. 
Figure 93 demonstrates how the peak areas affect by the volume of methanol (80%) in the third 
fraction. This was performed by examining different volumes (1, 2, 3, 4, 5 and 6 mL) of 
methanol (80%) in the preliminary method based on using values of other parameters optimised 
above. A proportional relationship between the peak areas and the volumes is apparent as it 
can be noticed in Figure 93, in which the peak areas of both compounds climb rapidly with 
increasing volume of methanol from 1 mL to 4 mL. Later on, the trend of the peak areas levels 
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off (reaches a plateau) with using of 5 mL and 6 mL of methanol. Based on these observations, 
the volume 4 mL of 80% methanol (3rd fraction) was chosen as a maximum value of the method 
and fixed in the experiment. 
  
Figure 93: Effect of volume of methanol (80%, 3 rd fraction) on the peak areas of 
pterosin B and pteroside B. 
 
5.3.2. OPTIMIZATION OF RP-HPLC-UV PARAMETERS 
The composition of the RP-HPLC solvent system was optimized in order to attain a good 
resolution between the chromatographic peaks. Different gradients of water:methanol mixture 
acidified with 0.1% formic acid and a mixture of water:acetonitrile (0.1% formic acid) were 
assayed separately. Water was denoted as solvent A. When methanol used as solvent B, the 
resultant chromatogram showed that the peaks were co-eluted, meanwhile the best resolution 
and peak shapes were achieved in the case of using acetonitrile as solvent B, and in addition 
the chromatogram was appeared better. The effect of flow rate was investigated by carrying 
out the experiment at various flow rates of 0.5, 1.0 and 1.5 ml/min. The flow rate of 1.0 ml/min 
was selected to be the optimal value as it gave a better resolution chromatogram than the others.  
Detection of the peaks were performed at different wavelengths of 220, 254, 280 and 320 nm. 
It was found that the peaks absorb the maximum energy at 254 nm as they exhibited higher 
absorbance unit. Furthermore, the influence of column temperature in range of 20-30 °C were 
examined, and 25 °C was chosen as the optimum temperature in which the chromatogram 
displayed a straight baseline of the peaks. The experiment also tested with different injection 
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volumes ranged 10-30 µL, the resulted chromatograms were all measurable and they were differing 
from each other in terms of their peak heights only, and hence 20 µL was selected as the optimum 
injection volume.  Figure 94 shows the HPLC-UV chromatograms of pterosin B and pteroside 
B in standards solutions, bracken tissues (rhizomes, fronds & stems) and soil sample.  
 
Figure 94: HPLC-UV chromatograms of pterosin B and pteroside B in bracken (rhizome, 
frond and stem), soil and standard solutions.
 Standard Pteroside B 
Standard Pterosin B 
Bracken rhizome 
Bracken rhizome 
Bracken frond 
Bracken stem 
Soil sample 
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Table 55: Linearity of pterosin B and pteroside B standards and sensitivity of the RP-HPLC-UV method. 
Compounds ID Samples 
Concentration range 
(µg/mL) 
Linear regression 
equation 
r n 
LOD 
(µg/mL) 
LOQ 
(µg/mL) 
P
te
ro
si
n
 B
 
BR a, BS b and BF c 2014 0.2-10 d Y = 0.8458x – 0.0141 0.9999 5 0.14 0.48 
BR 2014 10-30 e Y = 0.8477x + 0.0537 0.9991 5 1.13 3.77 
BS and BF 2014 10-60 e Y = 0.8149x + 0.4594 0.9998 7 1.13 4.04 
Water samples 2015 
BR 2015 
0.2-1 d Y = 0.6639x – 0.0068 0.9998 5 0.02 0.07 
BR 2015 1-25 e Y = 1.0452x + 0.0862 0.9999 9 0.42 1.42 
BS and BF 2015 
1-5 d 
5-70 e 
Y = 1.0680x – 0.0291 
Y = 1.0360x + 0.0979 
0.9999 
0.9997 
8 
5 
0.86 
0.12 
2.87 
0.40 
Soil samples 2014 & 2015 0.2-2 Y = 0.6844x – 0.018 0.9998 6 0.04 0.12 
P
te
ro
si
d
e 
B
 
BR 2014 & 2015 
0.5-30 d  
20-300 e 
Y = 0.5817x + 0.0167 
Y = 0.4176x + 0.1307 
0.9999 
0.9999 
8 
8 
0.44 
2.91 
1.46 
9.69 
BS and BF 2014 1-100 Y = 0.4155x + 0.1554 0.9999 7 0.85 2.83 
BS and BF 2015 
1-10 d 
0.5-30 e 
Y = 0.7413x + 0.0397 
Y = 0.5817x + 0.0167 
0.9999 
0.9999 
6 
8 
0.16 
0.44 
0.54 
1.46 
Soil samples 2014 & 2015 
Water samples 2015 
0.2-1 Y = 0.7603x + 0.0006 0.9999 5 0.01 0.04 
a BR: Bracken rhizome; b BS: Bracken stem; c BF: Bracken frond; d First linear range; e Second linear range 
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5.3.3. RECOVERY OF PTEROSIN B AND PTEROSIDE B WITH SPE-HPLC-UV METHOD IN 
BRACKEN STEM SAMPLES  
The recoveries and relative standard deviation (RSD) of the target analytes in unspiked (used 
as a control) and spiked bracken stem samples were calculated in order to assess the efficiency 
of the extraction procedure and determine the accuracy of the developed SPE-HPLC-UV 
method for quantification of pterosin B and pteroside B. The recovery experiment was carried 
out by spiking known amount of the standard pterosin B and pteroside B to the bracken stem 
samples. Three different levels (1, 5 and 10 mg/L) covering the naturally observed range of 
each target compound were directly spiked to the aqueous extracts of bracken stem samples 
and analysed in triplicate (n=3), i.e. the recovery studies were carried out in triplicate. Recovery 
of both target analytes were calculated from a) the amount recovered and b) the spiked amount 
of each compound, by using Equation 5 (see section 5.2.9).  
Recoveries and associated RSDs are listed in Table 56. The recoveries ranged between 
90.29 − 96.23 % and 93.64 − 101.03 % in bracken stem samples for pterosin B and pteroside 
B, respectively, and this indicates the accuracy of the method. The inter-day precision of the 
method was ranged from 0.19 to 2.45 % for pterosin B and 0.43 to 2.25 % for pteroside B. 
Moreover, a reasonable linearity from the calibration curves of the standard compounds 
(prepared in particular for recovery experiment) was obtained for pterosin B (Y=1.4439x + 
0.0443) and pteroside B (Y=0.6603x + 0.0715) with the determination coefficients (R2) of 
0.9998 and 0.9997, respectively.  
Table 56: Recoveries (%) of pterosin B and pteroside B in bracken stem samples and the 
associated relative standard deviations (% RSD). 
Name of matrices 
Amount added (spiked)  
(mg/L) 
Amount recovered  
(mg/L) 
% RSD  
(n=3) 
% Recovery 
(n=3) 
P
tero
sin
 B
 
P
tero
sid
e B
 
P
tero
sin
 B
 
P
tero
sid
e B
 
P
tero
sin
 B
 
P
tero
sid
e B
 
P
tero
sin
 B
 
P
tero
sid
e B
 
Unspiked bracken stem 0 0 0 0 0.27 0.57 0 0 
Spiked bracken stem 1 1 1 0.96 0.95 2.45 2.25 96.23 94.53 
Spiked bracken stem 2 5 5 4.51 5.05 0.19 2.03 90.29 101.03 
Spiked bracken stem 3 10 10 9.46 9.36 1.24 0.43 94.56 93.64 
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5.3.4. BIOMASS AND WATER CONTENT MEASUREMENT OF BRACKEN ORGANS 
The variations percentage of dry matter and water content have been determined in bracken 
stems, fronds and rhizomes over a period of 18 months. Shoots emerge from rhizome. Croziers 
start to emerge above ground at a certain time (May to June) by uncurling. Stems are formed 
and fronds are elongated and grow from July to September. The tissue of crosiers is light green 
and soft, because of its high water content and growth is more apparent with little 
differentiation. Adult stems and fronds are much harder to the touch and have lower water 
content. Overall, from the biomass being solely rhizome during dormancy, above ground 
growth is equal in biomass (zero percentage) between stems and fronds from December to May 
(Figure 95). 
Figure 96 illustrates that the water content in fronds and stems has a similar trend and 
decreases gradually from May to October. The highest percentage of water (ca. 90%) 
accumulates in stems and fronds of young crosiers in May and June (Figure 96). On the 
other hand, even though rhizomes show a slight fluctuation in water content, it can be 
concluded that rhizomes contain almost the similar percentage of water (70-75%) during 
the whole season. This result is consistent with that reported previously in the literature 
(Alonso-Amelot et al., 1992b). 
 
 
Figure 95: Biomass percentage of bracken rhizomes, fronds and stems (calculated 
based on dry weight separately). 
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Figure 96: Water content percentage in bracken rhizomes, fronds and stems.  
5.3.5. SEASONAL VARIATIONS AD QUANTIFICATION OF PTEROSIN B AND PTEROSIDE B 
USING SOLID PHASE EXTRACTION AND RP-HPLC-UV METHOD 
Bracken is well-recognised to contain the main carcinogenic compound, ptaquiloside. 
Ptaquiloside is unstable due to the presence of a spirocyclopropane moiety. It is supposed that 
pterosin B is derived from the same biochemical pathway as ptaquiloside (Rasmussen et al., 
2013), i.e. the main degradation product of ptaquiloside is pterosin B (Hirono, 1986). Due to 
instability of ptaquiloside, it is difficult and challenge to establish an appropriate method to 
determine its quantity directly. Therefore, researchers were thought about development indirect 
methods in order to quantify it.  
Development of a method to quantify a stable compound, pterosin B, is found to be 
fundamental and important for assessment of the carcinogenic property of bracken fern, by 
which its concentration is equivalent to the amount of ptaquiloside present in the sample. 
Pterosin B may therefore serve as a memory to detect the presence of ptaquiloside (Clauson-
Kaas et al., 2014). From this perspective, scientific researchers were attempted keenly to 
establish various analytical methods to quantify the amount of this carcinogenic compound 
(Agnew and Lauren, 1991; Burkhalter et al., 1996; O’Driscoll et al., 2016; Smith et al., 1994). 
Research has been concentrated on the quantification of ptaquiloside in the plant (Alonso-
Amelot et al., 1992b; Rasmussen et al., 2003b), in biological samples, such as urine, milk and 
plasma (Aranha et al., 2014) and in soil and groundwater samples (Jensen et al., 2008). The 
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main goal here was the development of a new HPLC method for quantification of pterosin B 
and pteroside B, which can use as an indirect and reliable method for determination and 
detection of ptaquiloside in plant, soil and water samples. 
5.3.5.1. SEASONAL VARIATIONS AND QUANTIFICATION OF PTEROSIN B AND PTEROSIDE B IN 
BRACKEN RHIZOMES, STEMS AND FRONDS 
Pterosin B and pteroside B were quantified in the different bracken tissues for 2 active growth 
periods 2014 and 2015. Variations in concentrations of both compounds occurred in 
bracken rhizomes during the growing period (Figure 97). The two compounds were used 
because pterosin B is the main degradation product of ptaquiloside and the associated pteroside 
B was hypothesised to give a good estimation of glycosylation and possible translocation 
potential. It was found that the pteroside B was about one order of magnitude22 more 
concentrated in the tissues when compared to pterosin B (Figure 97). This could also be a 
reflection on the high starch and glucose content of bracken in the rhizome with 60% (Madeja 
et al., 2009; Rymer, 1976). There was a distinct spike in the pterosin B concentration early in 
the growth period, coinciding with shoot and crosier emergence (Figure 97-Figure 98). In stage 
of dormancy, extending from December to May, there is a fluctuate pattern in 
concentrations of pterosin B and pteroside B in bracken rhizomes. The lowest amount of 
each compounds recorded in January and April (Figure 97). 
It is expected to vary the emergence of bracken fronds between years and different locations 
with changing the atmospheric conditions, specifically with temperature (Ader, 1988; 
O’Driscoll et al., 2016). Figure 98 shows the variations of pterosin B content in both stems and 
fronds through the period starting from April 2014 to August 2015 with the exception of 
dormancy period (early May to December). Pterosin B levels in bracken fronds and stems were 
closely linked and showed similar trends i.e. there was no discernible difference in the pterosin 
B concentration between stems and fronds. The minimum concentration of pterosin B in 
fronds and stems was recorded in July to September (5-15 mg/kg fronds, 15-40 mg/kg 
stems). By May, the accumulation of pterosin B and pteroside B in both tissue types reached 
peak as they showed high initial concentration (Figure 98), and this refers to the growing of 
bracken crosiers. Surprisingly, the pteroside B concentration in stems and fronds was half that 
of pterosin B and when compared to the rhizome was almost one order of magnitude less. 
                                                          
22 The expression "orders of magnitude" sometimes appears in comparisons. One order of magnitude means one 
power of ten. So, the numbers 100 and 10,000 differ by two orders of magnitude; or we can say that 10,000 is two 
orders of magnitude greater than 100. Similarly, a meter and a micrometre differ by six orders of magnitude. 
Reference: http://pirate.shu.edu/~rawncarr/metric/change.htm.  
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While for pterosin B the concentrations in fronds and stems nearly overlapped (Figure 98), 
there was a different pattern observed for pteroside B with a lower concentration in fronds early 
in the growth period in 2014 and higher concentration in the stems (Figure 99). This could be 
attributed to the fronds growing and differentiating later compared to the stems. 
 
 
Figure 97: Seasonal variations of pterosin B (1) and pteroside B (2) in bracken rhizomes. 
The areas between the dashed lines represent A: solely dormant rhizomes; B: shoot 
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growing; C: stem extension and mature fronds; D: premature senescence fronds and E: 
dead fronds and stems. 
 
Figure 98: Seasonal variation of pterosin B in bracken stems and fronds. The areas 
between the dashed lines represent A: dead bracken and dormancy period; B: crosiers 
emergence; C: stem extension and mature fronds; D: premature senescence fronds. 
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Figure 99: Seasonal variation of pteroside B in bracken stems and fronds. The areas 
between the dashed lines represent A: dead bracken and dormancy period; B: crosiers 
emergence; C: stem extension and mature fronds; D: premature senescence fronds.  
5.3.5.2. SEASONAL VARIATIONS OF PTEROSIN B AND PTEROSIDE B IN SOIL SAMPLES 
The fate of ptaquiloside from plant to soil and then to groundwater has been researched in detail 
(Clauson-Kaas et al., 2014; Jensen et al., 2008; Rasmussen et al., 2003a). There are few reports 
for pterosin B and none for pteroside B. In this study could not detect any pteroside B in soil 
samples which might be a reflection on glycosides serving as a source of glucose for soil 
microorganisms. Pterosin B in soil ranged from below detection limit to 0.3 mg / kg soil. For 
both growth periods (2014-2015), increases in concentration were observed post bluebell 
flowering (April to early June) and after crosier emergence (early in active growth period). 
This coincides well with the concentrations observed above ground, in fact it concurs with 
roots described as being leaky. In addition, bracken has been shown to add ptaquiloside to 
rainwater, another potential route of pterosin B into soil. 
0
50
100
150
200
250
300
C
o
n
ce
n
tr
at
io
n
 (m
g/
kg
)
Harvesting date (2014-2015)
Stems
Fronds
A B C B C D A 
Chapter Five Seasonal variation and quantification of pterosins and pterosides in bracken samples 
 
180 
 
 
Figure 100: Seasonal variation of pterosin B in soil samples. The areas between the 
dashed lines represent A: solely dormant rhizomes; B: shoot growing; C: stem extension 
and mature fronds; D: premature senescence fronds and E: dead fronds and stems. 
5.3.5.3. SEASONAL VARIATIONS OF PTEROSIN B AND PTEROSIDE B IN WATER SAMPLES 
Water samples were taken near from bracken covered areas using groundwater and surface 
water (filtered and unfiltered). In addition, pre-treated tap water was also analysed and found 
to not contain pterosin B or pteroside B. The concentrations measured for pterosin B ranged 
from 0.009 to 0.085 µg/L (Figure 101), which agrees well with water samples that have been 
analysed for pterosin B produced from ptaquiloside (Jensen et al., 2008). 
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Figure 101: Concentrations of pterosin B and pteroside B in water samples.  
5.4. DISCUSSION 
In this study, it was observed that the aboveground bracken fronds in North Wales emerged in 
early-May and dieback occurred in November-December, and this is in agreement with the 
results observed by Rasmussen et al. (2015) who have studied bracken in Scotland, as opposed 
to Ireland where bracken frond growth began in late-May to early-June and die off happened 
in late October to November (O’Driscoll et al., 2016). 
Ptaquiloside has been quantified in different samples in the last two decades. These analyses 
were based on the conversion of ptaquiloside to pterosin B. Shown here are the concentrations 
of pterosin B and pteroside B in different tissues and soil samples for a UK population through 
two growth periods. There were no previous determinations of pteroside B in bracken tissues. 
The high concentration of pteroside B in rhizome through most of the observed period is 
thought to reflect the transformation of pterosin B to pteroside B in order to improve storage 
and increase mobility for translocation in bracken. This is also supported with the observation 
that stems and fronds contain only half the concentration of pteroside B compared to pterosin 
B (Figure 98-Figure 99). The translocation of ptaquiloside to roots and rhizomes has been 
anticipated (Rasmussen, 2003). Thus, the low pterosin B and pteroside B concentrations in 
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stems and fronds may suggest translocation into the rhizome, especially pteroside B where it 
was present in a magnitude higher concentration when compared with stems and fronds.  
The lowest concentrations of pteroside B in rhizome were determined around shoot emergence 
(May to June) (Figure 97) when the concentration is diluted due to increased biomass (Figure 
95). The translocation of pteroside B into the shoot gives protection for the growing tissue 
according to classical chemical defence theory (Wink, 2003). This may also contribute to the 
pterosin B spike observed in the above ground tissue during crosier emergence and early for 
stems and fronds.  
It is unclear whether pterosin B is solely a degradation product of ptaquiloside or is also 
biosynthesised. The only study that used radiolabelled substrate (Hikino et al., 1976) did not 
consider both possible routes. When spiking soil with ptaquiloside, an increased pterosin B 
concentration was noticed during analysis and hypothesised to derive from ptaquiloside 
degradation (Jensen et al., 2008). The results of this study show that while the concentration of 
pterosin B is very similar for stem and fronds, the concentrations differ for pteroside B with an 
initially lower concentration in the fronds which gradually increases until it equals the stems 
during senescence in 2014. This may suggest the formation of pteroside B due to glycosylation 
of pterosin B and is only indirectly related to ptaquiloside. 
The concentrations of pterosin B in the adjacent soil were three magnitudes lower compared to 
the rhizome concentration. However, the pattern of high pterosin B concentration during shoot 
and crosier emergence is reflected in the spikes in pterosin B concentration observed for the 
soil samples. Surprisingly, pteroside B was not detected in any soil sample. The abundance of 
glycosidases in soil may be responsible as glucose serves as a carbon source for soil 
microorganisms and extracellular glycosidases are common (Blagodatskaya and Kuzyakov, 
2008; German et al., 2011; Skujiņš and Burns, 1976). 
The concentrations of pterosin B found in this study compare well with the results of Alonso-
Amelot et al (1992a) who have reported pterosin B concentrations in bracken fronds and 
crosiers (Table 52). The results also showed a good agreement with the pterosin B 
concentrations in soil samples reported by Rasmussen et al. (2005). Jensen et al. (2008) 
quantified pterosin B in different types of soil and determined 0.0668 ± 0.0049 and 3.8 ± 0.88 
mg/kg (dry weight) of pterosin B in a sandy and an organic-rich forest soils, respectively. 
Contrary to the soil samples, pteroside B was detected in water samples, as was pterosin B. 
The locations followed a stream, that drained the field site where the concentration of pteroside 
B and pterosin B were 0.015 µg/L and 0.064 µg/L, respectively. In the same area, but from a 
higher elevation, the filtered and unfiltered surface water samples originated, whose 
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concentrations were slightly higher. Surprisingly, the filtered surface water sample had a higher 
pterosin B (0.085 µg/L) and pteroside B (0.047 µg/L) concentration compared to the unfiltered 
surface water sample, this may be due to the removal of microorganisms in the filtered surface 
water samples. As this was only a one-off sampling occasion, no causes for this could be 
attributed. The “surface water sample” originated at the same bracken covered hillside, but 
used a different watershed, and it was found that the concentrations of pterosin B (0.029 µg/L) 
and pteroside B (0.020 µg/L) were also similar. The Anglesey private well water (groundwater) 
sample originated from a limestone area with bracken presence on the watershed. The 
concentrations of pterosin B (0.016 µg/L) and pteroside B (0.009 µg/L) were slightly lower 
compared to the other water samples, but still detectable. Finally, the Welsh Water supplied 
tap water was also examined, but it did not show a detectable trace of either pterosin B or 
pteroside B. 
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CHAPTER SIX 
6. CONCLUSIONS 
6.1. STRUCTURAL ELUCIDATION OF THE ISOLATED COMPOUNDS 
This study describes the successful isolation and identification of 38 natural products from the 
rhizome of Pteridium aquilinum (L.) Kuhn. These compounds comprise 35 pterosin-type 
sesquiterpenoids including eight new pterosins (RH1 & RH3-RH9) and five new pterosides 
(RH2 & RH10-RH13), alongside 5-(β-hydroxy)ethyl-2, 2, 4, 6-tetramethyl-1, 3-indandione 
(RH36), a potent bracken carcinogen “ptaquiloside” (RH37) and 5-hydroxyisocalamenene 
(RH38). Their chemical structures were elucidated mainly by 1D and 2D NMR spectroscopic 
analysis along with using high resolution mass spectroscopy. A guideline in order to find the 
chemical structures of the isolated compounds in this thesis is shown in Table 57.  
The absolute configurations were also determined for six novel compounds by using either 
single crystal X-ray diffraction (RH10) or CD spectroscopy (RH1, RH2, RH6, RH7, and 
RH13). The X-ray structure of (2R)-pteroside B (RH31) was also established from its 
crystallographic data. Moreover, both techniques X-ray crystallography and CD spectroscopy 
were successfully used to determine the absolute configuration of pterosins RH15, RH17 and 
RH18 and (2S)-pteroside K (RH35). In addition, CD spectroscopy yielded the absolute 
configuration for the previously reported pterosins (RH19, RH22, RH23, RH27 and RH28) 
and pterosides (RH30 and RH32), whilst the stereochemistry of the rest known compounds 
were established based on comparison of their NMR spectroscopic and accurate MS data with 
those published in the literature. Because of the large perturbing influence of a glycosyl-residue 
in the structures of RH31 and RH34, comparison of their CD spectra with those of the 
corresponding aglycones is inconclusive. 
In this series of compounds outlined herein, compounds RH1, RH15, RH17, RH18, RH19, 
RH22, RH23, RH27, RH28, RH29, RH30, RH32 and RH35 present CD spectra with vibronic 
fine structure, while compounds RH2, RH6, RH7, RH13, RH14 and RH34 render relatively 
featureless CD spectra. The rest of the compounds (except RH11, RH26, RH33, RH36, RH37 
and RH38) which are of the pterosin B type failed to show CD spectra as a result of 
epimerisation.   
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Table 57: A guideline to find the chemical structures of RH compounds throughout the thesis 
RH compounds Name of compounds Location Page number 
RH1 (2S)-Rhedynosin A a Figure 18 41 
RH2 (2S)-Rhedynoside A Figure 30 50 
RH3 Rhedynosin B Figure 40 56 
RH4 Rhedynosin C Figure 42 58 
RH5 Rhedynosin D Figure 44 60 
RH6 (3S)-Rhedynosin E Figure 51 66 
RH7 (2S)-Rhedynosin F Figure 49 64 
RH8 Rhedynosin G Figure 46 62 
RH9 Rhedynosin H Figure 50 65 
RH10 (2R)-Rhedynoside B Figure 52 68 
RH11 Rhedynoside C Figure 54 70 
RH12 Rhedynoside D Figure 55 71 
RH13 (3R)-Rhedynoside F Figure 56 73 
RH14 (2S)-Rhedynosin I b Table 19 76 
RH15 (2S)-Pterosin A Table 22 82 
RH16 (2R)-Pterosin B Table 20 77 
RH17 trans-Pterosin C Table 25 89 
RH18 cis-Pterosin C Table 26 91 
RH19 (3S)-Pterosin D Table 30 98 
RH20 (2R)-Pterosin E Table 32 103 
RH21 (2R)-Pterosin F Table 28 95 
RH22 trans-Pterosin J Table 29 97 
RH23 (2S)-Pterosin K Table 33 104 
RH24 (2S)-Pterosin N Table 35 108 
RH25 (2S)-Pterosin P Table 36 110 
RH26 Pterosin Z Table 37 111 
RH27 (2S)-2-Hydroxymethylpterosin E Table 39 116 
RH28 trans-Histiopterosin A Table 27 93 
RH29 (2S)-12-Hydroxypterosin A Table 40 118 
RH30 (2S)-Pteroside A Table 23 85 
RH31 (2R)-Pteroside B Table 21 80 
RH32 (3S)-Pteroside D Table 31 101 
RH33 Pteroside Z Table 38 114 
RH34 (2S)-Pteroside A2 Table 24 87 
RH35 (2S)-Pteroside K Table 34 106 
RH36 
5-(β-hydroxy)ethyl-2, 2, 4, 6-tetra 
methyl-1, 3-indandione 
Table 41 120 
RH37 Ptaquiloside Table 42 121 
RH38 5-hydroxycalamenene Table 43 124 
a The blue colours are representing the novel compounds. 
b The red colours are representing the known isolated compounds. 
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Careful pair-wise comparison of the CD spectra of the isolated compounds with identical 
chromophore cores (Figure 102) and similar dissymmetric environments enabled correlation. 
Comparison of the CD spectra with X-ray data or published CD data (Kuroyanagi et al., 1979a) 
revealed that the stereogenic centre in the core aglycone (Figure 102) of the compounds RH1, 
RH2, RH7, RH14, RH15, RH23, RH27, RH29, RH30, RH34 and RH35 can be assigned as 
2S.  
 
Figure 102: Chromophore core in compounds RH1, RH2, RH7, RH14, RH15, RH23, 
RH27, RH29, RH30, RH34 and RH35. 
Pterosin glycoside compounds so far reported possess the glucose residue at different positions, 
for example, (2R, 3R)-pterosin L 3-O-β-D-glucopyranoside (Chen et al., 2008) and (2S, 3S)-
pterosin C 3-O-β-D-glucoside (Sengupta et al., 1976) at position C-3; pterosides A2 and K 
(Castillo et al., 2003; Kuroyanagi et al., 1979a) at position C-11 and pterosides A, B, C, D, P 
and Z (Hikino et al., 1972, 1971; Kuroyanagi et al., 1979a) at position C-14. Thus, rhedynoside 
B (RH10) is first example for pterosides bearing glucose portion at the position C-2. To the 
best of our knowledge, rhedynosides C (RH11) and D (RH12) are the first reported glucosides 
with the glucose moiety on the position C-12 of the aglycone. In addition, one previously 
unreported sulfate-containing pterosin, rhedynosin H (RH9), together with two other reported 
compounds, (2R, 3R)-histiopterosin A (RH28) and (2S)-pteroside A2 (RH34), were isolated 
for the first time from the rhizomes of bracken. For the first time compounds (2S)-rhedynosin 
I (RH14), (2S)-2-Hydroxymethylpterosin E (RH27) and (2S)-12-hydroxypterosin A (RH29) 
were isolated from the plant source (bracken rhizomes). Previously, they were isolated as 
metabolite products of (2S)-pterosin A from rat urine 24 hrs after oral administration (100 
mg/kg) (Lee et al., 2012). Furthermore, the two novel compounds, rhedynosin A (RH1) and 
rhedynoside A (RH2), have a relatively rare aglycone, containing a six-membered cyclic ether.  
The origin of the pterosins and pterosides reported could be either by direct biosynthesis in 
planta or are products of ptaquiloside degradation. Also further chemical modification through 
environmental conditions in planta or during plant processing could have occurred. The 
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methodology employed was not able to address this questions, however, a grouping of the 
compounds identified (Figure 103-Figure 106) allows to develop hypotheses that further 
research may target. Ptaquiloside degradation results in pterosin B being the major product 
(Figure 6-Figure 7). Pterosin B arises due to the final ring opening step of the cyclopropane 
moiety that captures the nearest and most abundant nucleophile: hydroxyl group (OH−). Of 
the reported compounds (RH1 - RH35) nine equally contain the resulting hydroxyl substitution 
on position C-14 (Figure 103). The structural variation observed in this grouping relates mostly 
to the variation in the five-membered ring. Ptaquiloside contained a methyl substitution on 
position C-2 with R configuration, as was found for RH16. The α-position to the carbonyl 
functionality leads to easy racemisation on position C-2 resulting in RH25. Hydroxylation at 
position C-2 for RH24 and position C-3 for RH17 and RH18 was observed, possibly caused 
by additional environmental hydroxylation. Compounds RH19 and RH26 have two methyl 
substituents on position C-2, which are unlikely to have derived from environmental conditions 
during ptaquiloside degradation. RH15 and RH29 have an additional hydroxymethyl 
substituent on position C-2. A biosynthetic origin for this substitution is thought more likely. 
 
Figure 103: Pterosin compounds having OH substitution on position C-14 hypothesised 
to have arisen from ptaquiloside degradation. 
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In addition to hydroxyl group, other nucleophiles such as chloride (Cl−), sulfate (SO4
2−) and 
formate (HCOO−)  are present in planta and position C-14 was found to show chloride (Cl−), 
hydrogen sulfate (HSO4
−) and formate (HCOO−) substitution (Figure 104). As argued above, 
RH9, RH20 and RH21 are hypothesised to be direct ptaquiloside degradation products. RH5, 
RH8, RH22, RH29 show additional hydroxylation at positions C-2, C-3 and C-13. When 
considering the substitutions on the five-membered ring, again the presence of two methyl 
substituents on position C-2 for RH6 or an additional hydroxymethyl substituent on position 
C-2 for RH7, RH23 and RH27 was noted for which a biosynthetic origin is thought more 
likely. 
An additional six-membered ring containing an ether functionality formed part of RH1 while 
RH3, RH4 and RH14 contain six-membered cyclic esters (Figure 105). These structural 
features are hypothesised to have derived from intramolecular cyclisation reactions. For 
example, RH1 could be the product of nucleophilic substitution from RH29.  While no possible 
precursors for RH3, RH4 and RH14 have been isolated, they would require both formate and 
hydroxyl substitution on positions C-14 and C-12. 
In addition to alterations due to environmental conditions, enzymatic activity from enzymes 
present within the plant could have caused hydroxylation and glycosylation (Figure 106) which 
are well known degradation pathways. In addition, glycosylation is often employed to increase 
aqueous solubility. Pterosin A was isolated in the highest yield (Table 44) and was the only 
aglycone for which the corresponding glycoside with linkage at position C-14 (RH30) and 
position C-11 (RH2) was isolated (Figure 106). Pterosin B was the second highest yielding 
isolated pterosin followed by pterosin D. Both corresponding glycosides RH31 and RH32 
along with RH33 showed a glycosidic linkage at position C-14. The position C-14 has the least 
steric hindrance of all the hydroxyl substitutions present in the pterosin aglycones, and RH33 
also. The hydroxymethyl substitution at position C-2 provides the second least sterically 
hindered hydroxyl for glycosylation that was determined for RH2, RH34 and RH35. Equal 
distance from the bicyclic pterosin core is present at position C-12 and RH11 and RH12 were 
glycosylated there. Only two pterosides showed glycosylation to hydroxy groups directly 
attached to the bicyclic system at position C-2 for RH10 and position C-3 for RH13. 
Overall, the structural diversity observed suggests that the majority of the pterosins isolated are 
a product of ptaquiloside degradation. The presence of two methyl groups on position C-2 
require further investigation in view of whether there is ptaquiloside homologues present in 
bracken. 
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Figure 104: Pterosin compounds having Cl and HSO4 substitutions on position C-14 or 
COOH group on position C-13 hypothesised to have arisen from ptaquiloside 
degradation. 
 
Figure 105: Examples for six-membered cyclic pterosins in bracken. 
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Figure 106: Pterosin glycoside compounds with glucose-O-linkage to the aglycones at 
positions a) C-14, b) C-11 and c) C-2, C-3 and C-12. 
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6.2. BIOLOGICAL ACTIVITIES OF THE ISOLATED COMPOUNDS  
Bracken has been known for a long time to be a successful colonising plant whose consumption 
is detrimental to livestock. There are many examples of bracken extracts that have shown 
distinct biological effects on model systems. Ptaquiloside has been identified as the main 
compound in bracken with adverse effects on different biological processes, particularly 
showing DNA adduct formation and hence being carcinogenic. This study continued to search 
for biologically active compounds from bracken and the 35 isolated pterosins and pterosides 
were used in different assays. Historically bracken was used as an antihelminthic (Marrs and 
Watt, 2006), hence 20 compounds were used in a motility assay for the intestinal flatworm 
Schistosoma mansoni, however, none of the compounds showed any significant activity. 
Because of the tendency of bracken to take over whole areas of countryside, it was suspected 
to contain potential agrochemicals. A screen undertaken by Syngenta to assess the anti-fungal, 
anti-insecticidal and herbicidal activity, did not yield any positive responses when compared 
to the best commercially available product. However, because mild, moderate and low 
antifungal activity was detected for 7 out of the 20 submitted compounds on at least one 
occasion, this was considered worth following up. A different anti-fungal screen targeting the 
medically-relevant Candida albicans species was utilised for 21 compounds, however, no 
susceptibility to any compound was returned. Pterosins have been patented as anti-diabetics 
thus 6 compounds, consisting of matched aglycones and glycosides, were used in a glucose 
transport assay. It was concluded that they exhibited negligible inhibitory effect on the main 
glucose transporters found in the intestine. Finally, a subset of 21 compounds was used to 
investigate their antitrypanosomal activity and rhedynosin G (RH8) was found to give 79% 
inhibition against Trypanosoma brucei brucei at a rate of 20 µM. All other compounds were 
found to be almost inactive. When testing for the anti-bacterial activity, only moderate 
inhibition at 100 µM was found for RH35 again Mycobacterium marinum. Compounds RH2, 
RH8, RH20, RH30 and RH34 showed moderate activity against Klebsiella pneumonia at 100 
µM. 
The absence of biological activity, even for conditions where traditional use of bracken has 
been known or pterosins have been patented for, was unexpected. However, this suggest a 
surprising efficiency on behalf of bracken in its biosynthesis of ptaquiloside as it is thought 
that the main biological active compound in bracken is ptaquiloside. As pterosins and 
pterosides are more stable when compared to ptaquiloside, they may be a second line of 
chemical defence that requires a higher concentration to exert a biological effect.  
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6.3. QUANTIFICATION AND SEASONAL VARIATIONS OF PTEROSIN B AND PTEROSIDE B 
The environmental fate of pterosin B and pteroside B was assessed by quantifying its presence 
in all bracken tissues (rhizomes, stems and fronds), associated soil and water. This was 
undertaken for two growth periods of bracken (2014 and 2015). Quantitation of the two 
compounds (pterosin B and pteroside B) was performed by using an accurate and precise 
developed RP-HPLC-UV method. A SPE method (using 500 mg SPE cartridges) has also 
been developed and used for preconcentration, clean-up and sample preparation.  
The recovery and % RSD for both analytes were calculated. Acceptable and satisfactory 
recoveries ranging from  90.29 − 96.23 % (pterosin B) and  93.64 − 101.03 % (pteroside B) 
were obtained with the developed SPE-HPLC-UV method (Table 56). This supports that the 
developed method is accurate. The method can be used for quantification of pterosin B and 
pteroside B in plant tissues, water and soil samples. Also, the method is recommended to be 
used for indirect detection and quantification of ptaquiloside in water and soil samples after 
degradation of ptaquiloside resulting in formation of a stable natural pterosin B. 
As it was expected, the amounts of both pterosin B and pteroside B decreased from the crosiers 
to the mature fronds. In general, the highest concentration of pterosin B was found in all parts 
of bracken and soil samples when shoots emerged and crosiers started to grow, i.e. in mid-May 
to July (Figure 97-Figure 100). It was found that the rhizome is the main storage organ for 
pteroside B as its concentration was reached about 3000 mg/kg (Figure 97) which is much 
higher than that found in the stems and fronds (Figure 99). Pterosin B, on the other hand, had 
a similar concentration range in fronds and stems (Figure 98), while its concentration declined 
to half in rhizomes especially at the beginning of bracken growth in May to June (Figure 97). 
The excess of pteroside B was thought to derive for two main reasons. Firstly, it is the glycoside 
of the main ptaquiloside degradation product pterosins B. By being glycosylated, pteroside B 
is easier to translocate within the plant, and is also thought to derive as a consequence of the 
starch richness of bracken. It seems that pteroside B is not catabolised on senescence, rather it 
accumulates in the storage organ, the rhizome. Secondly, it presents a means of chemical 
defence for bracken by being available for transport to tissue in need of most defence, 
particularly the crosiers. The increased concentration in the crosiers and the young stems and 
fronds support this (Figure 99). 
The soil samples equally picked up the increased pterosin B concentration during the critical 
young tissue formation between May to June (Figure 100), which supports the overall 
relocation of pterosin B, most probably in the form of the glycoside pteroside B. Young tissues, 
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such as shoots and crosiers, are characterised by abundant growth and little differentiation, 
meaning that the cell wall is probably not fully formed, making it leaky. To our knowledge, no 
pteroside B is detected in the soil which contradicts the quantification of pteroside B in the 
water samples, and this absence may be attributed to the abundance of glycosidases in soil. 
Considering the overall secondary metabolism of bracken as investigated here, it can be 
concluded that bracken has evolved with ptaquiloside as its main agent for chemical defence. 
In an environment that induces hydrolysis, the structure of ptaquiloside lends itself to latch 
onto the nearest susceptible target. This study showed clearly that the structural variety of 
pterosins and pterosides are conceivably ptaquiloside degradation products. Following the 
environmental fate of the main aglycone pterosin B and glycoside pteroside B, it was shown 
that the glycoside is used for storage in the carbohydrate-rich bracken. From the plant, pterosins 
are sufficiently stable to translocate into the soil and to be leached out into the groundwater. 
The reduction in concentration is roughly a factor 1000 less in the soil and another factor 10000 
less in the water.
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Appendices 
Appendix I: NMR spectra of compounds RH3 - RH38. 
1) NMR spectra of compound RH3 in CDCl3. 
 
Figure A-1: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH3. 
 
Figure A-2: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH3. 
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Figure A-3: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH3. 
 
Figure A-4: 1H-13C HSQC NMR spectrum of compound RH3 in CDCl3. 
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Figure A-5: 1H-13C HMBC NMR spectrum of compound RH3 in CDCl3. 
2) NMR spectra of compound RH4 in CD3OD. 
 
Figure A-6: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH4. 
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Figure A-7: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH4. 
 
Figure A-8: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH4. 
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Figure A-9: 1H-13C HSQC NMR spectrum of compound RH4 in CD3OD. 
 
Figure A-10: 1H-13C HMBC NMR spectrum of compound RH4 in CD3OD. 
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3) NMR spectra of compound RH5 in CDCl3. 
 
Figure A-11: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH5. 
 
Figure A-12: 13C NMR (CDCl3, 100 MHz) spectrum of compound RH5. 
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Figure A-13: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH5. 
 
Figure A-14: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH5. 
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Figure A-15: 1H-13C HSQC NMR spectrum of compound RH5 in CDCl3. 
 
Figure A-16: 1H-13C HMBC NMR spectrum of compound RH5 in CDCl3. 
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4) NMR spectra of compound RH6 in CD3OD. 
 
Figure A-17: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH6. 
 
Figure A-18: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH6. 
 Appendices 
  
 
218 
 
 
Figure A-19: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH6. 
 
Figure A-20: 1H-13C HSQC NMR spectrum of compound RH6 in CD3OD. 
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Figure A-21: 1H-13C HMBC NMR spectrum of compound RH6 in CD3OD. 
5) NMR spectra of compound RH7 in CDCl3. 
 
Figure A-22: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH7. 
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Figure A-23: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH7. 
 
Figure A-24: 13C NMR (CDCl3, 100 MHz) spectrum of compound RH7. 
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Figure A-25: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH7. 
 
Figure A-26: 1H-13C HSQC NMR spectrum of compound RH7 in CDCl3. 
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Figure A-27: 1H-13C HMBC NMR spectrum of compound RH7 in CDCl3. 
6) NMR spectra of compound RH8 in (CD3)2CO. 
 
Figure A-28: 1H NMR ((CD3)2CO, 400 MHz) spectrum of compound RH8. 
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Figure A-29: DEPTQ NMR ((CD3)2CO, 100 MHz) spectrum of compound RH8. 
 
Figure A-30: 1H-1H COSY NMR ((CD3)2CO, 400 MHz) spectrum of compound RH8.  
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Figure A-31: 1H-13C HSQC NMR spectrum of compound RH8 in (CD3)2CO. 
 
Figure A-32: 1H-13C HMBC NMR spectrum of compound RH8 in (CD3)2CO. 
 Appendices 
  
 
225 
 
7) NMR spectra of compound RH9 in CD3OD. 
 
Figure A-33: 1H NMR (CD3OD, 500 MHz) spectrum of compound RH9. 
 
Figure A-34: DEPTQ NMR (CD3OD, 125 MHz) spectrum of compound RH9. 
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Figure A-35: 1H-13C HMBC NMR spectrum of compound RH9 in CD3OD. 
8) NMR spectra of compound RH10 in CD3OD. 
 
 
Figure A-36: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH10. 
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Figure A-37: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH10 (3.0 – 3.75 ppm). 
 
Figure A-38: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH10 after acetylation. 
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Figure A-39: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH10. 
 
Figure A-40: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH10. 
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Figure A-41: 1H-13C HSQC NMR spectrum of compound RH10 in CD3OD. 
 
Figure A-42: 1H-13C HMBC NMR spectrum of compound RH10 in CD3OD. 
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9) NMR spectra of compound RH11 in CD3OD. 
 
Figure A-43: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH11. 
 
Figure A-44: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH11 (2.9 – 4.1 ppm). 
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Figure A-45: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH11 after acetylation. 
 
Figure A-46: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH11. 
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Figure A-47: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH11. 
 
Figure A-48: 1H-13C HSQC NMR spectrum of compound RH11 in CD3OD. 
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Figure A-49: 1H-13C HMBC NMR spectrum of compound RH11 in CD3OD. 
10)  NMR spectra of compound RH12 in CD3OD. 
 
Figure A-50: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH12. 
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Figure A-51: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH12 (2.6 – 4.0 ppm). 
 
Figure A-52: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH12 after acetylation. 
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Figure A-53: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH12. 
 
Figure A-54: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH12 after 
acetylation. 
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Figure A-55: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH12. 
 
Figure A-56: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH12 after 
acetylation. 
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Figure A-57: 1H-13C HSQC NMR spectrum of compound RH12 in CD3OD. 
 
Figure A-58: 1H-13C HMBC NMR spectrum of compound RH12 in CD3OD. 
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11)  NMR spectra of compound RH13 in CD3OD. 
 
Figure A-59: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH13. 
 
Figure A-60: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH13 (3.2 – 4.6 ppm). 
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Figure A-61: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH13 after acetylation. 
 
Figure A-62: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH13. 
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Figure A-63: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH13 after 
acetylation. 
 
Figure A-64: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH13. 
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Figure A-65: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH13 after 
acetylation. 
 
Figure A-66: 1H-13C HSQC NMR spectrum of compound RH13 in CD3OD. 
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Figure A-67: 1H-13C HMBC NMR spectrum of compound RH13 in CD3OD. 
 
Figure A-68: 1H-1H NOESY NMR (CD3OD, 400 MHz) spectrum of compound RH13. 
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12)  NMR spectra of compound RH14 in CD3OD. 
 
Figure A-69: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH14. 
 
Figure A-70:  Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH14 (2.8 – 4.6 ppm). 
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Figure A-71: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH14. 
 
Figure A-72: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH14. 
 Appendices 
  
 
245 
 
 
Figure A 73: 1H-13C HSQC NMR spectrum of compound RH14 in CD3OD. 
 
Figure A-74: 1H-13C HMBC NMR spectrum of compound RH14 in CD3OD. 
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13)  NMR spectra of compound RH15 in CD3OD. 
 
Figure A-75: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH15. 
 
Figure A-76: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH15 (2.7 – 3.7 ppm). 
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Figure A-77: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH15. 
 
Figure A-78: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH15. 
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Figure A-79: 1H-13C HSQC NMR spectrum of compound RH15 in CD3OD. 
 
Figure A-80: 1H-13C HMBC NMR spectrum of compound RH15 in CD3OD. 
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14)  NMR spectra of compound RH16 in CDCl3. 
 
Figure A-81: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH16. 
 
Figure A-82: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH16 (2.5 – 3.8 ppm). 
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Figure A-83: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH16. 
 
Figure A-84: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH16. 
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Figure A-85: 1H-13C HSQC NMR spectrum of compound RH16 in CDCl3. 
 
Figure A-86: 1H-13C HMBC NMR spectrum of compound RH16 in CDCl3. 
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15)  NMR spectra of compound RH17 in CD3OD. 
 
Figure A-87: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH17. 
 
Figure A-88: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH17 (2.4 – 3.7 ppm). 
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Figure A-89: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH17. 
 
Figure A-90: 1H-13C HSQC NMR spectrum of compound RH17 in CD3OD. 
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Figure A-91: 1H-13C HMBC NMR spectrum of compound RH17 in CD3OD. 
16)  NMR spectra of compound RH18 in CD3OD. 
 
Figure A-92: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH18. 
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Figure A-93: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH18 (2.4 – 3.7 ppm). 
 
Figure A-94: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH18. 
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Figure A-95: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH18. 
 
Figure A-96: 1H-13C HSQC NMR spectrum of compound RH18 in CD3OD. 
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Figure A-97: 1H-13C HMBC NMR spectrum of compound RH18 in CD3OD. 
17)  NMR spectra of compound RH19 in CD3OD. 
 
Figure A-98: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH19. 
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Figure A-99: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH19. 
 
Figure A-100: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH19. 
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Figure A-101: 1H-13C HSQC NMR spectrum of compound RH19 in CD3OD. 
 
Figure A-102: 1H-13C HMBC NMR spectrum of compound RH19 in CD3OD. 
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18)  NMR spectra of compound RH20 in CDCl3. 
 
Figure A-103: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH20. 
 
Figure A-104: 1H-13C HSQC NMR spectrum of compound RH20 in CDCl3. 
 Appendices 
  
 
261 
 
 
Figure A-105: 1H-13C HMBC NMR spectrum of compound RH20 in CDCl3. 
19)  NMR spectra of compound RH21 in CDCl3. 
 
Figure A-106: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH21. 
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Figure A-107: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH21 (2.5 – 3.6 ppm). 
 
Figure A-108: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH21. 
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Figure A-109: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH21. 
 
Figure A-110: 1H-13C HSQC NMR spectrum of compound RH21 in CDCl3. 
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Figure A-111: 1H-13C HMBC NMR spectrum of compound RH21 in CDCl3. 
20)  NMR spectra of compound RH22 in CDCl3. 
 
Figure A-112: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH22. 
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Figure A-113: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH22 (2.4 – 3.6 ppm). 
 
Figure A-114: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH22. 
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Figure A-115: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH22. 
 
Figure A-116: 1H-13C HSQC NMR spectrum of compound RH22 in CDCl3. 
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Figure A-117: 1H-13C HMBC NMR spectrum of compound RH22 in CDCl3. 
21)  NMR spectra of compound RH23 in CDCl3. 
 
Figure A-118: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH23. 
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Figure A-119: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH23 (2.70-3.85 ppm). 
 
Figure A-120: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH23. 
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Figure A-121: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH23. 
 
Figure A-122: 1H-13C HSQC NMR spectrum of compound RH23 in CDCl3. 
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Figure A-123: 1H-13C HMBC NMR spectrum of compound RH23 in CDCl3. 
22)  NMR spectra of compound RH24 in CD3OD. 
 
Figure A-124: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH24. 
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Figure A-125: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH24. 
 
Figure A-126: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH24. 
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Figure A-127: 1H-13C HSQC NMR spectrum of compound RH24 in CD3OD. 
 
Figure A-128: 1H-13C HMBC NMR spectrum of compound RH24 in CD3OD. 
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23)  NMR spectra of compound RH25 in CDCl3. 
 
Figure A-129: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH25. 
 
Figure A-130: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH25 (2.6 – 4.0 ppm). 
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Figure A-131: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH25. 
24)  NMR spectra of compound RH26 in CDCl3. 
 
Figure A-132: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH26. 
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Figure A-133: DEPTQ NMR (CDCl3, 100 MHz) spectrum of compound RH26. 
 
Figure A-134: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH26. 
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Figure A-135: 1H-13C HSQC NMR spectrum of compound RH26 in CDCl3. 
 
Figure A-136: 1H-13C HMBC NMR spectrum of compound RH26 in CDCl3. 
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25)  NMR spectra of compound RH27 in CD3OD. 
 
Figure A-137: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH27. 
 
Figure A-138: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH27 (2.7 – 3.8 ppm). 
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Figure A-139: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH27. 
 
Figure A-140: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH27. 
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Figure A-141: 1H-13C HSQC NMR spectrum of compound RH27 in CD3OD. 
 
Figure A-142: 1H-13C HMBC NMR spectrum of compound RH27 in CD3OD. 
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26)  NMR spectra of compound RH28 in CD3OD. 
 
Figure A-143: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH28. 
 
Figure A-144: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH28. 
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Figure A-145: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH28. 
 
Figure A-146: 1H-13C HSQC NMR spectrum of compound RH28 in CD3OD. 
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Figure A-147: 1H-13C HMBC NMR spectrum of compound RH28 in CD3OD. 
27)  NMR spectra of compound RH29 in CD3OD. 
 
Figure A-148: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH29. 
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Figure A-149: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH29 (2.7 – 3.7 ppm). 
 
Figure A-150: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH29. 
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Figure A-151: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH29. 
 
Figure A-152: 1H-13C HSQC NMR spectrum of compound RH29 in CD3OD. 
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Figure A-153: 1H-13C HMBC NMR spectrum of compound RH29 in CD3OD. 
28)  NMR spectra of compound RH30 in CD3OD. 
 
Figure A-154: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH30. 
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Figure A-155: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH30 (2.6 – 3.9 ppm). 
 
Figure A-156: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH30. 
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Figure A-157: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH30. 
 
Figure A-158: 1H-13C HSQC NMR spectrum of compound RH30 in CD3OD. 
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Figure A-159: 1H-13C HMBC NMR spectrum of compound RH30 in CD3OD. 
29)  NMR spectra of compound RH31 in CD3OD. 
 
Figure A-160: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH31. 
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Figure A-161: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH31 (3.1 – 3.9 ppm). 
 
Figure A-162: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH31. 
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Figure A-163: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH31. 
 
Figure A-164: 1H-13C HSQC NMR spectrum of compound RH31 in CD3OD. 
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Figure A-165: 1H-13C HMBC NMR spectrum of compound RH31 in CD3OD. 
30)  NMR spectra of compound RH32 in CD3OD. 
 
Figure A-166: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH32. 
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Figure A-167: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH32 (3.1 – 4.4 ppm). 
 
Figure A-168: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH32. 
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31)  NMR spectra of compound RH33 in CD3OD. 
 
Figure A-169: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH33. 
 
Figure A-170: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH33 (3.1 – 3.9 ppm). 
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Figure A-171: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH33. 
 
Figure A-172: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH33. 
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Figure A-173: 1H-13C HSQC NMR spectrum of compound RH33 in CD3OD. 
 
Figure A-174: 1H-13C HMBC NMR spectrum of compound RH33 in CD3OD. 
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32)  NMR spectra of compound RH34 in CD3OD. 
 
Figure A-175: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH34. 
 
Figure A-176: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH34 (2.7 – 4.2 ppm). 
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Figure A-177: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH34. 
 
Figure A-178: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH34. 
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Figure A-179: 1H-13C HSQC NMR spectrum of compound RH34 in CD3OD. 
 
Figure A-180: 1H-13C HMBC NMR spectrum of compound RH34 in CD3OD. 
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33)  NMR spectra of compound RH35 in CD3OD. 
 
Figure A-181: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH35. 
 
Figure A-182: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH35 (3.2 – 3.8 ppm). 
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Figure A-183: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH35. 
 
Figure A-184: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH35. 
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Figure A-185: 1H-13C HSQC NMR spectrum of compound RH35 in CD3OD. 
 
Figure A-186: 1H-13C HMBC NMR spectrum of compound RH35 in CD3OD. 
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34)  NMR spectra of compound RH36 in CD3OD. 
 
Figure A-187: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH36. 
 
Figure A-188: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH36. 
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35)  NMR spectra of compound RH37 in CD3OD. 
 
Figure A-189: 1H NMR (CD3OD, 400 MHz) spectrum of compound RH37. 
 
Figure A-190: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH37 (0.4 – 2.8 ppm). 
 Appendices 
  
 
304 
 
 
Figure A-191: Expanded 1H NMR (CD3OD, 400 MHz) spectrum of RH37 (3.2 – 4.6 ppm). 
 
Figure A-192: DEPTQ NMR (CD3OD, 100 MHz) spectrum of compound RH37. 
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Figure A-193: 1H-1H COSY NMR (CD3OD, 400 MHz) spectrum of compound RH37. 
 
Figure A-194: 1H-13C HSQC NMR spectrum of compound RH37 in CD3OD. 
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Figure A-195: 1H-13C HMBC NMR spectrum of compound RH37 in CD3OD. 
36)  NMR spectra of compound RH38 in CDCl3. 
 
Figure A-196: 1H NMR (CDCl3, 400 MHz) spectrum of compound RH38. 
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Figure A-197: Expanded 1H NMR (CDCl3, 400 MHz) spectrum of RH38 (0.8 – 3.1 ppm). 
 
Figure A-198: 13C NMR (CDCl3, 100 MHz) spectrum of compound RH38. 
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Figure A-199: 1H-1H COSY NMR (CDCl3, 400 MHz) spectrum of compound RH38. 
 
Figure A-200: 1H-13C HSQC NMR spectrum of compound RH38 in CDCl3. 
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Figure A-201: 1H-13C HSQC-TOCSY NMR spectrum of compound RH38 in CDCl3. 
 
Figure A-202: 1H-13C HMBC NMR spectrum of compound RH38 in CDCl3. 
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Appendix II: Accurate MS spectra of compounds RH3 - RH38. 
 
Figure A-203: FT-ICR-MS spectrum of compound RH3 in [M+H]+ positive ion mode 
 
Figure A-204: FT-ICR-MS spectrum of compound RH4 in [M-H]- negative ion mode. 
 
Figure A-205: FT-ICR-MS spectrum of compound RH5 in [M+H]+ positive ion mode. 
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Figure A-206: FT-ICR-MS spectrum of compound RH6 in [M+H]+ positive ion mode. 
 
Figure A-207: FT-ICR-MS spectrum of compound RH7 in [M+H]+ positive ion mode. 
 
Figure A-208: FT-ICR-MS spectrum of compound RH8 in [M+H]+ positive ion mode. 
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Figure A-209: FT-ICR-MS spectrum of compound RH9 in [M-H]- negative ion mode. 
 
Figure A-210: FT-ICR-MS spectrum of compound RH10 in [M+H]+ positive ion mode. 
 
Figure A-211: FT-ICR-MS spectrum of compound RH11 in [M+H]+ positive ion mode. 
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Figure A-212: FT-ICR-MS spectrum of compound RH12 in [M-H]- negative ion mode. 
 
Figure A-213: FT-ICR-MS spectrum of compound RH13 in [M-H]- negative ion mode. 
 
Figure A-214: HR-ESI-MS spectrum of compound RH14 in [M+H]+ positive ion mode. 
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Figure A-215: HR-ESI-MS spectrum of compound RH15 in [M+H]+ positive ion mode. 
 
Figure A-216: HR-ESI-MS spectrum of compound RH16 in [M+H]+ positive ion mode. 
 
Figure A-217: HR-ESI-MS spectrum of compound RH17 in [M+H]+ positive ion mode. 
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Figure A-218: HR-ESI-MS spectrum of compound RH18 in [M+H]+ positive ion mode. 
 
Figure A-219: HR-ESI-MS spectrum of compound RH19 in [M+H]+ positive ion mode. 
 
Figure A-220: HR-ESI-MS spectrum of compound RH20 in [M-H]- negative ion mode. 
5. cis-pterosin C (18) #267 RT: 10.48 AV: 1 NL: 2.95E8
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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7. Pterosin E (20) #428 RT: 16.69 AV: 1 NL: 1.31E8
T: FTMS {1,2}  - p ESI Full ms [150.00-1500.00]
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Figure A-221: HR-ESI-MS spectrum of compound RH21 in [M+H]+ positive ion mode. 
 
Figure A-222: HR-ESI-MS spectrum of compound RH22 in [M+H]+ positive ion mode. 
 
Figure A-223: HR-ESI-MS spectrum of compound RH23 in [M+H]+ positive ion mode. 
8. Pterosin F (21) #679 RT: 26.19 AV: 1 NL: 2.16E8
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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9. Pterosin J (22) #497 RT: 19.30 AV: 1 NL: 1.40E8
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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Figure A-224: HR-ESI-MS spectrum of compound RH24 in [M+H]+ positive ion mode. 
 
Figure A-225: HR-ESI-MS spectrum of compound RH25 in [M+H]+ positive ion mode. 
 
Figure A-226: HR-ESI-MS spectrum of compound RH26 in [M+H]+ positive ion mode. 
11. Pterosin N (24) #287 RT: 11.13 AV: 1 NL: 3.22E8
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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12. Pterosin P (25) #299 RT: 11.12 AV: 1 NL: 7.05E7
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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13. Pterosin Z (26) #483 RT: 19.07 AV: 1 NL: 5.70E8
T: FTMS {1,1}  + p ESI Full ms [150.00-1500.00]
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Figure A-227: HR-ESI-MS spectrum of compound RH27 in [M-H]- negative ion mode. 
 
Figure A-228: HR-ESI-MS spectrum of compound RH28 in [M-H]- negative ion mode. 
 
Figure A-229: HR-ESI-MS spectrum of compound RH29 in [M+H]+ positive ion mode. 
14. (2S)-2-hydroxymethyl pterosin E (27) #346 RT: 12.68 AV: 1 NL: 1.42E8
T: FTMS {1,2}  - p ESI Full ms [150.00-1500.00]
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15. Histopterosin A (28) #320 RT: 11.12 AV: 1 NL: 1.75E7
T: FTMS {1,2}  - p ESI Full ms [150.00-1500.00]
245.0 245.5 246.0 246.5 247.0 247.5 248.0 248.5 249.0 249.5 250.0
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
247.0968
C 14 H15 O4 = 247.0970
7.5 RDBE
248.1001
C 14 H16 O4 = 248.1049
7.0 RDBE
246.0845
C 14 H14 O4 = 246.0892
8.0 RDBE
249.1041
C 14 H17 O4 = 249.1127
6.5 RDBE
16. (2S)-12-hydroxy pterosin A (29) #245 RT: 9.05 AV: 1 NL: 6.22E7
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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Figure A-230: HR-ESI-MS spectrum of compound RH30 in [M+H]+ positive ion mode. 
 
Figure A-231: HR-ESI-MS spectrum of compound RH31 in [M+H]+ positive ion mode. 
 
Figure A-232: HR-ESI-MS spectrum of compound RH32 in [M+H]+ positive ion mode. 
17. Pteroside A (30) #275 RT: 9.62 AV: 1 NL: 6.71E7
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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18. Pteroside B (31) #315 RT: 12.13 AV: 1 NL: 1.49E7
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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19. Pteroside D (32) #265 RT: 9.14 AV: 1 NL: 2.63E6
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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Figure A-233: HR-ESI-MS spectrum of compound RH33 in [M+H]+ positive ion mode. 
 
Figure A-234: HR-ESI-MS spectrum of compound RH34 in [M+H]+ positive ion mode. 
 
Figure A-235: HR-ESI-MS spectrum of compound RH35 in [M+H]+ positive ion mode. 
20. Pteroside Z (33) #353 RT: 13.31 AV: 1 NL: 5.12E7
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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21. Pteroside A2 (34) #265 RT: 9.80 AV: 1 NL: 1.26E8
T: FTMS {1,1}  + p ESI Full ms [150.00-1500.00]
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22. Pteroside K (35) #391 RT: 15.12 AV: 1 NL: 1.07E8
T: FTMS {1,1}  + p ESI Full ms [150.00-1500.00]
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Figure A-236: HR-ESI-MS spectrum of compound RH36 in [M+H]+ positive ion mode. 
 
Figure A-237: HR-ESI-MS spectrum of compound RH37 in [M-H]- negative ion mode. 
 
Figure A-238: HR-ESI-MS spectrum of compound RH38 in [M-H]- negative ion mode. 
23. 5-(β-hydroxy)ethyl-2,2,4,6-tetramethyl-1,3-indandione (36) #463 RT: 16.60 AV: 1 NL: 1.10E8
T: FTMS {1,1}  + p ESI Full lock ms [150.00-1500.00]
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26. Ptaquiloside (37) #424 RT: 15.99 AV: 1 NL: 7.28E3
T: FTMS {1,2}  - p ESI Full ms [150.00-1500.00]
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T: FTMS {1,2}  - p ESI Full ms [150.00-1500.00]
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Appendix III: IR spectra of compounds RH2 - RH13. 
 
 
Figure A-239: FT-IR spectrum of compound RH2 in CH3OH. 
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Figure A-240: FT-IR spectrum of compound RH3 in CHCl3. 
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Figure A-241: FT-IR spectrum of compound RH4 in CH3OH. 
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Figure A-242: FT-IR spectrum of compound RH5 in CHCl3. 
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Figure A-243: FT-IR spectrum of compound RH6 in CH3OH. 
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Figure A-244: FT-IR spectrum of compound RH7 in CHCl3. 
 
 Appendices 
  
 
328 
 
 
 
Figure A-245: FT-IR spectrum of compound RH8 in CH3OH. 
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Figure A-246: FT-IR spectrum of compound RH9 in CH3OH. 
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Figure A-247: FT-IR spectrum of compound RH10 in CH3OH. 
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Figure A-248: FT-IR spectrum of compound RH11 in CH3OH. 
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Figure A-249: FT-IR spectrum of compound RH12 in CH3OH. 
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Figure A-250: FT-IR spectrum of compound RH13 in CH3OH.
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Appendix IV: UV spectra of compounds RH2 - RH13. 
 
Figure A-251: UV spectrum of compound RH2 in CH3OH. 
 
Figure A-252: UV spectrum of compound RH3 in CH3OH. 
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Figure A-253: UV spectrum of compound RH4 in CH3OH. 
 
Figure A-254: UV spectrum of compound RH5 in CH3OH. 
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Figure A-255: UV spectrum of compound RH6 in CH3OH. 
 
Figure A-256: UV spectrum of compound RH7 in CH3OH. 
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Figure A-257: UV spectrum of compound RH8 in CH3OH. 
 
Figure A-258: UV spectrum of compound RH9 in CH3OH. 
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Figure A-259: UV spectrum of compound RH10 in CH3OH. 
 
Figure A-260: UV spectrum of compound RH11 in CH3OH. 
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Figure A-261: UV spectrum of compound RH12 in CH3OH. 
 
Figure A-262: UV spectrum of compound RH13 in CH3OH. 
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Appendix V: Glucose transport assays. 
1) Routine cell culture 
 Human epithelial colorectal adenocarcinoma (Caco-2) cells were obtained from the 
American Type Culture Collection (ATCC) and cultured in Growth Medium consisting 
of Dulbecco’s modiﬁed Eagle's medium (containing Glutamax-1, 4.5 g/L D-Glucose & 
25 mM Hepes (Invitrogen)), 10% Fetal Bovine Serum (Sigma), 1% Non-Essential 
Amino Acids (Invitrogen) & 1 mM Sodium pyruvate (Sigma).  The cells were routinely 
passaged at approximately 80% confluence using TrypLE™ Express Stable Trypsin-
Like Enzyme (Invitrogen) to detach the cells, and seeded at approximately 114 cells per 
mm2 in fresh tissue culture flasks.  Only cells between the passage numbers 45 and 49 
were used for experiments. 
2) Preparation of differentiated Caco-2 cell monolayers 
Corning® HTS Transwell® 96 well permeable insert supports (Sigma) were collagen 
coated with 40 μl of 50 μg/ml Rat Tail Collagen Type I (BD Biosciences) in 0.02 M 
acetic acid for one hour at room temperature under sterile conditions.  The inserts were 
washed twice in Phosphate Buffered Saline (PBS (Invitrogen)) and the Caco-2 cells 
seeded into the inserts at 9.6 x 105 cell/ml (75 μl per insert) in Growth Medium and 30 
ml of Growth medium added to the feeder plate below.  The cells were left to attach to 
the collagen matrix and form monolayers over 48 hrs at 37 ºC, 5% CO2.  Both inserts 
and feeder plate were washed in PBS and the cells incubated with BD Entero-STIM™ 
Enterocyte Differentiation Medium containing MITO+™ Serum Extender solution (both 
BD Biosciences),75 μl per insert & 30 ml in feeder plate, for a further 48 hrs at 37 ºC, 
5% CO2.   
 
 
 
 
